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John A. Milligan, Ph.D. 
University of Pittsburgh, 2018
Chapter one of this thesis discusses the hydrophosphination of carbodiimides with 
secondary phosphine boranes. These reactions provide access to phosphaguanidine boranes, which 
have previously not been studied. A cyclic carbodiimide was also prepared, and 
hydrophosphination of this substrate provided access to structurally unique phosphaguanidines 
that bear resemblance to cyclophanes.  
Chapter two delineates the extension of this hydrophosphination method to functionalize 
strained carbocycles, namely bicyclo[1.1.0]butanes. The scope and stereoselectivity of this 
transformation was investigated, and further transformations of the cyclobutyl phosphine products 
were conducted. Studies on the addition of aromatic and heteroaromatic thiols to 
bicyclo[1.1.0]butanes are also described in this chapter. 
Chapter three describes a strain-relieving deoxyfluorination of bicyclo[1.1.0]butyl 
alcohols. The products of these transformations are fluorinated methylenecyclobutanes, which can 
be oxidatively transformed into cyclobutanones. Bicyclo[1.1.0]butyl amides were also subjected 
to fluorination with a high degree of diastereoselectivity. 
Chapter four details the development of bicyclo[1.1.0]butyl amides as potential androgen 
receptor antagonists for the treatment of castration-resistant prostate cancer. In the course of these 
medicinal chemistry studies, an acid-mediated isomerization of bicyclo[1.1.0]butanes to 
cyclobutenes was discovered. 
v 
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1.0  HYDROPHOSPHINATION OF CARBODIIMIDES WITH PHOSPHINE BORANES 
1.1 INTRODUCTION 
1.1.1 Hydrophosphination of Carbodiimides 
The hydrophosphination of carbon-carbon and carbon-heteroatom multiple bonds is a highly atom 
economical means to prepare substituted phosphines. The earliest hydrophosphinations, which 
were reported in the 1950's, involved reacting alkenes with primary phosphines under harsh 
conditions.1 An array of catalytic methods for alkene and alkyne hydrophosphination have since 
been developed, including methods that are mediated by bases2, organocatalysts,3 radical 
initiators,4 or Lewis acids.5 Hydrophosphinations have also been catalyzed by late transition 
metals6 or lanthanides.7 More recently, overarching efforts to develop more sustainable catalytic 
methods have produced hydrophosphination catalysts derived from coinage8 and alkali earth9 
metals. The development of catalytic, asymmetric hydrophosphinations of hydrocarbons is also an 
area of ongoing research.10 
Although carbodiimides are most prominently known as peptide coupling agents,11 they 
too can been subjected to hydrophosphination. Early protocols for these transformations involved 
harsh conditions such as heating a neat mixture of a secondary phosphine with a carbodiimide.12 
In modern practice, various methods using base, transition metal, or lanthanide catalysts are 
available for the hydrophosphination of carbodiimides.13 Deprotonated secondary phosphines can 
be used to formally hydrophosphinate carbodiimides through attack of the phosphide anion onto 
 2 
the carbodiimide followed by aqueous workup.14  The hydrophosphination of other electrophiles 
such as isocyanates, isothiocyanates, and aldehydes has also been investigated (Figure 1).15 
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Figure 1. General overview of hydrophosphination chemistry. 
1.1.2 Hydrophosphination with Phosphine Boranes 
Phosphine boranes are Lewis acid/base adducts that have been known for over a century, but 
interest in the chemistry of these molecules has increased in recent decades.16 Aside from serving 
as air-stable precursors of functionalized phosphines, these adducts have been used as hydrogen 
atom donors in Barton-McCombie deoxygenations17 and as polyphosphinoborane monomers.18 A 
marked advantage of phosphine boranes is their tendency to be air-stable crystalline solids, 
whereas the parent phosphines (particularly primary and secondary alkyl phosphines) are often air 
sensitive, pyrophoric, and/or malodorous. These adducts are generally synthesized from the 
corresponding phosphines with BH3•THF or BH3•SMe2 as the borane donor, although alternative 
methods for their preparation have been described, such as a one-pot reduction/boron 
complexation of phosphine oxides.19 
 3 
 In addition to protecting the phosphine against oxidation, the borane decreases the 
magnitude of the pKa of hydrogens adjacent to phosphorus (as with tertiary phosphine boranes) or 
directly attached to phosphorus (in the case of secondary phosphine boranes).20 This property 
enables phosphine boranes to be convenient, air-stable reagents that can be readily elaborated into 
more complex phosphines. For example, dimethylphenyl tertiary phosphine boranes can be 
subjected to an enantioselective deprotonation using s-BuLi and (–)-sparteine. Subsequent 
addition of a copper (II) salt promotes oxidative anion dimerization to provide access to P-chiral 
dppe derivatives.21 The P–H bond in secondary phosphine boranes (1-6) can be deprotonated with 
n-BuLi, NaH, or t-BuOK, and the resulting anion can be subjected to a hydrophosphination or 
alkylation reaction. 
Imamoto and co-workers first reported in 1990 that secondary phosphine boranes (1-6) can  
hydrophosphinate Michael acceptors in the presence of substoichiometric potassium hydroxide.22 
Since Imamoto's pioneering work, Gaumont and co-workers have found that hydrophosphinations 
of alkenes and alkynes can be conducted with secondary phosphine boranes by simply heating a 
neat mixture of the two reactants (Figure 2).23 For example, terminal alkynes were 
hydrophosphinated to afford vinyl phosphines (1-8) with high regioselectivity and E/Z 
selectivity.24  Similar selectivity was observed in the thermal hydrophosphination of vinyl ethers25 
(1-9) and 1,1-disubstituted alkenes.26 A thermal hydrophosphination of β-pinene afforded the 
limonene-derived product 1-10 through a ring opening, which suggests that these thermal 
transformations proceed through a radical mechanism.26  
4Figure 2. Thermal hydrophosphinations of secondary phosphine boranes. 
In 2009, Busacca and co-workers serendipitously discovered a base-mediated 
hydrophosphination of alkynes using secondary phosphine boranes. This unprecedented reaction 
was discovered while attempting to prepare ligand 1-14 through nucleophilic aromatic substitution 
of imidazoline 1-11 (Scheme 1). Further investigation revealed that the hydrophosphination is 
general for a range of substituted alkynes. Vinyl phosphine boranes such as 1-13 with are obtained 
in good yields and E:Z ratios ranging from 3:1 to >20:1.27  In cases where differentially substituted 
alkynes were used, complete regioselectivity was attained based on the electronic parameters of 
the alkyne substituents. This method offers advantages over Gaumont's thermal 
hydrophosphination in that it is effective on internal alkynes, proceeds at ambient temperature, and 
does not require a large excess of the alkyne. 
Scheme 1. Discovery of a base-mediated hydrophosphination of internal alkynes.
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5 
This operationally simple hydrophosphination method enables access to phosphines that 
are potentially useful for catalytic applications. The vinyl phosphines derived from alkyne 
hydrophosphination (1-15) were enantioselectively hydrogenated with cationic rhodium and (R, 
R)-Skewphos28 to afford chiral monodentate phosphine boranes with >99% ee.27 Alkyne 
derivatives such as propargyl amines, and propargyl alcohols, allenyl phosphine oxides also 
effectively undergo this hydrophosphination (1-16 and 1-17, Figure 3).29 These more highly 
functionalized hydrophosphination products can also serve as ligand precursors. For example, the 
allene hydrophosphination products (1-16) are protected equivalents of bis-phosphine 
monooxides, which are a useful class of ligands for catalysis.30 The products of propargyl amine 
or alcohol hydrophosphination are also precursors to P–N or P–O bidentate ligands. The bidentate 
binding mode of 1-17 (X = NHPh) was confirmed by preparing an 15N labeled substrate and 
evaluating the 15N and 31P coupling constants of Pt or Rh complexes.29 
Figure 3. Base-mediated hydrophosphinations with phosphine boranes.
Given the simplicity of this base-mediated hydrophosphination protocol, it became of 
interest to extend this method to the hydrophosphination of heterocumulenes such as 
carbodiimides. In an initial screening effort, Busacca and co-workers found that secondary 
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phosphine boranes do indeed hydrophosphinate carbodiimides to provide phosphaguanidine 
boranes 1-19 – 1-24 (Table 1). Carbodiimides with N,N’-dialkyl, N,N’-diaryl and N-alkyl, N’-aryl 
substituents undergo this transformation equally well (entry 1 vs. entry 3). Di-t-butyl and 
dicyclohexyl phosphine boranes were also similarly effective in the reaction. The products of the 
reaction were typically crystalline solids that were easily purified by chromatography on SiO2. X-
ray crystal structures of two representative phosphaguanidine boranes (1-21 and 1-23) were 
obtained (Figure 4).31  
Table 1. Preliminary results from Busacca et al. on the hydrophosphination of carbodiimides.
Figure 4. Phosphaguanidine boranes crystallized by Busacca et al. 
1-21
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Cy
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NHN
PhPh
Cy
P
Cy
H3B
NHN
PhCy
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1.1.3 Structure and Utility of Phosphaguanidines 
Guanidines have long been of interest to the chemistry community due to their structure, reactivity, 
and occurrence in biologically active natural products.32 The guanidine structure is well-
represented among common nucleophilic organocatalysts,33 and a significant number of chiral 
guanidines have been designed to accomplish various asymmetric catalytic transformations.34 
Phosphaguanidines, wherein one nitrogen from the guanidine unit is substituted for a phosphine, 
have received significantly less attention. These molecules are typically prepared by the 
hydrophosphination of carbodiimides with secondary phosphines.13a  
An extensive NMR, computational, and crystallographic study of phosphaguanidines was 
undertaken by Coles and co-workers.35 Their research demonstrated that phosphaguanidines have 
distinct conformational preferences that are governed by the nature of the P and N substituents. A 
nomenclature system was developed to define the eight possible conformations of a given 
phosphaguanidine that arise from three binary factors: E vs Z stereochemistry about the C=N bond, 
syn vs anti orientation of the N–R substituents and α vs  β alignment of the guanidine N–H with 
the P–R substituents (Figure 5). It was found that these orientations are dependent on the nature of 
the P–R substituent: P-diphenyl phosphines appear only in the Esyn α conformation, whereas P-
cyclohexylphosphines show a mixture of Esyn α and Zanti α/β  isomers. When the phosphines were 
transformed to the corresponding phosphine sulfides or selenides, a mixture of Esyn β and Zsyn 
β conformers were observed, with the former being preferred in P-diphenyl phosphines and the 
latter in P-dicyclohexyl phosphines. 
8 
Figure 5. Eight possible conformations of phosphaguanidines annotated with the observations of Coles et al.32
The Zsyn β conformation allows for an interaction between the guanidine N–H and the 
chalcogen atom in the phosphine sulfides and selenides. In the case of the phosphine selenide 1-
25, the interaction was evident through a JSeH NMR coupling of 6 Hz. A similar alignment between 
the N–H and the borane was observed in the crystal structures of phosphaguanidine boranes 1-21 
and 1-23, as illustrated in Figure 6. The distances between the phosphaguanidine N–H and 
boron/selenium atoms are comparable between the two structures (2.68 Å H–Se distance vs. 2.57 
Å H–B distance). 
Figure 6. Comparison between the conformations of phosphine borane 1-21 and phosphine selenide 1-25. 
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As part of their study, Coles and co-workers prepared the first example of a 
phosphaguanidine borane (1-27) by treating 1-26 with BH3•THF (Scheme 2).35 While this 
synthesis was successful in providing crystals of 1-27 suitable for X-ray diffraction, the yield of 
the transformation was low, and the product was reported to be unstable in solution. Interestingly, 
1-26 adopted an Esyn (pseudo) α conformation in the solid state, which stands in contrast to the 
Zsyn β  conformation observed in the phosphaguanidine boranes 1-21 and 1-23 prepared by Busacca 
and co-workers (Figure 4).  
P
PhPh
N NH
Cy
Cy
BH3•THF (1 eq)
THF, rt, 12 h
22%
P Ph
Ph
N NH
Cy
Cy
H3B
1-26 1-27  
Scheme 2: Phosphaguanidine borane 1-27 prepared by Coles et al.35 
Despite these studies on the preparation and structure of phosphaguanidines, no examples 
of their use in catalysis have been reported to date. This is somewhat surprising considering that 
phosphaguanidines have been shown to exhibit either mono- or bidentate binding modes to metals 
such as molybdenum.14b Upon deprotonation of the phosphaguanidine N–H, the resulting anion 
has exhibited a wide array of binding modes to lithium,14a aluminum,36 titanium,36 zirconium,36 
thallium,37 and rhodium.38 Similarly, there have been no reports on the application of 
phosphaguanidines or their borane-protected analogs as organocatalysts, where the nitrogen atoms 
could plausibly participate in nucleophilic33 or hydrogen bonding39 catalysis. The opportunity to 
identify new types of catalysts provided further motivation to develop a convenient method for the 
hydrophosphination of carbodiimides to produce phosphaguanidine boranes. 
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1.2 RESULTS AND DISCUSSION 
1.2.1 Hydrophosphination of Acyclic Carbodiimides 
Given the previous success with using deprotonated secondary phosphine boranes to conduct 
hydrophosphination reactions,27, 29 we sought to extend the scope of this method to include the 
hydrophosphination of carbodiimides. Preliminary studies by collaborators at Boehringer 
Ingelheim suggested that under the previously developed conditions (NaH in DMAc), 
hydrophosphination of alkyl and aryl carbodiimides could be conducted with aliphatic phosphine 
boranes (Table 1). However, it remained to be explored as to whether aromatic phosphine boranes 
or other carbodiimides would be tolerated in the transformation.  
Thus, a series of carbodiimides containing both electron-rich and electron-poor aryl 
substituents was prepared by desulfurization of the corresponding disubstituted thioureas.40 In 
cases where the necessary thioureas were not commercially available or obtained from 
collaborators, they were prepared by reacting the appropriate primary amine with an 
isothiocyanate. This approach provided convenient access to carbodiimides 1-28–1-31 (Table 2). 
Table 2. Preparation of carbodiimides through desulfurization of the corresponding thioureas. 
 
These carbodiimides, along with commercially available dicyclohexylcarbodiimide 
(DCC), were tested in the hydrophosphination reaction (Table 3).31 Both electron-rich and 
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electron-poor aryl carbodiimides were effective substrates (entries 1–3), although a diallyl 
carbodiimide gave a somewhat lower yield (entry 4). Aryl secondary phosphine boranes showed 
poor reactivity, regardless of the nature of the carbodiimide (entry 5). Commercially available N, 
N’-bistrimethylsilyl carbodiimide could not be hydrophosphinated with either cyclohexyl or t-
butyl phosphine boranes, perhaps due to the high steric encumbrance of this substrate (entry 6).  
Table 3. Hydrophosphination of carbodiimides. 
 
While the borane motif on products 1-32–1-35 prevents oxidation of the phosphaguanidine, 
it must ultimately be removed to enable ligation of the phosphine to a metal center. Heating a 
toluene solution of a phosphine borane with DABCO is an effective approach for the deboronation 
of aromatic phosphine boranes.31 Alternatively, removal of the borane can be conducted with HBF4 
to provide a tralkylphosphonium tetrafluoroborate salt. These phosphonium salts can be free-based 
in situ, and thus serve as convenient air-stable surrogates of alkyl phosphines for use in catalysis.41 
Phosphaguanidine 1-19 was subjected to this acid-mediated deboronation. These 
conditions, however, did not cleave the alkyl phosphaguanidine boranes, but rather protonated the 
guanidine functionality to afford phosphaguanidinium borane tetrafluoroborate salt 1-36 (Scheme 
4). In contrast to generic trialkylphosphines, the protonation of the guanidine apparently 
deactivates the phosphine borane and consequently prevents deboronation. The structure of 1-36, 
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which was confirmed by X-ray crystallography, features an unmodified borane and a 
phosphaguanidinium core with identical C–N bond lengths of 1.316 Å. The guanidinium 
substituents of 1-36 crystallized in an Esyn/Zanti conformation, much like a similar 
phosphaguanidinium salt that was previously crystallized by Mansfield et al.42 
 
Scheme 3. Attempted acidic deboronation with HBF4 results in tetrafluoroborate salt 1-36. 
The oxidation of the free phosphaguanidines to the phosphaguanidine oxides was also 
explored. Interestingly, Hitchcock and co-workers reported that phosphaguanidines undergo C–P 
bond cleavage when treated with t-BuOOH to afford an amidinium phosphinate salt.42 In 
agreement with this result, treatment of phosphine 1-37 with t-BuOOH using Hitchcock’s 
procedure resulted in a complex mixture that likely contains an analogous species (Table 4). A 
cleaner oxidation occurred when m-CPBA was used as the oxidant, and the desired phosphine 
oxide 1-38 was isolated in 33% yield after chromatography on SiO2. Dilute aqueous hydrogen 
peroxide, however, provided phosphine oxide 1-38 in nearly quantitative yield. This series of 
experiments suggests that despite their relative paucity in the literature,43 phosphaguanidine oxides 
are stable entities that can be prepared through the oxidation of phosphaguanidines with the 
appropriate oxidizing agent. 
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Table 4. Oxidation of phosphaguanidine 1-37. 
1.2.2 Preparation and Hydrophosphination of a Cyclic Carbodiimide 
While this base-mediated hydrophosphination of acyclic carbodiimides is operationally 
convenient, the method has limitations. Aryl phosphine boranes showed poor reactivity, which 
significantly limits the scope of the phosphaguanidines that can be obtained. In addition, 
the products have a congested steric environment around the phosphorous center that 
disfavors the binding of metals and reduces the ability of the guanidine motif to act as an 
organocatalyst. Attempts to use the deprotected phosphaguanidines in Cu-catalyzed 
conjugate additions, Rh-catalyzed hydrogenation, and organocatalytic transformations were 
unsuccessful. These results may suggest that the phosphine center of these molecules is poorly 
accessible for metal binding. Further complicating this structural issue is the fact that some 
phosphaguanidine products are a mixture of E/Z isomers in solution (for example, 
tetracyclohexyl product 1-19 is a 2:1 mixture of Zsyn/Esyn isomers as judged by 13C NMR).31 
This isomerism suboptimal for the design of phosphaguanidine ligands for use in 
stereoselective catalysis.  
To produce phosphaguanidines with a greater potential for catalytic applications, analogs 
with a well-defined rigid structure and a more accessible phosphorus center were pursued. The 
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most intriguing approach toward this end is to constrain the nitrogen substituents in a Zsyn 
conformation by embedding them in a medium-sized ring. Efficient access to such a scaffold could 
be achieved through the hydrophosphination of a cyclic carbodiimide. Although seven-membered 
or smaller cyclic carbodiimides are unprecedented, eight-membered carbodiimides have been 
prepared from cyclic thioureas or amidooximes.44 These cyclic molecules are useful tools for 
experimental studies of the nitrogen inversion barrier in carbodiimides.45 
 Molina and co-workers have reported an efficient preparation of cyclic carbodiimide 1-41 
from commercially available 2,2’-ethylenedianiline 1-39 (Scheme 4).46 A diazotization/azidation 
sequence, formation of a bis-iminophosphorane, and double Staudinger-aza-Wittig ring closure 
with CO2 provided an efficient access to the cyclic carbodiimide 1-41. Although the originally 
reported preparation used stoichiometric DMAP and Boc2O to form a CO2 equivalent in situ,47 
bubbling CO2 gas through the solution with a balloon was found to be a more convenient and 
equally effective means to conduct this ring closure. The three-step sequence is operationally 
straightforward, uses inexpensive reagents, and requires only one chromatographic purification.  
 
Scheme 4. Preparation of cyclic carbodiimide 1-41. 
 The nine-membered cyclic carbodiimide 1-41 is a strain-activated molecule. Although this 
ring strain has not been experimentally quantified, the strained nature of 1-41 and related 
derivatives has been verified spectroscopically.46, 48 For example, the abnormally high 
carbodiimide IR stretch of 1-41 (2186 cm-1, as compared to the typical range of 2120-2145 cm-1) 
is suggestive of a strain-induced weakening of the carbodiimide C=N bonds. This strain activation 
may render 1-41 more reactive than DCC and other acyclic carbodiimides in hydrophosphination 
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chemistry. Nonetheless, carbodiimide 1-41 is a bench-stable solid that showed no detectable 
decomposition after several months of storage at room temperature under air. 
 The hydrophosphination of carbodiimide 1-41 was conducted with a variety of phosphine 
boranes (Table 5). In contrast to acyclic carbodiimides, consistent yields were obtained for both 
aliphatic (entries 1, 2) and aromatic (entries 3, 4) secondary phosphine boranes using the standard 
hydrophosphination conditions. A mixed phenylcyclohexyl phosphine borane also performed well 
(entry 5). This improved reaction scope may be attributed to the enhanced reactivity of 
carbodiimide 1-41, which benefits from strain-activated C=N bonds and high accessibility of the 
central sp-hybridized carbon. The products resulting from hydrophosphination of 1-41 (1-42–1-
46) constitute the first examples of a phosphaguanidines that are embedded in a medium ring 
system. 
Table 5. Hydrophosphinations on cyclic carbodiimide 1-41. 
 
The cyclic phosphaguanidines were typically colorless, crystalline solids that could be 
purified by chromatography on SiO2 or by recrystallization. Single crystal X-ray diffraction was 
conducted on suitable crystals of phosphaguanidines 1-42 and 1-44. Interestingly, in both cases, 
the nine-membered ring adopts a compact boat-like conformation (Figure 7). This produces a tight 
dihedral angle (17–24°) for the H-C-C-H bonds of the ethylene bridge. Consequently, the aromatic 
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rings of the guanidine sit nearly aligned, with an average inter-ring distance of about 4 Å. Although 
the shortest inter-ring distances (2.8 Å) are comparable to those of [2,2]-p-cyclophanes (2.7–3.2 
Å) and graphite (3.4 Å), the rings angle outward to give much longer maximal inter-ring distances 
(5.2–5.3 Å) (Table 6).49  
Figure 7. Crystal structures for compounds 1-42 and 1-44.  
Table 6. Pertinent data from the crystal structures of 1-42 and 1-44. 
In addition, 1-42 and 1-44 were found to have an α (eclipsed) orientation between the N–
H and BH3 in the solid state. This phenomenon was also observed in the acyclic phosphaguanidines 
1-21 and 1-23 that were crystallized by Busacca and co-workers (Figure 6). Modeling studies of 
t-butyl phosphine borane 1-42 at the HF/6-311+G** level of theory revealed that the
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α (Ν−Η eclipsed) orientation is preferred over the β orientation by 10 kcal/mol, although the exact 
origin of this preference is not known. 
Deprotection of the aromatic cyclic phosphaguanidine boranes using DABCO in toluene 
proceeded smoothly to provide phosphines 1-47 and 1-48 (Table 7). The mixed aromatic/aliphatic 
phosphaguanidine borane 1-46 also successfully underwent deprotection to afford racemic 
phosphine 1-49. The free phosphines 1-47 and 1-48 were oxidized using dilute hydrogen peroxide 
to provide phosphine oxides 1-50 and 1-51 in high yield with no evidence of phosphaguanidine 
cleavage (Table 8). 
Table 7. Deprotection of cyclic phosphaguanidine boranes. 
Table 8. Oxidation of cyclic phosphaguanidines. 
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1.2.3 Hydrophosphination with Phospholane Boranes and Attempted Catalytic 
Applications 
The use of strained cyclic carbodiimide 1-41 as a hydrophosphination substrate enabled the 
preparation of both aromatic and aliphatic phosphaguanidine boranes in good yield (Table 5). As 
evidenced by crystallography studies on cyclic phosphaguanidine boranes 1-42 and 1-44 
(Figure 7), these products adopt predictable, well-defined geometries that can enable the rational 
design of ligands and organocatalysts. Moreover, the ability to readily remove the borane and 
expose the free phosphines 1-47–1-49 (which can be manipulated on the benchtop using standard 
precautions) also bodes well for the application of the molecules as phosphine ligands in catalytic 
applications. 
Ideally, chirality could be introduced into cyclic phosphaguanidine scaffold to provide 
access to molecules that can catalyze enantioselective transformations. Attempts were made to 
produce a chiral derivative of cyclic carbodiimide 1-41 by installing a cyclic acetal on the ethylene 
backbone, but these efforts were unsuccessful. Alternatively, chirality can be introduced by 
conducting the hydrophosphinations with a chiral secondary phosphine borane. If the chiral 
secondary phosphine borane was also cyclic in nature, this approach could provide a 
phosphaguanidine core with a highly accessible phosphine center. 
Five-membered phospholane boranes have the greatest precedent among cyclic secondary 
phosphine boranes, and were the primary targets of this study. Phospholane borane 1-54 was 
prepared from 1,4-dibromobutane 1-52 through double Grignard formation, trapping with a 
dichlorophosphine, formation of a tertiary phosphine borane, and reduction with lithium metal 
(Scheme 5).50 This preparation was low yielding, but the inexpensive reagents allowed the 
reactions to be sufficiently scaled to provide >200 mg of 1-54. 
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Scheme 5. Preparation of phospholane borane 1-54. 
Chiral C2 symmetric phospholanes have been prepared by introducing phenyl substituents 
at the 2- and 5-positions of the phospholane ring. These chiral phospholanes are the basis of the 
BPE ligand class, which are useful for asymmetric hydrogenation and other transformations.51 
Several methods to prepare these phospholanes have been reported; however, the method 
previously used by Busacca proved to be the most effective.27 The phospholane scaffold was 
accessed from diene 1-55 by using a McCormack [4+1] cyclization.52 Subsequent hydrogenation 
and epimerization/hydrolysis afforded phosphinic acid 1-57, which was subjected to a classical 
resolution with quinine. Reduction with phenylsilane and borane complexation then afforded each 
enantiomer of phospholane borane 1-58 (Scheme 6). 
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Scheme 6. Preparation of chiral phospholane borane 1-58. 
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The phospholanes 1-54 and 1-58 were used in hydrophosphination reactions with cyclic 
carbodiimide 1-41 (Table 9). While unsubstituted phospholane borane 1-54 was less effective in 
the transformation, each of the 1-58 enantiomers underwent hydrophosphination in moderate to 
good yield to afford chiral phospholane borane 1-60. It was found that the sign of the specific 
rotation for 1-60 is opposite of that of the corresponding secondary phosphine borane precursor 
(1-58). 
Table 9. Hydrophosphination of cyclic carbodiimide 1-41 with phospholane boranes. 
 
Like the other phosphaguanidines, 1-60 can be deprotected by heating in the presence of 
excess DABCO (Scheme 7). The resulting phosphine 1-61 is sufficiently air-stable to be briefly 
manipulated in air, but the material was placed under an inert atmosphere for storage. The potential 
of this phosphine to bind to transition metals was evaluated by forming a complex with platinum 
(II) chloride. When a solution of 1-61 in CH2Cl2 was treated with 0.5 equivalents of PtCl2 and left 
undisturbed, the trans-PtCl2(phosphine)2 complex 1-62 formed as light yellow prisms. The 
structure of this complex was confirmed by X-ray crystallography (Figure 8). The observed Pt–P 
bond length (2.305 Å) and JPtP coupling constant (2352 Hz) of 1-62  is consistent with similar 
PtCl2 complexes with sterically bulky phosphines.53 
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Scheme 7. Deprotection and platinum complex formation with chiral phosphine borane 1-61. 
 
Figure 8. X-ray crystal structure of platinum complex 1-62. Hydrogens are omitted for clarity. 
Despite the success in forming complex 1-62, the application of 1-61 in asymmetric 
catalysis did not yield successful results. For example, enantioselective borylation54 or Heck 
reactions55 were 1-61 was used as a ligand either showed poor conversion or gave extensive 
decomposition of the substrate. Rhodium-catalyzed hydrogenation was successfully carried out 
using 1-61; however, the hydrogenated product had no detectable enantiomeric excess.  
Attempts to use the either the free phosphaguanidines or their borane complexes as 
guanidine-type hydrogen bonding catalysts were similarly unsuccessful. The addition of 
diphenylphosphite to nitrostyrene (1-63), for example, is reported to proceed in excellent yield and 
enantioselectivity using a chiral, bicyclic guanidine catalyst (Table 10).56 However, 20 mol% of 
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achiral phosphine borane 1-59 was required to get similarly high yields in this transformation. 
Disappointingly, when the same catalyst loading of the chiral derivative 1-60 was used, a much 
lower yield was obtained. This is possibly due to the steric encumbrance of the phosphaguanidine 
motif imparted by the phenyl rings on the phospholane. In general, the poor catalytic activity of 
these molecules suggests that alternative phosphaguanidine architectures will need to be 
considered for the preparation of phosphaguanidines with high utility in catalysis. 
Table 10. Attempted hydrogen bonding catalysis with phosphaguanidine boranes. 
 
1.3 CONCLUSIONS 
A method for the hydrophosphination of carbodiimides using air-stable secondary phosphine 
boranes was developed. Various aromatic and aliphatic substituents were tolerated on the 
carbodiimide substrate in the transformation. However, aryl phosphine boranes were less effective 
than alkyl phosphine boranes. An acidic deboronation protocol was attempted on the alkyl 
phosphaguanidine products, but protonation of the guanidine occurred and phosphaguanidinium 
borane salts were isolated. The free phosphines could, however, be oxidized to phosphine oxides 
in good yield without cleavage of the C–P bond. 
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A cyclic carbodiimide was prepared, which underwent a facile hydrophosphination with a 
wider scope of phosphine boranes. Thus, a series of nine-membered cyclic phosphaguanidines 
were prepared, which were found to have interesting boat-like structures that were elucidated by 
X-ray crystallography. Chiral derivatives of the cyclic phosphaguanidines were prepared through 
hydrophosphination with chiral, cyclic phospholane boranes. The chiral phospholane borane was 
deprotected, and a crystalline platinum (II) complex was prepared with this material. 
Unfortunately, attempts to use this chiral phosphaguanidine either as a ligand in asymmetric 
catalysis or as an organocatalyst were not fruitful. 
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2.0  NUCLEOPHILIC ADDITIONS TO BICYCLO[1.1.0]BUTYL NITRILES 
2.1 INTRODUCTION 
2.1.1 Bicyclo[1.1.0]butanes: Structure and Reactivity 
The concept of molecular strain has a storied history that dates back to the proclamations of Adolf 
von Baeyer in the late ninetieth century.57 Indeed, strain activation underlies many aspects of 
modern synthetic chemistry, such as strategic design in total synthesis,58 strain-enabled reaction 
methods,59 and bioorthogonal tranformations.60 Numerous strained molecules containing three- 
and four-membered rings have been designed and applied in target-oriented synthesis.61 
Among these strained rings, bicyclo[1.1.0]butanes are distinguished by their high strain 
energy (64 kcal/mol) and unique structural properties.57 Though they are quite strained, many 
derivatives are readily prepared and are bench-stable. The first synthesis of an authentic 
bicyclo[1.1.0]butane derivative was published by Wiberg in 1959, who prepared methyl 
bicyclo[1.1.0]butanoate by ring contraction of 3-bromocyclobutane methyl ester.62 The parent 
bicyclo[1.1.0]butane hydrocarbon, which is a gas at room temperature (boiling point 8 °C), can be 
synthesized in a similar fashion through intramolecular Wurtz coupling of 1,3-
dihalocyclobutanes.63 More versatile synthetic methods to access functionalized 
bicyclo[1.1.0]butanes have since been developed, including those based on Simmons-Smith 
chemistry,64 intramolecular carbenoid cyclizations,65 or ring closures of appropriately substituted 
cyclopropanes.66 
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Studies of the structure and bonding in bicyclo[1.1.0]butanes have elucidated several 
unique features of these molecules. For example, bicyclo[1.1.0]butanes adopt a “butterfly” like 
geometry, with an interflap angle of about 123° (Figure 9). The C–C bond distances of both the 
lateral and central bonds are 1.507 Å, which is slightly shorter than those of typical cyclopropanes 
(1.512 Å).67 The C–H bonds range in length from 1.142 Å (methine) to 1.194 Å (exo methylene). 
 
Figure 9. Key structural parameters of bicyclo[1.1.0]butanes.67a 
Although the C–C bonds of bicyclo[1.1.0]butanes are equal in length, the central bond is 
distinguished from the lateral bonds by its substantial π character.68 Experimental verification of 
this character was reported by Moore and co-workers, who found that bicyclo[1.1.0]butane dimer 
2-1 has a substantial UV absorption at 195 nm that is characteristic of a conjugated π system 
(Figure 10).69 The nature of this central bond imparts a high s character to the methine C–H bonds, 
which is manifested by an unusually large 13C–H coupling constant (202 Hz) that is intermediate 
between ethylene (156 Hz) and acetylene (249 Hz).62b  
Much like cyclopropanes,70 the central bond of bicyclo[1.1.0]butanes can impact the 
reactivity of adjacent carbinols through hyperconjugative stabilization. In fact, the hydrolysis of 
bicyclo[1.1.0]butane ester 2-3 was found to be 3 orders of magnitude faster than the corresponding 
cyclopropane ester 2-2 (Figure 10).62b In contrast to cyclopropane 2-2, which formed the expected 
cyclopropylmethanol upon hydrolysis, bicyclobutane 2-3 reacted preferentially at the central bond 
to produce cyclobutanols. 
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Figure 10. Experimental verifications of the unusual π character of the central bond of bicyclo[1.1.0]butanes. 
 Despite the very interesting structure and reactivity of bicyclo[1.1.0]butanes, their 
application in preparative organic synthesis has been limited. Most synthetic studies of these 
strained hydrocarbons have focused on their solvolysis and transition-metal mediated 
isomerizations to dienes and related structures, which was a popular research focus in the 1970’s 
and early 1980’s.71 Various metals were studied in this context, including palladium, nickel, 
rhodium, silver, and platinum.72  
More recently, Walczak and Wipf have demonstrated the value of bicyclo[1.1.0]butanes as 
precursors of structurally novel heterocycles (Scheme 8).73 For example, an intramolecular Rh-
mediated isomerization of alkene-tethered bicyclo[1.1.0]butanes (2-4) can selectively provide 
pyrrolidine 2-5 or azepine 2-6 in good yield, depending on the ligand and rhodium source 
employed.74 When phenyl-substituted bicyclo[1.1.0]butyl phosphinamides are alkylated with allyl 
and propargyl electrophiles using phase-transfer catalysis, the intermediate alkylated products 
spontaneously rearrange to spirocyclic cyclobutenes such as 2-7 through an Alder-ene reaction. In 
contrast, the use of cinnamyl bromide derivatives enables the synthesis of pyrrrolidines such as 2-
8 through a formal [2+2] reaction pathway.75 Studies of these thermal transformations using 
electron spin resonance spectroscopy suggest that they occur through biradical intermediates.76 
The unique heterocycles that can be obtained from bicyclo[1.1.0]butanes have been applied in 
medicinal chemistry studies77 and in a synthetic approach toward the daphniglaucin family of 
polycyclic alkaloids.78 
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Scheme 8. Intramolecular transformations of bicyclo[1.1.0]butanes developed by Walczak and Wipf.74-75 
aThe thermal rearrangements were conducted through phase-transfer allylations of the bicyclobutyl phosphinamides 
with the appropriate allyl bromide. The intermediate allylated materials (i.e., 2-4) underwent rearrangement in situ at 
rt. 
2.1.2 Nucleophilic Additions to Bicyclo[1.1.0]butanes 
Both the highly-strained nature of the bicyclo[1.1.0]butane scaffold and the substantial π character 
of its central bond enable ring-opening transformations to provide cyclobutanes. In fact, the ability 
of bicyclo[1.1.0]butanes to undergo facile hydrolysis to cyclobutanol derivatives was recognized 
soon after the initial discovery of these carbocycles.62b, 79 Bicyclo[1.1.0]butanes have been 
converted into functionalized cyclobutanes through acidic solovolysis,80 electrophilic 
halogenation,81 and photochemical irradiation.82 These reactions provide an intriguing alternative 
to [2+2] cyclizations for the selective synthesis of 1,3-difunctionalized cyclobutane derivatives. 
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 The importance of these studies notwithstanding, the addition of carbon-based 
nucleophiles through an anionic pathway provides a more versatile and synthetically useful 
method for the synthesis of cyclobutanes from bicyclo[1.1.0]butanes. The high π character of the 
strained central bond enables bicyclo[1.1.0]butanes to be functional equivalents of Michael 
acceptors, especially when substituted with an electron withdrawing group at the ring junction. 
Gaoni and co-workers were the first to study this mode of reactivity by investigating the addition 
of organocuprates to sulfones such as 2-9 (Scheme 9).83 These additions were found to be quite 
facile, but the cyclobutane products such as 2-10 were typically formed as inseparable mixtures of 
cis/trans-diastereomers.84 However, the researchers later designed a series of constrained 
polycyclic bicyclo[1.1.0]butane derivatives that underwent diastereoselective organocuprate 
additions.83b, 83c This synthetic method was also applied to the total synthesis of citrilol acetate, a 
cyclobutane-containing monoterpene natural product.83b  
 
Scheme 9. Nucleophilic addition to bicyclo[1.1.0]butane sulfones developed by Gaoni et al. 
Fox and co-workers have developed a tandem approach to functionalized cyclobutanes 
through an enantioselective bicyclo[1.1.0]butane formation and nucleophilic addition sequence.65a 
Upon treatment of diazo ester 2-11 with a chiral rhodium carboxylate complex, 
bicyclo[1.1.0]butane ester 2-12 is formed with good enantioselectivity (typically >90% ee, Scheme 
10). The ester can be either isolated or subjected to an in situ nucleophilic attack by an 
organocuprate. Unfortunately, the nucleophilic addition proceeds with negligible 
diastereoselectivity. An epimerization method was therefore developed whereby 2-13 can be 
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deprotonated and treated with a bulky proton source (BHT) to provide the desired cyclobutanes 
with >20:1 diastereoselectivity. 
 
Scheme 10. Enantioselective bicyclo[1.1.0]butane synthesis/nucleophilic addition sequence. 
Until recently, the nucleophilic addition of heteroatomic nucleophiles to 
bicyclo[1.1.0]butanes was typically limited to solvolysis-type reactions.80 However, Baran and co-
workers realized the potential of bicyclo[1.1.0]butyl sulfones (along with related strained 
molecules such as aza-bicyclo[1.1.0]butane and [1.1.1]propellane) to enable the late-stage 
derivation of biologically relevant amines, which is a synthetic paradigm they dubbed “strain-
release amination” (Scheme 11).85 Upon heating a secondary amine with sulfone 2-14, for 
example, an excellent yield of aminocyclobutane 2-15 was obtained. Various sulfones were 
screened in this transformation, and it was found that electron-deficient sulfones such as the 
difluorophenyl derivative 2-14 are necessary to promote efficient nucleophilic attack of the amine. 
This addition lacked diastereoselectivity. However, this was inconsequential as the sulfonyl group 
was typically removed under reductive conditions to provide the cyclobutyl amine (2-16). This 
method was successfully used for many amine substrates, as well as for the selective 
cyclobutylation of cysteine residues of peptides. 
 
Scheme 11. “Strain-release amination” protocol developed by Baran et al. 
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2.1.3 Cyclobutyl Phosphines: Synthesis and Utility 
Phosphines have played an indispensable role in the development of organometallic chemistry and 
asymmetric catalysis. Many of the most frequently employed phosphines are bidentate derivatives 
that are supported by a chiral backbone, such as BINAP.86 The ability of chiral, monodentate 
phosphines to effectively moderate catalytic transformations has more recently come to be 
appreciated.87 Perhaps the most widely employed of the monodentate phosphines are the Buchwald 
biaryl ligands. Extensive structural analyses of this ligand class have revealed that steric bulk at 
phosphorus, often provided through cyclohexyl phosphine substituents, is essential for their 
effective performance in Suzuki-Miyaura cross-couplings.88 Therefore, the design of novel 
phosphines with bulky, cyclic substituents may give rise to ligands that are useful for transition-
metal mediated transformations.  
A cyclobutane is an intriguing substituent to consider for the development of phosphine 
ligands. Aside from providing some degree of steric bulk, the cyclobutane architecture allows for 
the introduction of substituents adjacent to the phosphine center with a well-defined spatial 
relationship. One of the few phosphine derivatives that is based on this architecture is 
tetraphosphine 2-17, which was prepared through photochemical [2+2] dimerization of an alkenyl 
diphosphine.89 Treatment of 2-17 with (cylcooctadiene)palladium (II) chloride affords a mixture 
of complexes 2-18 and 2-19, both of which were studied by X-ray crystallography (Scheme 12). 
Although the catalytic applications of these tetraphosphines have been limited to CO-ethylene 
copolymerization reactions, these studies illustrate the potential of cyclobutanes to be effective 
scaffolds on which to design phosphines with specific structural parameters. Modulating the bite 
angle of bidentate ligands is known to have a major effect on their performance in catalysis,90 thus, 
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bidentate ligands derived from this underexplored cyclobutane scaffold may find unique catalytic 
applications in organic synthesis. 
Scheme 12. Cyclobutyl tetraphosphines as ligands in palladium complexes. 
 Aside from this example, few other cyclobutyl phosphines have been prepared to date, 
and many of them are highly unusual structures that lack functional handles for further 
diversification. For example, phosphine oxide 2-2091 and phosphine 2-2192 have been prepared 
from pre-formed phosphinane or carbohydrate scaffolds, respectively (Figure 11). 
Functionalization of cubane and [1.1.1]-propellane has been exploited to produce 
phosphines 2-22,93 2-23,94 and 2-24.95 Intramolecular cyclization of phosphine borane 
2-25 has recently been used to prepare cyclobutylphosphine borane 2-26, but this 
approach is not amenable to the synthesis of functionalized cyclobutyl phosphines 
(Scheme 13).96 To the best of our knowledge, none of these phosphines based on the cyclobutane 
architecture have been applied in catalysis.  
Figure 11. Examples of cyclobutylphosphines. 
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Scheme 13. Preparation of cyclobutyl phosphine borane 2-26 through intramolecular cyclization. 
As these examples illustrate, a general method to produce functionalized 
cyclobutylphosphines is lacking, as are studies on their utility in catalytic transformations. This 
prompted the development of a hydrophosphination reaction of bicyclo[1.1.0]butanes with 
secondary phosphine boranes to produce cyclobutylphosphines. Unlike existing methods, the 
preparation of cyclobutylphosphines through a hydrophosphination approach would allow for a 
modular synthesis and would provide products with functional handles for further diversification. 
Although hydrophosphination with secondary phosphine boranes has been successfully conducted 
on carbodiimides31 and alkynes,27 extension of the method to include strained carbocycles would 
provide access to novel phosphines that are rich in sp3 carbons. Moreover, while the addition of 
carbon and nitrogen nucleophiles to bicyclo[1.1.0]butanes have been demonstrated (Section 2.1.2), 
the development of a method to add phosphorus nucleophiles would further expand the synthetic 
utility of these strained rings. 
2.2 RESULTS AND DISCUSSION 
2.2.1 Hydrophosphination of Bicyclo[1.1.0]butyl Nitriles 
Studies on the hydrophosphination of strained rings commenced with a screening of potential 
reaction substrates. It was initially anticipated that the relief of ring strain would be a driving force 
to enable the synthesis of a wide variety of phosphine derivatives through hydrophosphination. 
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Unfortunately, this was not the case. As shown in Figure 12, bicyclo[1.1.0]butyl alcohols (2-27, 
2-28), methylenecyclopropanes (2-29), cyclopropenes (2-30), bicyclic ethers (2-31), and activated
cyclobutanes (2-32) were all inert to the standard hydrophosphination conditions. 
Figure 12. Initial screening studies for the hydrophosphination of strained rings. 
In contrast, bicyclo[1.1.0]butanes substituted with an electron withdrawing group at the 
ring junction (2-33, 2-34) reacted to afford a complex mixture of products. This result suggests 
that the “hydrophosphination” reaction is, to some degree, a Michael addition of a deprotonated 
phosphine borane nucleophile onto the electron deficient central bond of the bicyclo[1.1.0]butane. 
As previously noted (Section 2.1.1), the central bond of this strained ring has substantial π 
character that presumably facilitates such an addition. This finding is also consistent with  previous 
studies of nucleophilic addition to the central bond of bicyclo[1.1.0]butanes, where sulfone83, 85 or 
ester65a substituents were found to be necessary for effective cyclobutane formation (Section 
2.1.2).  
Based on this hypothesis, a nitrile was selected as the optimal activating group to promote 
the hydrophosphination. Unlike aldehydes (2-33) or primary amides (2-34), nitriles are not 
affected by deprotonated secondary phosphine boranes. The bicyclo[1.1.0]butyl nitrile of choice 
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for these studies was 2-37, which can be efficiently accessed in two steps from commercially 
available methylenecyclobutane 2-35 (Scheme 14).80 Using this protocol, 2-35 was subjected to 
HBr addition to afford 2-36 as a mixture of diastereomers. Treatment of 2-36 with NaH in THF at 
reflux affords bicyclobutane 2-37 as a liquid that can be purified by bulb-to-bulb distillation. In 
this manner, nitrile 2-37 was prepared on decagram scale. Differential scanning calorimetry studies 
of 2-37 showed that this strained molecule is a moderate explosion hazard upon heating, with a 
decomposition energy of 1600 J/g at an onset temperature of ~100 °C. Nitrile 2-37 was therefore 
stored in a –20 °C freezer and handled with appropriate personal protective equipment. 
 
Scheme 14. Synthesis of bicyclo[1.1.0]butyl nitrile 2-37. 
When 2-37 was subjected to the previously developed hydrophosphination conditions with 
dicyclohexylphosphine borane, a ~2:1 mixture of cyclobutane diastereomers cis-2-38 and trans-
2-38 was obtained upon workup (Scheme 15).97 Notably, and in contrast to previous 
bicyclo[1.1.0]butane nucleophilic addition studies, these two phosphine borane diastereomers had 
significantly distinct Rf values on SiO2 and could be readily separated by chromatography.  
 
Scheme 15. Hydrophosphination of nitrile 2-37 with dicyclohexylphosphine borane. 
The identity of the major cis-diastereomer was assigned by NOESY (Figure 13). The 
characteristic correlation between the methyl doublet at 1.52 ppm (3JHP = 9.2 Hz) and the methine 
at 3.39 ppm, along with the correlation of both peaks to a single methylene at 2.05 ppm, provides 
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strong spectroscopic evidence for this assignment of relative stereochemistry. This assignment was 
later confirmed by obtaining an X-ray crystal structure of a cis-cyclobutane derivative (Section 
2.2.3). 
Figure 13. NOESY spectrum of cis-2-38. 
An isomerization study was conducted to investigate the nature of the diastereoselectivity 
in the transformation. When either pure diastereomer of 2-38 was subjected to the reaction 
conditions (1.2 eq NaH in DMAc), HPLC analysis of a quenched aliquot showed formation of the 
original 2:1 mixture of isomers (Scheme 16). This suggests that the diastereoselectivity is 
thermodynamic in origin. Therefore, a higher yield of the cis-isomer (which is potentially more 
valuable for the preparation of bidentate phosphine ligands) can be achieved by iterative 
“recycling” of the minor trans-isomer through isomerization and purification by chromatography 
on SiO2. 
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Scheme 16. Isomerization studies of 2-38. 
The hydrophosphination of nitrile 2-37 was conducted with various phosphine boranes 
(Table 11). A variety of aliphatic and aromatic phosphine boranes were effective in the 
transformation, each giving a ~2:1 mixture of readily separable diastereomers. A generally 
consistent yield was obtained for all the substrates except for furyl derivative 2-41. In each case, 
the identity of the major cis-isomer was confirmed by NOESY and by the similarity of the 1H 
NMR shifts to other analogs.  
 
Table 11. Hydrophosphinations of nitrile 2-37. 
 
A chiral cyclobutylphosphine borane was also prepared using this method. Secondary 
phosphine borane 2-46 (which was prepared by collaborators at Boehringer Ingelheim over several 
steps from naproxen) was used to prepare cyclobutane 2-47 in the typical ~2:1 ratio of readily 
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separable diastereomers (Scheme 17). The hydrophosphination was also attempted with chiral 
phospholane borane 1-58. However, unlike in the previous carbodiimide studies, the phospholane 
underwent epimerization under the reaction conditions to afford a mixture of 4 products (cis-and 
trans-cyclobutane isomers, each with a pair of C2-symmetric or meso phospholanes). 
 
Scheme 17. Preparation of chiral phosphine borane 2-47. 
2.2.2 Preparation and Hydrophosphination of other Bicyclo[1.1.0]butane Nitriles 
Nitrile 2-37 was suitably reactive in hydrophosphination reactions, convenient to prepare, and 
stable upon storage. Despite these advantages, the exclusive use of 2-37 as the hydrophosphination 
substrate only provides access to phosphines with a methyl substituent on the cyclobutane. Access 
to bicyclo[1.1.0]butyl nitriles with other substituents at the ring junction would enable the 
preparation of a wider range of cyclobutyl phosphines. However, published methods for the 
synthesis of bicyclo[1.1.0]butyl nitriles require multiple steps and lack generality.98  
A more versatile approach to bicyclo[1.1.0]butane nitriles was envisioned to proceed 
through the direct installation of a nitrile onto a bicyclo[1.1.0]butane scaffold rather than a ring 
contraction of a cyclobutylnitrile. In practice, this could be accomplished by trapping a 
bicyclo[1.1.0]butyllithium species with an electrophilic “CN+” source rather than an imine or 
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aldehyde (the method commonly used for the synthesis of bicyclo[1.1.0]butyl amines and alcohols 
by Wipf and co-workers).73a Coincidentally, our collaborators at Boehringer Ingelheim had 
recently developed a convenient method that could enable such a transformation. As part of a 
research effort to develop new methods for the process-scale preparation of aryl nitriles, it was 
found that dimethylmalononitrile is a safe and inexpensive reagent for the electrophilic cyanation 
of aryl lithiums and Grignard reagents.99 The cyanation reaction is proposed to proceed through 
the addition of an organometallic reagent to this dinitrile reagent followed by a retro-Thorpe 
collapse of the anionic intermediate to afford the desired aryl nitrile.  
When dibromocyclopropane 2-48 was subjected to the previously reported dilithiation 
sequence,66a, 73b the resulting anion 2-49 underwent this “transnitrilation” to afford nitrile 2-50 
(Scheme 18). The analogous bicyclo[1.1.0] butyllithium species 2-52 also underwent this 
transformation to provide nitrile 2-53, albeit in a low yield of 18%. This poor yield may be 
attributed to the lack of an aryl substituent to provide conjugative stabilization of the central 
bicyclo[1.1.0]butane bond. Nonetheless, this approach provided efficient access to these 
alternative bicyclo[1.1.0]butane nitriles for hydrophosphination studies. 
 
Scheme 18. Preparation of bicyclobutane nitriles 2-50 and 2-53. 
The hydrophosphination of nitriles 2-50 and 2-53 was conducted with dicyclohexyl and di-
p-tolyl phosphine boranes using the established protocol.97 Hydrophosphinations of 2-50 afforded 
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a nearly 1:1 mixture of diastereomers that were readily separable on SiO2 (Table 12). In contrast, 
hydrophosphinations of unsubstituted nitrile 2-53 afforded only the cis-cyclobutane products, 
albeit in modest yield (Table 13). These lower yields may be a consequence of the somewhat 
unstable nature of 2-53, which showed significant decomposition and polymerization after several 
days at –20 °C. 
Table 12. Hydrophosphination of bicyclobutane nitrile 2-50. 
 
Table 13. Hydrophosphination of bicyclobutane nitrile 2-53.  
 
These studies suggest that the ratio of cis/trans-isomers obtained through this 
hydrophosphination is heavily influenced by the substituent at the bicyclo[1.1.0]butane ring 
junction. This can be rationalized in light of the extensive studies on the stereochemical course of 
nucleophilic additions to bicyclo[1.1.0]butanes conducted by Hoz and co-workers.100   Both 
theoretical and experimental evidence suggests that upon equatorial attack by a nucleophile, the 
incipient nitrile anion will adopt the thermodynamically less favored tetrahedral conformation 
wherein the nitrile is trans to the nucleophile.100b The anion will equilibrate between two 
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diastereomeric species prior to workup, presumably through the intermediacy of a planar 
keteneimine tautomer.100a The isomerization study shown in Scheme 16 demonstrates that the 
thermodynamically favored cis- isomer, wherein both substituents sit in equatorial positions, is 
preferentially formed under thermodynamic equilibration (Figure 14). As the A-value of the R2 
substituent increases from 1.7 (methyl) to 3 (phenyl), the thermodynamic differentiation between 
the two anionic forms is less pronounced. Thus, a mixture of diastereomers is obtained upon 
aqueous workup of the reaction. 
 
Figure 14. Explanation for the diastereoselectivity observed in the hydrophosphination of bicyclo[1.1.0]butyl 
nitriles. 
2.2.3 Utility of Cyclobutylphosphine Products 
An advantage of using nitriles as hydrophosphination substrates is the potential to diversify the 
cyclobutyl phosphine products. This strategy can be leveraged to enable the synthesis of an array 
of diversified phosphines. Attempts were made to enact this strategy by converting the 
cyclobutylnitrile to an imidazoline through a Pinner reaction. This would provide access to 
cyclobutyl analogs of the bidentate phosphine/imidazoline “BIPI” ligands,101 but unfortunately, 
this effort was unsuccessful. However, the cyclobutyl nitriles could be readily be reduced. A two-
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step reduction of 2-42 and 2-43 using DIBAL and NaBH4 afforded the corresponding primary 
alcohols 2-60 and 2-61 (Scheme 19). 
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Scheme 19. Reduction of cyclobutyl nitriles. 
The alcohols 2-60 and 2-61 are versatile precursors of bidentate ligands. For example, the 
primary alcohol could be treated with a (RO)2PCl reagent to produce a phosphine/phosphite 
bidentate system. This class of ligands has been used in asymmetric catalysis, most frequently in 
asymmetric hydrogenations and hydroformylations.102 To prepare this type of ligand on the cis-
cyclobutane scaffold, phosphine borane 2-60 was first deprotected using the standard DABCO 
method. The free phosphine was then subjected to the chlorophosphite derived from PCl3 and S-
BINOL to afford ligand 2-63 (Scheme 20). 
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Scheme 20. Synthesis of phosphine/phosphite 2-63. 
When ligand 2-63 was treated with [Rh(COD)Cl]2 in DCE-d4, evidence of bidentate Rh 
binding was observed by 31P NMR: the phosphite shifted upfield from 144.9 to 134.7 ppm and a 
JRh-P of 262 Hz was observed, while the phosphine shifted downfield from 11.2 to 45.7 ppm and a 
JRh-P of 151 Hz was observed. Encouraged by this data, 2-63 was applied in several asymmetric 
catalytic transformations. The asymmetric hydrogenation of dehydrophenylalanine derivative 2-
42
64 with ligand 2-63 and a cationic rhodium source provided the unnatural enantiomer of N-
phenylalanine methyl ester (2-65) in 91% ee (Scheme 21). The absolute configuration of 2-65 was 
confirmed by optical rotation, and the ee was determined using chiral SFC. Unfortunately, ligand 
2-63 did not provide high reactivity or selectivity in the asymmetric hydrogenation of more
challenging alkene substrates or in the asymmetric hydrocyanation of alkenes. 
Scheme 21. Application of 2-63 in enantioselective hydrogenation. 
The preparation of diphosphines from alcohol 2-61 was also explored through formation 
of a sulfonate ester and treatment with a phosphine borane nucleophile. While the mesylation of 
alcohol 2-61 was effective, the resulting mesylate was an insufficiently reactive electrophile. The 
more reactive p-bromosulfonate of 2-61 was thus prepared (Scheme 22). Treatment of the 
sulfonate with a diaryl phosphine borane and base afforded diphosphine borane 2-66. The structure 
of this diphosphine borane was secured by X-ray crystallography, which confirms the assignment 
of relative stereochemistry on the cyclobutane (which was previously based on NOESY). 
Scheme 22. Synthesis and X-ray crystal structure of diphosphine borane 2-66. 
The application of 2-66 and monophosphines such as 2-42 and 2-43 (as HBF4 salts) in 
catalysis proved difficult. For example, application of these ligands in challenging C–H 
activations resulted in low conversion and/or extensive substrate decomposition.
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While these cyclobutyl phosphines were effective some Suzuki cross-couplings, the yields 
of the reactions were no better than those employing other more accessible ligands.104 Future 
studies should be conducted to identify transformations where the structural rigidity 
of this cyclobutylphosphine scaffold would be particularly advantageous in facilitating 
catalysis.  
2.2.4 Addition of Thiols to Bicyclo[1.1.0]butanes 
The success of phosphine borane additions to bicyclo[1.1.0]butyl nitriles raised the 
question of whether thiols, which are similarly good nucleophiles, could add to these strained 
rings to afford 1,3-difunctionalized cyclobutyl thioethers. Other approaches to cyclobutyl 
thioethers and their oxidized analogs (sulfoxides and sulfones) include [2+2] cycloaddtions,105 
additions of thiol nucleophiles to cyclobutyl bromides,106 or additions to pre-
formed sulfonyl bicyclo[1.1.0]butanes.107 In contrast, the nucleophilic addition of thiols 
to readily obtained bicyclo[1.1.0]butyl nitriles offers a straightforward access to versatile 
1,3-difunctionalized cyclobutyl thioethers. Moreover, this operationally simple approach is a 
viable alternative to photochemical irradiation, which has previously been used to 
add thiols across bicyclo[1.1.0]butanes.82 
Interestingly, early reports on the reactivity of nitrile 2-37 noted that hydrolysis 
and aminolysis reactions of the central bond occur with complete trans-diastereoselectivity.108 
This selectivity was also observed when thiophenol was added to 2-37 in methanol. 
Experimental and theoretical studies of this addition concluded that the trans diastereomer is 
kinetically favored, and fast protonation of the anionic intermediate in protic solvents 
selectively provides the trans product.100b 
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Despite these insightful mechanistic studies, the addition of thiols to bicyclobutanes 
appears to have gained limited traction from a preparative standpoint. No systematic study has 
investigated the scope, yield, and selectivity for the addition of a range of thiophenol nucleophiles, 
nor have additions of heterocyclic thiols been studied. We were therefore encouraged to develop 
this addition as a method to access stereodefined cyclobutylthioethers as potentially useful 
synthetic building blocks. There is also an increasing interest in the development of small 
molecules that are capable of selective covalent modification of cysteine residues in enzyme active 
sites.109 Bicyclo[1.1.0] butanes are bench-stable, strain activated electrophiles that are well suited 
for this purpose. In fact, the bioconjugation of peptides with a sulfonyl bicyclo[1.1.0]butane 
bearing an 131I radiolabel has quite recently been described.110 Further investigation of the scope 
and parameters of thiol additions to bicyclo[1.1.0]butanes will enable a better understanding of the 
potential of these strained rings to be used as tools for medicinal chemistry and chemical biology 
applications. 
In contrast to the studies with phosphine boranes, treatment of a mixture of thiophenol and 
2-37 with NaH in DMAc afforded only a modest yield of adduct 2-67 with low diastereoselectivity. 
However, in agreement with previous studies,100b treatment of the mixture with K2CO3 at room 
temperature cleanly afforded the desired cyclobutane with high trans-diastereoselectivity. A series 
of thiophenol derivatives were then employed in the reaction, all of which reacted with similarly 
high yield and diastereoselectivity (Table 14). Like the cyclobutylphosphine boranes, the mixture 
of diastereomers obtained upon workup were quite separable by chromatography on SiO2.  
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Table 14. Addition of thiophenol derivatives to bicyclobutane 2-37. 
 
 Various heterocyclic thiols were tested in the addition reaction (Table 15). Except for an 
electron-rich indole-based thiol (entry 5), these substrates required heating and longer reaction 
times (usually 12–24 h) to reach completion. The yields of these transformations were slightly 
lower than those with thiophenols, however, the trans-diastereoselectivity remained high. An 
exception to this trend was the poorly nucleophilic tetrazole-based thiol (entry 4). In this case, a 
non-nucleophilic alcohol solvent (CF3CH2OH) was necessary to prevent degradation of the 
tetrazole product 2-75. 
The fact that bicyclo[1.1.0]butyl nitriles only react with heterocyclic thiols at elevated 
temperature suggests that they may be stable and selective bioconjugation agents. These studies, 
along with the related bioconjugation studies by Baran and co-workers,85 bodes well for the 
potential of bicyclo[1.1.0]butanes as components of targeted covalent inhibitors that are not prone 
to attack by glutathione and other off-target nucleophiles. 
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Table 15. Addition of heterocyclic thiols to bicyclobutane 2-37. 
2.3 CONCLUSIONS 
The ability of bicyclo[1.1.0]butyl nitriles to undergo addition by phosphorous and sulfur 
nucleophiles has been demonstrated. Most these studies were conducted with methyl-substituted 
bicyclo[1.1.0]butyl nitrile 2-37. To expand the reaction scope, the transnitrilation method 
developed by Reeves and co-workers99 was applied to access bicyclo[1.1.0]butyl nitriles 2-50 and 
2-53, and the previously developed hydrophosphination conditions were used to hydrophosphinate 
these substrates. Modifications of the resulting cyclobutyl nitrile products were conducted, which 
provided access to phosphine/phosphite 2-63 and diphosphine borane 2-66. The addition of 
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thiophenols and heterocyclic thiols to 2-37 was also investigated. These transformations were 
found to proceed with high trans-diastereoselectivity. 
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3.0  FLUORINATION OF BICYCLO[1.1.0]BUTANES 
3.1 INTRODUCTION 
3.1.1 Overview of Selective Monofluorination in Organic Chemistry 
With a bond dissociation energy of 105 kcal/mol, the carbon-fluorine bond is the strongest of 
those commonly encountered in organic chemistry. Fluorine is also the most electronegative of 
the elements, therefore, C–F bonds can induce a substantial dipole moment in fluorinated 
molecules. However, the poor polarizability of the fluorine atom renders these strong bonds inert 
in many transformations such as oxidative addition and nucleophilic substitution. This feature, 
along with the similarity of the C–O and C–F bond lengths (1.43 Å and 1.35 Å, respectively) and 
atomic radii (1.52 Å and 1.47 Å, respectively), make the C–F bond an effective isostere of ethers 
and other polar functional groups.111 Strategic incorporation of C–F bonds in organic molecules 
has become a popular way to modulate the conformation, solubility, reactivity, and 
intermolecular interactions of molecules. Consequently, fluorinated molecules are well 
represented in the pharmaceutical, agrochemical, and material industries.112 
Due to this demand, the development of methods to selectively fluorinate organic 
molecules has been a subject of intensive research efforts.113 These methods can be broadly divided 
into three categories: electrophilic fluorination, where a carbon nucleophile attacks an F+ 
equivalent; radical fluorination, where carbon and fluorine radicals join; and nucleophilic 
fluorination, where an F– source attacks an organic molecule, often with the aid of H+ or another 
activator (Figure 15). 
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Figure 15. General overview of fluorination methods. 
Electrophilic fluorination is very commonly employed.114 Historically, F+ sources such as 
F2 gas, CF3OF, and XeF2 have been used in these transformations, although the drawbacks 
associated with their handling (F2, CF3OF) and expense (XeF2) have limited their widespread 
adoption. Most electrophilic fluorinations are now conducted with N–F reagents such as 
Selectfluor®, NFSI, and fluoropyridinium salts. A wide range of substrates have been employed in 
electrophilic fluorination, including alkenes, arenes, heterocycles, glycals, and enol ethers.114 The 
wide scope of electrophilic fluorination with N–F reagents enables access to fluorinated organic 
molecules for a variety of applications. 
Radical fluorination is a less developed methodology. Recent studies by Boger115 and 
Hiroya116 have demonstrated that N–F reagents can be used to conduct radical fluorinations of 
alkenes in the presence of an iron or cobalt catalyst. Radial fluorination has also been investigated 
in the context of the burgeoning field of photoredox catalysis. For example, MacMillan and co-
workers have developed a photocatalytic method for the conversion of carboxylic acids to the 
corresponding alkyl fluorides.117 The activation of SF6 gas through photoredox catalysis has also 
been recently used as a method for alcohol deoxyfluorination.118 
Nucleophilic fluorination is a well-studied field that has several variations. Direct SN2 
reactions with inexpensive and easily handled fluoride salts is an ideal approach for fluorine 
introduction. However, the poor solubility and low nucleophilicty of F– (~1600-fold less reactive 
toward CH3I than Br– in MeOH119) make this approach less effective. In certain cases, anhydrous 
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tetraalkylammonium fluorides can affect the nucleophilic fluorination of good electrophiles, but 
the generality of this transformation is limited.120 
A more effective approach to nucleophilic fluorination is the use of HF to activate a Lewis 
basic substrate, which is then attacked by F– to provide a fluorinated product. Anhydrous HF has 
been used for this purpose, but its low boiling point (19.6 °C) and extreme toxicity significantly 
deter its use. In the 1970’s, Olah and co-workers discovered that HF can be dissolved in pyridine 
to provide poly(hydrogen fluoride, pyridine • 9 HF), a much more easily handled source of HF 
that is now widely known as Olah’s reagent.121 Pyridine • 9 HF can effectively fluorinate alkenes, 
alcohols, and isocyanates, among other functional groups. Alternative reagents have been 
developed where HF is dissolved in solvents such as DPMU.122 Quite recently, it has been reported 
that HF can be condensed with solid KHSO4 to yield a stable liquid HF reagent.123 These 
alternative HF reagents are reported to be superior to Olah’s reagent in some nucleophilic 
fluorinations. 
The concept of using a single reagent to both activate a substrate and conduct a nucleophilic 
attack with fluoride is also the basis of the deoxyfluorination of alcohols, which is a widely popular 
fluorination method. The most commonly employed reagents for deoxyfluorination are sulfur 
trifluoride reagents such as diethylaminosulfur trifluoride (DAST) and the closely related 
Deoxofluor®.124 Despite their utility, the toxicity and explosive potential of these reagents have 
prompted the development of innocuous and bench stable deoxyfluorination reagents. Examples 
of deoxyfluorination reagents that have recently gained popularity include the pyridine sulfonyl 
fluoride (PyFluor) developed by Doyle and co-workers,125 the fluoroimidiazolium salts 
(PhenoFluor™/AlkylFluor™) developed by Ritter and co-workers,126 and the bench-stable sulfur 
trifluoride (Fluolead™) developed by Umemoto and co-workers (Figure 16).127 
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Figure 16. Recently developed deoxyfluorination reagents. 
The fluorination of organic molecules through activation by transition metal catalysis is 
also a growing area of research.128 The fluorination of alkenes and alkynes can be enabled by late 
transition metals such as palladium129 or gold.130 Palladium catalysis has been used to form allylic 
fluorides by attack of F– onto π-allyl complexes.131 A few examples of Pd-catalyzed C–H 
fluorination have also been reported,132 however, these transformations require directing groups 
and/or are limited in scope. The development of selective, widely applicable C–H fluorination 
methods (and C–H activation methods in general) is a major unsolved challenge in organic 
synthesis. 
3.1.2 Fluorinations Involving the Opening of Strained Rings 
Although many classes of molecules have been subjected to nucleophilic and electrophilic 
fluorination reactions, the fluorination of molecules containing strained rings is somewhat 
underdeveloped. By leveraging the inherent strain energy of small carbocyclic rings and 
heterocycles, efficient and selective fluorinations can lead to structurally novel fluorinated 
chemotypes.  
Illustrative examples of unique fluorinated products that can be accessed through the 
fluorination of strained rings of can be found in the work of Roberts and co-workers (Scheme 23). 
Upon treatment with Et3N • 3 HF, ketone 3-1 undergoes diastereoselective fluorination to provide 
cyclobutanone 3-2 in good yield.133 A similar approach was also used to prepare a fluorinated 
 52 
analog of 3’-azidothymidine (AZT), the antiretroviral molecule that is one of the great triumphs 
of 20th century medicinal chemistry. This AZT analog was prepared from ketone 3-3 through a 
diastereoselective fluorination with Et3N • 3 HF to afford 3-4. Through a series of steps, 3-4 was 
converted into the carbocyclic AZT analog 3-5. Unfortunately, 3-5 had much weaker antiretroviral 
activity than the parent compound (AZT).134 
 
Scheme 23. Nucleophilic fluorination of strained cyclopropanes 3-1 and 3-3. 
Not all cyclopropanes undergo such facile nucleophilic fluorination. Despite being 
activated by diester substituents, cyclopropyl lactone 3-6 was inert to fluorination under a variety 
of standard conditions (Scheme 24). Only upon prolonged heating of 3-6 with excess Et3N • 3 HF 
and FeF3 did sufficient conversion to primary fluoride 3-7 occur. This transformation was 
investigated while developing a process-scale route to the antidiabetic agent carmegliptin, but the 
harsh nature of this fluorination prompted the researchers to develop an alternative route involving 
the deoxyfluorination of a primary alcohol.135 
 
Scheme 24. Nucleophilic fluorination of lactone 3-6. 
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Alternatively, cyclopropanes can be subjected to nucleophilic difluorination through an 
oxidative ring-opening (Scheme 25).136 This method was recently developed by Jacobsen and co-
workers as an extension of similar oxidative fluorinations of alkenes137 and alkenyl lactones.138 
The transformation is presumed to occur through the catalytic formation of a hypervalent iodonium 
fluoride, which facilitates ring-opening of the cyclopropane. Variations of the reaction were 
developed to provide access to other 1,3-difunctionalized products from 3-8. 
  
Scheme 25. Oxidative difluorination of cyclopropanes developed by Jacobsen and co-workers. 
Electrophilic N–F reagents have been used to conduct fluorinations of cyclopropyl or 
cyclobutyl carbinols with concomitant ring expansion (Scheme 26). In the presence of catalytic 
silver nitrate, Selectfluor® promotes a radical-based ring opening fluorination of cyclopropane 3-
10 to afford ketone 3-11.139 Photocatalysis has also been used to conduct similar 
transformations.140 Alexakis and co-workers have used chiral phosphoric acids to prepare 
enantioenriched fluorinated ketones through this approach. A representative  transformation of this 
type is the conversion of cyclobutane carbinol 3-12 to spirocyclic ketone 3-13.141 
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Scheme 26. Ring expansion of carbinols using electrophilic fluorination. 
The ring-opening fluorination of three- and four-membered heterocycles has been 
explored, and many of these transformations do not require the use of HF complexes (Scheme 
27).142 For example, the symmetrical epoxide 3-14 undergoes diastereoselective fluorination when 
treated with excess BF3 • OEt2 at room temperature for an extended time.143 Aziridines can be 
fluorinated under similar conditions, or alternatively, through nucleophilic catalysis by using an 
acyl fluoride as a fluorine source. This  method was used for the conversion of aziridine 3-16 to 3-
17.144  Although oxetanes are less strained than their epoxide counterparts, fluorination of oxetane 
3-18 was accomplished with SiF4 and Me2S.145 In contrast, fluorination of the highly strained 
azabicyclo[1.1.0]butane heterocycle 3-20 is reported to occur in excellent yield upon treatment 
with Olah’s reagent.146 However, no method for the fluorination of the carbocyclic analogs 
(bicyclo[1.1.0]butanes) has been reported. 
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Scheme 27. Fluorination of 3- and 4-membered heterocycles. 
3.1.3 Synthesis and Utility of Fluorinated Cyclobutanes 
The introduction of fluorine substituents can modulate the reactivity and conformational 
preferences of cyclobutanes.147 For example, perfluorocyclobutanes and related carbocycles 
exhibit unique isomerization behavior, and studies of this reactivity have broadened 
modern understanding of fluorine substitution effects in organic molecules.148 In the context of 
medicinal chemistry, fluorinated carbocycles have been leveraged to improve the 
potency and pharmacokinetic properties of lead compounds.149 The structural rigidity of 
the cyclobutane scaffold makes fluorinated cyclobutanes particularly intriguing for the 
exploitation of carbon-fluorine bond interactions with specific residues in enzyme active sites.147 
Three examples of monofluorinated cyclobutanes that have been developed by 
pharmaceutical companies for various indications are shown in Scheme 28. The cyclobutyl 
nucleoside analog 3-24 was developed by Bristol-Myers Squibb as a treatment for herpes 
infections.150 This fluorinated cyclobutane was prepared through a diastereoselective [2+2] 
cycloaddition between fumarate 3-22 and a fluorinated ketene acetal. However, cycloaddition 
product 3-23 was obtained in modest yield and with low diastereoselectivity. 
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Scheme 28. Synthetic approaches to monofluorinated cyclobutanes of medicinal interest. 
Deoxyfluorination of cyclobutyl alcohols has more commonly been used to access 
monofluorinated cyclobutanes. For example, deoxyfluorination of secondary alcohol 3-25 with 
DAST afforded 3-26 as a single diastereomer in 79% yield (Scheme 29). This intermediate was 
carried forward through 5 steps to triazole 3-27, which is a hydroxysteroid dehydrogenase inhibitor 
for the treatment of cardiovascular ailments.151 Deoxyfluorination was also used in the last step of 
a process-scale route to cyclobutane 3-30, an H3 receptor antagonist developed by Pfizer for the 
treatment of neurological disorders.152 
The preparation of fluorinated cyclobutanes through fluorinations that involve the opening 
of strained rings is a mechanistically intriguing alternative to [2+2] or deoxyfluorination 
approaches. An early example of such a transformation was reported as a side reaction by Adcock 
and co-workers. As part of a studies on the isomerization behavior of bicyclo[1.1.1]pentanes, it 
was found that [1.1.1] propellane (3-31) undergoes rearrangement to 3-
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fluoromethylenecyclobutane 3-32 in the presence of XeF2 (Scheme 29).153 The transformation is 
presumably mediated by trace amounts of HF generated under the reaction conditions. 
 
Scheme 29. Rearrangement of [1.1.1]-propellane. 
Substituted 3-fluoromethylenecyclobutanes can be prepared through the ring expansion of 
methylenecyclopropyl alcohols. When treated with nonafluorobutanesulfonyl fluoride, alcohol 3-
33 underwent ring expansion to provide a mixture of fluorinated product 3-34 and ether 3-35 
(Scheme 30).154 Similarly, alcohol 3-36 underwent DAST-mediated ring expansion to provide 
fluorocyclobutane 3-37 in good yield.155 These transformations are proposed to proceed through 
formation of a non-classical bicyclobutonium carbocation,156 which is then trapped with a fluoride 
nucleophile to afford the cyclobutane product. The conversion of 3-33 to a cyclobutyl amide has 
also been accomplished through a Ritter reaction on this putative non-classical carbocation 
intermediate.157 
 
Scheme 30. Expansions of methylenecyclopropanes to fluorinated methylenecyclobutanes. 
A series of conceptually similar fluorinations involving cyclopropane ring expansion were 
developed by Yoshioka and co-workers (Scheme 31).158 These transformations are conducted with 
Olah’s reagent that is modified with KHF2 and diisopropyl amine to provide a more nucleophilic 
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and monomeric source of fluoride. When alcohol 3-38 (R = H) is treated with this reagent, 3-39 is 
obtained in good yield as a single alkene isomer.159 This method provides superior access to the 
homoallylic fluoride motif, as the direct treatment of homoallylic alcohols with deoxyfluorination 
reagents is often complicated by side reactions. When derivatives of 3-38 where R is an alkyl or 
aryl substituent were employed, a ring expansion occurred to provide tertiary fluorocyclobutane 
3-40 in good yield with high diastereoselectivity.160 Electrophilic ring opening of an epoxide can 
also be used to trigger the ring expansion and fluorination. This is exemplified by the conversion 
of 3-41 to primary alcohol 3-42.160 An extension of this method was developed that provides access 
to fluorinated cyclopentenones.161 The method also was used as a key step in the total synthesis of 
a fluorinated analog of grandisol, a cyclobutane-containing monoterpene.162 
 
Scheme 31. Fluorinations involving cyclopropane ring expansion developed by Yoshioka et al.158 
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3.2 RESULTS AND DISCUSSION 
3.2.1 Deoxyfluorination of Bicyclo[1.1.0]butyl Alcohols 
The successful development of methods to add phosphorus and sulfur nucleophiles to 
bicyclo[1.1.0]butanes prompted consideration as to whether poor nucleophiles could also be used 
in these strain-releasing transformations. The addition of fluoride, a prototypical poor nucleophile, 
would provide an intriguing access to monofluorinated cyclobutane products. However, despite 
the substantial strain energy of bicyclo[1.1.0]butanes, preliminary attempts to use fluoride salts to 
fluorinate bicyclobutyl amides, sulfones, and nitriles were unsuccessful. In the representative 
transformation shown in Scheme 32, potassium fluoride fails to fluorinate amide 3-43 even with 
extensive heating in the presence of 18-crown-6. When heated above 110 °C, 3-43 began to 
decompose.  
 
Scheme 32. Attempted direct fluorination of bicyclo[1.1.0]butyl amide 3-43 with KF/18-crown-6. 
Since the direct addition of fluoride salts appeared unfeasible, a fluorination method 
involving the activation of bicyclo[1.1.0]butyl alcohols was developed. The work of Yoshioka and 
co-workers on the deoxyfluorination of cyclopropanes158 (Scheme 31) was an inspiration toward 
this end, and the modified reagent that they developed (KHF2/i-Pr2NH/pyridine • 9 HF) was 
expected to fluorinate the structurally related bicyclo[1.1.0]butyl alcohols. Some accounts from 
the literature also suggested that bicyclo[1.1.0]butyl alcohols could be converted to 
methylenecyclobutanes through deoxygenation and nucleophilic attack. Wiberg and co-workers 
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noted in the original full paper on bicyclo[1.1.0]butanes that treatment of bicyclo[1.1.0]butyl 
methanol with HBr resulted in a rearrangement to form 3-bromomethylenecyclobutane.62b 
Additionally, Szeimies and co-workers prepared a 3-chloromethylenecyclobutane from the 
corresponding bicyclo[1.1.0]butyl methanol using N-chlorosuccinimide and dimethyl sulfide.163 
Alcohol 3-45 was successfully converted to methylenecyclobutane 3-46 in moderate yield 
when subjected to the HF reagent developed by Yoshioka (Table 16). A substantial increase in 
yield was realized by adding the substrate to the pre-mixed reagent, as opposed to adding reagents 
to a solution of the substrate (entry 1 vs entry 2). The yield was also found to be correlated to the 
stoichiometry of pyridine • 9 HF: the yield dropped when less than 50 equivalents of HF was used 
(entry 1 vs entry 3), but no advantage was observed with >70 equivalents. The use of a large excess 
of pyridine • 9 HF (100 eq HF) is also required for the difluorination chemistry recently developed 
by Jacobsen and co-workers.136-138 Despite this high stoichiometric excess, only 1.8 mL of pyridine 
• 9 HF (1 mL reagent = 38 mmol HF) is required to fluorinate 1 mmol of a bicyclobutyl alcohol 
using this newly developed method. While the hazardous and corrosive nature of pyridine • 9 HF 
necessitates the use of a plastic reaction vessel (typically a polypropylene syringe sealed on one 
end), the reagent can be safely quenched upon workup with aqueous NaOH. Unfortunately, less 
reactive and more easily handled sources of HF such as Et3N • 3 HF or KHF2 alone did not enable 
this fluorination (entries 4 and 5).  
Standard deoxyfluorination reagents such as DAST and Deoxofluor® also successfully 
converted alcohol 3-45 to the fluorinated methylenecyclobutane 3-46 (Table 16, entries 6 and 7). 
However, the yields of these transformations tended to be lower and their purification was often 
complicated by side products. Sulfonyl fluoride-based deoxyfluorination reagents such as 
nonfluorobutanesulfonyl fluoride (NfF) and PyFluor125 provided only modest amounts of 3-46 
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(entries 8-11). The use of alkali fluoride salts in combination with various Lewis or Bronsted acids 
was also ineffective (entry 12). 
Table 16. Screening of deoxyfluorination conditions. 
 
  
The conversion of alcohol 3-45 to methylenecyclobutane 3-46 likely proceeds through an 
acid-mediated dehydration to form a cationic intermediate (Scheme 33). This putative cation is 
highly stabilized, as it has both benzylic and non-classical bicyclobutonium character.156 Evidence 
for the non-classical character of the bicyclo[1.1.0]butyl-1-carbinyl cation was found through 
spectroscopic and computational studies by Wiberg and co-workers.164 Attack of this stable 
cationic intermediate by the fluoride nucleophile at the ring junction results in an opening of the 
bicyclic system to relieve ~17 kcal/mol of ring strain and provide product 3-46.  
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Scheme 33. Proposed mechanism for the deoxyfluorination of 3-45. 
A mechanistic alternative is that the benzylic cation rearranges to a tertiary 3-
methylenecyclobutyl cation prior to fluoride attack. However, the computational studies conducted 
by Wiberg and co-workers at the MP4/6-31G* level of theory suggest that the 3-
methylenecyclobutyl cation is 16.6 kcal/mol less stable than the non-classical bicyclo[1.1.0]butyl-
1-carbinyl cation.164 This bicyclo[1.1.0]butane/methylenecyclobutane isomerization is a rare 
instance in which one isomeric form (the bicyclobutane) is strongly favored as the cationic 
intermediate, while the other (the methylenecyclobutane) is preferred as the product. 
To evaluate the scope of this deoxyfluorination, a series of bicyclo[1.1.0]butyl alcohols 
were prepared (Table 17). This was accomplished using the method discovered by Brinker66a and 
adapted by Walczak and Wipf,73b where a trihalocyclopropane is dilithiated and trapped with an 
aldehyde or ketone electrophile. The R2 substituent on the alcohol products was easily varied by 
trapping with various benzaldehyde derivatives (entries 1–6). Acetophenone (entry 7) and 3-
pentanone (entries 16 and 17) were also successfully trapped to provide tertiary alcohols. The R1 
substituent was varied by using several trihalocyclopropane precursors, which were in turn 
prepared through dibromocyclopropanation of the appropriate allylic halides (entries 8–17). 
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Table 17. Preparation of bicyclo[1.1.0]butyl alcohol substrates. 
 
The deoxyfluorination of these bicyclo[1.1.0]butyl alcohols was evaluated using the 
pyridine • 9 HF/KHF2/i-Pr2NH reagent (Table 18). The yields for these transformations generally 
ranged from 40–65%. Tertiary (entries 7, 14, and 15) and secondary alcohols performed equally 
well in the deoxyfluorination. Although the presence of a benzylic alcohol presumably facilitates 
the transformation by providing a more stabilized cationic intermediate, benzylic activation is not 
required as evidenced by the successful preparation of 3-71, albeit with a reduced yield (entry 11). 
Appended functional groups appeared detrimental to the reaction, as evidenced by the lower yield 
of allyloxy-substituted derivative 3-66. The only heterocyclic alcohol attempted, pyridine 3-51, 
afforded a complex mixture under the reaction conditions. 
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Table 18. Deoxyfluorination of bicyclo[1.1.0]butyl alcohols. 
 
No side products were isolated upon purification of these reactions. However, the fact that 
some yellow/brown material is typically adsorbed to the base of the SiO2 column suggests that 
some degree of polymerization or decomposition occurs. Despite moderate yields obtained in these 
transformations, this method is the first example of a bicyclo[1.1.0]butane fluorination and is one 
of the only means available for the synthesis of substituted 3-fluoromethylenecyclobutanes.154 
3.2.2 Anomalous Deoxyfluorination Substrates 
Not all the bicyclo[1.1.0]butyl alcohols that were tested in the deoxyfluorination reaction provided 
the expected methylenecyclobutane product. These limitations revealed some interesting aspects 
of the deoxyfluorination mechanism and the stability of the methylenecyclobutane products. For 
example, when t-butyl-substituted alcohols 3-57 and 3-58 were subjected to the deoxyfluorination 
conditions, allylic alcohols 3-76 and 3-77 (respectively) were obtained in low yield (Scheme 34). 
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The structure of these alcohols was assigned using a combination of one- and two-dimensional 
NMR experiments. It is hypothesized that 3-76 and 3-77 originate from the expected 3-
methylenecyclobutane, but the unfavorable stearic clash between the t-butyl group and the 
cyclobutane render the products unstable. Upon aqueous workup, hydrolytic alkene transposition 
would relieve both this interaction and the cyclobutane ring strain to afford the observed allylic 
alcohol product. 
 
Scheme 34. Deoxyfluorination of 3-57 and 3-58 affords rearranged allylic alcohol products. 
The deoxyfluorination was also impacted by substitution at the bicyclo[1.1.0]butane ring 
junction. As Table 18 shows, a variety of alkyl and aryl substituents are tolerated in the 
transformation. In contrast, the attempted deoxyfluorination of bicyclobutane 3-78 (which does 
not bear a substituent at the ring junction) afforded aldehyde 3-79 in low yield (Scheme 35). This 
aldehyde may arise from protonation of the bicyclo[1.1.0]butane at the less substituted ring 
junction, which would trigger a semipinicol rearrangement (1,2-arene shift) of the resulting tertiary 
carbocation to afford 3-79. Although products resulting from alternative reaction pathways are 
presumably formed, 3-79 was the only tractable product isolated from the crude reaction mixture. 
 
Scheme 35. Attempted deoxyfluorination of bicyclobutanes without a ring junction substituent. 
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Sulfonyl-substituted bicyclo[1.1.0]butane 3-80 was completely inert to the pyridine • 9 HF 
reagent (Scheme 36). When treated with Deoxofluor®, however, a deoxfluorination occurred to 
provide bicyclo[1.1.0]butyl fluoride 3-81 with no formation of a methylenecyclobutane or other 
rearranged product. The failure of 3-80 to undergo rearrangement supports the hypothesis that the 
fluorination proceeds through a delocalized carbocation intermediate. The formation of such an 
intermediate would be strongly disfavored by the strong electron withdrawing capacity of the 
sulfone at the ring junction. 
 
Scheme 36. Deoxyfluorination of sulfonyl bicyclobutane 3-80. 
It was hypothesized that cyclopropenyl carbinols, inasmuch as they are structurally and 
functionally similar to the bicyclo[1.1.0]butyl alcohols previously studied, would form fluorinated 
methylenecyclopropanes when subjected to the deoxyfluorination conditions. Encouragingly, 
cyclopropene 3-82 has been converted to metheylenecyclopropanes through organocuprate 
addition or [2,3]-sigmatropic rearrangement.165 However, when 3-82 was subjected to the 
deoxyfluorination conditions, allene 3-83 was the only product obtained (Scheme 37). This allene 
product is presumably formed though activation of the alcohol and attack of the fluoride 
nucleophile on the cyclopropyl methylene. While the rearrangement of similar cyclopropene 
carbinols to allenes has been accomplished using perchloric acid166 or silica gel,167 this is the first 
example of a rearrangement of this type involving fluorination. A potentially fruitful line of future 
research would identify divergent conditions that provide selective access to either fluorinated 
allenes or methylenecyclopropanes with various substitution patterns. 
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Scheme 37. Deoxyfluorination of cyclopropene alcohol 3-82 provides allene 3-83. 
3.2.3 Transformations of Fluorinated Methylenecyclobutanes 
With a method to access 3-fluoromethylenecyclobutanes established, the utility of these products 
was explored. A prime objective along these lines was to convert the methylenecyclobutanes into 
3-fluorocyclobutanones through oxidative scission of the exocyclic alkene. These cyclobutanone
products were envisioned to be versatile precursors to more complex fluorinated carbocycles. 
Moreover, there are only a few scattered reports of 3-fluorocyclobutanones in the patent literature, 
and their utility remains unexplored. 
A problematic aspect of this oxidative scission was the loss of material due to the 
generation of volatile, low molecular weight ketones in small quantities. Thus, the larger 
phenethylamine substituted methylenecyclobutane 3-70 was the primary substrate used in these 
studies. When subjected to a two-step sequence of dihydroxylation and oxidative diol cleavage, 
cyclobutanone 3-84 was obtained (Scheme 38). Ketone 3-84 was converted into oxime 3-85, which 
is a potential precursor of fluorinated cyclobutyl amines168 or fluorinated spirocycles through [3+2] 
dipolar cycloaddition.169 Reduction of ketone 3-84 occurred with moderate diastereoselectivity to 
afford alcohol 3-86 in 66% yield and a 6.3:1 diastereomeric ratio, and the relative stereochemistry 
of the major alcohol isomer was tentatively assigned by NOESY. 
OH
Ph
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F
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Scheme 38. Transformations of ketone 3-84. 
Unfortunately, ketone 3-84 and analogs thereof appear to be unstable to acid-mediated 
transformations. When an oxidative alkene cleavage was conducted on n-propyl substituted 
methylenecyclobutane 3-68, the cyclobutanone product 3-87 was carried directly forward to a 
reductive amination due to concerns of volatility (Scheme 39). No secondary amine was isolated 
from this reaction, but rather, the unexpected vinylogous amide product 3-88 was obtained in 34% 
yield. Similarly, when ketone 3-84 was subjected to an Ugi multicomponent reaction, vinylogous 
amide 3-89 was obtained in 47% yield, with no evidence of Ugi product formation. The structure 
of these vinylogous amides was assigned by 1H NMR, 13C NMR, DEPT 135, and HMBC. The 
connectivity of the molecule was confirmed by analysis of HMBC correlations (Figure 17). The 
alkene geometry was assigned on the basis of the high N–H 1H NMR shift (11.17 ppm) that is 
indicative of intramolecular hydrogen bonding in these systems.170 
 
Scheme 39. Attempted acid-mediated transformations of cyclobutanones result in vinylogous amides. 
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Figure 17. Key HMBC correlations of 3-88. 
The formation of these vinylogous amides likely occurs by enol formation, 4π electrocyclic 
ring opening, and addition/elimination of the amine nucleophile into the β−fluoroenone (Scheme 
40). Alternatively, an initial elimination of fluoride from 3-84 would provide a reactive 
cyclobuteneone that undergoes nucleophilic attack by the amine, 4π electrocyclic ring opening, 
and tautomerization to afford 3-89.  
 
Scheme 40. Possible mechanism for the conversion of 3-84 to 3-89. 
 Other transformations were investigated that retain the aryl substituent of the 
deoxyfluorination products. Bromohydrin formation of 3-63 proceeded with regio- and 
diastereoselectivity to provide 3-90 as a single regioisomer and as a separable 5.8:1 mixture of 
diastereomers (69% and 12% isolated yields, Scheme 41). The structure and relative 
stereochemistry of 3-90 was assigned using 1H NMR, 13C NMR, NOESY, and HSQC. The 
secondary alcohol of the bromohydrin was converted to the corresponding ketone 3-91 in 87% 
yield using Dess-Martin periodinane. Attempted Bayer-Villager oxidation of 3-91 was 
unsuccessful, as this ketone was resilient to m-chloroperbenzoic acid and other oxidation 
conditions. 
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Scheme 41. Regio- and diastereoselective bromohydrin formation from 3-63. 
3.2.4 Diastereoselective Fluorination of Bicyclo[1.1.0]butyl amides 
With the demonstrated ability of the pyridine • 9 HF/KHF2/i-Pr2NH reagent to conduct 
deoxyfluorination reactions, the fluorination of other bicyclo[1.1.0]butane derivatives was 
considered. Specifically, a bicyclo[1.1.0]butane substituted with a Lewis basic functional group 
such as an amide was expected to undergo a ring-opening fluorination when treated with this HF 
reagent. This transformation would provide access to fluorinated cyclobutyl amides, which are 
useful structures in medicinal chemistry and other applications (Section 3.1.3). 
To test this hypothesis, a series of bicyclo[1.1.0]butyl amides were prepared through 
dilithiation of the appropriate trihalocyclopropane precursor and trapping with an isocyanate 
(Table 19). The yields of isocyanate trapping tend to be lower than those of aldehyde or imine 
trapping. In the case where R1 was an n-propyl substituent, the yield was poor (entry 4). 
Nonetheless, amides 3-92–3-96 were obtained in sufficient quantity to test their feasibility in 
fluorination reactions. 
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Table 19. Preparation of bicyclo[1.1.0] butyl amides. 
 
Treatment of the bicyclo[1.1.0]butyl amides with the modified pyridine • 9 HF reagent 
afforded 3-fluoro-3-alkylcyclobutyl amides (Table 20). The reaction tended to be slower than the 
alcohol deoxyfluorination, thus, an additional time period at 0 °C was added to ensure full 
conversion. The products were obtained as single regioisomers, and the diastereoselectivity of the 
transformation was also high. In cases where R1 = CH3 (entries 1–3) only one diastereomer (with 
the methyl and amide in a cis relationship) was isolated after chromatography. Larger substituents 
at the ring junction, however, resulted in attenuated diastereoselectivity. This was most 
pronounced in the fluorination of 3-96 (R1 = Ph), which yielded 3-101 as separable diastereomers 
in isolated yields of 39 and 25%. The poor diastereoselectivity in this case may be the consequence 
of the more planar stabilized benzylic cation that is a putative intermediate in the conversion of 3-
96 to 3-101. 
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Table 20. Diastereoselective fluorination of bicyclo[1.1.0]butyl amides. 
 
The relative stereochemistry of each of the major amide isomers was assigned by NOESY 
(in 3-97, for example, the methyl and methine protons each correlate to methylene protons on 
opposite faces of the cyclobutane). To confirm these assignments, a single crystal of amide 3-98 
was grown and analyzed by X-ray crystallography. The crystal structure obtained for 3-98 
confirms the regio- and stereochemical assignments of the cyclobutane products (Figure 18). 
 
Figure 18. X-ray crystal structure of amide 3-98. 
As observed in bicyclo[1.1.0]butyl alcohol deoxyfluorinations, attempted fluorination of a 
bicyclobutane derivative without a ring junction substituent resulted in an unexpected product. 
When amide 3-43 was treated under the typical reaction conditions, attack of the fluoride 
nucleophile at the bicyclobutane methylene afforded racemic cyclopropane 3-102 as the major 
product in 32% yield (Scheme 42). An inseparable mixture of byproducts was also obtained upon 
purification, a component of which appears to be the expected 3-fluorocyclobutyl amide. While 
the acidic methanolysis of bicyclo[1.1.0]butanes is known to produce a mixture of 3-
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methoxycyclobutane and trans-cyclopropane products,79-80 the origin of the preference for the 
cyclopropane product in this case is not obvious. 
 
Scheme 42. Fluorination of amide 3-43 affords cyclopropane 3-102. 
This amide fluorination reaction is interesting from a methodological and mechanistic 
perspective, but unlike the alcohol deoxyfluorination, viable alternatives exist to access the 
fluorinated products. Commercially available 3-oxocyclobutanecarboxylic acid can be used as a 
synthetic building block to access fluorinated amides such as 3-88–3-93. For example, a three-step 
sequence of amide coupling, treatment with a Grignard reagent, and deoxyfluorination with 
Deoxofluor® was used to access the fluorinated amide 3-30 on process scale (Scheme 28).152 
However, the de novo preparation of the cyclobutane ring via a bicyclo[1.1.0]butane 
provides opportunities for unique modifications such as isotopic labelling. As a demonstration of 
this potential, deuterium-labeled bicyclo[1.1.0]butyl amide 3-107 was prepared and fluorinated to 
afford the labeled and fluorinated cyclobutane 3-108 (Scheme 43). Substrate 3-107 was accessed 
through copper-catalyzed addition of phenyl magnesium bromide to propargyl alcohol (3-103), 
which upon quenching with D2O provides allylic alcohol 3-104 as a single alkene isomer.171 This 
alcohol was then protected, subjected to dibromocyclopropanation, and deprotected to afford 
racemic alcohol 3-105. Conversion to bromide 3-106 and subjection of the resulting tribromide to 
the dilithiation/isocyanate trapping procedure afforded racemic bicyclo[1.1.0]butane 3-107 in 
good yield. Like the non-labeled material 3-96, fluorination of 3-107 proceeded with very little 
diastereoselectivity. However, the 3-108 diastereomers were readily separable on SiO2, and each 
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has a trans-relationship between the deuterium and amide substituents. One could envision using 
a similar strategy to produce fluorinated cyclobutanes with other substitution patterns or isotopic 
labels (such as 13C). 
 
Scheme 43. Preparation and fluorination of a deuterium labeled bicyclo[1.1.0]butane. 
3.3 CONCLUSIONS 
A method to convert bicyclo[1.1.0]butyl alcohols to fluorinated methylenecyclobutanes has been 
developed. Screening of a variety of deoxyfluorination conditions revealed that a modified version 
of Olah’s reagent (pyridine • 9 HF with KHF2 and i-Pr2NH additives) was most effective in this 
reaction. A series of bicyclo[1.1.0]butyl alcohols with various substitution patterns was prepared 
and subjected to the optimized deoxyfluorination conditions. Many of these alcohols reacted 
smoothly to form the expected methylenecyclobutane products, but derivatives with sterically 
demanding appendages or alternative ring junction substituents gave unexpected products. The 
utility of the fluorinated methylenecyclobutane products was explored through oxidative cleavage 
of the exocyclic alkene or diastereoselective bromohydrin formation. Preliminary studies on the 
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fluorination of bicyclo[1.1.0]butyl amides were also undertaken, and a deuterium-labelled 
cyclobutyl amide was prepared using this method. 
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4.0  SYNTHESIS OF ANDROGEN RECEPTOR ANTAGONISTS CONTAINING 
STRAINED CARBOCYCLES  
4.1 INTRODUCTION 
4.1.1 Androgen Receptor Antagonists as Prostate Cancer Therapeutics 
Prostate cancer is the third most common type of cancer diagnosed in the United States. 
Approximately 12% of men will be diagnosed with prostate cancer in their lifetime, and 
an estimated 161,000 new cases were diagnosed in the United States in 2017 alone. 
Fortunately, current treatment technologies limit the fatality rate from prostate cancer to 20.1 per 
100,000 men in the U.S.172 A common method to treat high-risk prostate cancer is radiation 
therapy (with or without prostatectomy) followed by androgen deprivation therapy, including 
chemical castration. While this approach is an effective short-term treatment, 10-20% of 
prostate cancer treated by castration progresses to castration-resistant prostate cancer (CRPC) 
within 5 years. The estimated period of survival for individuals living with CRPC is 14 
months.173 
A key player in the development of CRPC is the androgen receptor (AR), a nuclear 
transcription factor that regulates the growth of healthy prostate cells. Upon binding to 
endogenous 5α–dihydrotestosterone, the androgen receptor translocates into the prostate cell 
nucleus.174 It has been demonstrated that excessive AR localized in the cell nucleus enables the 
progression of CRPC.175 Thus, treatment with a small-molecule AR antagonist is a viable 
strategy to slow CRPC progression. Enzalutamide (4-1, Figure 19) is an FDA-approved AR 
antagonist for the treatment of CRPC, but it is not completely effective and enables an extension 
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of patient lifespan by just 3–5 months.176 Therefore, there is a need for new AR antagonists that 
show an improved ability to slow the progression of CRPC, perhaps through a novel mechanism 
of action. 
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4-1 (enzalutamide)
Figure 19. Enzalutamide, an FDA-approved treatment for castration-resistant prostate cancer. 
4.1.2 Previous Medicinal Chemistry Efforts in the Wipf group 
In an effort to identify new small molecule AR antagonists for the potential treatment of CRPC, a 
library of 219,055 compounds was screened for suppression of AR activity in the prostate cell 
nucleus.177 The compounds were tested in a castration-resistant prostate cancer cell line (C4-2) 
transfected with an AR expression vector containing a green fluorescent protein tag (2GFP-AR). 
A promising hit from this screening was isoxazole thioether 4-2 (Figure 19). In a similar luciferase 
reporter assay using C4-2 CRPC cells transfected with luciferase-tagged AR vector (C4-2-PSA-
rl), 4-2 showed promising inhibition of AR activity with an EC50 of 7.3 µM. 
An extensive structure-activity relationship study of 4-2 was conducted in the Wipf group 
with the aim of developing more potent analogs.178 Specific features of 4-2 that were evaluated 
include the isoxazole appendage, thioether and amide linkages, piperazine heterocycle, and arene 
appendage (Figure 20). These studies revealed the importance of the o-methyl aniline and 
piperazine features. The isoxazole and thioether, however, were found to be replaceable. More 
potent analogs were attained by substituting the flexible thioether with a more rigid cyclopropane. 
The most successful compound in this series was 4-3 (known as JJ-450). Aside from having a >2 
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fold improvement in activity over 4-2, cyclopropane 4-3 has a higher drug-likeness score and 
eliminates the metabolically liable thioether motif. Extensive evaluations of the capability of 4-3 
to treat CRPC in vivo is ongoing. 
 
Figure 20. Optimization of high-throughput screening hit 4-2 yielded lead 4-3. 
4.2 RESULTS AND DISCUSSION 
4.2.1 Synthesis of Androgen Receptor Antagonists Containing Bicyclo[1.1.0]butanes  
Despite the high potency (EC50 = 1.7 µM) of (–)-4-3 in the luciferase reporter assay, the metabolic 
stability of this compound is suboptimal. When tested in human, mouse, and dog liver microsomes, 
(–)-4-3 displayed poor stability with half-lives of 31.7, 5.3, and 5.6 min, respectively. The aryl 
cyclopropane, piperazine heterocycle, and o-methyl arene substituent are each features of 4-3 that 
may contribute to this fast metabolic degradation by cytochrome P450 enzymes.179 Mass 
spectrometry analyses of the degradation products from these microsomal stability assays affirmed 
that oxidative cleavage of the cyclopropane is a major metabolic pathway. 
To mitigate these metabolic shortcomings and discover compounds with even greater 
potency, modifications and replacements of the cyclopropane core of 4-3 were developed. 
 79 
Alternative carbocycles such as bicyclo[1.1.0]butanes were envisioned to be structurally novel 
cyclopropane replacements. Others have found that unusual carbocycles such as 
bicyclo[1.1.1]pentanes and cubanes can be used to enhance the properties of lead compounds.180 
Despite the structural rigidity and novelty of bicyclo[1.1.0]butanes, to our knowledge, they have 
not been exploited for this purpose. While the potential for undesired reactivity of bicyclobutanes 
substituted with an electron withdrawing group (such as an amide) may raise concerns of off-target 
reactivity, previous thiol addition studies (Section 2.2.4) suggest that endogenous nucleophiles 
such as glutathione would only add to these systems at elevated temperature or in the presence of 
base.  
In order to prepare bicyclo[1.1.0]butane-derived analogs of 4-3, it was necessary to prepare 
the appropriate tribromide precursors with electron deficient arenes (Scheme 44). The p-
fluorophenyl tribromide 4-6 was prepared through allylic bromination of commercially available 
methyl styrene 4-4 and dibromocyclopropanation of the resulting allylic bromide product (4-5). 
The same approach has been used to prepare the parent phenyl tribromide,73b however, the 
presence of the fluoride substituent decreased the yield for this transformation. Bromination of 
more highly deactivated trifluoromethyl styrene was completely ineffective. An alternative 
procedure involving the Cu-mediated addition of p-trifluoromethyl magnesium bromide to 
propargyl alcohol was therefore used to access allylic alcohol 4-8.181 The alcohol 4-8 was then 
subjected to a protection/dibromocyclopropanation/deprotection sequence to provide alcohol 4-9. 
Bromination of 4-9 afforded the tribromide 4-10. 
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Scheme 44. Preparation of tribromides 4-6 and 4-10. 
 With the necessary tribromides in hand, a dilithiation and trapping sequence was proposed 
to access the amide targets. As outlined in Section 3.2.4, bicyclo[1.1.0]butyl amides can be 
accessed by trapping the bicyclo[1.1.0]butyl lithium species with isocyanates, but this 
transformation cannot provide direct access to the tertiary amides needed for these studies. 
Attempts were made to trap electrophiles (such as 1,1-carbonyldiimidazole (CDI) or 
chloroformates) that would provide a bicyclobutyl amide precursor at the correct oxidation state. 
Ultimately, the most successful approach was trapping of the bicyclobutane anion with CO2 to 
form a carboxylic acid (Table 21). By conducting a pH-controlled workup of this reaction, 
bicyclo[1.1.0]butyl acids 4-11 and 4-12 were obtained in acceptable purity without purification by 
chromatography. Although some reports describe the preparation of certain bicyclo[1.1.0]butyl 
carboxylic acids through anionic trapping of CO2,83c, 182 this work is the first example of a general 
approach to aryl-substituted bicyclo[1.1.0]butyl carboxylic acids.  
Table 21. Preparation of carboxylic acids 4-11 and 4-12. 
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The bicyclo[1.1.0]butane carboxylic acids 4-11 and 4-12 were coupled to the appropriate 
aryl piperizines using the T3P® reagent (Table 22).183 These piperazine coupling partners were 
prepared by collaborators through Buchwald-Hartwig coupling of N-Boc piperazine with an aryl 
bromide.178 The carbamate protecting group was then removed with HCl in dioxane to afford the 
piperazine HCl salts, which were typically free-based before amide coupling. In this manner, three 
bicyclobutyl amide analogs 4-13, 4-14, and 4-15 were prepared for testing of their AR antagonist 
activity. 
Table 22. Amide coupling of carboxylic acids 4-11 and 4-12. 
4.2.2 Rearrangement of Bicyclo[1.1.0]butyl Amides to Cyclobutenes 
Initially, the amide couplings described in Table 22 were conducted by pre-mixing a solution of 
bicyclo[1.1.0]butane carboxylic acid with piperazine HCl salt, treating with excess Et3N, and then 
adding the T3P® coupling reagent. This approach gave perplexingly inconsistent results. While the 
expected bicyclo[1.1.0]butyl amides were isolated in some cases, in many others an unexpected 
cyclobutene product was obtained in low yield (as in the conversion of 4-12 to 4-16, Scheme 45). 
Through a systematic evaluation of reaction parameters, it was determined that this cyclobutene 
formation was triggered by excess HCl in the piperazine HCl salt, possibly resulting from 
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incomplete washing of the solid during large-scale preparations. When the piperazine HCl salt was 
partitioned between CH2Cl2 and 1 M NaOH before use in the coupling, bicyclobutyl amides such 
as 4-15 could be reliably prepared. 
With this knowledge, several acids were screened for their effectiveness in promoting the 
isomerization of bicyclobutane 4-15 to cyclobutene 4-16. The optimally clean and high yielding 
protocol was found to be treatment of a CH2Cl2 solution of 4-15 with a catalytic (15 mol %) amount 
of camphorsulfonic acid followed by heating at 60 °C. Camphorsulfonic acid is an advantageous 
acid source in that it is an easily weighed solid that does not exist as a hydrate. Acids with 
appreciable water content tended to promote the competitive formation of a cyclobutanol hydration 
product in addition to cyclobutene formation. 
To confirm the structure of cyclobutene 4-16, it was subjected to hydrogenation to afford 
cyclobutane 4-17 as a single diastereomer (Scheme 45). Bicyclo[1.1.0]butyl amide 4-15 was also 
subjected to hydrogenation across the strained central bond at elevated pressure to afford the same 
cyclobutane product (4-17), which affirms the structural assignment of 4-16. The relative 
stereochemistry of cyclobutane 4-17 was confirmed by NOESY, wherein a correlation is observed 
from both methines to one of the two methylenes. 
 
Scheme 45. Preparation of cyclobutane 4-16 and confirmation of structure through conversion to 4-17. 
 83 
The isomerization of bicyclo[1.1.0]butanes to cyclobutenes has been conducted with cobalt 
(II) porphyrin complexes,184 photochemical irradiation,185 or reduction over lithium metal.186 
However, no general method for the isomerization of functionalized bicyclobutanes under mild 
conditions has been described. The scope of this catalytic acid-mediated isomerization was 
therefore investigated (Table 23). Both secondary (NHPh) and tertiary (piperazine) amides were 
well tolerated in the isomerization (entries 1–5). The electronic nature of the arene ring was 
unimportant, as evidenced by the similar yields obtained in entries 4 (R1 = H) and 5 (R1 = CF3). A 
ketone substrate (obtained through DMP oxidation of the corresponding bicyclo[1.1.0]butyl 
alcohol) afforded the expected cyclobutane in modest yield (entry 6). The lower yield may be 
attributed to the poor stability of bicyclo[1.1.0]butyl ketones, which are more susceptible to 
decomposition than other bicyclobutane derivatives. 
Table 23. Conversion of bicyclo[1.1.0]butyl amides to cyclobutenes. 
 
An arene substituent at the ring junction is necessary for this isomerization. When methyl-
substituted amide 3-92 was subjected to the optimized conditions, no conversion occurred. More 
vigorous heating at 120 °C eventually triggered formation of methylenecyclobutane 4-23 in 17% 
yield (Scheme 46). This result is consistent with an isomerization mechanism whereby amide 
protonation results in a cyclobutyl cation that is stabilized by the aryl substituent. Elimination then 
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affords the racemic cyclobutene product. In the case of 4-23, thermodynamic formation of the less 
strained methylenecyclobutane is favored over cyclobutene formation. 
 
Scheme 46. Conversion of amide 3-92 to methylenecyclobutane 4-23. 
4.2.3 Biological Activity of Amide Analogs 
Bicyclo[1.1.0]amides 4-13, 4-14, and 4-15, as well as cyclobutane 4-17 (all of which are achiral) 
were tested for their ability to inhibit AR activity in the prostate cell nucleus using the AR 
luciferase dual-reporter assay.177 Select analogs were subjected to additional microsome stability 
tests and cell proliferation assays in both AR positive (22Rv1) and AR negative (PC3) CRPC cell 
lines (Table 24). The respective enantiomers of cyclobutane 4-16 (which is chiral due to the 
desymmetrization from the cyclic olefin) were separated by preparative chiral SFC and evaluated 
separately in the assays. Although many other analogs were prepared by collaborators and tested 
in these assays, only one (oxetane 4-24) contained a four-membered ring. The biological data for 
both enantiomers of 4-24 are shown in Table 24 to enable comparison to cyclobutane 4-17. Assay 
data for both enantiomers of the lead compound 4-3 (JJ-450) are also shown for comparison.  
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Table 24. Biological testing of androgen receptor antagonist analogs. 
 
 While the p-fluoro bicyclo[1.1.0]butyl amide 4-13 showed >25 µM activity in the 
luciferase dual-reporter assay and was not considered for cell-based evaluation (entry 3), p-
trifluoromethyl substrates 4-14 and 4-15 were comparable in activity to lead structure (–)-4-3 
(entries 4 and 5 vs 1 and 2). Like (–)-4-3, these bicyclobutanes showed strong and selective growth 
inhibition of the human 22Rv1 (androgen receptor positive) CRPC cell line over the PC3 
(androgen receptor negative) CRPC cell line. The stability of these bicyclo[1.1.0]butane substrates 
in human liver microsomes was comparable to lead compound (–)-4-3. In the case of mice liver 
microsomes, however, the half-life was nearly an order of magnitude greater. These results suggest 
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that despite their high strain energy, bicyclo[1.1.0]butanes can serve as cyclopropane, cyclobutane, 
or cis-alkene substitutes that are stable to metabolic degradation in vivo. 
 Cyclobutane 4-17 was significantly less potent than many other analogs (including oxetane 
4-24) in both the luciferase reporter and cell growth assays (entry 8). However, 4-17 exhibited 
dramatically higher microsomal stability than any of the comparison substrates. Others have 
observed that cyclobutane derivatives of lead structures have an enhanced metabolic stability,180a 
and molecules containing cyclobutanes have shown effective pharmacokinetic performance in 
human clinical trials.187  Taken together, these results encourage continued studies of these and 
other small carbocyclic ring systems in medicinal chemistry.  
4.3 CONCLUSIONS 
Several bicyclo[1.1.0]butyl amides were prepared as part of a medicinal chemistry to identify 
androgen receptor antagonists for the treatment of castration-resistant prostate cancer. A method 
for the synthesis of aryl bicyclo[1.1.0]butane carboxylic acids was developed to attain the 
necessary synthetic targets. These new analogs had comparable androgen receptor antagonist 
activity and greater microsomal stability than the previous lead compound 4-3 (JJ-450). During 
these studies, an acid-mediated isomerization of bicyclo[1.1.0]butanes to cyclobutenes was 
discovered. The scope of this transformation was investigated. 
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5.0  EXPERIMENTAL 
5.1 GENERAL EXPERIMENTAL 
All glassware was oven dried and cooled in a desiccator prior to use. All moisture sensitive 
reactions were performed under an atmosphere of dry N2 or Ar. Reactions carried out below 0 °C 
employed an acetone/dry ice bath. Reagents obtained from commercial sources were used as 
received unless otherwise specified. THF and Et2O were distilled from sodium/benzophenone 
ketyl and CH2Cl2 and toluene were distilled over CaH2. Concentrating under reduced pressure 
refers to the use of a rotary evaporator connected to a PIAB Lab Vac H40, followed by a 1–
1.5 torr high vacuum pump to remove residual solvent. 
Melting points were determined using a Laboratory Devices Mel-Temp II in open 
capillary tubes and are uncorrected. Infrared spectra were determined as neat solids or oils on a 
Smiths Detection IdentifyIR FT-IR spectrometer. 1H NMR, 13C NMR, 11B NMR, 19F NMR and 
31P NMR spectra were recorded on a Bruker Advance 300 MHz, 400 MHz, or 500 MHz 
instruments. 1H NMR and 13C NMR chemical shifts (δ) were reported in parts per million with 
the residual solvent peak used as an internal standard δ and are tabulated as follows: chemical 
shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), number of 
protons, and coupling constant(s). 13C NMR spectra were obtained using a proton-decoupled 
pulse sequence and are tabulated by observed peak. 11B NMR, 19F NMR, and 31P NMR spectra 
were taken without an internal standard. Thin-layer chromatography was performed using pre-
coated silica gel 60 F254 plates (EMD, 250 μm thickness) and visualization was accomplished 
with a 254 nm UV light and by staining with a KMnO4 solution (1.5 g of KMnO4 and 1.5 g of 
K2CO3 in 100 mL of a 0.1% 
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NaOH solution). Flash chromatography on SiO2 (Silicycle, Silia-P Flash Silica Gel or SiliaFlash® 
P60, 40-63 μm) was used to purify crude reaction mixtures.  
Unless otherwise stated, starting materials were purchased from commercial sources and 
used without further purification. Thiourea starting materials were either obtained from 
commercial sources, from collaborators, or were prepared from the corresponding primary amine 
and isocyanate. Secondary phosphine boranes were supplied from Boehringer-Ingelheim 
(Ridgefield, CT) or were prepared according to the referenced procedure. 
5.2 CHAPTER 1 EXPERIMENTAL PART 
General Procedure A (Carbodiimide formation from the corresponding thiourea): N-(3, 5-
Bistrifluoromethyl)phenyl N’-cyclohexylcarbodiimide (1-28). A 25 mL round bottom flask was 
charged with the corresponding thiourea (0.263 g, 0.710 mmol), triethylamine (0.30 mL, 1.4 mmol, 
2.0 eq), DMAP (0.004 g, 0.03 mmol, 5 mol %) and CH2Cl2 (5 mL). The reaction mixture was 
cooled to 0 oC and mesyl chloride (0.10 mL, 1.4 mmol, 2.0 eq) was added via syringe over 5 min. 
The solution was stirred at room temperature for 1 h then was concentrated under reduced pressure. 
The crude material was slurried in hexane and filtered through a plug of Celite®. The filtrate was 
concentrated under reduced pressure and purified by chromatography on SiO2 (hexanes) under N2 
pressure to afford 1-28 (0.197 g, 0.585 mmol, 83%) as a colorless oil: 1H NMR (400 MHz, CDCl3) 
δ 7.56 (s, 1 H), 7.46 (s, 2 H), 3.63-3.58 (m, 1 H), 2.03-2.00 (m, 2 H), 1.77 (dd, 2 H, J = 9.6, 4.0 
Hz), 1.60-1.49 (m, 3 H), 1.43-1.40 (m, 3 H); 13C NMR (100 MHz, CDCl3) δ 143.8, 133.4 (q, 2JCF 
89 
= 33 Hz), 123.2 (3JCF = 3 Hz), 123.0 (q, 1JCF = 271 Hz), 117.6 (3JCF = 4 Hz), 56.8, 34.7, 25.2, 24.1; 
MS (ESI)+ m/z 337 (100); HRMS (ESI)+ m/z calcd for C15H15N2F6 [M+H] 337.1139, found 
337.1141. 
N-2-Methoxyphenyl N’-cyclohexylcarbodiimide (1-29). Prepared according to General
Procedure A from the corresponding thiourea (0.327 g, 1.23 mmol), DMAP (0.008 g, 0.06 mmol), 
triethylamine (0.52 mL, 3.7 mmol) and mesyl chloride (0.19 mL, 2.5 mmol) in CH2Cl2 (15 mL). 
Purification by chromatography on SiO2 afforded 1-29 (0.204 g, 0.885 mmol, 72%) as a colorless 
oil: 1H NMR (300 MHz, CDCl3) δ 7.12-6.97 (m, 2 H), 6.91-6.81 (m, 2 H), 3.88 (s, 3 H), 3.49-3.36 
(m, 1 H), 2.08-1.93 (m, 2 H), 1.84-1.68 (m, 2 H), 1.62-1.08 (m, 6 H); 13C NMR (100 MHz, 
CDCl3) δ 154.0, 136.4, 129.3, 125.2, 124.6, 121.0, 111.2, 56.5, 55.7, 34.6, 25.5, 24.5; IR (ATR) 
3027, 2134, 1593, 1485, 1232, 1192, 827, 769, 692 cm-1; MS (ESI)+ m/z 249 (100, M + H2O), 231 
(10), 149 (7); HRMS (ESI)+ m/z calcd for C14H19N2O2 [M+H+H2O] 249.1603, found 249.1655. 
N-4-Methoxyphenyl N’-phenylcarbodiimide (1-30).188 Prepared according to General
Procedure A from the corresponding thiourea (1.63 g, 6.31 mmol), triethylamine (2.66 mL, 18.9 
mmol, 3.00 eq), mesyl chloride (0.97 mL, 13 mmol, 2.0 eq) and DMAP (0.039 g, 0.32 mmol, 5 
mol%) in CH2Cl2 (60 mL). Purification by chromatography on SiO2 (5% EtOAc/hexanes) afforded 
1-30 (1.23 g, 5.49 mmol, 87%) as a colorless oil: 1H NMR (300 MHz, CDCl3) δ 7.35-7.30 (m, 2
H), 7.19-7.13 (m, 5 H), 6.85 (dd, 2 H, J = 6.9 Hz, 2.4 Hz), 3.80 (s, 3 H). 
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N, N'-Diallylcarbodiimide (1-31). Prepared according to General Procedure A from the 
corresponding thiourea (1.00 g, 6.40 mmol), DMAP (0.039 g, 0.32 mmol), triethylamine (2.69 
mL, 19.2 mmol), and mesyl chloride (1.00 mL, 12.8 mmol) in CH2Cl2 (30 mL). Purification by 
filtration through Celite afforded carbodiimide 1-31 (0.456 g, 3.73 mmol, 58%) as a clear oil: 1H 
NMR (400 MHz, CDCl3) δ 5.90, 5.27, 5.18 (ABX, 2 x 3 H, JAX = 17.2 Hz, JBX  = 10.0 Hz, JAB = 
1.6 Hz), 3.82 (d, 2 x 2 H, J = 4.8 Hz). 13C NMR (100 MHz, CDCl3) δ 141.0, 134.6, 116.4, 48.8.  
 
 
General Procedure B (Hydrophosphination of Carbodiimides): (N-Cyclohexyl, N’-(3, 5-
trifluoromethyl) phenylcarbamimidoyl)-dicyclohexylphosphine borane (1-32). A 5 mL vial 
was flushed with Ar and charged with di-tert-butyl phosphine borane (0.064 g, 0.40 mmol) and 
carbodiimide 1-30 (0.075 g, 0.33 mmol). These materials were dissolved in dimethylacetamide (2 
mL) and sparged with Ar for 10 min. The flask was then cooled in an ice bath. Sodium hydride 
(0.016 g, 0.40 mmol, 60% dispersion) was then added at once, causing immediate gas evolution, 
and foaming to a white suspension. After 15 min, the ice bath was removed and then the reaction 
mixture allowed to warm to rt. After 15 min at rt, the reaction was stirred vigorously while open 
to the air for 30 minutes (the solution had a distinct green color). The reaction mixture was treated 
with sat aq NH4Cl (2 mL), and extracted with diethyl ether (2 x 30 mL). The combined organic 
phases were then washed with water (30 mL), dried (Na2SO4), and concentrated to give a crude 
sticky oil. Purification by chromatography on SiO2 (5% EtOAc/hexane) afforded 1-32 (0.100 g, 
 91 
0.260 mmol, 78%) as a clear oil: 1H NMR (500 MHz, CDCl3) δ  7.96 (s, 0.5 H), 7.86 (s, 0.5 H), 
6.96-6.86 (m, 2 H), 6.82 (t, 0.5 H, J = 7.5 Hz), 6.69 (t, 0.5 H, J = 7.5 Hz), 6.61-6.46 (m, 4 H), 6.44 
(dd, 1 H, J = 7.0 Hz, 2.0 Hz), 3.65 (s, 3 H), 1.53 (s, 9 H), 1.51 (s, 9 H), 1.1-0.3 (br, 3 H); 13C NMR 
(100 MHz, CDCl3, 1JCP not resolved) δ 128.0, 127.9, 124.1, 123.7, 122.1, 121.8, 121.3, 120.4, 
113.4 (3JCP = 14 Hz), 55.5, 33.8, 28.4, 27.3; 31P NMR (162 MHz, CDCl3) δ 52.1; 11B NMR (128 
MHz, CDCl3) δ –43; HRMS (ESI)+ m/z calcd for C22H32N2OP [M+H–BH3] 371.2252, found 
371.2265. This compound exhibits rotomers and/or E-Z isomers by NMR.  
 
 (3,5-Bis(trifluoromethyl)phenyl)-N-cyclohexylcarbamimidoyldicyclohexyl 
phosphine borane (1-33).31 Prepared according to General Procedure B from 
dicyclohexylphosphine borane (0.080 g, 0.38 mmol), carbodiimide 1-28 (0.106 g, 0.315 mmol) 
and sodium hydride (0.015 g, 0.38 mmol, 60%) in DMAc (1.2 mL). Purification by 
chromatography on SiO2 (5% EtOAc/hexane) afforded phosphine borane 1-33 (0.095 g, 0.17 
mmol, 55%) as a clear oil that solidified to a colorless solid on standing: Mp 97.5–98.9 oC; 1H 
NMR (400 MHz, CDCl3) δ 6.43 (t, 1 H, J = 9.2 Hz), 6.30 (d, 2 H, J = 6.8 Hz), 5.84 (br s, 1 H), 
3.07 (br s, 1 H), 2.10-2.00 (m, 2 H), 1.90-0.75 (m, 30 H), 1.0-0.0 (br, 3 H); 13C NMR (100 MHz, 
CDCl3, CF3 not resolved) δ 164.5, 164.3, 162.0, 161.9, 153.2, 147.9 (d, 1JCP = 68 Hz), 103.5 (d, 
3JCP = 25 Hz), 97.2 (t, 3JCP = 27 Hz), 52.0, 33.1, 32.3, 31.9, 26.9, 26.69, 26.66, 25.9, 25.2, 24.2; 
31P NMR (162 MHz, CDCl3) δ 41.1; 11B NMR (128 MHz, CDCl3) δ −44; HRMS (ESI)+ m/z calcd 
for C27H38F6N2P [M+H–BH3] 535.2677, found 535.2661.  
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(N-Phenyl, N’-2-methoxylphenylylcarbamimidoyl)-dicyclohexylphosphine borane (1-34). 
Prepared according to general Procedure B from dicyclohexylphosphine borane (0.536 g, 2.53 
mmol), carbodiimide 1-29 (0.485 g, 2.10 mmol) and sodium hydride (0.101 g, 1.06 mmol, 60%) 
in DMAc (10 mL). Purification by chromatography on SiO2 (5% EtOAc/hexane) afforded 
phosphine borane 1-34 (0.540 g, 1.22 mmol, 58%) as a colorless oil: 1H NMR (400 MHz, 
CDCl3) δ 6.93 (t, 1 H, J = 7.6 Hz), 6.86-6.71 (m, 3 H), 5.67 (t, 3 H, J = 3.2 Hz), 3.75 (s, 3 H), 
2.95-2.79 (m, 1 H), 2.23-2.07 (m, 2 H), 1.95-1.48 (m, 18 H), 1.45-0.70 (m, 13 H); 13C NMR 
(100 MHz, CDCl3) δ 150.2, 147.0 (1JCP = 77 Hz), 139.6 (3JCP = 13 Hz), 122.8, 121.1, 120.5, 
110.6, 55.1, 51.5 (3JCP = 6 Hz), 34.7, 33.7, 32.1, 31.8, 31.6, 26.8, 26.82, 26.77, 26.69, 26.65, 
26.63, 26.61, 25.29, 25.26, 24.4, 14.1; 31P NMR (162 MHz, CDCl3) δ 39.1; 11B NMR (128 MHz, 
CDCl3) δ –45; HRMS (ESI)+ m/z calcd for C26H45N2OPB [M+H] 443.3362, found 433.3353.  
(N, N'-Diallylcarbamimidoyl)-dicyclohexylphosphine borane (1-35). Prepared according to 
General Procedure B from carbodiimide 1-31 (0.150 g, 1.23 mmol), dicyclohexylphosphine borane 
(0.312 g, 1.47 mmol), and NaH dispersion (0.059 g, 1.47 mmol) in DMAc (6 mL). Purification by 
chromatography on SiO2 (5% EtOAc in hexane) to afforded 1-35 (0.153 g, 0.458 mmol, 37%) as 
a yellow oil: 1H NMR (400 MHz, CDCl3) δ 6.08-5.70 (m, 2 H), 5.35-5.04 (m, 4 H), 4.14 (s, 2 H), 
3.95 (s, 2 H), 2.40-1.05 (m, 22 H), 0.90-0.05 (br, 3 H); IR (ATR): 3368, 2934, 2376, 1629, 1450, 
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1077, 982, 917 cm-1; 31P NMR (162 MHz, CDCl3) δ 38.4; 11B NMR (128 MHz, CDCl3) δ –44; 
HRMS m/z calcd for C19H34N2P [M+H–BH3] 321.2454, found 321.2432. Significant broadening 
was observed in the 1H and 13C NMR spectra. 
 
(N, N’-Dicyclohexylcarbamimidoylium)- dicyclohexylphosphine borane tetrafluoroborate 
(1-36).31 A solution of phosphine borane 1-19 (0.077 g, 0.18 mmol) in CH2Cl2 (1.5 mL) was cooled 
to 0 °C under Ar and treated with HBF4 diethyl ether complex (0.37 mL, 2.8 mmol, 15 eq). After 
30 min at 0 °C, the reaction was warmed to rt over 30 min. The solution was opened to air, treated 
with aq HBF4 (1.5 mL), and stirred for 30 min more. The solution was then diluted with water (5 
mL) and extracted with CH2Cl2 (2 x 15 mL). The combined extracts were washed with brine, dried 
(Na2SO4) and were concentrated to afford 1-36 (0.075 g, 0.15 mmol, 81%) as a colorless crystalline 
solid: Mp 259–261 oC; 1H NMR (400 MHz, CDCl3) δ 7.46-7.34 (br s, 1 H), 4.75-4.65 (m, 1 H), 
3.62-3.38 (m, 2 H), 2.40-2.25 (m, 2 H), 1.95-1.10 (m, 41 H); 13C NMR (100 MHz, CDCl3, ) δ 
158.1 (1JCP = 30 Hz), 156.2 (1JCP = 27 Hz), 58.6, 53.3 (3JCP = 3 Hz), 34.9, 34.7, 32.8, 32.6, 32.1, 
31.8, 31.2, 28.3, 27.8, 27.7, 27.2, 26.42, 26.38, 26.3, 26.0, 25.9, 25.8, 25.7, 25.42, 25.40, 25.1, 
25.0, 24.4, 24.2, 23.2; 31P NMR (162 MHz, CDCl3) δ 60.0, 56.9; 11B NMR (128 MHz, CDCl3, 
measured without lock) δ –0.9, –45.4. A single crystal suitable for X-ray analysis was grown from 
hexanes/acetone (1:1). The X-ray crystal structure data for the compound has been deposited with 
CCDC #997593. 
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N-Cyclohexyl, N’-phenylcarbamimidoyl)-di-(3, 5-dimethyl-4-methoxyphenyl)
phosphine oxide (1-38).31 A solution of phosphine 1-37 (0.052 g, 0.10 mmol, obtained from 
collaborators) in acetone (1 mL) was treated with hydrogen peroxide (0.12 mL, 0.11 mmol, 3% 
aq. solution). The reaction mixture was stirred for 1 h at rt; TLC analysis (10% EtOAc/hexanes) 
showed a clean and quantitative oxidation. The solution was diluted with water (5 mL) and 
extracted with Et2O (2 x10 mL). The combined organic extracts were washed with water (10 mL), 
brine (10 mL), dried (Na2SO4), and concentrated to afford phosphine oxide 1-38 (0.053 g, 0.10 
mmol, 99%) as a sticky colorless gum: 1H NMR (400 MHz, CDCl3) (significant broadening) δ 
7.60-7.41 (m, 4 H), 7.22-6.60 (m, 5 H), 6.30-6.20 (br s, 1 H), 3.74 (s, 6 H), 2.28 (s, 12 H), 1.78-
0.95 (m, 11 H); 13C NMR (100 MHz, CDCl3) δ 160.4 (s), 132.9, 132.8, 131.3, 131.2, 128.2, 126.3, 
125.3, 122.0, 120.8, 59.6, 33.3, 25.4, 24.7, 16.2; 31P NMR (162 MHz, CDCl3) δ 20.0; HRMS 
(ESI)+ m/z calcd for C31H40N2O3P [M+H] 519.2777, found 519.2764. 
5, 6-Didehydro-12, 13-dihydrodibenzodiazonine (1-41).46 A solution of dianiline 1-39 (3.50 g, 
16.4 mmol) in 2 M HCl (60 mL) was cooled to 0 oC and treated dropwise with a solution of sodium 
nitrite (3.41 g, 49.5 mmol, 3.00 eq) in H2O (30 mL). The yellow solution was stirred for 1 h at 0 
oC, then was treated dropwise with a solution of sodium azide (4.29 g, 65.0 mmol, 4.00 eq) in 
water (35 mL), which caused considerable foaming. The mixture warmed to rt and stirred for 24 
 95 
h, which resulted in formation of a tan precipitate. After addition of CH2Cl2 (75 mL) and water 
(10 mL), the layers were separated and the organic layer was dried (Na2SO4) and concentrated in 
vacuo. The crude material was filtered through a short plug of SiO2 with 30% EtOAc in hexanes. 
Concentration of the eluent afforded diazide 1-40 (3.61 g, 13.7 mmol, 83%) as a tan solid: 1H 
NMR (400 MHz, CDCl3) δ 7.26 (td, 2 H, J = 9.0 Hz, 1.8 Hz), 7.12 (t, 4 H, J = 6.6 Hz), 7.04 (app 
t, 2 H, J = 7.2 Hz), 2.82 (s, 4 H); IR (ATR) 3085, 2993, 2115, 1485, 1286, 1163, 751 cm-1. 
A solution of diazide 1-40 (3.61 g, 13.7 mmol) in Et2O (100 mL) under N2 at rt was treated 
with triphenylphosphine (7.17 g, 27.3 mmol). The opaque brown solution was stirred at rt for 20 
h and developed a brown precipitate. The solvent was removed in vacuo to afford the 
iminophosphorane (10.1 g) as a buff solid that was used without further purification: 1H NMR 
(400 MHz, CDCl3) δ 7.85-7.23 (m, 32 H), 7.12-7.01 (d, 3 H, J = 6.6 Hz), 6.80-6.45 (m, 6 H), 3.23-
3.05 (s, 4 H); IR (ATR) 3026, 1594, 1479, 1450, 1340, 1103, 726, 691cm-1.  
A suspension of the iminophosphorane (2.40 g, 3.27 mmol) in CH2Cl2 (200 mL) was 
sparged with a balloon CO2 at rt for 4 h, over which period the reaction mixture turned from opaque 
to transparent yellow/brown. The reaction mixture was concentrated, and the concentrate was 
purified by chromatography on SiO2 (10% EtOAc/hexane) to afford carbodiimide 1-41 (0.68 g, 
3.1 mmol, 94%) as a colorless solid: Mp 141.9–142.8 °C; 1H NMR (400 MHz, CDCl3) δ 7.37-7.20 
(m, 4 H), 7.16-7.01 (m, 4 H), 3.41-3.27 (m, 2 H), 3.12-2.97 (m, 2 H); IR (ATR) 2974, 2104, 2091, 
1737, 1595, 1450, 1140, 734 cm-1. This material contained ca. 10% of dimeric bis-carbodiimide 
that was readily removed in subsequent transformations. 
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6-(Di-t-butylphosphanyl)-12, 13-dihydrodibenzodiazonine borane (1-42).31 Prepared 
according to General Procedure B from carbodiimide 1-41 (0.065 g, 0.30 mmol), di-t-butyl 
phosphine borane (0.057 g, 0.35 mmol) and NaH (0.014 g, 0.35 mmol, 60% dispersion) in DMAc 
(1.2 mL). Purification by chromatography on SiO2 (5% EtOAc/hexanes) afforded 1-42 (0.075 g, 
0.20 mmol, 67%) as a colorless crystalline solid: Mp 174–177 oC; 1H NMR (400 MHz, CDCl3) δ 
7.61 (s, 1 H), 6.92-6.73 (m, 5 H), 6.69 (d, 1 H, J = 7.2 Hz), 6.63 (t, 1 H, J = 7.2 Hz), 6.49 (d, 1 H, 
J = 7.6 Hz), 3.45-3.26 (m, 2 H), 2.97-2.83 (m, 2 H), 1.58 (s, 9 H), 1.54 (s, 9 H), 1.2-0.1 (br, 3 H); 
13C NMR (100 MHz, CDCl3) δ 147.9 (3JCP = 11 Hz), 146.3 (1JCP = 75 Hz), 137.7, 137.5 (3JCP = 8 
Hz), 130.9, 130.2, 128.4, 127.0, 126.7, 126.6, 126.5, 122.3, 120.3, 34.3 (1JCP = 27 Hz), 33.6 (1JCP 
= 26 Hz), 30.4 (2JCP = 7 Hz), 28.8, 28.2; 31P NMR (162 MHz, CDCl3) δ 52.6; 11B NMR (128 MHz, 
CDCl3) δ –42; HRMS (ESI)+ m/z calcd for C23H34N2PB [M+H] 381.2631, found 381.2622. The 
X-ray crystal structure data for this compound has been deposited (CCDC #1008171). 
 
6-(Dicyclohexylphosphanyl)-12, 13-dihydrodibenzodiazonine borane (1-43). Prepared 
according to General Procedure B from carbodiimide 1-41 (0.15 g, 0.68 mmol), 
dicyclohexylphosphine borane (0.173 g, 0.817 mmol), and NaH (0.032 g, 0.82 mmol, 60% 
dispersion) in DMAc (3 mL). Purification by chromatography on SiO2 (10% EtOAc/hexane) 
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afforded phosphine borane 1-43 (0.212 g, 0.049 mmol, 72%), with a trace amount of inseparable 
phosphine borane starting material, as a clear oil: 1H NMR (400 MHz, CDCl3) δ 7.25-7.20 (s, 1 
H), 6.91-6.73 (m, 5 H), 6.67 (d, 1 H, J = 7.2 Hz), 6.60 (t, 1 H, J = 7.2 Hz), 6.42 (d, 1 H, J = 7.6 
Hz), 3.36-3.23 (m, 2 H), 3.02-2.80 (m, 2 H), 2.47-2.20 (m, 2 H), 2.15-1.18 (m, 20 H), 0.9-0.1 (br, 
3 H); 13C NMR (100 MHz, CDCl3) δ 148.0 (d, 3JCP = 12 Hz), 145.9 (d, 1JCP = 78 Hz), 137.4 (d, 
3JCP = 8 Hz), 130.8, 130.4, 128.5, 126.9, 126.7, 126.6, 126.1, 122.5, 120.2, 32.0, 31.63, 31.57, 
31.2, 30.7, 30.0, 29.4, 29.3, 29.1, 28.7, 27.7, 27.0, 26.83, 26.76, 26.72, 26.67, 26.65, 26.6, 26.5, 
26.4, 26.3, 26.1, 26.1, 25.8; 31P NMR (162 MHz, CDCl3) δ 38.3; 11B NMR (128 MHz, CDCl3) δ 
–43.1; IR (ATR) 3334, 2933, 2862, 2378, 1629, 1480, 1325, 1215, 1077, 767, 734 cm-1; HRMS
(ESI)+ m/z calcd for C27H39N2PB [M+H] 433.2944, found 433.2930. 
6-(Ditolylphosphanyl)-12, 13-dihydrodibenzodiazonine borane (1-44).31 Prepared according to 
General Procedure B from carbodiimide 1-41 (0.200 g, 0.907 mmol), di-tolyl phosphine borane 
(0.249 g, 1.09 mmol) and NaH (0.022 g, 0.55 mmol, 60% dispersion) in DMAc (5 mL). 
Purification by chromatography on SiO2 (10% EtOAc/hexanes) afforded phosphine borane 1-44 
(0.319 g, 0.712 mmol, 78%) as a colorless crystalline solid: Mp 189.7–191.5 oC; 1H NMR (400 
MHz, CDCl3) δ 8.01 (d, 1 H, J = 8.0 Hz), 7.98 (d, 1 H, J = 8.4 Hz), 7.85 (d, 1 H, J = 8.0 Hz), 7.82 
(d, 1 H, J = 8.4 Hz), 7.42 (s, 1 H), 7.31 (td, 4 H, J = 6.4 Hz, 2.0 Hz), 6.86-6.80 (m, 3 H), 6.79-6.72 
(m, 2 H), 6.63-6.54 (m, 2 H), 6.42 (d, 1 H, J = 7.6 Hz), 3.23-3.15 (m, 1 H), 2.97-2.86 (m, 1 H), 
2.78-2.66 (m, 2 H), 2.43 (s, 3 H), 2.41 (s, 3 H), 1.5-0.8 (br, 3 H); 13C NMR (100 MHz, CDCl3) δ 
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148.7 (1JCP = 91 Hz), 148.0 (3JCP = 13 Hz), 142.7 (4JCP = 2 Hz), 142.1 (4JCP = 2 Hz), 137.3 (3JCP = 
10 Hz), 136.9, 133.6 (2JCP = 10 Hz), 133.2 (2JCP = 10 Hz), 130.7, 130.4, 129.6 (3JCP = 11 Hz), 
128.4, 126.6, 126.5, 125.4, 124.2 (1JCP = 64 Hz), 123.3 (1JCP = 61 Hz), 122.6, 119.6, 31.1, 29.2, 
21.7, 21.6; 31P NMR (162 MHz, CDCl3) δ 19.4; 11B NMR (128 MHz, CDCl3) δ –40.4; IR (ATR) 
3340, 3026, 2378, 1637, 1486, 1356, 1128, 1045, 908, 802, 734 cm-1; HRMS (ESI)+ m/z calcd for 
C29H28N2P [M+H–BH3] 435.1990, found 435.1975. An X-ray crystal structure was obtained for 
this molecule. 
 
6-(Di-(3, 5-dimethyl-4-methyoxy)phenylphosphanyl)-12, 13-dihydrodibenzodiazonine 
borane (1-45).31 Prepared according to General Procedure B from carbodiimide 1-41 (0.084 g, 
0.38 mmol), di-(3,5-dimethyl-4-methoxy)phosphine borane (0.133 g, 0.545 mmol) and NaH 
(0.018 g, 0.46 mmol, 60% dispersion) in DMAc (3 mL). Purification by chromatography on SiO2 
(10% EtOAc/hexanes) afforded phosphine borane 1-45 (0.171 g, 0.319 mmol, 83%) as a colorless 
foam: 1H NMR (400 MHz, CDCl3) δ 7.79 (d, 2 H, J = 10.8 Hz), 7.54 (d, 2 H, J = 11.2 Hz), 7.43 
(s, 1 H), 6.89-6.83 (m, 3 H), 6.80-6.74 (m, 2 H), 6.63-6.55 (m, 2 H), 6.44 (d, 1 H, J = 7.6 Hz), 3.79 
(s, 3 H), 3.76 (s, 3 H), 3.27-3.18 (m, 1 H), 2.92-2.81 (m, 1 H), 2.79-2.68 (m, 2 H), 2.36 (s, 6 H), 
2.33 (s, 6 H), 1.5-0.2 (br, 3 H); 13C NMR (125 MHz, CDCl3) δ 160.5 (4JCP = 2 Hz), 159.9 (4JCP = 
2 Hz), 149.2 (1JCP = 91 Hz), 148.0 (3JCP = 13 Hz), 137.3 (3JCP = 10 Hz), 136.6, 134.3 (2JCP = 11 
Hz), 133.8 (2JCP = 10 Hz), 131.8 (3JCP = 24 Hz), 131.8, 130.6 (3JCP = 17 Hz), 128.4, 126.7, 126.5, 
126.4, 125.1, 122.6, 122.0 (1JCP = 65 Hz), 120.9 (1JCP = 60 Hz), 119.4, 59.8, 59.7, 31.2, 28.8, 16.4, 
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16.3; 31P NMR (162 MHz, CDCl3) δ 19.8; 11B NMR (128 MHz, CDCl3) δ –38.3; IR (ATR) 3345, 
2934, 2378, 1637, 1480, 1278, 1114, 917, 734 cm-1; HRMS (ESI)+ m/z calcd for C33H36N2O2P 
[M+H–BH3] 523.2514, found 523.2494. 
 
6-(Cyclohexylphenylphosphanyl)-12, 13-dihydrodibenzodiazonine borane (1-46).31 Prepared 
according to general Procedure B from carbodiimide 1-41 (0.100 g, 0.454 mmol), 
phenylcyclohexyl phosphine borane (0.112 g, 0.545 mmol) and NaH (0.022 g, 0.55 mmol, 60% 
dispersion) in DMAc (2 mL). Purification by chromatography on SiO2 (hexanes) to afforded 
phosphine borane 1-46 (0.134 g, 0.314 mmol, 69%) as a colorless solid that is an equilibrating 
mixture of rotomers/isomers in solution: Mp 164–166 oC; IR (ATR) 3353, 2934, 2385, 1644, 1474, 
1435, 1260, 726, 692 cm-1;1H NMR (400 MHz, CDCl3) δ 8.18-8.09 (m, 2 H), 7.63-7.48 (m, 3 H), 
7.28 (s, 0.7 H), 7.13 (s, 0.3 H), 6.93-6.74 (m, 4 H), 6.69 (d, 1 H, J = 7.6 Hz), 6.65-6.54 (m, 2 H), 
6.49 (d, 1 H, J = 7.6 Hz), 3.20-3.09 (m, 0.5 H), 3.10 (dd, 1 H, J = 9.6 Hz, 2.4 Hz), 3.04-2.71 (m, 
1.5 H), 2.69-2.60 (m, 1 H), 2.58-2.43 (m, 1.5 Hz), 2.30-2.15 (m, 1 H), 1.97-1.86 (m, 1 H), 1.80-
1.65 (m, 3 H), 1.48-1.17 (m, 6 H), 1.1-0.4 (br, 3 H); 13C NMR (100 MHz, CDCl3) δ 148.1, 148.0, 
147.4 (1JCP = 57 Hz), 137.2, 137.1, 133.0, 132.9, 132.1, 130.7, 130.5, 130.4, 128.8, 128.7, 128.7, 
128.6, 128.5, 127.1, 126.8, 126.5, 126.4, 126.3, 125.5, 124.9, 122.6, 119.9, 119.8, 33.5, 33.2, 33.1, 
31.1, 30.7, 30.2, 28.4, 26.7, 26.5, 26.4, 25.9, 25.2; 31P NMR (162 MHz, CDCl3) δ 27.1, 25.3; 11B 
NMR (128 MHz, CDCl3) δ –44.3; HRMS (ESI)+ m/z calcd for C27H33N2PB [M+H] 427.2474, 
found 427.2466. 
 100 
 
General Procedure C (Phosphine borane deprotection): 6-(Di-tolylphosphanyl)-12, 13-
dihydrodibenzodiazonine (1-47).31 A solution of phosphine borane 1-44 (0.071 g, 0.16 mmol) in 
toluene (2 mL) was treated under an Ar atmosphere with DABCO (0.025 g, 0.22 mmol) and stirred 
at 60 oC for 90 min. After cooling to rt, the reaction mixture was purified by chromatography on 
SiO2 (5% EtOAc/hexanes) to afford phosphine 1-47 (0.056 g, 0.13 mmol, 81%) as clear sticky oil: 
1H NMR (400 MHz, CDCl3) δ 7.72-7.48 (m, 4 H), 7.25-7.19 (m, 3 H), 6.88-6.76 (m, 3 H), 6.76-
6.59 (m, 4 H), 6.54 (d, 2 H, J = 7.6 Hz), 3.38 (d, 2 H, J = 8.8 Hz), 2.83 (d, 2 H, J = 9.2 Hz), 2.38 
(s, 6 H); 13C NMR (100 MHz, CDCl3) δ 156.5, 139.9, 134.3 (d, 3JCP = 19 Hz), 131.3 (d, 3JCP = 11 
Hz), 130.4, 129.9, 129.8, 126.3, 30.5, 21.4; 31P NMR (162 MHz, CDCl3) δ –3.7; HRMS (ESI)+ 
m/z calcd for C29H28N2P [M+H] 435.1990, found 435.1991. 
 
6-(Di-(3, 5-dimethyl-4-methoxy)phenylphosphanyl)-12, 13-dihydrodibenzo]diazonine (1-
48).31 Prepared according to General Procedure C from phosphine borane 1-45 (0.176 g, 0.328 
mmol) and DABCO (0.147 g, 1.31 mmol) in toluene (2 mL). Purification by chromatography on 
SiO2 (5% EtOAc/hexanes) afforded phosphine 1-48 (0.112 g, 0.214 mmol, 65%) as a sticky oil: 
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1H NMR (400 MHz, CDCl3) δ 7.60-7.29 (br m, 4 H), 6.89-6.50 (br m, 8 H), 6.25-6.10 (br s, 1 H), 
3.80 (s, 6 H), 3.65-3.15 (br m, 2 H), 3.00-2.68 (br m, 2 H), 2.35 (s, 12 H); 13C NMR (100 MHz, 
CDCl3) δ 158.5, 156.7, 156.6, 135.2, 135.0, 131.7, 130.5, 129.5, 129.4, 126.3, 59.7, 31.4, 29.5, 
16.3; 31P NMR (162 MHz, CDCl3) δ –3.2; HRMS (ESI)+ m/z calcd for C33H36N2O2P [M+H] 
523.2514, found 523.2494. 
 
6-(Cyclohexylphenylphosphanyl)-12, 13-dihydrodibenzodiazonine (1-49).31 Prepared 
according to General Procedure C from phosphine borane 1-46 (0.099 g, 0.23 mmol) and DABCO 
(0.104 g, 0.929 mmol) in toluene (2 mL). Purification by chromatography on SiO2 (5% 
EtOAc/hexanes) afforded phosphine 1-49 (0.090 g, 0.22 mmol, 94%) as a colorless oil that is an 
equilibrating mixture of diastereomers in solution: 1H NMR (400 MHz, CDCl3) δ 7.98-7.75 (m, 2 
H), 7.51-7.38 (m, 3 H), 6.94-6.73 (m, 4 H), 6.74-6.63 (m, 2 H), 6.63-6.51 (m, 2 H), 6.51-6.43 (m, 
2 H), 6.03-6.08 (s, 0.3 H), 3.52-3.23 (m, 1.5 H), 3.04-2.57 (m, 2.5 H), 2.49 (d, 1 H, J = 7.6 Hz), 
2.39-2.24 (m, 1 H), 1.95-1.28 (m, 9 H); 13C NMR (100 MHz, CDCl3) δ 155.1, 149.5, 138.6, 136.4, 
135.1, 135.0, 134.7, 134.6, 133.9, 133.8, 130.6, 130.4, 130.1, 128.8, 128.4, 126.6, 126.4, 126.1, 
125.5, 125.1, 124.1, 121.7, 120.3, 119.6, 35.8, 34.8, 31.6, 31.1, 30.7, 30.2, 29.9, 29.8, 28.6, 28.2, 
27.7, 27.6, 26.8, 26.5, 26.3, 26.1, 25.9; 31P NMR (162 MHz, CDCl3) δ 3.6, 2.5; HRMS (ESI)+ m/z 
calcd for C27H30N2P [M+H] 413.2147, found 413.2144. 
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6-(Di-tolylphosphanyloxide)-12, 13-dihydrodibenzodiazonine (1-50). A solution of phosphine 
1-47 (0.019 g, 0.044 mmol) in acetone (1 mL) was treated with hydrogen peroxide (0.05 mL, 0.04 
mmol, 3% aq. soln) at rt. After stirring for 15 min, the reaction mixture was partitioned between 
water and EtOAc (10 mL each). The phases were separated, and the aqueous phase was re-
extracted with EtOAc (10 mL). The combined organic phases were washed with water (15 mL), 
brine (15 mL), dried (Na2SO4) and concentrated to afford phosphine oxide 1-50 (0.017 g, 0.038 
mmol, 86%) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 8.10-7.91 (m, 5 H), 7.33 (dd, 4 H, J 
= 7.6 Hz, 2.4 Hz), 6.91-6.72 (m, 5 H), 6.67-6.54 (m, 2 H), 6.42 (d, 1 H, J = 7.6 Hz), 3.16-3.04 (m, 
1 H), 3.02-2.90 (m, 1 H), 2.81-2.65 (m, 2 H), 2.43 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 150.6, 
149.1, 147.7, 147.5, 142.9, 142.9, 142.8, 142.8, 137.0, 137.0, 136.9, 132.3, 132.2, 132.1, 132.0, 
130.7, 130.3, 129.3, 129.3, 129.2, 129.2, 128.6, 128.3, 128.1, 127.2, 127.0, 126.6, 126.6, 126.5, 
125.8, 122.5, 120.0, 30.9, 29.4, 21.7; 31P NMR (162 MHz, CDCl3) δ 18.2. 
 
6-(Di-(3, 5-dimethyl-4-methoxy)phenylphosphanyloxide)-12, 13-dihydrodibenzo- 
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diazonine (1-51).31 A solution of phosphine 1-48 (0.094 g, 0.16 mmol) in acetone (1 mL) was 
treated with hydrogen peroxide (0.2 mL, 0.2 mmol, 3% aq. soln) at rt. After stirring for 15 min, 
the reaction mixture was partitioned between water and EtOAc (20 mL each). The phases were 
separated, and the aqueous phase was extracted with EtOAc (20 mL). The combined organic 
phases were washed with water (25 mL) and brine (25 mL), then were dried (Na2SO4) and 
concentrated to afford phosphine oxide 1-51 (0.088 g, 0.16 mmol, 91%) as a colorless crystalline 
solid: Mp 236–238 oC; 1H NMR (400 MHz, CDCl3) δ 7.90 (d, 1 H, J = 2.8 Hz), 7.81 (d, 2 H, J = 
12.0 Hz), 7.76 (d, 2 H, J = 12.0 Hz), 6.89-6.73 (m, 5 H), 6.66-6.56 (m, 2 H), 6.43 (d, 1 H, J = 7.6 
Hz), 3.79 (s, 3 H), 3.78 (s, 3 H), 3.21-3.09 (m, 1 H), 2.98-2.87 (m, 1 H), 2.81-2.66 (m, 2 H), 2.34 
(s, 12 H); 13C NMR (100 MHz, CDCl3) δ 160.7, 160.6, 160.5, 160.5, 150.6, 149.1, 147.8, 147.6, 
137.1, 137.0, 136.7, 133.1, 133.0, 132.8, 132.6, 131.6, 131.5, 131.5, 131.4, 130.7, 130.4, 128.7, 
126.7, 126.5, 126.5, 126.1, 125.9, 125.6, 125.0, 124.9, 122.6, 119.9, 59.7, 59.7, 31.0, 29.0, 16.3, 
16.2; 31P NMR (162 MHz, CDCl3) δ 18.5; IR (ATR) 3202, 2934, 1627, 1480, 1286, 1215, 1163, 
1115, 994, 758 cm-1; HRMS (ESI)+ m/z calcd for C33H36N2PO3 [M+H] 539.2458, found 539.2443. 
 
6-(Phospholan-1-yl)-12,13-dihydro-5H-dibenzo[1,3]diazonine borane (1-59). Prepared 
according to General Procedure B from phospholane borane 1-54 (0.080 g, 0.78 mmol), 
carbodiimide 1-41 (0.207 g, 0.942 mmol) and sodium hydride (0.037 g, 0.94 mmol, 60% 
dispersion) in DMAc (3 mL). Purification by was chromatography on SiO2 (hexanes to 15% 
EtOAc/hexanes) afforded 1-59 (0.153 g, 0.475 mmol, 35%) as a colorless solid: Mp 118–121 oC; 
1H NMR (400 MHz, CDCl3) δ 7.19 (s, 1 H), 6.92-6.75 (m, 5 H), 6.64 (d, 1 H, J = 6.4 Hz), 6.60 (t, 
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1 H, J = 7.2 Hz), 6.42 (d, 1 H, J = 7.6 Hz), 3.26 (td, 1 H, J = 10.0 Hz, 2.8 Hz), 3.20-3.10 (m, 1 H), 
2.95 (t, 1 H, J = 10.4 Hz, 2.8 Hz), 2.83 (ddd, 1 H, J = 12.8 Hz, 10.0 Hz, 6.4 Hz), 2.57 (ddd, 1 H, J 
= 14.4 Hz, 6.8 Hz, 6.8 Hz), 2.51-2.40 (m, 1 H), 2.21-1.97 (m, 4 H), 0.83 (q, 3 H, 1JBH = 82 Hz); 
13C NMR (100 MHz, CDCl3) δ 149.5 (1JCP = 78 Hz), 147.7 (3JCP = 12 Hz), 137.2, 137.1, 136.6, 
130.7, 130.4, 128.1, 126.8, 126.7, 126.6, 125.5, 122.6, 119.9, 30.8, 29.8, 27.6, 27.5 (3JCP = 8 Hz), 
29.9 (1JCP = 36 Hz), 26.1 (1JCP = 36 Hz), 24.2 (1JCP = 38 Hz); 31P NMR (161 MHz, CDCl3) δ 40.1; 
11B NMR (128 MHz, CDCl3) δ –39; IR (ATR) 3358, 2951, 2365, 1629, 1474, 1053, 751 cm-1; MS 
(ESI)+ m/z 321, 309, 221; HRMS (ESI)+ m/z calcd for C19H22N2P [M+H–BH3] 309.1521, found 
309.1514. 
 
6-(2,5-Diphenylphospholan-1-yl)-12,13-dihydro-5H-dibenzo[1,3]diazonine borane (1-60). 
Prepared according to General Procedure B from phosphine borane (S, S)-1-5827 (0.119 g, 0.468 
mmol), carbodiimide 1-41 (0.086 g, 0.39 mmol), and sodium hydride (0.019 g, 0.47 mmol, 60%) 
in DMAc (2 mL). Purification by chromatography on SiO2 (5% EtOAc/hexane) afforded 1-60 
(0.113 g, 0.238 mmol, 61%) as a colorless solid: [α]D +22 (c = 0.5, CH2Cl2); Mp 184–188 oC; IR 
(ATR) 3340, 3026, 3058, 2951, 2378, 1629, 1485, 907, 727 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.67-7.53 (m, 2 H), 7.52-7.21 (m, 8 H), 6.89-6.73 (m, 2 H), 6.71-6.48 (m, 4 H), 6.34 (d, 0.5 H, J 
= 7.6 Hz), 5.56 (d, 0.5 H, J = 7.2 Hz), 4.89-4.73 (m, 1 H), 3.96-3.75 (m, 1 H), 3.19 (app d, 1 H, J 
= 8.4 Hz), 2.91-2.73 (m, 1 H), 2.74-2.15 (m, 6 H), 1.35-1.15 (m, 2 H), 1.1-0.1(br q, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 147.9 (2JCP = 12 Hz), 147.5 (2JCP = 12 Hz), 146.8 (1JCP = 72 Hz), 146.3 (1JCP 
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= 74 Hz), 138.0, 137.1, 137.0, 136.9, 136.7, 136.5, 136.4, 135.8 (JCP = 5 Hz), 136.7 (JCP = 5 Hz), 
130.4 (1JCP = 73 Hz), 130.5, 130.4, 130.0, 129.0, 128.8, 128.7, 128.61, 128.59, 128.54, 128.49, 
128.3 (JCP = 4 Hz), 128.0 (JCP = 4 Hz), 127.6, 127.5, 127.3, 127.1, 126.7, 126.6, 126.5, 126.4, 
126.3, 125.4, 122.8, 122.5, 120.5, 120.3, 120.3, 48.0 (1JCP = 29 Hz), 47.5 (1JCP = 29 Hz), 45.6 (1JCP 
= 32 Hz), 43.4 (1JCP = 32 Hz), 38.8, 32.8 (2JCP = 5 Hz), 32.5 (2JCP = 6 Hz), 30.9, 30.8, 30.5 (2JCP = 
6 Hz), 29.9, 29.0; 31P NMR (162 MHz, CDCl3) δ 51.7; HRMS (ESI)+ m/z calcd for C31H33N2PB 
[M+H] 475.2469, found 475.2473. 
HN N
P PhPh
1-61  
6-(2,5-Diphenylphospholan-1-yl)-12,13-dihydro-5H-dibenzo[1,3]diazonine (1-61). Prepared 
according to General Procedure C from phosphine borane 1-60 (0.050 g, 0.11 mmol) and DABCO 
(0.047 g, 0.42 mmol) in toluene (1.5 mL). Purification by chromatography on SiO2 (5% 
EtOAc/hexane) afforded phosphine 1-61 (0.037 g, 0.080 mmol, 76%) as a colorless oil: 31P NMR 
(202 MHz, CDCl3) δ 28.0. 
 
Bis[6-(2,5-Diphenylphospholan-1-yl)-12,13-dihydro-5H-dibenzo[1,3]diazonine] platinum 
chloride complex (1-62). A solution of phosphine 1-61 (0.169 g, 0.38 mmol) in CH2Cl2 (3 mL) 
was treated with PtCl2 (0.102 g, 0.380 mmol).  The vial was sealed under Ar and stirred at rt for 1 
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h, at which point NMR indicated formation of a complex. The heterogeneous reaction mixture was 
filtered through a syringe filter, and the eluent was placed in a vapor diffusion chamber with methyl 
t-butyl ether (30 mL). After standing for 9 days, yellow rectangular crystals Pt complex 1-62 
formed: 31P NMR (202 MHz, CDCl3) δ 52.9 (JPtP = 2532 Hz). An X-ray crystal structure was 
obtained for this complex. 
5.3 CHAPTER 2 EXPERIMENTAL PART 
 
3-Methylbicyclo[1.1.0]butane-1-carbonitrile (2-37).97 A mixture of 3-
methylenecyclobutanecarbonitrile 2-35 (10.0 g, 0.107 mol) and 48% HBr (21 mL, 0.376 mol, 3.5 
eq) was vigorously stirred at room temperature for 24 h. The reaction mixture was partitioned 
between water and ether (100 mL), the phases were separated, and the aqueous layer was extracted 
with ether (2 x 75 mL). The combined ethereal solution was washed with water (100 mL) then sat. 
aq. NaHCO3 (100 mL). The organic layer was dried (MgSO4), filtered, and concentrated to afford 
the bromocyclobutane 2-36 (13.44 g, 77.20 mmol, 72%) as a colorless liquid with a dr of 1.7:1. 
Characteristic signal for the major isomer: 1H NMR (300 MHz, CDCl3) δ 1.95 (s, 3 H). 
Characteristic signal for the minor isomer: 1H NMR (300 MHz, CDCl3) δ 1.89 (s, 3 H). 
A solution of bromide 2-36 (13.43 g, 77.17 mmol) in THF (70 mL) in a dry 3-necked 250-
mL round bottom flask fitted with a stopper, septum, and N2 inlet was treated with NaH (3.06 g, 
77.2 mmol) in portions over 5 min. The flask was stirred at 35 °C for 12 h, then at reflux for 5 h. 
After cooling, the grey/brown reaction mixture was quenched with sat. aq. NH4Cl (25 mL). The 
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reaction mixture was then partitioned between diethyl ether (100 mL) and water (100 mL), the 
layers were separated, and the aqueous layer was re-extracted with ether (75 mL). The combined 
organic layers were washed with water (100 mL) and brine (100 mL), dried (Na2SO4) and 
concentrated to afford a yellow-tinted cloudy liquid. The crude material was purified by bulb-to-
bulb distillation (bath temp 75 °C, 2 mmHg)) to afford bicyclobutane 2-37 (3.54 g, 38.0 mmol, 
49%) as a colorless liquid: 1H NMR (300 MHz, CDCl3) δ 1.97 (s, 2 H), 1.71 (s, 3 H), 1.28 (s, 2 
H); 13C NMR (75 MHz, CDCl3) δ 120.2, 40.5, 37.0, 23.1, 12.7, -3.4. SAFETY NOTE: The 
distillation should be conducted using the strongest accessible vacuum source and the minimum 
possible temperature.  Although we encountered no difficulty conducting this distillation, 
differential scanning calorimetry analysis suggests that it is unsafe to heat this material above ~100 
°C. 
 
General Procedure D (Bicyclo[1.1.0]butane hydrophosphination): 3-
(Dicyclohexylphosphanyl)-3-methylcyclobutane-1-carbonitrile borane (2-38).97 A solution of 
bicyclobutane 2-37 (0.472 g, 5.07 mmol, 1.2 eq) and dicyclohexyl phosphine borane (0.896 g, 4.22 
mmol) in DMAc (20 mL) was sparged with Ar for 10 min, cooled to 0 °C, and treated with NaH 
(0.203 g, 5.07 mmol, 60% in oil) in one portion. The reaction mixture was stirred for 10 min at 0 
°C, then the bath was removed and the solution was warmed to rt over 2 h. The orange/brown 
reaction mixture was quenched with sat. aq. NH4Cl (5 mL), and the material was partitioned 
between water (30 mL) and diethyl ether (30 mL). The aqueous layer was extracted with ether (30 
mL). The combined extracts were washed with water (40 mL) and brine (40 mL), then were dried 
(Na2SO4) and concentrated. The crude residue was purified by chromatography on SiO2 (15% 
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EtOAc/hexane) to afford cis-2-38 (0.634 g, 2.08 mmol, 49%) and trans-2-38 (0.197 g, 0.645 g, 
15%), both as colorless solids. cis-2-38: Mp 193–195 °C; IR (ATR) 2933, 2386, 1450, 1070, 840 
cm-1; MS (ESI+) m/z 306, 245, 215, 172; 1H NMR (400 MHz, CDCl3) δ 3.37 (pent, 1 H, J = 9.6 
Hz), 3.22-3.09 (m, 2 H), 2.08-2.01 (m, 2 H), 1.91-1.77 (m, 8 H), 1.77-1.67 (br s, 2 H), 1.66-1.58 
(m, 2 H), 1.55 (d, 3 H, 3JPH = 9.2 Hz), 1.48-1.31 (m, 4 H), 1.30-1.15 (m, 6 H), 0.9-0.1 (br q, 3 H); 
31P NMR (162 MHz, CDCl3) δ 35.8; 13C NMR (125 MHz, CDCl3) δ 120.5 (4JCP = 2.5 Hz), 36.3, 
32.7 (1JCP = 26 Hz), 31.5 (1JCP = 29 Hz), 27.69, 27.67, 27.66, 27.65, 27.2, 27.11, 27.08, 27.0, 
25.95, 25.94, 22.1, 22.1, 19.7 (JCP = 17 Hz); HRMS (ESI+) m/z calcd for C18H34BNP [M+H] 
306.2516, found 306.2506. trans-2-38: Mp 165–168 °C; 1H NMR (400 MHz, CDCl3) δ 3.32-3.23 
(m, 1 H), 3.11 (dd, 2 H, J = 10.8 Hz, 2.4 Hz), 2.16-2.07 (m, 2 H), 1.88-1.75 (m, 8 H), 1.75-1.61 
(m, 2 H), 1.67 (d, 3 H, 3JPH = 9.6 Hz), 1.47-1.32 (m, 4 H), 1.30-1.14 (m, 8 H), 0.7-0.0 (br q, 3 H); 
31P NMR (162 MHz, CDCl3) δ 34.3; 13C NMR (100 MHz, CDCl3) δ 122.9 (4JCP = 1.0 Hz), 36.4, 
33.0 (1JCP = 26 Hz), 31.3 (1JCP = 29 Hz), 27.9, 27.1, 27.03, 26.98, 26.9, 25.8, 25.1 (JCP = 3 Hz), 
17.8 (JCP = 9 Hz); IR (ATR) 2933, 2390, 1442, 1072, 734 cm-1; HRMS (ESI+) m/z calcd for 
C18H34BNP [M+H] 306.2516, found 306.2502. 
 
 
 
3-(Di-t-butylphosphanyl)-3-methylcyclobutane-1-carbonitrile borane (2-39).97 Prepared 
according to General Procedure D from di-t-butyl phosphine borane (0.363 g, 2.27 mmol), 
bicyclobutane 2-37 (0.264 g, 2.84 mmol), and NaH (0.100 g, 2.49 mmol, 60% dispersion in oil) in 
DMAc (8 mL). Purification by chromatography on SiO2 (10-30% EtOAc in hexanes) afforded cis-
2-39 (0.327 g, 1.29 mmol, 57%) and trans-2-39 (0.147 g, 0.58 mmol, 26%), both as colorless 
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solids. cis-2-39: Mp 125–127 °C; 1H NMR (400 MHz, CDCl3) δ 3.47-3.31 (m, 3 H), 2.14-2.02 (m, 
2 H), 1.83 (d, 3 H, 3JPH = 8.8 Hz), 1.33 (s, 9 H), 1.30 (s, 9 H), 0.61 (br q, 3 H, 1JBH = 98 Hz); 13C 
NMR (100 MHz, CDCl3) δ 120.6 (4JCP = 3 Hz), 38.1, 35.8 (1JCP = 20 Hz), 35.1 (1JCP = 23 Hz), 
29.6, 23.7 (JCP = 4 Hz), 20.1 (JCP = 18 Hz); 31P NMR (162 MHz, CDCl3) δ 54.7; IR (ATR) 2974, 
2378, 2235, 1480, 1072 cm-1; MS (ESI+) m/z 240, 223, 208, 196, 162, 142, 114; HRMS (ESI+) m/z 
calcd for C14H30BNP [M+H] 254.2203, found 254.2197. trans-2-39: Mp 53–56 °C; 1H NMR (400 
MHz, CDCl3) δ 3.48 (app q, 2 H, J = 12.4 Hz), 3.27-3.17 (m, 1 H), 2.09 (d, 3 H, 3JPH = 9.2), 2.13-
2.05 (m, 2 H), 1.35 (s, 9 H), 1.32 (s, 9 H), 0.53 (br q, 3 H, 1JBH = 98 Hz); 13C NMR (100 MHz, 
CDCl3) δ 123.5, 37.5, 36.9 (1JCP = 20 Hz), 35.1 (1JCP = 23 Hz), 29.6, 26.5 (JCP = 4 Hz), 19.3 (JCP 
= 15 Hz);  31P NMR (162 MHz, CDCl3) δ 53.6. 
 
 
 
3-(Cyclohexyl(phenyl)phosphanyl)-3-methylcyclobutane-1-carbonitrile borane (2-40).97 
Prepared according to General Procedure D from racemic phenyl cyclohexyl phosphine borane 
(0.275 g, 1.33 mmol), bicyclobutane 2-37 (0.136 g, 1.47 mmol, 1.20 eq), and NaH (0.059 g, 1.5 
mmol, 1.2 eq) in DMAc (8 mL). Purification by chromatography on SiO2 (15-40% EtOAc/hexane) 
afforded cis-2-40 (0.189 g, 0.632 mmol, 47%) as a colorless solid and trans-2-40 (0.092 g, 0.31 
mmol, 23%) as a colorless oil. cis-2-40: Mp 137–139 °C; IR (ATR) 2934, 2397, 1448, 1072, 751 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.68 (td, 2 H, J = 8.4, 1.6 Hz), 7.55-7.42 (m, 3 H), 3.30 (pent, 
1 H, J = 9.2 Hz), 3.13 (ddd, 1 H, J = 12.8 Hz, 10.0 Hz, 7.6 Hz), 2.90 (ddd, 1 H, J = 13.6 Hz, 11.6 
Hz, 9.6 Hz), 2.41-2.28 (m, 1 H), 2.10 (ddd, 1 H, J = 16.0 Hz, 4.4 Hz, 3.2 Hz), 1.93-1.83 (m, 1 H), 
1.79-1.55 (m, 5 H), 1.51-1.18 (m, 5 H), 1.42 (d, 3 H, 3JPH = 11.2 Hz), 1.1-0.3 (br m, 3 H); 13C 
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NMR (100 MHz, CDCl3) δ 132.9 (JCP = 7 Hz), 131.5 (JCP = 3 Hz), 128.8, 128.7, 125.0, 124.5, 
120.7, 34.8, 34.2, 32.2 (1JCP = 30 Hz), 30.3 (1JCP = 33 Hz), 26.6, 26.5, 26.4, 26.3, 25.7, 20.9, 18.3 
(2JCP = 18 Hz); 31P NMR (162 MHz, CDCl3) δ 32.0; MS (ESI+) m/z 300, 286, 231, 209, 173, 150; 
HRMS (ESI+) m/z calcd for C18H28BNP [M+H], 300.2047, found 300.2060. trans-2-40: IR (ATR) 
2939, 2858, 2384, 2239, 1437, 1109, 1066, 742 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.70 (td, 2 H, 
J = 8.0 Hz, 1.2 Hz), 7.54-7.41 (m, 3 H), 3.32 (dddd, 1 H, J = 9.6 Hz, 9.6 Hz, 7.2 Hz, 7.2 Hz), 3.15 
(app q, 1 H, J = 12.0 Hz), 2.71 (td, 1 H, J = 13.2 Hz, 11.2 Hz), 2.42-2.29 (m, 1 H), 2.23 (ddd, 1 H, 
J = 12.4 Hz, 6.8  Hz, 6.4 Hz), 1.91-1.78 (m, 2 H), 1.77-1.62 (m, 3 H), 1.53 (d, 3 H, 3JPH = 10.4 
Hz), 1.49-1.38 (m, 1 H), 1.38-1.15 (m, 5 H), 1.2-0.2 (br m, 3 H); 13C NMR (100 MHz, CDCl3) δ 
133.1 (JCP = 8 Hz), 131.7 (JCP = 2 Hz), 128.8, 128.7, 124.7, 124.2, 122.6, 35.7 (JCP = 3 Hz), 34.9, 
32.3 (1JCP = 28 Hz), 30.6 (1JCP = 33 Hz), 26.6 (JCP = 5 Hz), 26.5, 26.4, 26.3, 26.2, 25.6, 24.0 (JCP 
= 3 Hz), 17.0 (JCP = 7 Hz); 31P NMR (162 MHz, CDCl3) δ 30.2; IR (ATR) 2939, 2858, 2384, 2239, 
1437, 1109, 1066, 742 cm-1 
 
 
3-(n-Butyl(furan-2-yl)phosphanyl)-3-methylcyclobutane-1-carbonitrile borane (2-41).97 
Prepared according to General Procedure D from racemic furyl butyl phosphine borane (0.261 g, 
1.54 mmol), bicyclobutane 2-37 (0.172 g, 1.8 mmol, 1.20 eq), and NaH (0.074 g, 1.8 mmol, 1.2 
eq, 60% in oil) in DMAc (8 mL). Purification by chromatography on SiO2 (15-40% 
EtOAc/hexane) afforded cis-2-41 (0.115 g, 0.437 mmol, 28%) and trans-2-41 (0.052 g, 0.20 mmol, 
13%), both as colorless oils. cis-2-41: IR (ATR) 2956, 2933, 2386, 2240, 1456, 1128, 1072, 757 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.74 (s, 1 H), 7.18-7.15 (m, 1 H), 6.53-6.50 (m, 1 H), 3.28 
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(pent, 1 H, J = 9.2 Hz), 2.88 (td, 1 H, 13.2 Hz, 9.2 Hz), 2.69 (td, 1 H, 13.6 Hz, 9.2 Hz), 2.19-1.98 
(m, 3 H), 1.77-1.66 (m, 1 H), 1.60-1.47 (m, 1 H), 1.44 (d, 3 H, 3JPH = 14.4 Hz), 1.35 (sextet, 2 H, 
J = 7.2 Hz), 1.28-1.13 (m, 1 H), 0.87 (t, 3 H, J = 7.2 Hz), 1.1-0.0 (br q, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 149.1 (3JCP = 3 Hz), 143.2 (1JCP = 61 Hz), 125.8 (2JCP = 18 Hz), 121.1 (4JCP = 2 Hz), 
111.3 (3JCP = 8 Hz), 34.1, 33.9, 32.7 (1JCP = 35 Hz), 25.0, 24.1 (2JCP = 14 Hz), 22.1, (3JCP = 3 Hz), 
19.0 (1JCP = 36 Hz), 17.1 (2JCP = 16 Hz), 13.6; 31P NMR (162 MHz, CDCl3) δ 18.6; MS (ESI+) m/z 
264, 250, 228, 200, 184, 154, 110; HRMS (ESI+) m/z calcd for C14H24BNOP [M+H] 264.1683, 
found 264.1685. trans-2-41: IR (ATR) 2958, 2380, 2238, 1555, 1458, 1212, 1128, 1071, 1049, 
1007, 909, 732 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.71 (s, 1 H), 7.16 (d, 1 H, J = 1.2 Hz), 6.51 
(t, 1 H, J = 1.6 Hz), 2.98 (pent, 1 H, J = 7.6 Hz), 2.89-2.77 (m, 2 H), 2.32-2.12 (m, 2 H), 2.08 (dd, 
1 H, J = 14.8, 4.0 Hz), 1.76-1.63 (m, 1 H), 1.58-1.44 (m, 1 H), 1.53 (d, 3 H, 3JPH = 12.0 Hz), 1.35 
(pent, 2 H, J = 7.2 Hz), 1.29-1.18 (m, 1 H), 0.86 (t, 3 H, J = 7.2 Hz), 1.1-0.1 (br q, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 148.9 (3JCP = 3 Hz), 143.2 (1JCP = 61 Hz), 125.5 (2JCP = 18 Hz), 122.1, 111.4 
(3JCP = 8 Hz), 35.0, 34.9 (3JCP = 3 Hz), 33.2 (1JCP = 33 Hz), 25.0, 24.1 (2JCP = 13 Hz), 18.8 (1JCP = 
36 Hz), 16.2 (3JCP = 5 Hz), 13.6; 31P NMR (202 MHz, CDCl3) δ 17.6.  
 
 
3-(Di-p-tolylphosphanyl)-3-methylcyclobutane-1-carbonitrile borane (2-42).97 Prepared 
according to General Procedure D from di-p-tolylphosphine borane (0.500 g, 2.19 mmol), 
bicyclobutane 2-37 (0.245 g, 2.63 mmol), and NaH (0.105 g, 2.63 mmol) in DMAc (10 mL). 
Purification by chromatography on SiO2 (20-40% EtOAc/hexane) afforded cis-2-42 (0.341 g, 1.06 
mmol, 48%) as a colorless solid and trans-2-42 (0.199 g, 0.620 mmol, 28%) as a colorless foam. 
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cis-2-42: Mp 162–163 °C; IR (ATR) 2392, 1429, 1066, 807 cm-1;1H NMR (400 MHz, CDCl3) δ 
7.53 (d, 2 H, J = 8.4 Hz), 7.51 (d, 2 H, J = 8.0 Hz), 7.29 (d, 2 H, J = 8.0 Hz), 7.28 (d, 2 H, J = 8.0 
Hz), 3.31 (pent, 1 H, J = 9.2 Hz), 2.88-2.78 (m, 2 H), 2.40 (s, 6 H), 2.34-2.26 (m, 2 H), 1.54 (d, 3 
H, 3JPH = 14.0 Hz), 1.2-0.5 (br q, 3 H); 13C NMR (125 MHz, CDCl3) δ 142.2 (JCP = 2 Hz), 133.4 
(JCP = 7 Hz), 129.8 (JCP = 8 Hz), 123.3, 122.8, 120.5 (4JCP = 2 Hz), 34.7, 33.4 (1JCP = 34 Hz), 22.1 
(JCP = 5 Hz), 21.5, 18.2 (2JCP = 17 Hz); 31P NMR (202 MHz, CDCl3) δ 27.7; MS (ESI+) m/z 240, 
219, 167, 139, 122; HRMS (ESI+) m/z calcd for C20H26BNP [M+H] 322.1890, found 322.1879. 
trans-2-42: IR (ATR) 2956, 2386, 1498, 1066, 814 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.51 (d, 2 
H, J = 8.4 Hz), 7.49 (d, 2 H, J = 8.0 Hz), 7.28 (d, 2 H, J = 8.0 Hz), 7.27 (d, 2 H, J = 8.0 Hz), 3.07 
(ddd, 2 H, J = 13.6 Hz, 13.6 Hz, 10.0 Hz), 2.80 (ddd, 1 H, J = 17.0 Hz, 9.6 Hz, 7.6 Hz), 2.46-2.36 
(m, 2 H), 2.39 (s, 6 H), 1.60 (d, 3 H, 3JPH = 12.8 Hz), 1.4-0.5 (br q, 3 H); 13C NMR (125 MHz, 
CDCl3) δ 142.10, 142.08, 133.2, 133.1, 129.8, 129.7, 123.6, 123.2, 122.1 (4JCP = 0.5 Hz), 35.7, 
33.2 (1JCP = 31 Hz), 25.7 (JCP = 1.5 Hz), 21.5 (JCP = 1.0 Hz), 16.9 (2JCP = 6 Hz); 31P NMR (202 
MHz, CDCl3) δ 28.2. 
 
 
3-(Bis(3,5-dimethylphenyl)phosphanyl)-3-methylcyclobutane-1-carbonitrile borane (2-43). 
Prepared according to General Procedure D from di-m-xylyl phosphine borane (5.00 g, 19.5 
mmol), bicyclobutane 2-37 (3.1 mL, 29 mmol), and sodium hydride (0.780 g, 19.5 mmol, 60% 
dispersion) in DMAc (100 mL). Purification by chromatography on SiO2 (10-15-20-25% EtOAc 
in hexane) afforded cis-2-43 (3.24 g, 9.28 mmol, 48%) and trans-2-43 (1.66 g, 4.76 mmol, 24%),  
both as colorless solids: cis-2-43: Mp 162–165 °C; IR (ATR) 2932, 2390, 1448, 1128, 1066, 692 
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cm-1; 1H NMR (500 MHz, CDCl3) δ 7.23 (s, 2 H), 7.21 (s, 2 H), 7.16 (s, 2 H), 3.31 (pent, 1 H, J = 
9.5 Hz), 2.85 (td, 2 H, J = 10.0 Hz, 2.5 Hz), 2.35 (s, 12 H), 2.24-2.37 (m, 2 H), 1.53 (d, 3 H, 3JPH 
= 14.5 Hz), 1.2-0.5 (br q, 3 H); 31P NMR (202 MHz, CDCl3) δ 29.0; 13C NMR (125 MHz, CDCl3) 
δ 138.1 (JCP = 10 Hz), 137.8, 133.4 (JCP = 8 Hz), 131.6 (JCP = 8 Hz), 129.0 (JCP = 4 Hz), 128.7, 
127.6, 127.4, 125.4 (1JCP = 53 Hz), 120.2, 43.8 (3JCP = 25 Hz), 36.9, 35.8, 21.4, 19.2 (3JCP = 19 
Hz), 13.0; 31P NMR (162 MHz, CDCl3) δ 30.6; MS (ESI+) m/z 350, 259, 212, 155; HRMS (ESI+) 
m/z calcd for C22H30BNP [M+H] 350.2203, found 350.2190. trans-2-43: Mp 130–134 °C; IR 
(ATR) 2937, 2386, 1450, 1128, 852, 692 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.19 (s, 2 H), 7.17 
(s, 2 H), 7.14 (s, 2 H), 3.08 (td, 2 H, J = 13.5 Hz, 10.0 Hz), 2.83-2.75 (m, 1 H), 2.46-2.37 (m, 2 
H), 2.33 (s, 12 H), 1.62 (d, 3 H, 3JPH = 13.0 Hz), 1.4-0.5 (br q, 3 H); 31P NMR (202 MHz, CDCl3) 
δ 26.8; 13C NMR (125 MHz, CDCl3) δ 138.6, 138.5, 133.4, 133.4, 130.8, 130.7, 126.7, 126.3, 
122.2 (4JCP = 1 Hz), 35.8, 33.1 (1JCP = 31 Hz), 25.8 (JCP = 1 Hz), 21.4, 21.4, 16.9 (JCP = 6 Hz). 
 
 
(3-(Bis(4-methoxyphenyl)phosphanyl)-3-methylcyclobutane-1-carbonitrile borane (2-44).97 
Prepared according to General Procedure D from di-p-methoxy phosphine borane (0.222 g, 0.854 
mmol), and bicyclobutane 2-37 (0.254 g, 2.73 mmol) and NaH (0.038 g, 0.94 mmol) in DMAc (6 
mL). Purification by chromatography on SiO2 (10-30% EtOAc/hexane) afforded cis-2-44 (0.130 
g, 0.368 mmol, 43%) as a colorless foam and trans-2-44 (0.048 g, 0.14 mmol, 16%) as a colorless 
oil. cis-2-44: IR (ATR) 2394, 2385, 1600, 1499, 1245, 1109, 1021, 798 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.57 (t, 4 H, J = 9.2 Hz), 6.99 (dd, 4 H, J = 8.8 Hz, 1.6 Hz), 3.84 (s, 6 H), 3.31 (pent, 1 
H, J = 9.2 Hz), 2.79 (qd, 2 H, J = 10.0 Hz, 2.0 Hz), 2.34-2.24 (m, 2 H), 1.50 (d, 3 H, 3JPH  = 14.4 
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Hz), 1.2-0.3 (br m, 3 H); 13C NMR (100 MHz, CDCl3) δ 162.23, 162.21, 135.1, 135.0, 120.6 (4JCP 
= 2 Hz), 117.6, 117.0, 114.7, 114.6, 55.4, 34.6, 33.6 (1JCP = 34 Hz), 22.1 (JCP = 5 Hz), 18.2 (JCP = 
17 Hz); 31P NMR (162 MHz, CDCl3) δ 26.2; MS (ESI+) m/z 318, 316, 259, 247; HRMS (ESI+) 
m/z calcd for C20H26BNO2P [M+H] 354.1789, found 354.1793. trans-2-44: 1H NMR (400 MHz, 
CDCl3) δ 7.53 (tt, 4 H, J = 9.2 Hz, 2.0 Hz), 6.96 (dd, 4 H, J = 8.8 Hz, 1.6 Hz), 3.84 (s, 6 H), 3.04 
(td, 2 H, 13.6 Hz, 10.0 Hz), 2.74 (ddd, 1 H, J = 17.6 Hz, 9.6 Hz, 7.6 Hz), 2.39 (td, 2 H, J = 13.2 
Hz, 7.6 Hz), 1.59 (d, 3 H, 3JPH  = 12.8 Hz), 1.4-0.5 (br m, 3 H); 13C NMR (100 MHz, CDCl3) δ 
162.09, 162.07, 134.8, 134.7, 122.1, 117.8, 117.2, 114.6, 114.5, 55.3, 35.6, 33.4 (1JCP = 32 Hz), 
25.7 (JCP = 2 Hz), 16.8 (JCP = 6 Hz); 31P NMR (162 MHz, CDCl3) δ 26.3; IR (ATR) 2940, 2379, 
2237, 1902, 1594, 1501, 1289, 1253, 1180, 1061, 1024, 801 cm-1 
 
 
 
3-(Di([1,1'-biphenyl]-4-yl)phosphanyl)-3-methylcyclobutane-1-carbonitrile borane 
(2-45).97 Prepared according to General Procedure D from biphenylphosphine borane (0.300 g, 
0.850 mmol), bicyclobutane 2-37 (0.095 g, 1.0 mmol), NaH (0.036 g, 0.89 mmol) in DMAc (4 
mL). Purification by chromatography on SiO2 (15-30% EtOAc/hexane) afforded cis-2-45 (0.158 
g, 0.35 mmol, 42%) and trans-2-45 (0.083 g, 0.186 mmol, 22%), both as sticky waxes. cis-2-45: 
1H NMR (400 MHz, CDCl3) δ 7.79-7.70 (m, 8 H), 7.64-7.59 (m, 4 H), 7.48 (t, 4 H, J = 7.5 Hz), 
7.40 (t, 2 H, J = 7.2 Hz), 3.38 (pent, 1 H, J = 9.2 Hz), 2.94 (dd, 2 H, J = 12.8 Hz, 9.6 Hz), 2.42-
2.35 (m, 2 H), 1.61 (d, 3 H, 3JPH = 14.4 Hz), 1.4-0.7 (br q, 3 H); 13C NMR (100 MHz, CDCl3) δ 
144.6 (JCP = 2 Hz), 139.7, 134.0, 129.1, 128.3, 127.7, 127.3, 125.3, 124.7, 120.5, 34.8, 33.5 (1JCP 
 115 
= 33 Hz), 22.3 (JCP = 5 Hz), 18.3 (2JCP = 17 Hz); 31P NMR (202 MHz, CDCl3) δ 29.0; IR (ATR) 
3027, 2384, 1077, 911, 726 cm-1; MS (ESI+) m/z 423, 324, 292, 224, 124; HRMS (ESI+) m/z calcd 
for C30H30BNP [M+H] 446.2203, found 446.2211. trans-2-45: IR (ATR) 3029, 2980, 2374, 2236, 
1597, 1483, 1389, 1109, 1061, 1006, 909, 834, 736, 695 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.76-
7.68 (m, 8 H),7.61 (d, 4 H, J = 7.5 Hz), 7.49 (t, 4 H, J = 7.5 Hz), 7.42 (t, 2 H, J = 7.5 Hz), 3.20 
(dd, 2 H, J = 13.6 Hz, 10.0 Hz), 3.03-2.90 (m, 1 H), 2.49 (td, 2 H, J = 14.0 Hz, 7.0 Hz), 1.71 (d, 3 
H, 3JPH = 12.8 Hz), 1.4-0.7 (br m, 3 H); 13C NMR (100 MHz, CDCl3) δ 144.5 (JCP = 2 Hz), 139.6, 
133.8, 129.1, 128.4, 127.6, 127.2, 125.5, 125.0, 122.1, 35.7, 33.4 (1JCP = 31 Hz), 25.8, 17.1 (2JCP 
= 6 Hz); 31P NMR (202 MHz, CDCl3) δ 29.1. 
NC
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3-(Bis((S)-2-(6-methoxynaphthalen-2-yl)propyl)phosphanyl)-3-methylcyclobutane-1-
carbonitrile (2-47).97 Prepared according to General Procedure D from di-(S)-naproxen phosphine 
borane (3.77 g, 8.49 mmol), bicyclobutane nitrile 2-37 (0.790 g, 8.49 mmol) and NaH (0.340 g, 
8.49 mmol, 60% dispersion) in DMAc (40 mL). Purification by automated chromatography (120 
g SiO2 cartridge, 5-10-15-50% EtOAc in hexane) afforded cis-2-47 (1.73 g, 3.22 mmol, 38%) and 
trans-2-47 (0.773 g, 1.43 mmol, 17%), both as colorless solids. cis-2-47: Mp 162–163 °C; [α]D –
24.1 (c 0.220, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.73 (app t, 3 H, J = 9.2 Hz), 7.52 (d, 2 H, 
J = 8.4 Hz), 7.36 (dd, 1 H, J = 8.4 Hz, 2.0 Hz), 7.22-7.16 (m, 2 H), 7.14 (d, 1 H, J = 2.4 Hz), 7.09 
(dd, 1 H, J = 8.8 Hz, 2.4 Hz), 7.02 (d, 1 H, J = 2.4 Hz), 6.92 (dd, 1 H, J = 8.4, 1.6 Hz), 3.95 (s, 3 
H), 3.89 (s, 3 H), 3.51-3.40 (m, 1 H), 3.10 (pent, 1 H, J = 9.2 Hz), 2.97-2.86 (m, 1 H), 2.79 (app 
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q, 1 H, J  = 12.0 Hz), 2.66 (td, 1 H, J = 13.2 Hz, 10.0 Hz), 1.98-1.87 (m, 2 H), 1.70-1.59 (m, 2 H), 
1.46 (d, 3 H, J = 7.2 Hz), 1.21 (d, 3 H, 3JPH = 11.0 Hz), 1.26-1.14 (m, 1 H), 1.08 (ddd, 1 H, J = 
15.2 Hz, 9.2 Hz, 6.4 Hz), 0.92 (d, 3 H, J = 6.8 Hz), 1.0-0.3 (br m, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 157.7, 157.5, 141.5, 141.4, 141.04, 141.00, 133.6, 133.3, 129.2, 129.03, 128.98, 128.8, 
127.5, 127.2, 126.0, 125.6, 125.5, 124.9, 120.6 (4JCP = 2 Hz), 105.67, 105.57, 55.4, 55.3, 35.2, 
35.0, 33.6, 31.9 (1JCP = 31 Hz), 30.0 (1JCP = 31 Hz), 29.3 (1JCP = 27 Hz), 25.6, 25.0, 20.5, 17.8 
(2JCP = 18 Hz); 31P NMR (162 MHz, CDCl3) δ 28.7; IR (ATR) 2933, 2386, 1603, 1450, 1215, 837 
cm-1; MS (ESI+) m/z 538, 500, 447, 338; HRMS (ESI+) m/z calcd for C34H42BNO2P [M+H] 
538.3041, found 538.3025. trans-2-47: [α]D +27.1 (c = 0.240, CH2Cl2); IR (ATR) 2933, 2395, 
1605, 1028, 857 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.78-7.72 (m, 3 H), 7.53 (dd, 2 H, J = 8.4 
Hz, 6.0 Hz), 7.38 (dd, 1 H, J = 8.4 Hz, 1.6 Hz), 7.24-7.15 (m, 3 H), 7.11 (dd, 1 H, J = 8.8 Hz, 2.4 
Hz), 7.05 (d, 1 H, J = 2.4 Hz), 6.89 (dd, 1 H, J = 8.4, 2.4 Hz), 3.96 (s, 3 H), 3.90 (s, 3 H), 3.53-
3.43 (m, 1 H), 3.21-3.13 (m, 1 H), 2.94-2.80 (m, 2 H), 2.49 (dd, 1 H, J = 13.2 Hz, 10.4 Hz), 2.11 
(td, 1 H, J = 12.4 Hz, 7.2 Hz), 1.94 (td, 1 H, J = 14.0 Hz, 9.6 Hz),  1.70-1.55 (m, 3 H), 1.47 (d, 3 
H, J = 6.4 Hz), 1.35 (d, 3 H, 3JPH = 10.4 Hz), 1.13-1.04 (m, 1 H), 0.93 (d, 3 H, J = 7.2 Hz), 1.0-0.3 
(br m, 3 H); 13C NMR (100 MHz, CDCl3) δ 157.7, 157.5, 141.6, 141.5, 140.9, 140.9, 133.7, 133.3, 
129.2, 129.0, 128.8, 127.6, 127.2, 126.1, 125.6, 125.3, 124.8, 122.5, 119.3, 105.7, 105.6, 55.4, 
55.3, 35.2, 35.0, 34.7, 34.3, 34.2, 34.2, 32.1 (1JCP = 31 Hz), 30.4 (1JCP = 32 Hz), 29.6 (1JCP = 27 
Hz), 25.7 (JCP = 11 Hz), 24.9 (JCP = 7 Hz), 23.6 (JCP = 3 Hz), 16.5 (2JCP = 7 Hz); 31P NMR (162 
MHz, CDCl3) δ 27.5. 
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General Procedure E (Bicyclobutane nitrile synthesis through transnitrilation): 3-
Phenylbicyclo[1.1.0]butane-1-carbonitrile (2-50).189 A solution of dibromocyclopropane (8.28 
g, 25.5 mmol) in diethyl ether (60 mL) was cooled to –78 °C under N2 in a 250-mL round bottom 
flask. Methyl lithium (15.6 mL, 25.5 mmol, 1.63 M in Et2O) was added dropwise via syringe over 
15 min. After stirring for 1 h at –78 °C, t-butyl lithium (15.0 mL, 25.5 mmol, 1.70 M in pentane) 
was added dropwise via syringe over 15 min. After stirring for an additional 1 h at –78 °C, dimethyl 
malononitrile (2.40 g, 25.5 mmol) was added as a solution in THF (10 mL), and the reaction 
mixture turned from a clear orange into an opaque yellow solution. The cooling bath was removed 
and the solution was warmed to rt over 1.5 h, affording an orange/brown suspension. The mixture 
was quenched with sat. aq. NH4Cl (20 mL), and partitioned between water (30 mL) and diethyl 
ether (50 mL). The aqueous layer was extracted with ether (50 mL). The combined organic extracts 
were washed with water (60 mL) and brine (60 mL), dried (Na2SO4) and concentrated. 
Chromatography of the crude black residue on SiO2 (5-20% EtOAc/hexane) afforded 
bicyclobutane 2-50 (1.71 g, 11.0 mmol, 43%) as a yellow oil: 1H NMR (300 MHz, CDCl3) δ 7.45-
7.29 (m, 5 H), 2.71 (s, 2 H), 1.68 (s, 2 H); 13C NMR (100 MHz, CDCl3) δ 131.8, 128.9, 128.5, 
128.0, 126.5, 118.8, 37.9, 29.5, 5.8. 
 
 
2,2-Dimethylbicyclo[1.1.0]butane-1-carbonitrile (2-53).98 Prepared according to General 
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Procedure E from dibromocyclopropane (10.0 g, 18.1 mmol), methyl lithium (22.2 mL, 36.2 
mmol, 1.63 M in Et2O), t-butyl lithium (21.3 mL, 36.2 mmol, 1.70 M in pentane), and 
dimethylmalononitrile (4.43 g, 47.0 mmol, 1.30 eq) in Et2O (80 mL). Purification by 
chromatography on SiO2 (5-20% EtOAc in hexanes) afforded 2-53 (0.694 g, 6.48 mmol, 18%) as 
a colorless oil: 1H NMR (300 MHz, CDCl3) δ 2.30 (dd, 1 H, J = 3.0 Hz, 3.0 Hz), 2.21 (t, 1 H, J = 
3.0 Hz), 1.86 (t, 1 H, J = 3.0 Hz), 1.35 (s, 3 H), 0.96 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 120.6, 
53.8, 35.3, 24.9, 22.0, 13.8, 2.6.  
 
3-(Dicyclohexylphosphanyl)-3-phenylcyclobutane-1-carbonitrile (2-54).97 Prepared according 
to General Procedure D from nitrile 2-50 (0.083 g, 0.54 mmol, 1.3 eq), dicyclohexyl phosphine 
borane (0.087 g, 0.41 mmol) and NaH (0.016 g, 0.41 mmol, 60% in oil) in DMAc (2 mL). 
Purification by chromatography on SiO2 (15% EtOAc/hexane) afforded less polar cis-2-54 (0.043 
g, 0.117 mmol, 28%) and the more polar trans-2-54 (0.058 g, 0.158 mmol, 38%), both as colorless 
solids. cis-2-54: Mp 198–201 °C; IR (ATR) 2934, 2844, 2391, 1448, 1072 cm-1; 1H NMR (300 
MHz, CDCl3) δ 7.45 (t, 2 H, J = 6.9 Hz), 7.35 (t, 3 H, J = 7.8 Hz), 3.64-3.48 (m, 2 H), 3.07 (pent, 
1 H, J = 9.2 Hz), 2.76 (tt, 2 H, J = 8.7 Hz, 3.0 Hz), 1.95-1.53 (m, 11 H), 1.32-1.05 (m, 11 H), 1.1-
0.1 (br m, 3 H); 13C NMR (100 MHz, CDCl3) δ 139.1 (JCP = 5 Hz), 128.9, 128.5, 127.8 (JCP = 2 
Hz), 127.6, 127.6, 124.5, 120.2 (4JCP = 3 Hz), 42.1 (1JCP = 21 Hz), 36.9, 36.6, 31.5 (1JCP = 28 Hz), 
27.4, 27.2, 27.1, 27.0, 26.9, 26.8, 25.9, 20.6 (2JCP = 18 Hz); 31P NMR (162 MHz, CDCl3) δ 39.6; 
MS (ESI+) m/z 385 (M+NH4+), 368, 273, 215; HRMS (ESI+) m/z calcd for C23H36BNP [M+H] 
368.2673, found 368.2696. trans-2-54: Mp 205–207 °C; IR (ATR) 2930, 2856, 2377, 2239, 1446, 
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1064, 760 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.41 (t, 2 H, J = 7.2 Hz), 7.33 (app t, 1 H, J = 7.6 
Hz), 7.13 (d, 2 H, J = 8.0 Hz), 3.67 (pent, 1 H, J = 9.2 Hz), 3.38 (td, 2 H, J = 13.2 Hz, 10.0 Hz), 
2.98-2.86 (m, 2 H), 1.95-1.49 (m, 10 H), 1.47-1.32 (m, 2 H), 1.32-1.02 (m, 10 H), 0.9-0.0 (br m, 
3 H); 13C NMR (100 MHz, CDCl3) δ 143.0 (2JCP = 6 Hz), 128.8, 127.4, 126.3 (3JCP = 3 Hz), 121.8, 
41.4 (1JCP = 21 Hz), 37.3, 31.3 (1JCP = 29 Hz), 28.6, 27.6, 27.2, 27.1, 26.7, 26.6, 25.8, 17.6 (2JCP = 
3 Hz); 31P NMR (162 MHz, CDCl3) δ 35.9. 
3-(Di-p-tolylphosphanyl)-3-phenylcyclobutane-1-carbonitrile (2-55).97 Prepared according to 
General Procedure D from nitrile 2-50 (0.621 g, 4.01 mmol), di-p-tolyl phosphine borane (0.684 
g, 3.00 mmol) and NaH (0.120 g, 3.0 mmol) in DMAc (15 mL). Purification by automated 
chromatography (80 g SiO2 cartridge, 5-10-50% EtOAc in hexane) afforded cis-2-55 (0.365 g, 
0.95 mmol, 32%) as a light yellow solid and trans-2-55 (0.457 g, 1.19 mmol, 40%) as a white 
crystalline solid. cis-2-55: Mp 68–72 °C; IR (ATR) 2368, 1600, 1497, 1446, 1190, 1063, 806, 655 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.48 (d, 2 H, J = 8.4 Hz), 7.45 (d, 2 H, J = 8.4 Hz), 7.24-7.13
(m, 7 H), 7.09-7.02 (m, 2 H), 3.30 (ddd, 2 H, J = 13.2 Hz, 10.0 Hz, 2.4 Hz), 3.03 (pent, 1 H, J = 
9.2 Hz), 2.91-2.84 (m, 2 H), 2.38 (s, 6 H), 1.5-0.5 (br m, 3 H); 13C NMR (100 MHz, CDCl3) δ 
142.2 (JCP = 2 Hz), 137.6, 133.9 (JCP = 6 Hz), 129.4 (JCP = 11 Hz), 128.9 (JCP = 3 Hz), 127.8, 
127.8, 127.7, 127.5, 127.4, 122.6, 122.1, 120.2 (4JCP = 3 Hz), 43.7 (1JCP = 27 Hz), 35.8, 21.5, 19.1 
(JCP = 19 Hz); 31P NMR (202 MHz, CDCl3) δ 29.0. trans-2-55: Mp 172–174 °C; IR (ATR) 2933, 
2391, 1604, 1450, 1064 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.44 (d, 2 H, J = 8.4 Hz), 7.42 (d, 2 
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H, J = 8.0 Hz), 7.25-7.13 (m, 7 H), 6.66 (dd, 2 H, J = 6.4 Hz, 1.6 Hz), 3.55 (pent, 1 H, J = 9.2 Hz), 
3.45-3.34 (m, 2 H), 2.96-2.87 (m, 2 H), 2.38 (s, 6 H), 1.3-0.7 (br m, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 142.3 (JCP = 3 Hz), 142.2 (JCP = 5 Hz), 134.2 (JCP = 98 Hz), 129.2, 129.1, 128.0 (JCP = 
2 Hz), 127.6 (JCP = 2 Hz), 127.1, 122.1, 121.7, 121.5, 42.9 (1JCP = 24 Hz), 36.7, 21.5, 17.7; 31P 
NMR (162 MHz, CDCl3) δ 25.7; IR (ATR) 2933, 2383, 1437, 1065, 757, 744 cm-1; MS (ESI+) m/z 
384, 370, 345, 155; HRMS (ESI+) m/z calcd for C25H28BNP [M+H] 384.2047, found 384.2038. 
 
3-(Dicyclohexylphosphanyl)-2,2-dimethylcyclobutane-1-carbonitrile (2-56).97 Prepared 
according to General Procedure D from bicyclobutane 2-53 (0.148 g, 1.37 mmol), dicyclohexyl 
phosphine borane (0.225 g, 1.06 mmol), NaH (0.055 g, 1.37 mmol, 60% in mineral oil) in DMAc 
(7.5 mL). Purification by chromatography on SiO2 (10-30% EtOAc/hexane) afforded 2-56 (0.144 
g, 0.339 mmol, 34%) as a colorless solid: Mp 135–139 °C; 1H NMR (400 MHz, CDCl3) δ 2.90 
(app t, 1 H, J = 8.8 Hz), 2.68 (pent, 1 H, J = 10.8 Hz), 2.50 (td, 1 H, J = 10.8 Hz, 8.0 Hz), 2.31 
(dtd, 1 H, J = 10.4 Hz, 8.0 Hz, 2.0 Hz), 2.05-1.96 (m, 1 H), 1.94-1.55 (m, 11 H), 1.51 (s, 3 H), 
1.28 (s, 3 H), 1.37-1.14 (m, 10 H), 1.1-0.0 (br m, 3 H); 13C NMR (100 MHz, CDCl3) δ 118.4 (4JCP 
= 6 Hz), 45.3 (3JCP = 1 Hz), 36.3 (1JCP = 25 Hz), 34.3 (1JCP = 23 Hz), 33.6 (JCP = 10 Hz), 33.3 (JCP 
= 9 Hz), 31.2, 27.8, 27.53, 27.46, 27.4, 27.3, 27.14, 27.05, 27.00, 26.95, 26.9, 26.0, 25.9 (JCP = 19 
Hz), 25.4, 21.9 (JCP = 4 Hz); 31P NMR (162 MHz, CDCl3) δ 26.7; IR (ATR) 2924, 2365, 1448, 
1066 cm-1; MS (ESI+) m/z 320, 306, 268, 241, 215, 273, 152; HRMS (ESI+) m/z calcd for 
C19H36BNP [M+H] 320.2673, found 320.2684. 
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(3-(Di-p-tolylphosphanyl)-2,2-dimethylcyclobutane-1-carbonitrile borane (2-57).97 Prepared 
according to General Procedure D from bicyclobutane 2-53 (0.049 g, 0.46 mmol), di-p-
tolylphosphine borane (0.081 g, 0.36 mmol), and NaH (0.018 g, 0.46 mmol, 60% in mineral oil) 
in DMAc (2.5 mL). Purification by chromatography on SiO2 (5-25% EtOAc/hexane) afforded 
0.032 g (0.095 mmol, 27%) of 2-57 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.59 (d, 1 H, 
J = 8.0 Hz), 7.56 (d, 1 H, J = 8.4 Hz), 7.45 (d, 1 H, J = 8.0 Hz), 7.42 (d, 1 H, J = 8.4 Hz), 7.27 (dd, 
2 H, J = 8.0 Hz, 2.0 Hz), 7.22 (dd, 2 H, J = 8.0 Hz, 1.6 Hz), 3.04 (ddd, 1 H, J = 11.2 Hz, 8.4 Hz, 
8.4 Hz), 2.93 (td, 1 H, J = 10.0 Hz, 0.8 Hz), 2.73 (pent, 1 H, J = 11.2 Hz), 2.48 (ddd, 1 H, J = 19.2 
Hz, 8.4 Hz, 2.4 Hz), 2.39 (s, 3 H), 2.37 (s, 3 H), 1.27 (s, 3 H), 1.16 (s, 3 H), 1.2-0.6 (br m, 3 H); 
13C NMR (100 MHz, CDCl3) δ 141.9 (1JCP = 35 Hz), 141.9 (1JCP = 35 Hz), 132.5 (2JCP = 15 Hz), 
132.4 (2JCP = 14 Hz), 129.7, 129.7, 129.6, 129.6, 126.3, 125.8, 125.3, 124.7, 118.5 (4JCP = 6 Hz), 
45.3, 39.9 (1JCP = 28 Hz), 33.8 (JCP = 25 Hz), 30.9, 24.9, 21.5, 21.5, 20.9 (3JCP = 5 Hz); 31P NMR 
(162 MHz, CDCl3) δ 13.7; IR (ATR) 2974, 2391, 2235, 1450, 1103, 1059, 734 cm-1; MS (ESI+) 
m/z 336, 322, 282, 249, 228, 209; HRMS (ESI+) m/z calcd for C21H28BNP [M+H] 336.2047, found 
336.2061. 
OHC
P
BH3
2-58  
3-(Ditolylphosphanyl)-3-methylcyclobutane-1-carbaldehyde borane (2-58).97 A solution of 
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nitrile cis-2-42 (0.755 g, 2.35 mmol) in THF (12 mL) was cooled to 0 °C under N2. DIBAL (3.5 
mL, 3.5 mmol, 1.5 eq, 1 M in hexanes) was added via syringe over 2 min. The ice bath was 
removed, and the resulting solution was stirred at rt for 16 h, then was quenched with 2 M H2SO4 
(10 mL). The solution was stirred for 1 h and gradually became an opaque white suspension. The 
suspension was partitioned between water (40 mL) and Et2O (40 mL), and the aqueous layer was 
extracted with Et20 (40 mL). The combined extracts were washed with water (40 mL), brine (40 
mL), dried (Na2SO4) and concentrated. The crude oil was purified by chromatography on SiO2 
(20% EtOAc in hexanes) to afford aldehyde 2-58 (0.484 g, 1.49 mmol, 64%) as a colorless foam: 
1H NMR (400 MHz, CDCl3) δ 9.24 (d, 1 H, J = 2.0 Hz), 7.54 (d, 2 H, J = 8.4 Hz), 7.52 (d, 2 H, J 
= 8.4 Hz), 7.26 (d, 2 H, J = 8.0 Hz), 7.25 (d, 2 H, J = 7.6 Hz), 3.26 (pent d, 1 H, J = 9.2 Hz, 2.4 
Hz), 2.88-2.74 (m, 2 H), 2.41 (s, 6 H), 2.13-2.04 (m, 2 H), 1.61 (d, 3 H, 3JPH = 14.8 Hz), 1.2-0.4 
(br q, 3 H); 13C NMR (100 MHz, CDCl3) δ 201.1, 141.8, 133.5, 133.4, 129.6, 129.5, 124.0, 123.5, 
40.3 (JCP = 12 Hz), 31.9 (1JCP = 32 Hz), 30.6, 23.6 (JCP = 5 Hz), 21.5; MS (ESI+) m/z 324, 311, 
295, 213; 31P NMR (162 MHz, CDCl3) δ 27.1; HRMS (ESI+) m/z calcd for C20H27BOP [M+H] 
325.1887, found 325.1892. 
OHC
P
BH3
2-59  
3-(Di-m-xylylphosphanyl)-3-methylcyclobutane-1-carbaldehyde borane (2-59). A solution of 
cis-2-43 (1.00 g, 2.86 mmol) in THF (25 mL) was cooled to 0 °C under N2 in a 100 mL flask. The 
solution was treated with DIBAL (4.29 mL, 4.29 mmol, 1 M in hexane, 1.5 eq) via syringe over 
20 s. The cooling bath was removed, and the resulting colorless solution was stirred at rt for 24 h. 
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The reaction was quenched with 2 M H2SO4 (15 mL). The resulting solution was stirred for 30 
min, was extracted with ether (2 x 50 mL). The combined extracts were washed with water (30 
mL), brine (30 mL), dried (Na2SO4), and concentrated. The crude material was purified by 
chromatography on SiO2 (15-25% EtOAc/hexane) to afford aldehyde 2-59 (0.556 g, 1.58 mmol, 
55%) as a colorless solid: Mp 133–134 °C; 1H NMR (400 MHz, CDCl3) δ 9.24 (d, 1 H, J = 2.0 
Hz), 7.25 (s, 2 H), 7.22 (s, 2 H), 7.13 (s, 2 H), 3.24 (pent, 1 H, J = 8.8 Hz), 2.87-2.75 (m, 2 H), 
2.33 (s, 12 H), 2.14-2.05 (m, 2 H), 1.60 (d, 3 H, 3JPH = 14.0 Hz), 1.2-0.3 (br q, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 201.2, 138.4, 138.3, 133.18, 133.16, 131.1, 131.0, 127.1, 126.6, 40.3 (JCP = 
11 Hz), 31.7 (1JCP = 31 Hz), 30.8, 23.8 (JCP = 5 Hz), 21.6, 13.8; 31P NMR (162 MHz, CDCl3) δ 
28.4 IR (ATR) 2933, 2373, 1713, 1128, 1069, 839, 692 cm-1; MS (ESI+) m/z 367, 353, 341, 241, 
212; HRMS (ESI+) m/z calcd for C22H31BOP [M+H] 353.2200, found 353.2180. 
P
BH3
2-60
HO
 
3-(Ditolyl-3-methylcyclobutyl)methanol borane (2-60).97 A solution of aldehyde 2-58 (0.608 g, 
1.88 mmol, 1.00 eq) in MeOH (10 mL) was cooled to 0 °C. Sodium borohydride (0.074 g, 2.0 
mmol, 1.1 eq) was added to the colorless solution in one portion. Bubbling ensued, and then 
subsided after ca. 10 min. The reaction mixture was stirred at rt for 2 h, and quenched with 1 M 
HCl (5 mL). The contents of the flask were then partitioned between ether (30 mL) and water (30 
mL), and the aqueous phase was extracted with ether (30 mL). The combined organic phases were 
washed with water (30 mL) and brine (30 mL), were (Na2SO4) and concentrated. The residue was 
purified by chromatography on SiO2 (25% EtOAc/hexane) to afford alcohol 2-60 (0.503 g, 1.54 
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mmol, 82%) as a colorless solid: Mp 108–110 °C; 1H NMR (400 MHz, CDCl3) δ 7.54 (d, 2 H, J 
= 8.0 Hz), 7.52 (d, 2 H, J = 8.8 Hz), 7.23 (d, 4 H, J = 6.8 Hz), 3.19 (d, 2 H, J = 6.4 Hz), 2.74 (pent, 
1 H, J = 8.0 Hz), 2.37 (s, 6 H), 2.38-2.23 (m, 2 H), 2.01-1.89 (m, 2 H), 1.54 (d, 3 H, 3JPH = 14.8 
Hz), 1.2-0.3 (br q, 3 H); 13C NMR (100 MHz, CDCl3) δ 141.49, 141.47, 133.54, 133.45, 129.4, 
129.3, 124.7, 124.2, 66.2, 33.1, 32.2 (2JCP = 13 Hz), 31.0 (1JCP = 32 Hz), 23.5 (JCP = 3 Hz), 21.5; 
31P NMR (162 MHz, CDCl3) δ 27.3. 
P
BH3
2-61
HO
 
3-((Di-m-xylylphosphanyl)-3-methylcyclobutyl)methanol borane (2-61). A solution of 
aldehyde 2-59 (0.414 g, 1.18 mmol) in MeOH (8 mL) and THF (3 mL) was treated with sodium 
borohydride (0.049 g, 1.3 mmol) at 0 °C. The ice bath was removed, and the colorless reaction 
mixture was stirred at rt for 1.25 h. The reaction was quenched with 1 M HCl (5 mL), then was 
partitioned between water (40 mL) and CH2Cl2 (40 mL), and the aqueous phase was re-extracted 
with CH2Cl2 (40 mL). The combined extracts were washed with water (30 mL), 1:1 water/brine 
(30 mL), dried (Na2SO4) and were concentrated. Chromatography on SiO2 (15-30% 
EtOAc/hexane) afforded alcohol 2-61 (0.318 g, 0.897 mmol, 76%) as a colorless solid: Mp 142–
144 °C; IR (ATR) 3360 (br), 2934, 2384, 1450, 1127, 911, 726 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.27 (s, 2 H), 7.25 (s, 2 H), 7.13 (s, 2 H), 3.25 (d, 2 H, J = 6.4 Hz), 2.75 (pent, 1 H, J = 7.6 Hz), 
2.42-2.24 (m, 2 H), 2.35 (s, 12 H), 2.03-1.92 (m, 2 H), 1.58 (d, 3 H, 3JPH = 14.4 Hz), 1.45 (br s, 1 
H), 1.3-0.5 (br q, 3 H); 13C NMR (100 MHz, CDCl3) δ 138.2, 138.1, 132.89, 132.87, 131.13, 
131.05, 127.8, 127.3, 66.2, 33.3, 32.2, (JCP = 12 Hz), 31.0 (1JCP = 30 Hz), 23.6 (3JCP = 3 Hz), 21.4; 
31P NMR (162 MHz, CDCl3) δ 28.4; HRMS (ESI+) m/z calcd for C22H31BOP [M–H] 353.2200, 
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found 353.2188. 
P
HO
2-62
3-(Ditolyl-3-methylcyclobutyl)methanol (2-62). Prepared according to General Procedure C 
from phosphine borane 2-60 (0.160 g, 0.512 mmol) and DABCO (0.230 g, 2.05 mmol) in 
toluene (2 mL) to afford phosphine 2-62 (0.119 g, 0.381 mmol, 78%) as a colorless oil: 1H NMR 
(400 MHz, CDCl3) δ 7.28 (d, 4 H, J = 7.2 Hz), 7.15 (d, 4 H, J = 9.6 Hz), 3.21 (d, 2 H, J = 6.4 
Hz), 2.68 (pent, 1 H, J = 8.0 Hz), 2.35 (s, 6 H), 2.07 (d, 1 H, J = 12.4 Hz), 2.02 (d, 1 H, J = 11.2 
Hz), 2.00-1.91 (m, 2 H), 1.48 (d, 3 H, 3JPH = 12.8 Hz); 31P NMR (162 MHz, CDCl3) δ 7.7. 
P
O
O
O
P
2-63
(11S)-4-((3-(Di-p-tolylphosphanyl)-3-methylcyclobutyl)methoxy)dinaphtho[2,1-d:1',2'-
f][1,3,2]dioxaphosphepine (2-63).97 S-BINOL (0.223 g, 0.778 mmol) was placed under N2 into a 
50-mL flask and treated with PCl3 (1.1 mL, 12 mmol, 17 eq) and N-methylpyrrolidone (1 drop).
The mixture was stirred at 60 °C for 15 min, cooled, and slowly concentrated under high vacuum 
to give a semi-solid. The residue was azeotroped with toluene (5 mL) and dissolved in THF (5 
mL). An NMR of an aliquot showed the clean chlorophosphite (31P NMR δ 174). In a separate 50-
mL flask, a solution of phosphine 2-62 (0.221 g, 0.707 mmol) in THF (3 mL) was cooled to 0 °C 
under N2. NaH (0.031 g, 0.79 mmol, 1.1 eq, 60% in oil) was added in one portion. The resulting 
alkoxide was stirred for 10 min at 0 °C. The chlorophosphine solution was then transferred to the 
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alkoxide solution via syringe at 0 °C. The cooling bath was removed, and the reaction mixture was 
stirred for 19 h at rt, concentrated, and purified by chromatography on SiO2 (5-40% 
EtOAc/hexane) to afford 2-63 (0.121 g, 0.193 mmol, 27%) as a colorless oil: 1H NMR (400 MHz, 
CDCl3) δ 7.96 (d, 1 H, J = 8.8 Hz), 7.95-7.86 (m, 3 H), 7.47 (d, 1 H, J = 8.8 Hz), 7.42 (td, 2 H, J 
= 6.8 Hz, 1.2 Hz), 7.37-7.22 (m, 9 H), 7.18-7.12 (m, 4 H), 3.55 (app dd, 1 H, 3JPH = 17.2 Hz, J = 
7.6 Hz), 3.37 (app dd, 1 H, 3JPH = 17.6 Hz, J = 7.6 Hz), 2.72 (pent, 1 H, J = 8.0 Hz), 2.34 (s, 6 H), 
2.05 (dd, 2 H, J = 20 Hz, 12 Hz), 1.96-1.88 (m, 2 H), 1.45 (d, 3 H, 3JPH = 12.8 Hz); 13C NMR (100 
MHz, CDCl3) δ 148.5 (JCP = 5 Hz), 147.5, 138.5 (JCP = 5 Hz), 134.3 (JCP = 6 Hz), 134.1 (JCP = 6 
Hz), 133.1, 133.0, 132.8, 132.6, 131.5, 131.0, 130.3, 129.9, 129.1 (JCP = 7 Hz), 128.3 (JCP = 6 Hz), 
127.0, 126.2 (JCP = 9 Hz), 125.0, 124.9, 124.1 (JCP = 5 Hz), 122.7 (JCP = 2 Hz), 121.9, 121.7, 68.5 
(2JCP = 7 Hz), 34.73, 34.69, 34.63, 34.55, 31.8 (1JCP = 18 Hz), 31.2, (JCP = 10 Hz), 26.9, 25.4, 25.3 
(JCP = 4 Hz), 21.4, 20.7, 14.2; 31P NMR (162 MHz, CDCl3) δ 142.8, 7.2; HRMS (ESI+) m/z calcd 
for C40H37O3P2 [M+H] 627.2212, found 627.2206. 
Methyl acetyl-D-phenylalaninate (2-65).97 A solution of 2-64 (0.116 g, 0.532 mmol) in MeOH 
(1 mL) in a stainless steel pressure vessel was charged with a solution of phosphine-phosphite 2-
63 (0.010 g, 0.016 mmol, 3 mol%) in MeOH (0.3 mL) and a solution of Rh(NBD)BF4 (0.002 g, 
0.005 mmol, 1 mol%) in MeOH (0.3 mL) under an Ar blanket provided by an inverted funnel. The 
resulting yellow solution was sealed in the Parr autoclave and placed under 13.99 bar of H2. After 
3.5 h, the remaining 13.96 bar was vented. The solution was concentrated, re-dissolved in CH2Cl2 
(1 mL), and filtered through neutral Al2O3 to afford 2-65 (0.086 g, 0.39 mmol, 73%) as a colorless 
solid: [α]D –0.855 (c = 1.0, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 7.38-7.21 (m 3 H), 7.16-7.07 
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(m, 2 H), 6.09 (d, 1 H, J = 6.6 Hz), 4.90 (ddd, 1 H, J = 7.8 Hz, 6.0 Hz, 5.7 Hz), 3.74 (s, 3 H), 3.21-
3.04 (m, 2 H), 1.99 (s, 3 H); Chiral SFC (Chiralpak IA, 5-15% i-PrOH modifier gradient) Tr 8.48 
min (major, D-isomer), 11.42 min (minor, L-isomer). 
P
BH3
P
BH3
2-66
((3-(Bis(3,5-dimethylphenyl)phosphanyl)-3-methylcyclobutyl)methyl)bis(3,5-
dimethylphenyl)phosphane diborane (2-66). A solution of alcohol 2-61 (0.119 g, 0.336 mmol) 
and Et3N (0.05 mL, 0.03 mmol) in CH2Cl2 (2 mL) was cooled to 0 °C under N2. Brosyl chloride 
(0.086 g, 0.34 mmol) was added in one portion. The solution was warmed to rt over 2.5 h, then 
was directly placed on an SiO2 column and purified by chromatography (10% EtOAc/hexane) to 
afford the corresponding p-bromosulfonate (0.068 g, 0.119 mmol, 35%) as a colorless oil: 1H 
NMR (300 MHz, CDCl3) δ 7.76-7.66 (m, 4 H), 7.20 (s, 2 H), 7.16 (s, 2 H), 7.11 (s, 2 H), 3.64 (d, 
2 H, J = 7.2 Hz), 2.85 (pent, 1 H, J = 8.1 Hz), 2.32 (s, 12 H), 2.35-2.22 (m, 2 H), 2.02-1.91 (m, 2 
H), 1.52 (d, 3 H, 3JPH = 14.1 Hz), 1.3-0.1 (br q, 3 H). 
 A solution of this brosylate (0.068 g, 0.119 mmol) and di-m-xylyl phosphine borane 
(0.046 g, 0.178 mmol) in DMAc (1 mL) under N2 was treated with sodium hydride (0.007 g, 0.2 
mmol, 60% in oil) in one portion. The reaction was stirred for 19 h at rt, then was quenched with 
sat aq NH4Cl (10 mL). The material was partitioned between ether and water (30 mL each), 
the layers were separated, and the aqueous layer was extracted with ether (30 mL). The 
combined extracts were washed with water (30 mL), brine (30 mL), then were dried 
(Na2SO4) and concentrated. Two iterations of chromatography on SiO2 (10% EtOAc/hexane)  
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afforded diphosphine borane 2-66 (0.034 g, 0.057 mmol, 48%) as a colorless solid: Mp 225–227 
°C; IR (ATR) 2933, 2378, 1737, 1461, 1128, 1066, 915, 734 cm-1; 1H NMR (500 MHz, CDCl3) δ 
7.18 (s, 2 H), 7.16 (s, 4 H), 7.14 (s, 2 H), 7.09 (s, 4 H), 2.85-2.74 (m, 1 H), 2.35-2.26 (m, 2 H), 
2.33 (s, 12 H), 2.31 (s, 12 H), 1.97 (dd, 2 H, J = 11.0 Hz, 7.0 Hz), 1.94-1.87 (m, 2 H), 1.42 (d, 3 
H, 3JPH = 14.0 Hz), 1.1-0.4 (br q, 6 H); 13C NMR (125 MHz, CDCl3) δ 138.3, 138.2, 138.1, 
138.0, 132.9, 132.8, 131.1, 131.0, 129.7, 129.6, 129.1, 127.7, 127.2, 38.0 (JCP = 9 Hz), 31.5 (JCP 
= 5 Hz), 31.2 (1JCP = 31 Hz), 25.4 (JCP = 14 Hz), 23.3, 21.4, 21.3; 31P NMR (202 MHz, CDCl3) δ 
29.5, 11.8. An X-ray crystal structure was obtained for this compound. 
S CNS CN
trans 2-67 cis 2-67
General Procedure F (Thiol additions to bicyclo[1.1.0]butyl nitriles): 3-Methyl-3-
(phenylthio)cyclobutane-1-carbonitrile (2-67). A 50 mL flask under N2 was charged with a 
solution of thiophenol (0.19 mL, 1.8 mmol) in MeOH (10 mL). This solution was treated with 
anhydrous K2CO3 (0.251 g, 1.82 mmol, 1.00 eq) and stirred 10 min at rt. Nitrile 2-37 (0.203 g, 
2.18 mmol, 1.20 eq) was then added neat by syringe over 1 min. The solution was stirred at rt for 
21 h, at which point it was concentrated. The crude, cloudy liquid was purified by chromatography 
on SiO2 (10-20% EtOAc/hexanes) to afford the less polar trans-2-67 (0.260 g, 1.27 mmol, 70%) 
and the more polar cis-2-67 (0.042 g, 0.21 mmol, 11%), both as colorless oils: trans-2-67: 1H NMR 
(400 MHz, CDCl3) δ 7.50-7.44 (m, 2 H), 7.39-7.32 (m, 3 H), 3.23 (pent, 1 H, J = 8.8 Hz), 2.60 
(ddd, 2 H, J = 10.8 Hz, 8.4 Hz, 2.4 Hz), 2.41 (ddd, 2 H, J = 10.4 Hz, 8.4 Hz, 2.4 Hz), 1.55 (s, 3 
H); 13C NMR (100 MHz, CDCl3) δ 135.5, 132.3, 129.0, 128.9, 122.2, 48.2, 39.6, 29.7, 16.7. cis-
2-67: 1H NMR (500 MHz, CDCl3) δ 7.49-7.45 (m, 2 H), 7.40-7.34 (m, 3 H), 3.05 (pent, 1 H, J =
129 
8.5 Hz), 2.64 (app dt, 2 H, J = 9.5 Hz, 2.5 Hz), 2.34 (ddd, 2 H, J = 10.5 Hz, 8.0Hz, 2.5 Hz), 1.49 
(s, 3 H); 13C NMR (125 MHz, CDCl3) δ 135.7, 131.9, 129.1, 129.0, 121.4, 46.3, 39.8, 39.6, 26.9, 
16.5; IR (ATR) 2956, 2235, 1720, 1474, 917, 745, 695 cm-1; MS (ESI+) m/z 204, 159, 118; HRMS 
(ESI+) m/z calcd for C12H14NS [M+H] 204.0842, found 204.0842. 
S CN
cis 2-68trans 2-68
S CN
3-Methyl-3-(naphthalen-2-ylthio)cyclobutane-1-carbonitrile (2-68). Prepared according to
General Procedure F from 2-naphthlenethiol (0.122 g, 0.761 mmol), K2CO3 (0.105 g, 0.761 mmol, 
1.00 eq), and nitrile 2-37 (0.203 g, 2.18 mmol, 1.20 eq) in MeOH (5 mL). Purification by 
chromatography on SiO2 (10-20% EtOAc/hexanes) afforded trans-2-68 (0.119 g, 0.470 mmol, 
62%) as a colorless solid and cis-2-68 (0.032 g, 0.13 mmol, 17%) as a colorless oil: trans-2-68: 
Mp 61–64 °C; IR (ATR) 2970, 2236, 1583, 1375, 1196, 1114, 863, 827, 749 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.99 (s, 1 H), 7.88-7.77 (m, 3 H), 7.57-7.48 (m, 3 H), 3.27 (pent, 1 H, J = 8.8 Hz), 
2.67 (ddd, 2 H, J = 11.2 Hz, 8.8 Hz, 2.4 Hz), 2.43 (ddd, 2 H, J = 10.8 Hz, 8.0 Hz, 2.4 Hz), 1.60 (s, 
3 H); 13C NMR (100 MHz, CDCl3) δ 135.0, 133.5, 133.0, 132.1, 129.8, 128.6, 127.82, 127.76, 
127.0, 126.8, 122.2, 48.6, 39.7, 29.8, 16.8. cis-2-68: 1H NMR (400 MHz, CDCl3) δ 7.99 (d, 1 H, 
J = 1.2 Hz), 7.88-7.75 (m, 3 H), 7.56-7.46 (m, 3 H), 3.08 (pent, 1 H, J = 8.8 Hz), 2.73 (dd, 2 H, J 
= 8.8 Hz, 2.4 Hz), 2.43 (ddd, 2 H, J = 10.4 Hz, 8.0 Hz, 2.0 Hz), 1.52 (s, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 135.2, 133.6, 133.1, 132.1, 129.3, 128.7, 127.82, 127.76, 126.9, 126.7, 121.5, 46.6, 40.0, 
27.0, 16.7; HRMS (ASAP) m/z calcd for C16H16NS [M+H] 254.1003, found 254.1035. 
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S CN
cis 2-69trans 2-69
S CN
3-Methyl-3-(o-tolylthio)cyclobutane-1-carbonitrile (2-69). Prepared according to General
Procedure F from nitrile 2-37 (0.050 g, 0.54 mmol), o-thiocresol (0.06 mL, 0.49 mmol), and K2CO3 
(0.074 g, 0.54 mmol) in MeOH (3 mL). Purification by chromatography on SiO2 (10-20% 
EtOAc/hexanes) to afford the less polar trans-2-69 (0.084 g, 0.39 mmol, 79%) and the more polar 
cis-2-69 (0.008 g, 0.04 mmol, 8%), both as colorless oils. trans-2-69: IR (ATR): 2940, 2238, 1732, 
1589, 1487, 1263, 1114, 1063, 748 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.36 (dd, 1 H, J = 7.2 Hz, 
0.8 Hz), 7.29-7.20 (m, 2 H), 7.17 (td, 1 H, J = 7.2 Hz, 1.2 Hz), 3.25 (pent, 1 H, J  = 8.8 Hz), 2.63 
(ddd, 2 H, J = 11.2 Hz, 9.2 Hz, 2.0 Hz), 2.48-2.39 (m, 2 H), 2.45 (s, 3 H), 1.60 (s, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 141.7, 134.7, 132.2, 130.8, 128.5, 126.4, 122.3, 48.7, 39.8, 29.5, 21.4, 17.0; 
HRMS (ESI)+ calcd for C13H16NS [M+H] 218.1003, found 218.0991. cis-2-69: 1H NMR (400 
MHz, CDCl3) δ 7.39 (d, 1 H, J = 7.2 Hz), 7.32-7.23 (m, 2 H), 7.19 (td, 1 H, J = 7.2 Hz, 2.4 Hz), 
3.05 (pent, 1 H, J  = 8.8 Hz), 2.63 (td, 2 H, J = 9.6 Hz, 2.4 Hz), 2.48-2.35 (m, 2 H), 2.44 (s, 3 H), 
1.49 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 142.3, 136.1, 131.6, 130.8, 129.0, 126.5, 45.8, 40.1, 
26.5, 21.5, 16.8. 
3-((2-Bromophenyl)thio)-3-methylcyclobutane-1-carbonitrile (2-70). Prepared according to 
General Procedure F from bicyclobutane 2-37 (0.210 g, 2.25 mmol, 1.20 eq), 2-bromothiophenol 
(0.22 mL, 1.87 mmol) and K2CO3 (0.286 g, 2.07 mmol, 1.10 eq) in MeOH (5 mL). Purification by 
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chromatography on SiO2 (20-30% EtOAc/hexanes) afforded trans-2-70 (0.367 g, 1.30 mmol, 
69%) and cis-2-70 (0.067 g, 0.24 mmol, 13%), both as colorless oils. trans-2-70: IR (ATR) 2940, 
2238, 1731, 1445, 1426, 1103, 1019, 712 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.65 (dd, 1 H, J = 
8.0 Hz, 1.6 Hz), 7.39 (dd, 1 H, J = 8.0 Hz, 1.6 Hz), 7.29 (td, 1 H, J = 7.6 Hz, 1.2 Hz), 7.16 (td, 1 
H, J = 7.6 Hz, 1.6 Hz), 3.37 (pent, 1 H, J = 8.8 Hz), 2.70 (ddd, 2 H, J = 10.8 Hz, 9.2 Hz, 2.4 Hz), 
2.48 (ddd, 2 H, J = 10.8 Hz, 8.4 Hz, 2.4 Hz), 1.66 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 134.5, 
134.4, 133.8, 129.3, 128.7, 122.0, 49.1, 39.8, 29.4, 17.2; MS (ESI)+ m/z 281, 261, 233, 212, 199, 
144, 127, 114; HRMS (ESI)+ calcd for C12H13NSBr [M+H] 281.9947, found 281.9938. cis-2-70: 
1H NMR (400 MHz, CDCl3) δ 7.68 (dd, 1 H, J = 8.0 Hz, 1.6 Hz), 7.47 (dd, 1 H, J = 7.6 Hz, 1.6 
Hz), 7.31 (td, 1 H, J = 7.6 Hz, 1.2 Hz), 7.20 (td, 1 H, J = 7.6 Hz, 1.6 Hz), 3.08 (pent, 1 H, J = 8.8 
Hz), 2.72 (td, 2 H, J =9.6 Hz, 2.4 Hz), 2.54-2.43 (m, 2 H), 1.53 (s, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 136.3, 133.9, 133.8, 130.0, 127.9, 121.3, 47.1, 40.3, 26.3, 17.0. 
 
3-((3-Fluorophenyl)thio)-3-methylcyclobutane-1-carbonitrile (2-71). Prepared according to 
General Procedure F from 3-fluorothiophenol (0.06 mL, 0.49 mmol), nitrile 2-37 (0.067 g, 0.72 
mmol, 1.1 eq) and K2CO3 (0.099 g, 0.72 mmol, 1.1 eq) in MeOH (3 mL). Purification by 
chromatography on SiO2 (10-20% EtOAc/hexanes) afforded the less polar trans-2-71 (0.074 g, 
0.33 mmol, 51%) and the more polar cis-2-71 (0.023 g, 0.10 mmol, 16%), both as colorless oils. 
trans-2-71: IR (ATR) 2942, 2262, 1597, 1578, 1472, 1261, 1215, 1112, 863 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.31 (td, 1 H, J = 8.0 Hz, 6.0 Hz), 7.20 (d, 1 H, J = 7.6 Hz), 7.14 (dt, 1 H, J = 8.0 
Hz, 2.0 Hz), 7.05 (td, 1 H, J = 8.0 Hz, 2.0 Hz), 3.28 (pent, 1 H, J = 8.4 Hz), 2.60 (ddd, 2 H, J = 
10.8 Hz, 9.2 Hz, 2.0 Hz), 2.44 (ddd, 2 H, J = 10.8 Hz, 8.4 Hz, 2.4 Hz), 1.60 (s, 3 H); 13C NMR 
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(100 MHz, CDCl3) δ 162.5 (1JCF = 248 Hz), 134.6 (3JCF = 7 Hz), 130.4 (4JCF = 3 Hz), 130.3 (3JCF 
= 9 Hz), 122.0, 121.3 (2JCF = 21 Hz), 115.8 (2JCF = 21 Hz), 48.4, 39.6, 29.6, 16.8; 19F NMR (376 
MHz, CDCl3) δ –111.7; HRMS (ESI)+ calcd for C12H13NSF [M+H] 222.0723, found 222.0753. 
cis-2-71: 1H NMR (400 MHz, CDCl3) δ 7.34 (td, 1 H, J = 8.0 Hz, 6.0 Hz), 7.22 (dt, 1 H, J = 7.6 
Hz, 1.2 Hz), 7.15 (dt, 1 H, J = 8.8 Hz, 2.0 Hz), 7.08 (tdd, 1 H, J = 8.4 Hz, 2.8 Hz, 0.8 Hz), 3.09 
(pent, 1 H, J  = 8.8 Hz), 2.67 (ddd, 2 H, J = 10.4 Hz, 8.8 Hz, 2.0 Hz), 2.43 (ddd, 2 H, J = 10.8 Hz, 
8.8 Hz, 2.0 Hz), 1.50 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 162.5 (1JCF = 248 Hz), 134.2 (3JCF 
= 8 Hz), 130.8 (4JCF = 3 Hz), 130.4 (3JCF = 8 Hz), 121.8 (2JCF = 22 Hz), 121.3, 116.0 (2JCF = 21 
Hz), 46.4, 40.0, 26.9, 16.7; 19F NMR (376 MHz, CDCl3) δ –111.7. 
S CN
N
cis 2-72trans 2-72
S CN
N
3-Methyl-3-(pyridin-2-ylthio)cyclobutane-1-carbonitrile (2-72). Prepared according to General
Procedure F from 2-mercaptopyridine (0.093 g, 0.84 mmol), nitrile 2-37 (0.086 g, 0.92 mmol) and 
K2CO3 (0.116 g, 0.839 mmol) in MeOH (4 mL) with heating at 70 °C. Purification by 
chromatography on SiO2 (25% EtOAc/hexanes) afforded trans-2-72 (0.088 g, 0.43 mmol, 51%) 
as a colorless oil that solidified upon standing and cis-2-72 (0.024 g, 0.12 mmol, 14%) as a 
colorless oil. trans-2-72: Mp 55–57 °C; IR (ATR)  2957, 2240, 1578, 1564, 1457, 1416, 1111, 
760, 723 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.41 (dt, 1 H, J = 4.0 Hz, 0.8 Hz), 7.48 (ddt, 1 H, J 
= 7.6 Hz, 2.0 Hz, 0.8 Hz), 7.14 (dd, 1 H, J = 8.4 Hz, 0.8 Hz), 7.04-6.98 (m, 1 H), 3.38 (pent, 1 H, 
J = 8.4 Hz), 2.91-2.81 (m, 2 H), 2.60-2.51 (m, 2 H), 1.79 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 
158.2, 149.6, 136.1, 123.9, 122.4, 120.1, 47.9, 40.0, 29.8, 17.4; MS (ESI)+ m/z 205, 171, 144, 112 
(5); HRMS (ESI)+ calcd for C11H13N2S [M+H] 205.0799, found 205.0781. cis-2-72: 1H NMR (400 
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MHz, CDCl3) δ 8.48 (d, 1 H, J = 4.0 Hz), 7.51 (td, 1 H, J = 7.6 Hz, 1.2 Hz), 7.16 (d, 1 H, J = 8.0 
Hz), 7.03 (t, 1 H, J = 6.0 Hz), 3.19 (pent, 1 H, J = 8.0 Hz), 3.13-3.04 (m, 2 H), 2.58 (ddd, 2 H, J = 
10.4 Hz, 8.8 Hz, 2.0 Hz), 1.69 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 158.2, 149.6, 136.2, 123.9, 
122.4, 122.0, 45.8, 40.0, 27.7, 17.3. 
 
3-Methyl-3-((5-methyl-1,3,4-thiadiazol-2-yl)thio)cyclobutane-1-carbonitrile (2-73). Prepared 
according to General Procedure F from 5-methylthiadiazole-2-thiol (0.084 g, 0.63 mmol), nitrile 
2-37 (0.065 g, 0.70 mmol, 1.1 eq), and K2CO3 (0.096 g, 0.70 mmol, 1.1 eq) in MeOH (3 mL) with 
heating at 60 °C. Purification by chromatography on SiO2 (10-20% EtOAc/hexanes) afforded the 
less polar trans-2-73 (0.075 g, 0.33 mmol, 52%) and the more polar cis-2-37 (0.015 g, 0.07 mmol, 
10%), both as colorless oils. trans-2-73: IR (ATR) 2963, 2239, 1426, 1383, 1190, 1039, 911, 726 
cm-1; 1H NMR (400 MHz, CDCl3) δ 3.37 (pent, 1 H, J = 8.8 Hz), 2.87 (ddd, 2 H, J = 12.0 Hz, 9.2 
Hz, 2.4 Hz), 2.72 (s, 3 H), 2.56 (ddd, 2 H, J = 11.6 Hz, 8.4 Hz, 2.8 Hz), 1.77 (s, 3 H); 13C NMR 
(125 MHz, CDCl3) δ 166.2, 161.8, 121.6, 50.7, 39.7, 29.3, 16.9, 15.5; HRMS (ESI)+ calcd for 
C9H12N3S2 [M+H] 226.0473, found 226.0479. cis-2-73: 1H NMR (400 MHz, CDCl3) δ 3.19 (pent, 
1 H, J = 8.8 Hz), 2.95-2.85 (m, 2 H), 2.75 (s, 3 H), 2.66 (ddd, 2 H, J = 11.2 Hz, 8.8 Hz, 2.4 Hz), 
1.75 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 166.3, 161.7, 121.2, 48.4, 40.2, 27.1, 17.2, 15.6. 
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N
N
S CN
N
N
2-74, 5:1 anti:syn (inseparable)
3-Methyl-3-((1-methyl-1H-imidazol-2-yl)thio)cyclobutane-1-carbonitrile (2-74). Prepared 
according to General Procedure F from bicyclobutane 2-37 (0.070 g, 0.75 mmol, 1.20 eq), 1-
methyl-2-mercaptoimidazole (0.072 g, 0.063 mmol) and K2CO3 (0.095 g, 0.69 mmol, 1.10 eq) in 
MeOH (3 mL) with heating at 60 °C. Purification by chromatography on SiO2 (5% MeOH/CH2Cl2) 
afforded 2-74 (0.097 g, 0.467 mmol, 75%) as a colorless oil. The material is an inseparable 5:1 
mixture of trans (major) and cis diastereomers: trans-2-74: IR (ATR) 3378, 2945, 2337, 1637, 
1453, 1310, 1214, 1112, 753 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.14 (d, 1 H, J = 1.2 Hz), 7.04 
(d, 1 H, J = 1.2 Hz), 3.71 (s, 3 H), 3.28 (pent, 1 H, J = 8.4 Hz), 2.82 (ddd, 2 H, J = 11.2 Hz, 9.2 
Hz, 2.8 Hz), 2.44 (ddd, 2 H, J = 10.8 Hz, 8.0 Hz, 2.8 Hz), 1.56 (s, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 138.8, 130.1, 123.3, 122.1, 50.8, 39.6, 34.0, 29.6, 16.6; HRMS (ESI)+ calcd for 
C10H14N3S [M+H] 208.0908, found 208.0902. 
trans 2-75
S CN
N
N
N
N Ph
trans-3-Methyl-3-((1-phenyl-1H-tetrazol-5-yl)thio)cyclobutane-1-carbonitrile (2-75). 
Prepared according to General Procedure F from bicyclobutane 2-37 (0.064 g, 0.69 mmol, 1.1 eq), 
N-phenyl 2-mercaptotetrazole (0.112 g, 0.063 mmol) and K2CO3 (0.087 g, 0.63 mmol, 1.0 eq) in
CF3CH2OH (3 mL) with heating at 60 °C. After stirring at 60 °C for 13 h, the reaction was 
concentrated and purified by chromatography on SiO2 (30% EtOAc/hexanes) to afford tetrazole 
2-75 (0.032 g, 0.118 mmol, 19%) as a colorless solid: Mp 119–120 °C; IR (ATR) cm-1 3064, 2962,
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2240, 1596, 1499, 1459, 1387, 1239, 1015, 762, 695; 1H NMR (400 MHz, CDCl3) δ 7.61-7.50 (m, 
5 H), 3.42 (pent, 1 H, J = 8.8 Hz), 2.99 (ddd, 2 H, J = 12.0 Hz, 9.6 Hz, 2.4 Hz), 2.68 (ddd, 2 H, J 
= 11.6 Hz, 8.4 Hz, 2.8 Hz), 1.89 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 152.2, 133.4, 130.4, 
129.9, 124.2, 121.6, 50.7, 39.9, 29.4, 17.2; MS (ESI)+ m/z 272, 262, 179, 151, 83; HRMS (ESI)+ 
calcd for C13H14N5S [M+H] 272.0964, found 272.0954. 
S
CN
HN
trans 2-76
3-((1H-Indol-3-yl)thio)-3-methylcyclobutane-1-carbonitrile (2-76). Prepared according to 
General Procedure F from indole-3-thiol (0.327 g, 2.20 mmol) nitrile 2-37 (0.225 g, 2.42 mmol, 
1.10 eq), and K2CO3 (0.304 g, 2.19 mmol, 1.00 eq) in MeOH (10 mL). Purification by 
chromatography on SiO2 (10-20% EtOAc/hexanes) afforded trans-2-76 (0.218 g, 0.900 mmol, 
41%) as a colorless solid in ~80-90% purity. The cis isomer co-eluted with several impurities and 
was not characterized. trans-2-76: IR (ATR) 3321, 2956, 2245, 1492, 1452, 1416, 1266, 1110, 
1009, 739 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.71 (s, 1 H), 7.82 (d, 1 H, J = 6.6 Hz), 7.51-7.46 
(m, 1 H), 7.37 (d, 1 H, J = 2.7 Hz), 7.34-7.23 (m, 2 H), 3.32-3.16 (m, 1 H), 2.61 (ddd, 2 H, J = 
11.4 Hz, 9.6 Hz, 1.8 Hz), 2.35 (ddd, 2 H, J = 11.1 Hz, 8.1 Hz, 2.1 Hz), 1.57 (s, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 136.2, 131.7, 130.5, 122.9, 122.7, 121.0, 119.4, 111.8, 103.2, 49.0, 39.3, 
29.7, 16.6; HRMS (ESI)+ calcd for C14H15N2S [M+H] 243.0951, found 243.0940. 
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5.4 CHAPTER 3 EXPERIMENTAL PART 
 
General Procedure G (Preparation of Bicyclo[1.1.0butyl alcohols/amides): (3-
Methylbicyclo[1.1.0]butan-1-yl)(phenyl)methanol (3-45).73b A solution of 1-chloromethyl-1- 
methyl-2,2-dibromocyclopropane (10 g, 38 mmol) in Et2O (50 mL) was cooled to –78 °C under 
N2. A solution of MeLi (25 mL, 38 mmol, c = 1.3 M in Et2O) was added via syringe over 15 min. 
After 1 h at –78 °C, a solution of t-BuLi (25 mL, 38 mmol, c = 1.5 M in pentane) was added via 
syringe over 15 min. The reaction mixture was stirred for an additional 1 h at –78 °C, then neat 
benzaldehyde (1.5 mL, 15 mmol) was added in one portion. The reaction mixture was quenched 
at –78 °C with sat aq NH4Cl (20 mL), warmed up to rt, and extracted (3 x 50 mL) with Et2O. The 
combined organic layers were washed with water (50 mL), brine (50 mL), dried (Na2SO4), and 
concentrated. The crude product was purified by Kugelrohr distillation (1 mmHg, fractions 
collected at 105-115 °C oven temperature) to afford alcohol 3-45 (2.13 g, 12.2 mmol, 80 %) as 
colorless liquid: IR (ATR) 3383, 1493, 1450, 1088 cm; 1H NMR (500 MHz, CDCl3) δ 7.42-7.26 
(m, 5 H), 5.05 (d, J = 4.2 Hz, 1 H), 1.96 (d, 1 H, J = 4.2 Hz,), 1.48 (d, 1 H, J = 6.6 Hz,), 1.46 (s, 3 
H), 1.13 (d, J = 6.6 Hz, 1 H), 0.73 (s, 1 H), 0.64 (s, 1 H); 13C NMR (125 MHz, CDCl3) δ 143.1, 
128.2, 127.5, 126.5, 73.3, 32.8, 32.6, 16.1, 11.1, 10.5; MS (EI) m/z 174 (71), 159 (66), 141 (53), 
115 (76), 105 (100), 91 (77), 77 (90); HRMS (EI) calcd for C12H14O [M+] 174.1045, found 
174.1042. 
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(3-Methylbicyclo[1.1.0]butan-1-yl)(4-(trifluoromethyl)phenyl)methanol (3-47). Prepared 
according to General Procedure G using 1-chloromethyl-1-methyl-2,2-dibromocyclopropane 
(2.00 g, 7.62 mmol, 2.50 eq), MeLi (4.7 mL, 7.6 mmol, 2.5 eq), t-BuLi (4.5 mL, 7.6 mmol, 2.5 
eq), and p-trifluoromethylbenzaldehyde (0.42 mL, 3.0 mmol, 1.0 eq). Purification by 
chromatography on SiO2 (15% EtOAc/hexanes) afforded 3-47 (0.472 g, 1.95 mmol, 64%) as a 
colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.60 (d, 2 H, J = 8.0 Hz), 7.50 (d, 2 H, J = 8.0 Hz), 
5.11 (d, 1 H, J = 4.0 Hz), 2.05 (d, 1 H, J = 3.2 Hz), 1.47 (s, 3 H), 1.10 (d, 1 H, J = 6.4 Hz), 0.71 
(s, 1 H), 0.64 (s, 1 H); 13C NMR (100MHz, CDCl3) δ 147.0, 129.8 (q, 2JCF = 32 Hz), 126.8, 125.5, 
125.3, 122.8, 72.8, 32.9, 32.6, 16.4, 11.3, 11.2. 
 
(4-Chlorophenyl)(3-methylbicyclo[1.1.0]butan-1-yl)methanol (3-48). Prepared according to 
General Procedure G using 1-chloromethyl-1- methyl-2,2-dibromocyclopropane (1.20 g, 4.57 
mmol, 2.50 eq), MeLi (2.9 mL, 4.6 mmol, 2.5 eq), t-BuLi (2.7 mL, 4.6 mmol, 2.5 eq) and p-
chlorobenzaldehyde (0.257 g, 1.83 mmol) in diethyl ether (8 mL). Purification by chromatography 
on SiO2 afforded 3-48 (0.215 g, 1.03 mmol, 56%) as a colorless oil: IR (ATR) 3358, 2923, 1489, 
1091, 1013, 967, 815 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.32 (s, 4 H), 5.02 (d, 1 H, J = 4.0 Hz), 
1.97 (d, 1 H, J = 3.6 Hz), 1.44 (d, 1 H, J = 6.0 Hz) 1.44 (s, 3 H), 1.09 (d, 1 H, J = 6.4 Hz), 0.70 (s, 
1 H), 0.62 (s, 1 H); 13C NMR (100 MHz, CDCl3) δ 141.6, 133.3, 128.5, 127.9, 72.9, 32.8, 32.6, 
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16.3, 11.2, 11.0; MS (ESI+) 191 (70), 177 (100), 146 (30), 133 (90); HRMS (ESI+) calcd for 
C12H12Cl [M+H–H2O] 191.0628, found 191.0622. 
 
(4-Methoxyphenyl)(3-methylbicyclo[1.1.0]butan-1-yl)methanol (3-49). Prepared according to 
General Procedure G using 1-chloromethyl-1-methyl-2,2-dibromocyclopropane (2.00 g, 7.62 
mmol, 2.50 eq), MeLi (4.8 mL, 7.6 mmol, 2.5 eq), t-BuLi (4.5 mL, 7.6 mmol, 2.5 eq), and p-
anisaldehyde (0.37 mL, 3.0 mmol, 1.0 eq). Purification by chromatography on SiO2 afforded 3-49 
(0.284 g, 1.30 mmol, 46%) as a colorless oil: IR (ATR) 3393, 2921, 1612, 1511, 1246, 1172, 1034, 
832 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.31 (d, 2 H, J = 8.7 Hz), 6.88 (d, 2 H, J = 8.7 Hz), 4.38 
(d, 1 H, J = 3.9 Hz), 3.81 (s, 3 H), 1.86 (d, 1 H, J = 3.9 Hz), 1.47 (d, 1 H, J = 6.6 Hz), 1.43 (s, 3 
H), 1.12 (d, 1 H, J = 6.6 Hz), 0.71 (s, 1 H), 0.62 (s, 1 H); 13C NMR (100 MHz, CDCl3) δ 159.1, 
135.6, 127.8, 113.9, 73.1, 55.3, 33.0, 32.6, 16.2, 11.2, 10.4; MS [ESI+] m/z 187 (100), 172 (40), 
139 (10), 121 (5); HRMS [ESI+] m/z calcd for C13H15O [M+H–H2O] 187.1117, found 187.1117. 
 
(2-(Allyloxy)phenyl)(3-methylbicyclo[1.1.0]butan-1-yl)methanol (3-50). Prepared according to 
General Procedure G using 1-chloromethyl-1-methyl-2,2-dibromocyclopropane (1.21 g, 4.62 
mmol, 2.50 eq), MeLi (2.9 mL, 4.6 mmol, 2.5 eq), t-BuLi (2.7 mL, 4.6 mmol, 2.5 eq), and a 
solution of O-allylsalicyaldehyde (0.300 g, 1.85 mmol, 1.00 eq) in THF (1 mL). Purification by 
chromatography on SiO2 afforded 3-50 (0.154 g, 0.669 mmol, 36%) as a colorless oil: IR (ATR) 
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3418, 2920, 1601, 1489, 1454, 1237, 998, 753 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.38 (dd, 1 H, 
J = 7.5 Hz, 1.8 Hz), 7.22 (td, 1 H, J = 7.5 Hz, 1.5 Hz), 6.96 (app t, 1 H, J = 7.2 Hz), 6.87 (d, 1 H, 
J = 8.1 Hz), 6.06, 5.42, 5.30 (ABX, 3 H, JAB = 1.5 Hz, JAX = 15.9 Hz, JBX = 10.5 Hz), 5.22 (d, 1 
H, J = 6.6 Hz), 4.58 (dt, 2 H, J = 5.1 Hz, 1.5 Hz), 2.90 (d, 1 H, J = 6.6 Hz), 1.51 (d, 1 H, J  = 6.3 
Hz), 1.42 (s, 3 H), 1.12 (d, 1 H, J = 6.6 Hz), 0.73 (s, 1 H), 0.64 (s, 1 H); 13C NMR (100 MHz, 
CDCl3) δ 155.6, 133.0, 131.6, 128.5, 128.2, 120.9, 117.7, 111.8, 70.0, 68.9, 33.4, 32.8, 15.3, 11.1, 
10.7; MS [ESI+] m/z 213 (100), 172 (35), 131 (15), 118 (20); HRMS [ESI+] calcd for C15H17O 
[M+H–H2O] 213.1274, found 213.1273. 
 
 
 
(3-Methylbicyclo[1.1.0]butan-1-yl)(pyridin-2-yl)methanol (3-51). Prepared according to 
General Procedure G from 1-chloromethyl-1-methyl-2,2-dibromocyclopropane (1.50 g, 5.72 
mmol), MeLi (3.6 mL, 5.7 mmol, c = 1.6 M in Et2O), t-BuLi (3.4 mL, 5.7 mmol, c = 1.7 M in 
pentane), and 2-pyridinecarboxaldehyde (0.22 mL, 2.3 mmol) in Et2O (12 mL). Purification by 
chromatography on SiO2 (15% EtOAc/hexanes) afforded alcohol 3-51 (0.198 g, 1.13 mmol, 49%) 
as a yellow oil: 1H NMR (400 MHz, CDCl3) δ 8.54 (d, 1 H, J = 4.4 Hz), 7.70 (td, 1 H, J = 7.6 Hz, 
1.6 Hz), 7.35 (d, 1 H, J = 8.0 Hz), 7.21 (dd, 1 H, J = 6.8 Hz, 5.2 Hz), 5.01 (d, 1 H, J = 4.0 Hz), 
4.45 (d, 1 H, J = 4.0 Hz), 1.58 (s, 3 H), 1.47 (d, 1 H, J  = 6.4 Hz), 1.35 (d, 1 H, J = 6.4 Hz), 0.71 
(s, 1 H), 0.53 (s, 1 H); 13C NMR (100 MHz, CDCl3) δ 161.3, 148.0, 136.6, 122.4, 121.0, 71.1, 
34.1, 31.3, 16.1, 10.5. 
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1-(3-Methylbicyclo[1.1.0]butan-1-yl)-1-phenylethan-1-ol (3-52). Prepared according to 
General Procedure G from 1-chloromethyl-1-methyl-2,2-dibromocyclopropane (2.00 g, 7.62 
mmol, 2.50 eq), MeLi (4.8 mL, 7.6 mmol, c = 1.6 M in Et2O), t-BuLi (4.5 mL, 7.6 mmol, c = 1.7 
M in pentane) and acetophenone (0.36 mL, 3.0 mmol). Purification by chromatography on SiO2 
(15% EtOAc/hexanes) to afforded 3-52 (0.440 g, 2.34 mmol, 77%) as a colorless oil: IR (ATR) 
3432, 2921, 1446, 1372, 1088, 961, 760, 698 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.54 (d, 2 H, J 
= 7.6 Hz), 7.34 (t, 2 H, J = 7.6 Hz), 7.25 (t, 1 H, J = 7.2 Hz), 1.89 (s, 1 H), 1.61 (s, 3 H), 1.60 (s, 
3 H), 1.34 (d, 1 H, J = 6.8 Hz), 1.26 (d, 1 H, J = 6.8 Hz), 0.58 (s, 1 H), 0.47 (s, 1 H); 13C NMR 
(100 MHz, CDCl3) δ 148.0, 128.0, 126.8, 125.2, 73.9, 32.2, 30.3, 28.6, 20.7, 12.6, 10.8; MS [ESI+] 
m/z 171 (60), 154 (30), 143 (100), 129 (50); HRMS [ESI+] m/z calcd for C13H15 [M+H–H2O] 
171.1174, found 171.1169. 
 
Phenyl(3-propylbicyclo[1.1.0]butan-1-yl)methanol (3-53). Prepared according to General 
Procedure G using the corresponding tribromide (2.03 g, 6.06 mmol, 2.54 eq), MeLi (3.8 mL, 6.1 
mmol, c = 1.6 M in Et2O), t-BuLi (3.6 mL, 6.1 mmol, c = 1.7 M in pentane), and benzaldehyde 
(0.25 mL, 2.4 mmol) in Et2O (15 mL). Purification by chromatography on SiO2 (15-25% 
EtOAc/hexanes) afforded alcohol 3-53 (0.165 g, 0.816 mmol, 34% over 3 steps) as a colorless oil: 
IR (ATR) 3353, 2926, 1453, 1085, 1002, 964, 754, 698 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.44-
7.27 (m, 5 H), 5.05 (d, 1 H, J = 3.9 Hz), 1.93 (d, 1 H, J = 4.2 Hz), 1.80-1.59 (m, 2 H), 1.52-1.38 
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(m, 2 H), 1.48 (d, 1 H, J = 6.6 Hz), 1.14 (d, 1 H, J = 6.6 Hz), 0.95 (t, 3 H, J = 7.2 Hz), 0.68 (s, 1 
H), 0.61 (s, 1 H); 13C NMR (100 MHz, CDCl3) δ 143.2, 128.4, 128.3, 127.6, 127.1, 126.6, 73.4, 
31.9, 31.5, 28.0, 22.7, 16.7, 15.0, 14.0; MS (ESI)+ m/z 185 (75), 143 (90), 129 (100); HRMS (ESI)+ 
m/z calcd for C14H17 [M+H–H2O] 185.1325, found 185.1325. 
 
(3-Isopropylbicyclo[1.1.0]butan-1-yl)(phenyl)methanol (3-54). Prepared according to General 
Procedure G using from the corresponding tribromide (3.30 g, 9.86 mmol, 2.17 eq), MeLi (7.1 
mL, 11.4 mmol, c = 1.6 M in Et2O), t-BuLi (6.7 mL, 11.4 mmol, c = 1.7 M in pentane), and 
benzaldehyde (0.46 mL, 4.5 mmol) in Et2O (20 mL). Purification by chromatography on SiO2 (15-
25% EtOAc/hexanes) afforded alcohol 3-54 (0.372 g, 1.84 mmol, 40%) as a colorless oil: IR 
(ATR) 3379, 2959, 1453, 1083, 1002, 963, 891, 751, 698 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.44-7.27 (m, 5 H), 5.12 (d, 1 H, J = 4.0 Hz), 2.04 (pent, 1 H, J = 6.8 Hz), 1.89 (d, 1 H, J = 4.4 
Hz), 1.51 (d, 1 H, J = 6.8 Hz), 1.18 (d, 1 H, J = 6.8 Hz), 1.01 (d, 3 H, J = 6.8 Hz), 0.95 (d, 3 H, J 
= 6.8 Hz), 0.53 (s, 1 H), 0.48 (s, 1 H); 13C NMR (100 MHz, CDCl3) δ 143.4, 128.4, 127.7, 126.6, 
72.7, 29.3, 28.3, 24.6, 21.8, 21.2, 18.8; MS (ESI)+ m/z 203, 201 (20), 185 (100), 157 (3); HRMS 
(ESI)+ m/z cald for C14H19O [M+H] 203.1430, found 203.1433. 
 
(3-Phenethylbicyclo[1.1.0]butan-1-yl)(phenyl)methanol (3-55). Prepared using General 
Procedure G from the corresponding tribromide (0.968 g, 2.44 mmol, 2.00 eq), MeLi (1.5 mL, 2.4 
mmol, c = 1.6 M in Et2O), t-BuLi (1.4 mL, 2.4 mmol, c = 1.7 M in pentane), and benzaldehyde 
(0.12 mL, 1.2 mmol) in Et2O (8 mL). Purification by chromatography on SiO2 (15-25% 
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EtOAc/hexanes) afforded alcohol 3-55 (0.153 g, 0.579 mmol, 47%) as a yellow tinted oil: IR 
(ATR) 3376, 3026, 2922, 1603, 1495, 1453, 1013, 699 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.41-
7.31 (m, 4 H), 7.30-7.26 (m, 3 H), 7.21-7.15 (m, 3 H), 5.02 (d, 1 H, J = 4.4 Hz), 2.82-2.66 (m, 2 
H), 2.18-2.08 (m, 1 H), 2.07-1.97 (m, 1 H), 1.86 (d, 1 H, J = 4.0 Hz), 1.48 (d, 1 H, J = 6.4 Hz), 
1.18 (d, 1 H, J = 6.8 Hz), 0.67 (s, 1 H), 0.60 (s, 1 H); 13C NMR (100 MHz, CDCl3) δ 143.2, 142.1, 
128.5, 128.4, 128.3, 127.7, 126.5, 125.8, 73.2, 35.7, 31.8, 31.4, 28.2, 17.5, 15.1. 
 
 
 
1-(3-Phenylbicyclo[1.1.0]butan-1-yl)pentan-1-ol (3-56). Prepared according to General 
Procedure G from the corresponding tribromide (0.957 g, 2.59 mmol, 2.50 eq), MeLi (1.6 mL, 2.6 
mmol, c = 1.62 M in Et2O), t-BuLi (1.5 mL, 2.6 mmol, c = 1.7 M in pentane), and valeraldehyde 
(0.11 mL, 1.0 mmol, 1.0 eq) in Et2O (6 mL). Purification by chromatography on SiO2 (10% 
EtOAc/hexanes) afforded alcohol 3-56 (0.181 g, 0.837 mmol, 81%) as a yellow-tinted oil: IR 
(ATR) 3396, 2929, 1602, 1446, 1104, 1026, 761, 695 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.31-
7.21 (m, 4 H), 7.14 (tt, 1 H, J = 6.8 Hz, 1.6 Hz), 3.81 (ddd, 1 H, J = 4.0 Hz, 4.0 Hz, 4.0 Hz), 2.35 
(d, 1 H, J = 6.8 Hz), 2.19 (dd, 1 H, J = 6.8 Hz, 0.8 Hz), 1.67-1.21 (m, 6 H), 1.15 (s, 1 H), 1.13 (d, 
1 H, J = 4.0 Hz), 1.09 (s, 1 H), 0.85 (t, 3 H, J = 6.8 Hz); 13C NMR (100 MHz, CDCl3) δ 137.0, 
128.6, 125.3, 125.2, 125.1, 70.2, 36.3, 12.2, 30.2, 27.6, 22.5, 17.4, 14.0; MS (ESI)+ m/z 217 (10), 
199 (100), 177 (15), 143 (40), 117 (10); HRMS (ESI)+ m/z calcd for C15H21O [M+H] 217.1587, 
found 217.1586. 
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2,2-Dimethyl-1-(3-phenylbicyclo[1.1.0]butan-1-yl)propan-1-ol (3-57). Prepared according to 
General Procedure G from the corresponding tribromide (2.24 g, 6.05 mmol, 1.75 eq), MeLi (4.31 
mL, 6.91 mmol, c = 1.6 M in Et2O), t-BuLi (4.07 mL, 6.91 mmol, c = 1.7 M in pentane), and neat 
trimethylacetaldehyde (0.40 mL, 3.5 mmol) in Et2O (12 mL). Purification by chromatography on 
SiO2 (25% EtOAc/hexanes) followed by a second chromatography on neutral Al2O3 (10% 
EtOAc/hexanes) to afford alcohol 3-57 (0.282 g, 1.30 mmol, 38%) as a light yellow oil: IR (ATR) 
3562, 2951, 2866, 1602, 1479, 1362, 1107, 1007, 950, 773, 695 cm-1; 1H NMR (300 MHz, CDCl3) 
δ 7.37-7.23 (m, 4 H), 7.21-7.13 (m, 1 H), 3.41 (d, 1 H, J = 3.3 Hz), 2.51 (d, 1 H, J = 6.3 Hz), 2.20 
(d, 1 H, J = 6.3 Hz), 1.28 (s, 1 H), 1.13 (s, 1 H), 1.01 (s, 9 H), 0.94 (s, 1 H); 13C NMR (100 MHz, 
CDCl3) δ 137.4, 128.7, 125.2, 125.1, 77.7, 36.6, 35.2, 29.6, 25.9, 25.7, 14.1; MS (ESI)+ m/z 217, 
215, 213, 247 (20), 231 (30), 215 (30), 199 (100), 143 (20); HRMS (ESI)+ m/z calcd for C15H21O 
[M+H] 217.1587, found 217.1586. 
 
2,2-Dimethyl-1-(3-(4-(trifluoromethyl)phenyl)bicyclo[1.1.0]butan-1-yl)propan-1-ol (3-58). 
Prepared according to General Procedure G from the corresponding tribromide (0.822 g, 1.88 
mmol, 2.00 eq), MeLi (1.2 mL, 1.9 mmol, c = 1.62 M in Et2O), t-BuLi (1.1 mL, 1.9 mmol, c = 1.7 
M in pentane), and trimethylacetaldehyde (0.11 mL, 0.94 mmol) in Et2O (5 mL). Purification by 
two iterations of chromatography on SiO2 (5-10% EtOAc/hexanes) afforded alcohol 3-58 (0.071 
g, 0.25 mmol, 27%) as a colorless solid: Mp 80–84 °C; IR (ATR) 2955, 1614, 1324, 1163, 1109, 
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1062, 1013, 951, 841, 688 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.50 (d, 2 H, J = 8.4 Hz), 7.32 (d, 
2 H, J = 8.4 Hz), 3.34 (d, 1 H, J = 4.4 Hz), 2.53 (d, 1 H, J = 6.4 Hz), 2.21 (dd, 1 H, J = 6.8 Hz, 1.2 
Hz), 1.34 (s, 1 H), 1.18 (s, 1 H), 1.01 (s, 1 H), 0.98 (s, 9 H), 0.95 (d, 1 H, J = 4.4 Hz); 13C NMR 
(100 MHz, CDCl3) δ 142.6, 129.4, 126.9 (q, 2JCF = 32 Hz), 125.4, 125.3 (q, 3JCF = 3 Hz), 124.4 (q, 
1JCF = 270 Hz), 80.8, 36.8, 35.5, 30.2, 28.1, 25.8, 14.5; 19F NMR (376 MHz, CDCl3) δ –62.1; MS 
(ESI)+ m/z 267 (100), 189 (40), 137 (50); HRMS (ESI)+ m/z calcd for C16H18F3 [M+H–H2O] 
267.1361, found 267.1354. 
 
 
Phenyl(3-(4-(trifluoromethyl)phenyl)bicyclo[1.1.0]butan-1-yl)methanol (3-59). Prepared 
according to General Procedure G the corresponding tribromide (1.49 g, 3.41 mmol, 2.00 eq), 
MeLi (2.1 mL, 3.4 mmol, c = 1.6 M in Et2O), t-BuLi (2.0 mL, 341 mmol, c = 1.7 M in pentane), 
and benzaldehyde (0.17 mL, 1.7 mmol, 1.0 eq) in Et2O (8 mL). Purification by chromatography 
on SiO2 (15% EtOAc/hexanes) afforded alcohol 3-59 (0.281 g, 54%) as a yellow tinted solid. 1H 
NMR revealed that the material was contaminated with minor impurities, so the material was 
recrystallized from hexanes (~20 mL) to afford 0.132 g (25%) of the product as light yellow 
crystals: Mp 99–102 °C; IR (ATR) 3327, 2922, 1617, 1324, 1106, 1065, 1006, 835 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.48 (d, 2 H, J = 8.4 Hz), 7.29-7.23 (m, 3 H), 7.19 (d, 2 H, J = 8.0 Hz), 7.15-
7.09 (m, 2 H), 4.85 (s, 1 H), 2.49 (d, 1 H, J = 6.8 Hz), 2.10 (dd, 1 H, J = 6.8 Hz, 0.8 Hz), 1.81 (d, 
1 H, J = 2.0 Hz), 1.31 (s, 1 H), 1.25 (s, 1 H); 13C NMR (100 MHz, CDCl3) δ 141.7, 141.3, 128.4, 
128.0, 127.2 (2JCF = 32 Hz), 126.5, 125.7, 125.1 (3JCF = 4 Hz), 124.5 (1JCF = 270), 123.1, 72.6, 
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32.6, 31.7, 29.8, 18.4; MS (ESI)+ m/z 287 (100), 238 (10), 200 (10), 159 (10); HRMS (ESI)+ m/z 
calcd for C18H14F3 [M+H–H2O] 287.1048, found 287.1038. 
 
(3-(4-Fhlorophenyl)bicyclo[1.1.0]butan-1-yl)(phenyl)methanol (3-60). Prepared according to 
General Procedure G from the corresponding tribromide (0.860 g, 2.13 mmol, 2.00 eq), MeLi (1.3 
mL, 2.1 mmol, c = 1.6 M in Et2O), t-BuLi (1.3 mL, 2.1 mmol, c = 1.7 M in pentane), and 
benzaldehyde (0.11 mL, 1.1 mmol, 1.0 eq) in Et2O (5 mL). Purification by chromatography on 
SiO2 (10-25% EtOAc/hexanes) afforded alcohol 3-60 (0.193 g, 0.713 mmol, 67%) as a red-tinted 
oil: 1H NMR (400 MHz, CDCl3) 7.30-7.24 (m, 3 H), 7.22, 7.04 (AA’BB’, 4 H), 7.17-7.12 (m, 2 
H), 4.85 (s, 1 H), 2.40 (d, 1 H, J = 6.4 Hz), 2.01 (d, 1 H, J = 6.8 Hz), 1.76 (s, 1 H), 1.24 (s, 1 H), 
1.18 (s, 1 H); 13C NMR (100 MHz, CDCl3) δ 141.8, 135.1, 130.9, 128.4, 128.3, 127.9, 126.9, 
126.5, 72.7, 32.4, 31.3, 28.3, 18.0, 14.2. 
 
 
3-(3-(4-(Trifluoromethyl)phenyl)bicyclo[1.1.0]butan-1-yl)pentan-3-ol (3-61). Prepared 
according to General Procedure G from the corresponding tribromide (0.911 g, 2.09 mmol, 2.50 
eq), MeLi (1.3 mL, 2.1 mmol, c = 1.6 M in Et2O), t-BuLi (1.2 mL, 2.1 mmol, c = 1.7 M in pentane), 
and 3-pentanone (0.09 mL, 0.83 mmol, 1.0 eq) in Et2O (5 mL). Purification by chromatography 
on SiO2 (15% EtOAc/hexanes) afforded alcohol 3-61 (0.149 g, 0.524 mmol, 63%) (OH not visible) 
as a colorless oil: IR (ATR) 3469, 2971, 1616, 1321, 1162, 1106, 841 cm-1; 1H NMR (400 MHz, 
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CDCl3) δ 7.51 (d, 2 H, J = 8.4 Hz), 7.37 (d, 2 H, J = 8.0 Hz), 2.31 (s, 2 H), 1.65, 1.40, 0.85 (ABX3, 
2+2+6 H, JAB = 7.6 Hz, ∂AB = 0.15 ppm), 1.02 (s, 2 H); 13C NMR (100 MHz, CDCl3) δ 142.2, 
126.9 (2JCF = 32 Hz), 126.0, 125.3 (3JCF = 4 Hz), 124.5 (1JCF = 269), 74.5, 34.1, 30.6, 30.5, 19.1, 
7.9; MS (ESI)+ m/z 267 (100), 225 (10), 173 (5); HRMS (ESI)+ m/z calcd for C16H18F3 [M+H-H2O] 
267.1361, found 267.1352. 
 
 
 
3-(3-(4-Chlorophenyl)bicyclo[1.1.0]butan-1-yl)pentan-3-ol (3-62). Prepared according to 
General Procedure G from the corresponding tribromide (1.14 g, 2.83 mmol, 2.50 eq), MeLi (1.8 
mL, 2.8 mmol, c = 1.6 M in Et2O), t-BuLi (1.7 mL, 2.8 mmol, c = 1.7 M in pentane), and 3-
pentanone (0.12 mL, 1.1 mmol, 1.0 eq) in Et2O (6 mL). Purification by chromatography on SiO2 
(10% EtOAc/hexanes) afforded alcohol 3-62 (0.202 g, 0.806 mmol, 71%) as a colorless oil: IR 
(ATR) 3469, 2971, 1616, 1321, 1162, 1106, 841 cm-1; 1H NMR (400 MHz, CDCl3) (OH not 
visible) δ 7.25-7.17 (m, 4 H), 2.23 (s, 2 H), 1.63, 1.41, 0.84 (ABX3, 2+2+6 H, JAB = 7.6 Hz, ∂AB = 
0.24 ppm), 0.96 (s, 2 H); 13C NMR (100 MHz, CDCl3) δ 135.9, 130.6, 128.6, 127.2, 74.5, 32.3, 
30.6, 30.2, 18.7, 8.0; MS (ESI)+ m/z 233 (100), 191 (20), 167 (20), 1491 (10), 135 (40); HRMS 
(ESI)+ m/z calcd for C15H18Cl [M+H-H2O] 233.1097, found 233.1090. 
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F 3-46  
General Procedure H (Alcohol Deoxyfluorination): ((3-Fluoro-3-
methylcyclobutylidene)methyl)benzene (3-46). To a suspension of KHF2 (0.070 g, 0.90 mmol) 
in dichloromethane (1 mL) was added diisopropylamine (0.51 mL, 3.6 mmol, 4.0 eq) in a 
polypropylene reaction vessel. The suspension was cooled under N2 to –78 °C, then pyridine • 9 
HF (1.2 mL, 46 mmol HF, 51 eq HF) was added. The suspension was stirred for 5 min at –78 °C, 
then a solution of alcohol 3-45 (0.157 g, 0.90 mmol) in CH2Cl2 (1 mL) was added over ~30 s. 
After stirring at –78 °C for 10 min, the mixture was quenched at –78 °C with sat aq. KF (5 mL), 
then the reaction was warmed to rt and diluted with water (25 mL). The material was extracted 
with ether (2 x 20 mL). The organic layers were washed with saturated aq. NaHCO3 (30 mL) and 
brine (30 mL), then were dried (Na2SO4) and concentrated. Chromatography on SiO2 (2.5% 
EtOAc/hexanes) afforded methylenecyclobutane 3-46 (0.090 g, 0.51 mmol, 57%) as a colorless 
oil: IR (ATR) 2794, 1602, 1490, 1448, 1381, 1241, 1145, 914, 738 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.32 (dd, 2 H, J = 8.0 Hz, 7.2 Hz), 7.20 (d, 3 H, J = 7.2 Hz), 6.31 (t, 1 H, J = 2.4 Hz), 
3.39 (tdd, 1 H, 3JHF = 18.0 Hz, J = 3.2 Hz, 3.2 Hz), 3.26 (tdd, 1 H, 3JHF = 18.4 Hz, J = 3.2 Hz, 3.2 
Hz), 3.11-3.00 (m, 1 H), 2.95-2.84 (m, 1 H), 1.56 (d, 3 H, 4JCF = 21.6 Hz); 13C NMR (100 MHz, 
CDCl3) δ 137.4, 131.9 (3JCF = 16 Hz), 128.5, 127.2, 126.5, 123.8, 123.7, 92.8 (1JCF = 206 Hz), 
46.1 (3JCF = 24 Hz), 45.7 (2JCF = 24 Hz), 24.2 (2JCF = 25 Hz); 19F NMR (376 MHz, CDCl3) δ –
131.2; HRMS [ES+] calcd for C12H13F [M+] 176.1001, found 175.0056. 
Notes on pyridine • 9 HF: For simplicity, the pyridine • 9 HF stoichiometry was initially 
calculated based on a molecular formula of C5H6FN (molecular weight = 99.11), which is 
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typically shown on data sheets for this reagent. However, it is more appropriate to consider 
stoichiometry in terms of equivalents of HF. The equivalents of HF can be calculated in the 
following manner: X mL reagent * 1.1 g/mL (density) * 0.7 (percentage HF by weight) / 20 g/mol 
(HF molecular weight) * 1000 = mmol HF. For reference, 1 mmol of pyridine • 9 HF (as calculated 
by a molecular weight of 99.11) = 3.5 mmol of HF. 
This reagent should be handled with great care using appropriate personal protective 
equipment. If skin contact with this reagent occurs, apply calcium gluconate gel immediately and 
liberally. After quenching the fluorinations with aqueous NaOH, the basicity of the aqueous layer 
should be confirmed by pH paper during the extraction step. 
F 3-63
CF3
 
1-((3-Fluoro-3-methylcyclobutylidene)methyl)-4-(trifluoromethyl)benzene (3-63). Prepared 
according to General Procedure H using KHF2 (0.051 g, 0.65 mmol, 1.0 eq), diisopropylamine 
(0.37 mL, 2.6 mmol, 4.0 eq), pyridine • 9 HF (1.2 mL, 46 mmol HF, 71 eq HF), and alcohol 3-47 
(0.158 g, 0.652 mmol, 1.00 eq) in CH2Cl2 (4 mL). Purification by chromatography on SiO2 (5% 
EtOAc in hexanes) afforded methylenecyclobutane 3-63 (0.073 g, 0.30 mmol, 46%) as a colorless 
oil: IR (ATR) 2977, 2919, 1617, 1415, 1382, 1323, 1243, 1164, 1121, 1067 cm-1; 1H NMR (500 
MHz, CDCl3) δ 7.56 (d, 2 H, J = 8.5 Hz), 7.28 (d, 2 H, J = 8.0 Hz), 6.34 (t, 1 H, J = 2.0 Hz), 3.41 
(ddt, 1 H, 3JFH  = 19.5 Hz, J = 17.0 Hz, 3.0 Hz), 3.41 (ddt, 1 H, 3JFH  = 19.0 Hz, J = 17.0 Hz, 3.0 
Hz), 3.10-3.01 (m, 1 H), 2.97-2.87 (m, 1 H), 1.56 (d, 3 H, 3JFH = 21.5 Hz); 13C NMR (125 MHz, 
CDCl3) δ 140.8, 135.4 (3JCF = 15 Hz), 128.2 (q, 1JCF = 32 Hz), 127.2,  125.6, 125.4 (q, 2JCF = 4 
Hz), 122.9, 122.8, 92.6 (d, 1JCF = 207 Hz), 46.2 (d, 2JCF = 23 Hz), 45.8 (d, 2JCF = 24 Hz), 24.2 (d, 
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2JCF = 25 Hz); 19F NMR δ (471 MHz, CDCl3) –131.4, –62.4; HRMS [ES] calcd for C13H12F4 [M] 
244.0875, found 244.0854. 
F 3-64
Cl
 
1-Chloro-4-((3-fluoro-3-methylcyclobutylidene)methyl)benzene (3-64). Prepared according to 
General Procedure H using KHF2 (0.035 g, 0.45 mmol, 1.0 eq), diisopropylamine (0.25 mL, 1.8 
mmol, 4.0 eq), pyridine • 9 HF (0.81 mL, 31 mmol HF, 69 eq HF), and alcohol 3-48 (0.094 g, 0.45 
mmol, 1.0 eq) in CH2Cl2 (3 mL). Purification by chromatography on SiO2 (5% EtOAc in hexanes) 
afforded methylenecyclobutane 3-64 (0.055 g, 0.26 mmol, 58%) as a colorless oil: IR (ATR) 2975, 
2913, 1655, 1492, 1405, 1381, 1242, 1146, 1092, 915, 827 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.27, 7.11 (AA’BB’, 4 H, JAB = 8.4 Hz, ∂AB = 0.13 ppm), 6.26 (t, 1 H, J = 2.4 Hz), 3.36 (ddt, 1 
H, 3JHF = 19.2 Hz, J = 16.4 Hz, 2.8 Hz), 3.25 (ddt, 1 H, 3JHF = 19.2 Hz, J = 16.8 Hz, 2.4 Hz), 3.07-
2.96 (m, 1 H), 2.95-2.84 (m, 1 H), 1.55 (d, 3 H, 3JHF = 21.6 Hz); 13C NMR (100 MHz, CDCl3) 
δ 135.9, 132.7 (3JCF = 15 Hz), 132.0, 128.6, 128.3, 122.7 (4JCF = 7 Hz), 92.7 (1JCF = 207 Hz), 46.1 
(2JCF = 24 Hz), 45.6 (2JCF = 24 Hz), 24.2 (2JCF = 25 Hz); 19F NMR (376 MHz, CDCl3) δ  –131.3; 
HRMS (ESI+) m/z calcd for C12H11ClF [M–H] 209.0533, found 209.0803. 
F 3-65
OMe
 
1-((3-Fluoro-3-methylcyclobutylidene)methyl)-4-methoxybenzene (3-65). Prepared according 
to General Procedure H using KHF2 (0.050 g, 0.64 mmol, 1.0 eq), diisopropylamine (0.36 mL, 2.6 
mmol, 4.0 eq), pyridine • 9 HF (1.16 mL, 44.7 mmol, 69.7 eq HF), and alcohol 3-49 (0.131 g, 
0.641 mmol, 1.00 eq) in CH2Cl2 (4 mL). Purification by chromatography on SiO2 (5% EtOAc in 
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hexanes) afforded methylenecyclobutane 3-65 (0.061 g, 0.30 mmol, 46%) as a colorless oil: IR 
(ATR) cm-1 2972, 1607, 1511, 1296, 1246, 1175, 1144, 1034, 830 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 7.14 (app d, 2 H, J = 8.7 Hz), 6.87 (app d, 2 H, J = 9.0 Hz), 6.25 (t, 1 H, J = 2.1 Hz), 
3.81 (s, 3 H), 3.44-3.16 (m, 2 H), 3.09-2.95 (m, 1 H), 2.95-2.80 (m, 1 H), 1.56 (d, 3 H, 3JHF = 21.6 
Hz); 13C NMR (100 MHz, CDCl3) δ 158.3, 130.5, 129.2, 129.0, 128.3, 123.2 (3JCF = 7 Hz), 114.0, 
92.8 (1JCF = 206 Hz), 55.3, 46.0 (2JCF = 24 Hz), 45.4 (2JCF = 23 Hz), 24.3 (2JCF = 25 Hz); 19F NMR 
(376 MHz, CDCl3) δ  –131.1; MS (ESI+) m/z 207 (100), 187 (90), 171 (20), 140 (20); HRMS 
(ESI+) m/z calcd for C13H16OF [M+H] 207.1185, found 207.1179. 
F
3-66
O
 
1-(Allyloxy)-2-((3-fluoro-3-methylcyclobutylidene)methyl)benzene (3-66). Prepared according 
to General Procedure H using KHF2 (0.019 g, 0.24 mmol, 1.0 eq), diisopropylamine (0.14 mL, 
0.96 mmol, 4.0 eq), pyridine • 9 HF (0.43 mL, 17 mmol HF, 69 eq HF), and alcohol 3-50 (0.155 
g, 0.239 mmol, 1.00 eq) in CH2Cl2 (1.5 mL). Purification by chromatography on SiO2 (5-20% 
EtOAc in hexanes) afforded methylenecyclobutane 3-66 (0.019 g, 0.082 mmol, 34%) as a colorless 
oil: IR (ATR) 2973, 2912, 1597, 1487, 1451, 1240, 1144, 997, 917, 748 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.24-7.13 (m, 2 H), 6.92 (t, 1 H, J = 7.2 Hz), 6.86 (d, 1 H, J = 8.0 Hz), 6.69 (app s, 1 H), 
6.08, 5.42, 5.29 (ABX, 3 H, JAB = 1.2, JAX = 17.2, JBX = 10.4 Hz), 4.56 (d, 2 H, J = 4.8 Hz), 3.44-
3.18 (m, 2 H), 3.05-2.85 (m, 2 H), 1.55 (d, 3 H, 3JHF = 21.6 Hz); 13C NMR (100 MHz, CDCl3) 
δ 155.2, 133.5, 131.4 (3JCF = 16 Hz), 127.5, 127.4, 126.7, 120.6, 117.9 (4JCF = 7 Hz), 117.4, 112.2, 
92.9 (1JCF = 207 Hz), 69.2, 46.2 (2JCF = 23 Hz), 45.7 (2JCF = 24 Hz), 24.2 (2JCF = 25 Hz); 19F NMR 
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(376 MHz, CDCl3) δ  –131.0; MS (ESI+) m/z 233 (15), 213 (100), 172 (30), 140 (30), 128 (30); 
HRMS (ESI+) m/z calcd for C15H18OF [M+H] 213.1342, found 213.1335. 
F
3-67  
(1-(3-Fluoro-3-methylcyclobutylidene)ethyl)benzene (3-67). Prepared according to General 
Procedure H using KHF2 (0.069 g, 0.88 mmol, 1.0 eq), diisopropylamine (0.50 mL, 3.5 mmol, 4.0 
eq), pyridine • 9 HF (1.59 mL, 61.2 mmol HF, 69.4 eq HF), and alcohol 3-52 (0.166 g, 0.882 
mmol, 1.00 eq) in CH2Cl2 (4 mL).  Purification by chromatography on SiO2 (2.5% EtOAc in 
hexanes) afforded methylenecyclobutane 3-67 (0.106 g, 0.557 mmol, 63%) as a colorless oil: IR 
(ATR) cm-1 2974, 1599, 1496, 1444, 1379, 1241, 1168, 912, 759, 697 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 7.34 (t, 2 H, J = 7.6), 7.29 (t, 2 H, J = 7.2 Hz), 7.22 (td, 1 H, J = 6.8 Hz, 1.2 Hz), 3.29 (t, 
1 H, J = 18.8 Hz), 3.23 (t, 1 H, J = 19.6 Hz), 2.87 (app q, 2 H, J = 12.4 Hz), 1.96 (s, 3 H), 1.52 (d, 
3 H, 3JHF = 21.6 Hz); 13C NMR (125 MHz, CDCl3) δ 140.8, 128.9, 128.1, 128.0, 126.54, 126.51, 
126.4, 125.8 (3JCF = 15 Hz), 92.1 (1JCF = 205 Hz), 45.4 (2JCF = 24 Hz), 44.5 (2JCF = 24 Hz), 24.4 
(2JCF = 25 Hz), 17.5; 19F NMR (470 MHz, CDCl3) δ  –132.4; HRMS (EI+) m/z calcd for C13H15F 
[M+] 190.1158, found 190.1192. 
Ph
F
3-68  
((3-Fluoro-3-propylcyclobutylidene)methyl)benzene (3-68). Prepared according to General 
Procedure H using KHF2 (0.029 g, 0.38 mmol, 1.0 eq), diisopropylamine (0.21 mL, 1.5 mmol, 4.0 
eq), pyridine • 9 HF (0.68 mL, 26.2 mmol HF, 68.9 eq HF), and alcohol 3-53 (0.076 g, 0.38 mmol, 
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1.0 eq) in CH2Cl2 (2 mL).  Purification by chromatography on SiO2 (5% EtOAc in hexanes) 
afforded methylenecyclobutane 3-68 (0.046 g, 0.23 mmol, 60%) as a colorless oil: IR (ATR) 2959, 
1598, 1449, 1254, 1128, 1028, 912, 735, 692 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.22 (app t, 2 
H, J = 7.6 Hz), 7.14-7.06 (m, 3 H), 6.20 (s, 1 H), 3.31 (ddt, 1 H, 3JFH = 20.0 Hz, J = 16.8 Hz, 2.8 
Hz), 3.18 (ddt, 1 H, 3JFH = 20.0 Hz, J = 17.2 Hz, 2.8 Hz), 3.14-3.02 (m, 1 H), 2.91-2.86 (m, 1 H), 
1.81-1.68 (m, 2 H), 1.47 (pent, 2 H, J = 7.6 Hz), 0.95 (t, 3 H, J = 7.2 Hz); 13C NMR (100 MHz, 
CDCl3) δ 137.6, 132.7, 132.6, 128.5, 127.2, 126.4, 123.6, 95.1 (1JCF = 208 Hz), 44.5 (2JCF = 41 
Hz), 44.2 (2JCF = 41 Hz), 39.4 (2JCF = 22 Hz), 16.8 (3JCF = 3 Hz), 14.3; 19F NMR (376 MHz, 
CDCl3) δ  –140.6; HRMS (ASAP) m/z calcd for C14H18F [M+H] 205.1393, found 205.1409. 
Ph
F
3-69  
((3-Fluoro-3-isopropylcyclobutylidene)methyl)benzene (3-69). Prepared according to General 
Procedure H using KHF2 (0.060 g, 0.77 mmol, 1.0 eq), diisopropylamine (0.43 mL, 3.1 mmol, 4.0 
eq), pyridine • 9 HF (1.4 mL, 53.9 mmol HF, 70 eq HF), and alcohol 3-54 (0.155 g, 0.77 mmol) 
in CH2Cl2 (2 mL). Purification by chromatography on SiO2 (5% EtOAc in hexanes) afforded 
methylenecyclobutane 3-69 (0.073 g, 0.36 mmol, 47%) as a colorless oil: IR (ATR) 2966, 1599, 
1471, 1448, 1240, 1113, 1017, 913, 693 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.38-7.29 (m, 2 H), 
7.25 (m, 3 H), 6.29 (t, 1 H, J = 2.4 Hz), 3.35-2.94 (m, 4 H), 1.92 (d heptet, 1 H, 3JFH = 25 Hz, J = 
6.8 Hz), 0.99 (d, 6 H, J = 6.4 Hz); 13C NMR (100 MHz, CDCl3) δ 137.6, 132.88, 132.75, 128.5, 
127.2, 126.4, 123.4 (3JCF = 6 Hz), 98.0 (1JCF = 210 Hz), 42.7 (2JCF = 25 Hz), 42.4 (2JCF = 24 Hz), 
34.9 (d,2JCF = 22 Hz), 15.73 (3JCF = 4 Hz), 15.71 (3JCF = 5 Hz); 19F NMR (376 MHz, CDCl3) δ  –
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152.6; GC-MS (ESI)+ m/z 204, 161, 129, 115, 91, 63, 51; HRMS (ASAP) m/z calcd for C14H17F 
[M+] 204.1314, found 204.1304. 
Ph
F
3-70
Ph
 
(2-(3-Benzylidene-1-fluorocyclobutyl)ethyl)benzene (3-70). Prepared according to General 
Procedure H using KHF2 (0.058 g, 0.75 mmol, 1.0 eq), diisopropylamine (0.42 mL, 3.0 mmol, 4.0 
eq), pyridine • 9 HF (1.4 mL, 52 mmol HF, 69 eq HF), and alcohol 3-55 (0.198 g, 0.75 mmol) in 
CH2Cl2 (3 mL).  Purification by chromatography on SiO2 (5% EtOAc in hexanes) afforded 
methylenecyclobutane 3-70 (0.160 g, 0.601 mmol, 48%) as a colorless oil: IR (ATR) 2915, 1599, 
1496, 1453, 1305, 1237, 1059, 913, 738, 692 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.38-7.27 (m, 4 
H), 7.25-7.17 (m, 6 H), 6.33 (t, 1 H, J = 2.0 Hz), 3.39 (ddt, 1 H, 3JHF = 19.6 Hz, J = 16.8 Hz, 3.2 
Hz), 3.25 (ddt, 1 H, 3JHF = 20.0 Hz, J = 16.8 Hz, 2.8 Hz), 3.45-3.32 (m, 1 H), 3.02-2.91 (m, 1 H), 
2.79, 2.13 (AA’BB’, 4 H,  J = 5.2 Hz); 13C NMR (100 MHz, CDCl3) δ 141.6, 137.5, 132.2, 128.51, 
128.49, 128.4, 127.2, 126.0, 124.0, 123.9, 94.8 (d, 1JCF = 210 Hz), 44.5 (d, 2JCF = 37 Hz), 44.2 (d, 
2JCF = 37 Hz), 39.2 (d, 2JCF = 23 Hz), 29.8 (d, 3JCF = 3 Hz); 19F NMR (376 MHz, CDCl3) δ  –141.7; 
HRMS (ES+) m/z calcd for C19H19F [M+] 266.1471, found 266.1465. 
F
3-71
Ph
 
(1-Fluoro-3-pentylidenecyclobutyl)benzene (3-71). Prepared according to General Procedure H 
using KHF2 (0.040 g, 0.51 mmol, 1.0 eq), diisopropylamine (0.28 mL, 2.0 mmol, 4.0 eq), pyridine 
• 9 HF (0.46 mL, 18 mmol HF, 34.7 eq HF), and alcohol 3-56 (0.110 g, 0.509 mmol) in CH2Cl2 (2 
mL).  Purification by chromatography on SiO2 (5% EtOAc in hexanes) afforded 
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methylenecyclobutane 3-71 (0.034 g, 0.16 mmol, 31%) as a colorless oil: IR (ATR) 2957, 2924, 
1449, 1301, 1229, 1065, 755, 697 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.50-7.45 (m, 2 H), 7.39 
(app t, 2 H, J = 7.6), 7.35-7.28 (m, 1 H), 5.44-5.36 (m, 1 H), 3.41-3.23 (m, 2 H), 3.22-3.10 (m, 2 
H), 1.97 (q, 2 H, J = 7.2 Hz), 1.41-1.26 (m, 4 H), 0.92 (t, 3 H, J = 7.2 Hz); 13C NMR (100 MHz, 
CDCl3) δ 142.8 (d, 2JCF = 22 Hz), 128.4, 127.71, 127.69, 125.6, 124.3 (d, 3JCF = 6 Hz), 124.0 (d, 
3JCF = 8 Hz), 94.2 (d, 1JCF = 207 Hz), 45.5 (d, 2JCF = 24 Hz), 44.0 (d, 2JCF = 25 Hz), 31.7, 28.5, 
22.3, 14.0; 19F NMR (376 MHz, CDCl3) δ –138.2; HRMS (ASAP) m/z calcd for C15H18F [M–H] 
217.1414, found 217.1393. 
Ph
F
3-72
F3C
 
1-(3-Benzylidene-1-fluorocyclobutyl)-4-(trifluoromethyl)benzene (3-72). Prepared according 
to General Procedure H using KHF2 (0.029 g, 0.37 mmol, 1.0 eq), diisopropylamine (0.21 mL, 1.5 
mmol, 4.0 eq), pyridine • 9 HF (0.68 mL, 26 mmol HF, 71 eq HF), and alcohol 3-59 (0.114 g, 
0.375 mmol, 1.00 eq) in CH2Cl2 (1 mL).  Purification by chromatography on SiO2 (5% EtOAc in 
hexanes) afforded methylenecyclobutane 3-72 (0.071 g, 0.023 mmol, 62%) as a colorless oil: IR 
(ATR) 2967, 1622, 1324, 1165, 1122, 1069, 841, 693 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.62 
(AB q, 4 H, JAB = 8.8 Hz, ∂AB = 0.04 ppm), 7.37 (app t, 2 H, J = 6.8 Hz), 7.30-7.21 (m, 3 H), 6.45 
(t, 1 H, J = 2.4 Hz), 3.79 (ddt, 1 H, 3JHF = 20.8 Hz, J = 17.2 Hz, 3.2 Hz), 3.65 (ddt, 1 H, 3JHF = 
21.6 Hz, J = 17.2 Hz, 2.8 Hz), 3.58-3.46 (m, 1 H), 3.41-3.30 (m, 1 H); 13C NMR (100 MHz, CDCl3) 
δ 146.4, (d, 2JCF = 23 Hz), 137.1, 130.6 (d, 3JCF = 14 Hz), 130.1 (q, 2JCF = 32 Hz), 128.6, 127.3, 
126.8, 125.5 (q, 3JCF = 4 Hz), 124.4 (d, 4JCF = 6 Hz), 124.3, 124.2 (d, 3JCF = 9 Hz), 124.1 (q, 1JCF 
= 271 Hz), 94.0 (d, 1JCF = 211 Hz), 47.5 (d, 2JCF = 25 Hz), 47.2 (d, 2JCF = 25 Hz); 19F NMR (376 
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MHz, CDCl3) δ  –62.6, –140.5; MS (ESI+) m/z 287 (100), 201 (20), 171 (45), 140 (60); HRMS 
(ESI+) m/z calcd for C18H14F3 [M–F] 287.1040, found 287.1048. 
 
Ph
F
3-73
Cl
 
 
1-(3-Benzylidene-1-fluorocyclobutyl)-4-chlorobenzene (3-73). Prepared according to General 
Procedure H using KHF2 (0.053 g, 0.68 mmol, 1.0 eq), diisopropylamine (0.38 mL, 2.7 mmol, 4.0 
eq), pyridine • 9 HF (1.2 mL, 46 mmol HF, 70 eq HF), and alcohol 3-60 (0.183 g, 0.676 mmol, 
1.00 eq). Purification by chromatography on SiO2 (2.5% EtOAc in hexanes) afforded 
methylenecyclobutane 3-73  (0.076 g, 0.28 mmol, 41%) as a yellow-tinted oil: IR (ATR) 2961, 
2913, 1599, 1493, 1398, 1301, 1242, 1092, 1010, 826, 692 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.41 (app d, 2 H, J = 8.8 Hz), 7.38-7.31 (m, 4 H), 7.25-7.20 (m, 3 H), 6.41 (t, 1 H, J = 2.0 Hz), 
3.74 (ddt, 1 H, 3JHF = 20.8 Hz, J = 17.6 Hz, 3.2 Hz), 3.67-3.43 (m, 2 H), 3.33 (dddd, 1 H, J = 16.8 
Hz, 13.2 Hz, 5.2 Hz, 3.2 Hz); 13C NMR (100 MHz, CDCl3) δ 140.8 (2JCF = 23 Hz), 137.2, 133.8 
(4JCF = 1 Hz), 131.1, 131.0, 128.61, 128.59, 127.3, 126.7, 125.5 (3JCF = 8 Hz), 124.2 (3JCF = 5 Hz), 
94.2 (1JCF = 209 Hz), 47.3 (2JCF = 25 Hz), 47.0 (2JCF = 25 Hz); 19F NMR (376 MHz, CDCl3) δ  –
137.8; GC-MS (EI+) 272, 752, 217, 202, 116. HRMS (ASAP) m/z calcd for C17H14FCl [M] 
272.0768, found 272.0361. 
F
3-74
F3C
 
1-(1-Fluoro-3-(pentan-3-ylidene)cyclobutyl)-4-(trifluoromethyl)benzene (3-74). Prepared 
according to General Procedure H using KHF2 (0.041 g, 0.52 mmol, 1.0 eq), diisopropylamine 
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(0.30 mL, 2.1 mmol, 4.0 eq), pyridine • 9 HF (0.94 mL, 36 mmol HF, 70 eq HF), and alcohol 3-
61 (0.149 g, 0.524 mmol, 1.00 eq). Purification by chromatography on SiO2 (5% EtOAc in 
hexanes) afforded methylenecyclobutane 3-74 (0.077 g, 0.27 mmol, 51%) as a colorless oil: IR 
(ATR) cm-1 2966, 1622, 1462, 1408, 1325, 1165, 1125, 1069, 843 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.63, 7.56 (AA’BB’, 4 H, JAB = 8.4 Hz, ∂AB = 0.07 ppm), 3.39-3.25 (m, 2 H), 3.11 (ddd, 
2 H, J = 14.4 Hz, 14.4 Hz, 3.6 Hz), 2.02 (q, 4 H, J = 7.6 Hz), 1.00 (t, 6 H, J = 7.6 Hz); 13C NMR 
(100 MHz, CDCl3) δ 147.4 (d, 2JCF = 23 Hz), 137.8 (d, 4JCF = 6 Hz), 129.8 (q, 2JCF = 31 Hz), 125.3 
(q, 3JCF = 4 Hz), 124.1 (d, 3JCF = 4 Hz), 124.1 (q, 1JCF = 270 Hz), 118.9 (d, 3JCF = 13 Hz), 93.2 (d, 
1JCF = 209 Hz), 43.5 (d, 2JCF = 24 Hz), 23.5, 12.6; 19F NMR (376 MHz, CDCl3) δ  – 62.6, –142.5; 
MS (ASAP) m/z 267 (100), 237 (75), 225 (75), 211 (70); HRMS (ASAP) m/z calcd for C16H17F3 
[M–HF] 266.1282, found 266.1298. 
F
3-75
Cl
 
1-Chloro-4-(1-fluoro-3-(pentan-3-ylidene)cyclobutyl)benzene (3-75). Prepared according to 
General Procedure H using KHF2 (0.063 g, 0.80 mmol, 1.0 eq), diisopropylamine (0.45 mL, 3.2 
mmol, 4.0 eq), pyridine • 9 HF (1.4 mL, 54 mmol HF, 67 eq HF), and alcohol 3-62 (0.201 g, 0.802 
mmol, 1.00 eq).  Purification by chromatography on SiO2 (2.5% EtOAc in hexanes) afforded 
methylenecyclobutane 3-75 (0.097 g, 0.38 mmol, 48%) as a colorless oil: IR (ATR) 2963, 1491, 
1300, 1093, 1013, 829 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.40-7.31 (m, 4 H), 3.35-3.20 (m, 2 
H), 3.14-3.02 (m, 2 H), 2.00 (q, 4 H, J = 7.6 Hz), 1.00 (t, 6 H, J = 7.6 Hz); 13C NMR (100 MHz, 
CDCl3) δ 141.8 (2JCF = 24 Hz), 137.5 (4JCF = 6 Hz), 133.4, 128.5, 125.4 (3JCF = 9 Hz), 119.2 (3JCF 
= 13 Hz), 93.4 (1JCF = 208 Hz), 44.5 (2JCF = 25 Hz), 23.5, 12.6; 19F NMR (376 MHz, CDCl3) δ  –
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139.7; MS (ASAP) m/z 233 (80), 232 (55), 217 (30), 209 (20); HRMS (ASAP) m/z calcd for 
C15H18Cl [M–F] 233.1097, found 233.1089. 
 
6-Fluoro-2,2-dimethyl-4-methylene-6-phenylhexan-3-ol (3-76). Prepared according General 
Procedure H from KHF2 (0.044 g, 0.56 mmol, 1.2 eq), diisopropylamine (0.32 mL, 2.3 mmol, 5.0 
eq), pyridine • 9 HF (0.76 mL, 29 mmol HF, 65 eq HF), and alcohol 3-58 (0.098 g, 0.45 mmol) in 
CH2Cl2 (1 mL). Purification by chromatography on SiO2 (2.5% EtOAc/hexanes) afforded allylic 
alcohol 3-77 (0.018 g, 0.076 mmol, 17%) as a colorless oil: IR (ATR) 3598, 2955, 1480, 1455, 
1362, 1059, 1004, 698 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.41-7.31 (m, 5 H), 5.57 (ddd, 1 H, 
2JHF = 48.0 Hz, J = 8.4 Hz, 4.0 Hz), 5.20 (s, 1 H), 5.18 (s, 1 H), 3.75 (s, 1 H), 2.87 (td, 1 H, J = 
15.2 Hz, 9.2 Hz), 2.48 (ddd, 1 H,3JHF = 32.4 Hz, J = 14.8 Hz, 4.0 Hz), 1.64 (s, 1 H), 0.92 (s, 9 H); 
13C NMR (100 MHz, CDCl3) δ 145.8 (d, 3JCF = 2 Hz), 139.9 (d, 2JCF = 20 Hz), 125.7 (d, 3JCF = 11 
Hz), 125.6 (d, 3JCF = 10 Hz), 116.0, 94.8 (d, 1JCF = 171 Hz), 82.3, 41.2 (d, 2JCF = 24 Hz), 35.5, 
26.3; 19F NMR (376 MHz, CDCl3) δ –172.5; HRMS (ESI+) m/z calcd for C15H19 [M–H2O–F] 
199.1487, found 199.1482. 
 
6-Fluoro-2,2-dimethyl-4-methylene-6-(4-(trifluoromethyl)phenyl)hexan-3-ol (3-77). Prepared 
according to General Procedure H from KHF2 (0.010 g, 0.13 mmol, 1.0 eq), diisopropylamine 
(0.07 mL, 0.51 mmol, 4.0 eq), pyridine • 9 HF (0.12 mL, 4.6 mmol HF, 36 eq HF), and alcohol 3-
57 (0.039 g, 0.13 mmol) in dichloromethane (1 mL). Purification by chromatography on SiO2 
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(2.5% EtOAc/hexanes) afforded 3-77 (0.014 g, 0.046 mmol, 34%) as a colorless oil: IR (ATR) 
3598, 2957, 1623, 1325, 1166, 1127, 1069, 1007, 841 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.64 
(d, 2 H, J = 8.4 Hz), 7.47 (d, 2 H, J = 8.0 Hz), 5.66 (ddd, 1 H, 2JHF = 47.6 Hz, J = 8.8 Hz, 4.4 Hz), 
5.17 (s, 1 H), 5.15 (s, 1 H), 3.80 (s, 1 H), 2.85 (td, 1 H, J = 15.2 Hz, 8.8 Hz), 2.48 (ddd, 1 H,3JHF 
= 32.0 Hz, J = 15.2 Hz, 4.4 Hz), 1.65 (s, 1 H), 0.92 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 145.0 
(d, 3JCF = 3 Hz), 143.9 (d, 2JCF = 20 Hz), 130.9 (q, 2JCF = 32 Hz), 125.9 (d, 3JCF = 7 Hz), 125.5 (q, 
3JCF = 4 Hz), 123.7 (q, 1JCF = 270 Hz), 116.3, 93.8 (d, 1JCF = 173 Hz), 82.4, 41.1 (d, 2JCF = 24 Hz), 
35.6, 26.3; 19F NMR (376 MHz, CDCl3) δ –176.1, −62.6; MS (ESI+) m/z 267 (100), 173 (10), 137 
(35); HRMS (ESI+) m/z calcd for C16H18F3 [M–H2O–F] 267.1361, found 267.1353. 
  
1-Phenylcyclobutane-1-carbaldehyde (3-79). Prepared according to General Procedure H from 
KHF2 (0.100 g, 1.29 mmol), diisopropylamine (0.73 mL, 5.1 mmol, 4.0 eq), alcohol 3-7873b (0.206 
g, 1.29 mmol), and pyridine • 9 HF (0.93 mL, 35.8 mmol HF, 28 eq HF) in dichloromethane (6 
mL). Purification by chromatography on SiO2 (2.5% EtOAc/hexanes) afforded aldehyde 3-79 
(0.028 g, 0.17 mmol, 14%) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 9.46 (s, 1 H), 7.27 (t, 
2 H, J = 7.6 Hz), 7.17 (t, 1 H, J = 7.6 Hz), 7.05 (dd, 2 H, J = 8.4 Hz, 1.2 Hz), 2.68-2.59 (m, 2 H), 
2.31 (ddd, 2 H, J = 19.2 Hz, 9.6 Hz, 2.4 Hz), 1.97-1.76 (m, 2 H); 13C NMR (100 MHz, CDCl3) 
δ 199.5, 141.0, 128.8, 128.5, 126.4, 57.6, 28.4, 15.9. 
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1-(Fluoro(phenyl)methyl)-3-(phenylsulfonyl)bicyclo[1.1.0]butane (3-81). A solution of 
alcohol 3-8083b (0.049 g, 0.16 mmol) in CH2Cl2 (2 mL) was treated with Deoxofluor® (0.03 mL, 
0.16 mmol) at 0 °C. The reaction was stirred at 0 °C for 2 h, then it was quenched with sat aq 
NaHCO3 (5 mL). The mixture was extracted with CH2Cl2 (5 mL), and the combined extracts were 
washed with water (30 mL) and brine (30 mL), then were dried (Na2SO4) and concentrated. 
Chromatography on SiO2 (25% EtOAc/hexanes) afforded bicyclobutane 3-81 (0.027 g, 0.089 
mmol, 55%) as a colorless oil: IR (ATR) 3065, 2958, 1447, 1317, 1307, 1146, 1084, 945, 724 cm-
1; 1H NMR (400 MHz, CDCl3) δ 7.98-7.91 (m, 2 H), 7.63 (tt, 1 H, J = 7.2 Hz, 1.2 Hz), 7.60-7.49 
(m, 4 H), 7.48-7.37 (m, 3 H), 6.15 (d, 1 H, 2JHF = 46.8 Hz), 2.77 (d, 1 H, J = 6.4 Hz), 2.36 (dd, 1 
H, J = 6.4 Hz, 0.8 Hz), 1.50 (t, 1 H, J = 0.8 Hz), 1.43 (d, 1 H, J = 4.8 Hz); 13C NMR (100 MHz, 
CDCl3) δ 142.0, 137.4 (2JCF = 22 Hz), 133.3, 129.3 (4JCF = 2 Hz), 129.2, 128.6, 127.3, 127.0 (3JCF 
= 5 Hz), 89.7 (1JCF = 174 Hz), 36.9, 36.1, 30.7 (2JCF = 39 Hz), 28.9; 19F NMR (376 MHz, CDCl3) 
δ –163.5; HRMS (ES+) m/z calcd for C17H15SO2F [M+] 302.0777, found 302.0785. 
Ph
3-83
F
 
(4-Fluoro-3-methylbuta-1,2-dien-1-yl)benzene (3-83). Prepared according to General Procedure 
H from KHF2 (0.060 g, 0.77 mmol), diisopropylamine (0.44 mL, 3.1 mmol, 4.0 eq), pyridine • 9 
HF (1.0 mL, 12 mmol, 15 eq), and cyclopropene 3-82190 (0.124 g, 0.77 mmol) in CH2Cl2 (2 mL). 
Purification by chromatography on SiO2 (hexanes) afforded fluorinated allene 3-83 (0.062 g, 0.38 
mmol, 49%) as a colorless oil: IR (ATR) 2984, 2885, 1956, 1599, 1497, 1464, 1374, 978, 693 cm-
1; 1H NMR (400 MHz, CDCl3) δ 7.32-7.07 (m, 5 H), 6.21 (ddd, 1 H, J = 4.8 Hz, 4.8 Hz, 2.8 Hz), 
4.84 (dd, 2 H, 2JHF = 47.6 Hz, J = 2.0 Hz), 1.91 (d, 3 H, J = 2.8 Hz); 13C NMR (100 MHz, CDCl3) 
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δ 204.1 (3JCF = 10 Hz), 134.1, 128.7, 127.2, 127.0, 100.3 (2JCF = 19 Hz), 95.2 (4JCF = 2 Hz), 84.4 
(1JCF = 170 Hz), 15.3; 19F NMR (376 MHz, CDCl3) δ –213.0. 
F
O
Ph
3-84
3-Fluoro-3-phenethylcyclobutan-1-one (3-84). To a solution of 3-70 (0.025 g, 0.094 mmol) in 
THF/H2O (10:1, 1 mL total) was added potassium osmate(VI) dihydrate (0.3 mg, ~1 µmol, 0.5 
mol%) and NMO (0.016 g, 0.12 mmol, 1.3 eq). The reaction mixture was stirred at room 
temperature for 19 h, then it was directly placed on an SiO2 column and purified by 
chromatography (25-50% EtOAc/hexanes) to afford the corresponding diol (0.024 g, 0.080 mmol, 
85%) as a colorless oil. The material is a ~1:1 mixture of diastereomers: 19F NMR (376 MHz, 
CDCl3) δ – 137.8, – 143.9.
A solution of  this diol (0.024 g, 0.080 mmol, 1.0 eq) in THF (0.5 mL) and water (0.5 mL) 
was treated with sodium periodate (0.019 g, 0.088 mmol, 1.1 eq). The reaction was stirred at rt for 
3 h. The reaction mixture was then directly placed on an SiO2 column and purified by 
chromatography (10% EtOAc/hexanes) to afford cyclobutanone 3-84 (0.009 g, 0.047 mmol, 59%) 
as a colorless film. The material contained a trace of benzaldehyde byproduct but was used 
without further purification: IR (ATR) 2918, 1792, 909, 730 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.34-7.28 (m, 2 H), 7.25-7.19 (m, 3 H), 3.45-3.32 (m, 2 H), 3.15-3.04 (m, 2 H), 2.87-2.81 (m, 2 
H), 2.34-2.22 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 202.9 (d, 3JCF = 12 Hz), 140.6, 128.6, 
128.4, 128.3, 126.3, 89.6 (d, 1JCF = 202 Hz), 57.9 (d, 2JCF = 25 Hz), 39.2 (d, 2JCF = 23 Hz), 30.4 (d, 
3JCF = 4 Hz); 19F NMR (376 MHz, CDCl3) δ –151.7. 
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F
N
Ph
OH
3-85  
3-Fluoro-3-phenethylcyclobutan-1-one oxime (3-85). A solution of ketone 3-84 (0.016 g, 0.08 
mmol) in EtOH (0.25 mL) and water (0.25 mL) was treated with hydroxylamine hydrochloride 
(0.007 g, 0.11 mmol) and sodium acetate (0.016 g, 0.19 mmol). The reaction mixture was sealed 
in a microwave vial and was heated at 60 °C for 4.5 h. The reaction mixture was then cooled to rt 
and purified by chromatography on SiO2 (30% EtOAc/hexanes) to afford oxime 3-85 (0.010 g, 
0.05 mmol, 58%) as a colorless oil: IR (ATR) 3262, 2925, 1466, 1710, 1455, 1238, 929, 700 cm-
1; 1H NMR (400 MHz, CDCl3) δ 7.30 (app t, 2 H, J = 7.6 Hz), 7.24-7.18 (m, 3 H), 3.28-2.92 (m, 
4 H), 2.77 (ddd, 2 H, J = 5.6 Hz, 5.6 Hz, 5.6 Hz), 2.20-2.07 (m, 2 H), 1.8-1.4 (br s, 1 H); 13C NMR 
(100 MHz, CDCl3) δ 140.9, 128.6, 128.4, 126.2, 92.4 (d, 1JCF = 206 Hz), 43.7 (d, 2JCF = 26 Hz), 
42.7 (d, 2JCF = 26 Hz), 39.2 (d, 2JCF = 23 Hz), 29.8 (d, 3JCF = 4 Hz); 19F NMR (376 MHz, CDCl3) 
δ –146.1; MS (ESI+) m/z 208 (60), 188 (100), 170 (40), 129 (65); HRMS (ESI+) m/z calcd for 
C12H15FNO [M+H] 208.1138, found 208.1131. 
FPh
OH
3-86  
3-Fluoro-3-phenethylcyclobutan-1-ol (3-86). A solution of cyclobutanone 3-84 (0.012 g, 0.062 
mmol) in THF (1 mL) was cooled to –78 °C under N2 and treated with LAH (1 drop of 4 M solution 
in ether). The reaction was slowly warmed to rt over 4 h, then it was quenched with water (5 mL) 
and extracted with CH2Cl2 (2 x 25 mL). The organic layers were dried (Na2SO4) and concentrated. 
Purification by chromatography on SiO2 afforded alcohol 3-86 (0.008 g, 0.041 mmol, 66%) as a 
colorless film. The material is a ~6.5:1 mixture of diastereomers: IR (ATR) 3344, 2936, 1603, 
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1496, 1455, 1238, 1040, 699 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.33-7.24 (m, 2 H), 7.22-7.13 
(m, 3 H), 3.64 (q, 1 H, J = 6.8 Hz), 2.72, 1.94, 1.88 (AA’BB’, 4 H, JAB = 5.2 Hz), 2.62 (dtd, 2 H, 
J = 10.4 Hz, 7.2 Hz, 3.2 Hz), 2.31 (dddd, 2 H, 3JHF = 23.2 Hz, J = 10.0 Hz, 7.2 Hz, 3.2 Hz), 1.62 
(s, 1 H); 13C NMR (100 MHz, CDCl3) δ 141.3, 128.5, 128.4, 128.3, 126.0, 89.3 (1JCF = 211 Hz), 
58.9, 44.5 (2JCF = 20 Hz), 40.4 (2JCF = 23 Hz), 29.6 (3JCF = 3 Hz); 19F NMR (376 MHz, CDCl3) δ 
–133.8. 
 
(E)-4-((4-Methoxybenzyl)amino)hept-3-en-2-one (3-88). Ketone 3-87 was prepared by the 
dissolving the corresponding diol (0.091 g, 0.38 mmol, 1.0 eq) in THF (1.5 mL) and water (0.5 
mL) and treating with sodium periodate (0.090 g, 0.42 mmol, 1.1 eq). The reaction was stirred at 
rt for 2 h, then was filtered through a 1" pipette column of SiO2 that was then flushed with THF (1 
mL). The filtrate was directly used without concentration or further purification. 
The filtrate was treated with 4-methoxybenzylamine (0.13 mL, 0.95 mmol, 2.5 eq), acetic acid 
(0.02 mL, 0.38 mmol, 1.0 eq) and sodium triacetoxyborohydride (0.283 g, 1.34 mmol, 3.50 eq). 
The reaction was stirred at rt for 15 h, then was quenched with 1 M NaOH (5 mL) and partitioned 
between water (30 mL) and EtOAc (30 mL). The combined extracts were washed with water (30 
mL), then were dried (Na2SO4) and concentrated. Chromatography on SiO2 (20-30% EtOAc in 
hexanes) afforded vinylogous amide 3-88 (0.032 g, 0.13 mmol, 34%) as a colorless oil: IR (ATR) 
2961, 1602, 1568, 1517, 1302, 1245, 1175, 1032, 811, 746; 1H NMR (300 MHz, CDCl3) δ 11.17 
(br s, 1 H), 7.16 (d, 2 H, J = 8.7 Hz), 6.85 (d, 2 H, J = 8.7 Hz), 5.02 (s, 1 H), 4.38 (d, 2 H, J  = 6.0 
Hz), 3.78 (s, 3 H), 2.17 (t, 2 H, J = 7.5 Hz), 2.02 (s, 3 H), 1.54 (pent, 2 H, J = 7.5 Hz), 0.96 (t, 3 
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H, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 195.3, 166.7, 159.0, 130.1, 128.1, 114.2, 94.7, 55.3, 
45.9, 33.9, 29.1, 21.4, 14.0; MS (ESI+) m/z 248 (2), 121 (100); HRMS (ESI+) m/z calcd for 
C15H22NO2 [M+H] 248.1642, found 248.1645. 
 
(E)-4-(Benzylamino)-6-phenylhex-3-en-2-one (3-89). A solution of crude ketone 3-84 (0.030 g, 
0.023 mmol) in MeOH (0.5 mL) was treated sequentially with benzylamine (0.02 mL, 0.17 mmol), 
t-butyl isonitrile (0.02 mL, 0.17 mmol), and propionic acid (0.01 mL, 0.17 mmol). The reaction 
was stirred at rt for 16 h, then was directly placed on an SiO2 column and chromatographed (30% 
EtOAc/hexanes) to afford vinylogous amide 3-89 (0.011 g, 49%) as a colorless oil: 1H NMR (300 
MHz, CDCl3) δ 11.29 (s, 1 H), 7.48-7.20 (m, 8 H), 7.20-7.11 (m, 2 H), 5.13 (s, 1 H), 4.43 (d, 2 H, 
J = 6.3 Hz), 2.83, 2.53 (AA’BB’, 4 H, JAB = 7.5 Hz, JA’B’ = 5.7 Hz), 2.09 (s, 3 H). 
 
1-Bromo-3-fluoro-3-methylcyclobutyl)(4-(trifluoromethyl)phenyl)methanol (3-90). A 
solution of methylenecyclobutane 3-46 (0.025 g, 0.10 mmol) in MeCN (0.75 mL) and water (0.25 
mL) was treated with NBS (0.037 g, 0.20 mmol, 2.0 eq). The reaction was stirred at 45 °C for 18 
h. After cooling, the material was directly chromatographed on SiO2 to afford bromohydrin 3-90 
(0.024 g, 0.070 mmol, 69%) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.63, 7.55 (ABq, 4 
H, JAB = 8.4 Hz), 4.88 (s, 1 H), 3.13 (app q, 2 H, J = 16.8 Hz), 2.79 (dddd, 1 H, J = 14.2 Hz, 13.6 
Hz, 4.4 Hz, 1.2 Hz), 2.65 (dddd, 1 H, J = 13.6 Hz, 13.2 Hz, 4.4 Hz, 1.2 Hz), 2.50 (br s, 1 H, 1.71 
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(d, 3 H, 3JHF = 22.4 Hz); 13C NMR (100 MHz, CDCl3) δ 143.2, 130.6 (q, 2JCF = 32 Hz), 127.9, 
125.0 (q, 3JCF = 4 Hz), 124.0 (q, 1JCF = 270 Hz), 91.6 (d, 1JCF = 202 Hz), 79.2, 60.7 (q, 3JCF = 14 
Hz), 50.2 (d, 2JCF = 23 Hz), 48.7 (d, 2JCF = 24 Hz), 26.4 (d, 2JCF = 25 Hz); 19F NMR (470 MHz, 
CDCl3) δ –62.6, –127.5. 
 
1-Bromo-3-fluoro-3-methylcyclobutyl)(4-(trifluoromethyl)phenyl)methanone (3-91). A 
solution of alcohol 3-90 (0.015 g, 0.044 mmol) in CH2Cl2 (1 mL) was cooled to 0 °C under N2. 
Dess-Martin periodinane (0.028 g, 0.032 mmol, 1.1 eq) was added in one portion. The reaction 
was stirred at rt for 2 h, then it was diluted with CH2Cl2 (10 mL) and sat aq NaHCO3 (10 mL). The 
organic layer was dried (Na2SO4) and concentrated. Purification by chromatography on SiO2 
afforded ketone 3-91 (0.013 g, 0.048 mmol, 87%) as a colorless semi-solid: 1H NMR (400 MHz, 
CDCl3) δ 8.11 (d, 2 H, J = 8.4 Hz), 7.74 (d, 2 H, J = 8.0 Hz), 3.45, 2.94 (AA’BB’, 4 H, 3JHF = 19.6 
Hz, J = 16.0 Hz, 12.0 Hz), 1.83 (d, 3 H, 3JHF = 22.4 Hz); 13C NMR (100 MHz, 
CDCl3) δ 192.0, 134.8 (q, 2JCF = 25 Hz), 130.5, 125.6 (q, 3JCF = 4 Hz), 123.4 (q, 1JCF = 271 Hz), 
91.1 (d, 1JCF = 204 Hz), 49.6 (d, 2JCF = 25 Hz), 49.3 (d, 3JCF = 14 Hz), 26.4 (d, 3JCF = 25 Hz); 19F 
NMR (470 MHz, CDCl3) δ –63.3, –127.3; HRMS (ASAP) m/z calcd for C13H12BrOF4 [M+H] 
339.0008, found 339.0029. 
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3-Methyl-N-phenylbicyclo[1.1.0]butane-1-carboxamide (3-92).73b Prepared according to 
General Procedure G from A solution of 1-chloromethyl-2,2-dibromocyclopropane (3.85 g, 14.7 
mmol), MeLi (9.8 mL, 14.7 mmol, 1.5 M in Et2O), t-BuLi (9.8 mL, 14.7 mmol, 1.5 M in pentane), 
and phenyl isocyanate (0.70 mL, 7.38 mmol) in Et2O (25 mL). Purification by chromatography on 
SiO2 (15% EtOAc/hexane) afforded amide 3-92 (0.538 g, 2.87 mmol, 49%) as a colorless solid: 
1H NMR (CDCl3, 300 MHz) δ 7.53 (d, J = 7.8 Hz, 2 H), 7.44 (br s, 1 H), 7.30 (t, J = 7.9 Hz, 2 H), 
7.08 (t, J = 7.4 Hz, 1 H), 2.22 (s, 2 H), 1.59 (s, 3 H), 1.24 (s, 2 H). 
 
N-(4-Methoxyphenyl)-3-methylbicyclo[1.1.0]butane-1-carboxamide (3-93). Prepared 
according to General Procedure G from 1-chloromethyl-2,2-dibromocyclopropane (3.50 g, 13.3 
mmol), MeLi (8.3 mL, 13.3 mmol, 1.6 M in Et2O), t-BuLi (7.8 mL, 13.4 mmol, 1.7 M in pentane), 
and 4-methoxyphenyl isocyanate (0.87 mL, 6.7 mmol) in Et2O (25 mL). Purification by 
chromatography on SiO2 (30-50% EtOAc/hexane) to afford amide 3-93 (0.961 g, 4.42 mmol, 66%) 
as a colorless solid: 1H NMR (300 MHz, CDCl3) δ 7.40 (d, 2 H, J = 9.0 Hz), 7.11 (s, 1 H), 6.85 (d, 
2 H, J = 9.0 Hz), 3.78 (s, 3 H), 2.12 (s, 2 H), 1.58 (s, 3 H), 1.22 (s, 2 H).  
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N-Allyl-3-methylbicyclo[1.1.0]butane-1-carboxamide (3-94). Prepared according to General 
Procedure G from 1-chloromethyl-2,2-dibromocyclopropane (1.00 g, 3.81 mmol), MeLi (2.4 mL, 
3.8 mmol, 1.6 M in Et2O), t-BuLi (2.2 mL, 13.4 mmol, 1.7 M in pentane), and allyl isocyanate 
(0.17 mL, 1.9 mmol) in Et2O (8 mL). Purification by chromatography on SiO2 (30-50% 
EtOAc/hexane) afforded amide 3-94 (0.129 g, 0.853 mmol, 45%) as a colorless oil: 1H NMR (300 
MHz, CDCl3) δ 6.03 (s, 1 H), 5.76, 5.08, 5.02 (ABX, 3 H, JAB = 17.2, JAX = 10.4 Hz), 3.82 (t, 2 H, 
J = 5.6 Hz), 2.02 (s, 2 H), 1.43 (s, 3 H), 1.04 (s, 2 H); 13C NMR (100 MHz, CDCl3) δ 170.8, 134.9, 
115.7, 42.0, 37.0, 23.7, 14.2, 12.2. 
 
N-Phenyl-3-propylbicyclo[1.1.0]butane-1-carboxamide (3-95). Prepared according to General 
Procedure G from the corresponding tribromide (2.42 g, 7.23 mmol), MeLi (4.5 mL, 7.2 mmol, 
1.6 M in Et2O), t-BuLi (4.3 mL, 7.2 mmol, 1.7 M in pentane), and phenyl isocyanate (0.39 mL, 
1.8 mmol). Purification by two iterations chromatography on SiO2 (30% EtOAc/hexane) afforded 
amide 3-95 (0.127 g 0.590 mmol, 16%) as a colorless oil: 1H NMR (300 MHz, CDCl3) δ 7.60-7.35 
(m, 3 H), 7.30-7.15 (m, 2 H), 7.11-7.02 (m, 1 H), 2.21 (s, 2 H), 1.85 (t, 2 H, J = 7.6 Hz), 1.49 (pent, 
2 H, J = 7.6 Hz), 1.18 (s, 2 H), 0.98 (t, 3 H, J = 7.2 Hz). The material was contaminated with ~12% 
(by mass) of inseparable N-phenyl acetamide (MeLi addition product). 
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N, 3-Diphenylbicyclo[1.1.0]butane-1-carboxamide (3-96). Prepared according to General 
Procedure G from the corresponding tribromide (1.31 g, 3.55 mmol), MeLi (2.2 mL, 3.6 mmol, 
1.6 M in Et2O), t-BuLi (2.1 mL, 3.6 mmol, 1.7 M in pentane), and phenyl isocyanate (0.15 mL, 
1.4 mmol) in Et2O (8 mL). Purification by chromatography on SiO2 (15-40% EtOAc/hexanes) 
afforded amide 3-96 (0.176 g, 0.71 mmol, 50%) as a tan crystalline solid: Mp 150–152 °C; 1H 
NMR (300 MHz, CD3OD) (N–H absent) δ 7.39-7.33 (m, 2 H), 7.33-7.24 (m, 4 H), 7.24-7.15 (m, 
3 H), 7.01 (tt, 1 H, J = 7.2 Hz, 1.2 Hz), 3.07 (s, 2 H), 1.62 (t, 2 H, J = 1.2 Hz); 13C NMR (100 
MHz, CD3OD) δ 168.6, 138.1, 133.8, 128.14, 128.06, 126.4, 125.6, 123.8, 120.7, 34.0, 31.5, 24.7; 
MS (ESI+) m/z 250 (100), 227 (5), 185 (5), 129 (5); HRMS (ESI+) m/z calcd for C17H16NO [M+H] 
250.1226, found 250.1225. 
 
General Procedure I (Bicyclo[1.1.0]butyl amide fluorination): 3-Fluoro-3-methyl-N-
phenylcyclobutane-1-carboxamide (3-97). To a suspension of KHF2 (0.012 g, 0.15 mmol) in 
CH2Cl2 (0.5 mL) in a polypropylene reaction vessel was added diisopropylamine (0.08 mL, 0.60 
mmol, 4.0 eq). The suspension was cooled under N2 to –78 °C, then pyridine • 9 HF (0.27 mL, 10 
mmol HF, 69 eq HF) was added. The mixture was stirred for 5 min at –78 °C, then a solution of 
the amide 3-9273b (0.028 g, 0.15 mmol) in CH2Cl2 (0.5 mL) was slowly added. After stirring at –
78 °C for 10 min, the mixture was warmed to 0 °C for 10 min and then quenched with sat aq. KF 
(2 mL), warmed to rt, and diluted with 2 M NaOH (50 mL). The material was extracted with ether 
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(2 X 20 mL). The organic layers were washed with saturated aq. NaHCO3 (30 mL) and brine (30 
mL), then were dried (Na2SO4) and concentrated. Chromatography on SiO2 (25% EtOAc/hexanes) 
afforded amide 3-97 (0.018 g, 0.09 mmol, 58%) as a colorless solid: Mp 159–161 °C; 1H NMR 
(500 MHz, CDCl3) δ 7.51 (d, 2 H, J = 6.4 Hz), 7.32 (t, 2 H, J = 6.4 Hz), 7.17 (br s, 1 H), 7.11 (t, 1 
H, J = 7.5 Hz), 3.20 (ddd, 1 H, J = 16.0 Hz, 9.0 Hz, 7.0 Hz), 2.65-2.46 (m, 4 H), 1.53 (d, 3 H, 3JHF 
= 22.5 Hz); 13C NMR (125 MHz, CDCl3) δ 172.5, 137.8, 129.1, 124.4, 119.8, 95.6 (1JCF  = 195 
Hz), 37.8 (2JCF = 24 Hz), 32.8 (3JCF = 4 Hz), 25.0 (2JCF = 25 Hz); 19F NMR (470 MHz, CDCl3) δ –
133.2; MS (ESI+) m/z 208 (100), 195 (10); HRMS (ESI+) m/z calcd for C12H15NOF [M+H] 
208.1138, found 208.1132 . 
 
3-Fluoro-N-(4-methoxyphenyl)-3-methylcyclobutane-1-carboxamide (3-98). Prepared 
according to General Procedure I from KHF2 (0.032 g, 0.41 mmol), diisopropylamine (0.23 mL, 
1.6 mmol, 4.0 eq), pyridine • 9 HF (0.73 mL, 28 mmol HF, 69 eq HF), and amide 3-93 (0.088 g, 
0.41 mmol) in CH2Cl2 (2.5 mL). Chromatography on SiO2 (20-50% EtOAc/hexanes) afforded 
amide 3-98 (0.048 g, 0.20 mmol, 50%) as a colorless solid: Mp 104–107 °C; 1H NMR (500 MHz, 
CDCl3) δ 7.39 (d, 2 H, J = 8.0 Hz), 7.35-7.20 (br s, 1 H), 6.83 (d, 2 H, J = 8.5 Hz), 3.78 (s, 3 H), 
3.16 (ddd, 1 H, J = 16.0 Hz, 9.0 Hz, 7.0 Hz), 2.64-2.38 (m, 4 H), 1.51 (d, 3 H, 3JHF = 22.5 Hz); 13C 
NMR (100 MHz, CDCl3) δ 172.5, 156.5, 130.9, 121.8, 114.1, 95.8 (1JCF  = 195 Hz), 55.5, 37.8 
(2JCF = 24 Hz), 32.6 (3JCF = 4 Hz), 25.1 (2JCF = 25 Hz); 19F NMR (470 MHz, CDCl3) δ –133.2; MS 
(ESI+) m/z 238 (100), 200 (5), 195 (5), 184 (5); HRMS (ESI+) m/z calcd for C13H17NO2F [M+H] 
238.1243, found 238.1236. An X-ray crystal structure was obtained for this compound. 
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N-Allyl-3-fluoro-3-methylcyclobutane-1-carboxamide (3-99). Prepared according to General 
Procedure I from KHF2 (0.066 g, 0.85 mmol), diisopropylamine (0.48 mL, 3.4 mmol, 4.0 eq), 
pyridine • 9 HF (1.5 mL, 58 mmol HF, 68 eq HF), and the corresponding amide (0.129 g, 0.853 
mmol) in CH2Cl2 (4 mL). Purification by chromatography on SiO2 (20-50% EtOAc/hexanes) 
afforded amide 3-99 (0.063 g, 0.37 mmol, 43%) as a colorless semi-solid: 1H NMR (400 MHz, 
CDCl3) δ 5.86-5.62 (br s, 1 H), 5.78, 5.13, 5.09 (ABX, 3 H, JAX = 18.4 Hz, JBX = 10.0 Hz), 3.84 
(t, 2 H, J = 5.6 Hz), 3.04 (ddd, 1 H, J = 16.0 Hz, 9.6 Hz, 6.8 Hz), 2.57-2.32 (m, 4 H), 1.47 (d, 3 H, 
3JHF = 22.4 Hz); 13C NMR (100 MHz, CDCl3) δ 174.1, 134.2, 116.4, 95.8 (1JCF  = 195 Hz), 42.0, 
37.8 (2JCF = 24 Hz), 31.6 (3JCF = 4 Hz), 25.0 (2JCF = 25 Hz); 19F NMR (376 MHz, CDCl3) δ –133.3; 
MS (ESI+) m/z 172 (100), 152 (5), 115 (2); HRMS (ESI+) m/z calcd for C9H15NOF [M+H] 
172.1138, found 172.1132. 
 
3-Fluoro-N-phenyl-3-propylcyclobutane-1-carboxamide (3-100). Prepared according to 
General Procedure I from KHF2 (0.046 g, 0.59 mmol), diisopropylamine (0.33 mL, 2.3 mmol, 4.0 
eq), pyridine • 9 HF (1.1 mL, 42 mmol, 72 eq HF), and amide 3-95 (0.127 g, 0.59 mmol) in CH2Cl2 
(3 mL). Chromatography on SiO2 (25% EtOAc/hexanes) afforded amide 3-100 (0.051 g, 0.22 
mmol, 37%) as a colorless oil that partially solidified on standing. The minor diastereomer was 
isolated (0.013 g, 9 %) but was contaminated with an elimination/diene product. Major isomer: 1H 
NMR (400 MHz, CDCl3) δ 7.51 (d, 2 H, J = 7.6 Hz), 7.32 (t, 2 H, J = 7.6 Hz), 7.25-7.14 (br s, 1 
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H), 7.11 (t, 1 H, J = 7.6 Hz), 3.24 (pent, 1 H, J = 8.4 Hz), 2.54 (d, 2 H, J = 8.0 Hz), 2.48 (d, 2 H, 
J = 8.4 Hz), 1.74 (AA’BB’, 2 H, JAB = 8.0 Hz, ∂AB = 0.05 ppm), 1.47-1.35 (m, 2 H), 0.93 (t, 3 H, 
J = 7.6 Hz); 13C NMR (100 MHz, CDCl3) δ 172.6, 137.8, 129.1, 124.4, 119.8, 97.9 (1JCF = 196 
Hz), 40.3 (2JCF = 23 Hz), 36.4 (2JCF = 24 Hz), 33.5, 16.1 (3JCF = 3 Hz), 14.1; 19F NMR (376 MHz, 
CDCl3) δ –144.5; MS (ESI+) m/z 236 (100), 216 (15); HRMS (ESI+) m/z calcd for C14H19NOF 
[M+H] 236.1451, found 236.1443. 
 
3-Fluoro-N,3-diphenylcyclobutane-1-carboxamide (3-101). Prepared according to General 
Procedure I from KHF2 (0.013 g, 0.16 mmol), diisopropylamine (0.09 mL, 0.64 mmol, 4.0 eq), 
pyridine • 9 HF (0.29 mL, 11 mmol HF, 70 eq HF), and amide 3-96 (0.040 g, 0.16 mmol) in CH2Cl2 
(1.5 mL). Chromatography on SiO2 (25% EtOAc/hexanes) afforded cis 3-101 (17 mg, 0.063 mmol, 
39%) as a colorless oil and trans 3-101 (11 mg, 0.041 mmol, 25%) as a colorless semi-solid. Major 
product cis 3-101: 1H NMR (500 MHz, CDCl3) δ 7.53 (d, 2 H, J = 7.5 Hz), 7.50 (d, 2 H, J = 8.0 
Hz), 7.40 (t, 2 H, J = 7.5 Hz), 7.36-7.29 (m, 3 H), 7.24 (br s, 1 H), 7.12 (t, 1 H, J = 7.6 Hz), 3.46 
(AB2X (app q), 1 H, J = 8.4 Hz), 3.12-2.93 (AB2X (m), 2 H), 2.88-2.75 (AB2X (m), 2 H); 19F NMR 
(470 MHz, CDCl3) δ –146.0. Minor product trans 3-101: 1H NMR (500 MHz, CDCl3) δ 7.54 (d, 
2 H, J = 8.0 Hz), 7.50 (d, 2 H, J = 8.0 Hz), 7.43 (t, 2 H, J = 7.5 Hz), 7.40-7.27 (m, 4 H), 7.12 (t, 1 
H, J = 7.5 Hz), 3.12-3.01 (AMX (m), 2 H), 2.91-2.82 (AMX (m), 2 H), 2.75 (AMX (app pent), 1 
H, J = 8.5 Hz); 13C NMR (125 MHz, CDCl3) δ 171.2, 140.9 (2JCF = 23 Hz), 137.8, 129.1, 128.6, 
128.5, 124.8 (3JCF = 6 Hz), 124.5, 119.8, 92.0 (1JCF = 211 Hz), 38.7 (2JCF = 25 Hz), 31.1 (3JCF = 
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13 Hz); 19F NMR (470 MHz, CDCl3) δ –119.3. MS (ESI+) m/z 250 (100), 225 (10), 184 (30), 128 
(20); HRMS (ESI+) m/z calcd for C17H16NO [M+H–HF] 250.1226, found 250.1225. 
N
H
O
Ph
F 3-102  
2-(Fluoromethyl)-N-phenylcyclopropane-1-carboxamide (3-102). Prepared according to 
General Procedure I from KHF2 (0.032 g, 0.40 mmol), diisopropylamine (0.23 mL, 1.6 mmol, 4.0 
eq), pyridine • 9 HF (0.72 mL, 28 mmol HF, 69 eq HF), and amide 3-43 (0.070 g, 0.40 mmol) in 
CH2Cl2 (3 mL). Chromatography on SiO2 (20-50% EtOAc/hexanes) afforded a less polar minor 
product (10 mg), which appears to be a ~ 1:1 mixture of a cyclopropane diastereomer and an 
unidentified product. The major product was identified as primary fluoride 3-102 (25 mg, 0.13 
mmol, 32%), a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.59 (br s, 1 H), 7.50 (d, 2 H, J = 8.0 
Hz), 7.35-7.24 (m, 3 H), 7.10 (t, 1 H, J = 7.2 Hz), 4.54 (ddd, 1 H, 2JHF = 48.4 Hz, J = 9.6 Hz, 5.6 
Hz), 4.17 (ddd, 1 H, 2JHF = 48.4 Hz, J = 8.4 Hz, 8.4 Hz), 1.97-1.84 (m, 1 H), 1.63-1.54 (m, 1 H), 
1.42-1.33 (m, 1 H), 0.95-0.86 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 137.9, 129.1, 129.0, 124.3, 
119.8, 84.9 (1JCF = 167 Hz), 21.0 (2JCF = 24 Hz), 11.74, 11.67; 19F NMR (376 MHz, CDCl3) δ –
214.4. 
 
(Z)-2-Phenylprop-2-en-3-d-1-ol (3-104). A 500 mL 3-neck flask affixed with an internal 
thermometer, septum, and condenser with N2 inlet was charged with magnesium turnings (2.25 g, 
92.8 mmol, 2.6 eq) and THF (120 mL). Bromobenzene (9.5 mL, 89 mmol, 2.5 eq) was added in 
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~1 mL portions. The system was heated with a heat gun to initiate Grignard formation. Upon 
complete formation of the Grignard reagent, the reaction was stirred until it cooled to rt. In a 
separate 500 mL 3-neck flask affixed with a septum, internal thermometer, and N2 inlet. Under an 
N2 atmosphere, CuI (0.679 g, 3.57 mmol, 0.100 eq), THF (80 mL), and propargyl alcohol (2.1 mL, 
36 mmol, 1.0 eq) were added sequentially. The solution was cooled to –78 °C. The Grignard 
solution was cannulated to this alcohol solution over a period of 1.5 h. After complete transfer, the 
cooling bath was removed and the reaction was warmed to rt and stirred for 17 h. The reaction was 
then cooled to –78 °C and treated with D2O (6.5 mL, 0.36 mol, 10 eq). After warming to rt, 1 M 
HCl (300 mL) was added. The material was extracted with ether (2 x 100 mL). The combined 
extracts were washed with water (70 mL) and brine (70 mL), then were dried (Na2SO4) and 
concentrated. Purification by chromatography on SiO2 (30% EtOAc/hexanes) afforded labelled 
alcohol (4.26 g, 35.8 mmol, 100%) as a yellow-tinted oil. The material contained trace EtOAc but 
was carried forward without further purification. 1H NMR suggests ~90% D incorporation at the 
alkene: 1H NMR (300 MHz, CDCl3) δ 7.52-7.18 (m, 5 H), 5.46 (s, 1 H), 4.55 (s, 2 H). 
 
 
2,2-Dibromo-1-phenylcyclopropyl-3-d)methanol (3-105). A solution of alcohol 3-104 (4.26 g, 
31.5 mmol) in CH2Cl2 (60 mL) was treated with 3,4-dihydro-2H-pyran (2.9 mL, 32 mmol, 1.2 eq) 
followed by PPTS (0.791 g, 3.15 mmol, 0.10 eq). The resulting solution was stirred at rt for 4 h. 
The reaction mixture was then concentrated on the rotovap. The residue was partitioned between 
ether and water (75 mL each). The layers were separated, and the organic layer was washed with 
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sat aq NaHCO3 (75 mL). The organic layer was then dried (Na2SO4) and concentrated to afford 
the protected alcohol (7.304 g). The material was used without further purification, and a 100% 
yield was assumed. 
A solution of protected alcohol (6.91 g, 31.5 mmol) and cetyltrimethyl ammonium bromide 
(0.116 g, 0.315 mmol, 1 mol %) in CH2Cl2 (10 mL) in a 250 mL 3-neck flask was affixed with an 
N2 inlet, mechanical stirrer, and septum. Bromoform (8.3 mL, 95 mmol, 3.00 eq) was added, and 
the solution was cooled to 0 °C. Sodium hydroxide (15.1 g, 0.378 mol, 12.0 eq) was added as a 
solution in water (30 mL, ~50 g/100 mL) via syringe over 10 min. The ice bath was removed and 
the flask was stirred for 25 h at 300 rpm. The reaction mixture became very dark and thick. The 
material was partitioned between water (50 mL) and CH2Cl2 (50 mL), filtered through Celite, and 
the layers were separated. The aqueous phase was extracted with CH2Cl2 (50 mL). The combined 
extracts were washed with water (25 mL), 1:1 water/brine (25 mL), then was dried (MgSO4), 
filtered through a pad of SiO2, and concentrated.  
This crude dark red oil was dissolved in MeOH (30 mL) and treated with p-toluenesulfonic 
acid monohydrate (0.599 g, 3.15 mmol, 10 mol %). After stirring at rt for 5 h, the reaction mixture 
was concentrated. The residue was partitioned between water and ether (75 mL each). The layers 
were separated and the organic layer was washed with water (75 mL), sat aq NaHCO3 (75 mL), 
and brine (75 mL). The organic layer was then dried (Na2SO4) and concentrated. Purification by 
chromatography on SiO2 (15-50% EtOAc/hexanes) afforded alcohol 3-105 (3.14 g, 10.2 mmol, 
32% over 4 steps) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.52-7.28 (m, 5 H), 4.05, 3.95 
(AB q, 2 H, JAB = 11.6 Hz), 2.09 (app s, 1 H), 1.72 (br s, 1 H); 13C NMR (100 MHz, CDCl3) 
δ 138.3, 129.7, 128.6, 128.0, 126.1, 70.3, 40.8, 32.4, 31.5 (1JCD = 27 Hz). 
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2,2-Dibromo-1-(bromomethyl)cyclopropyl-3-d)benzene (3-106). A solution of alcohol 3-105 
(3.14 g, 10.2 mmol) in CH2Cl2 (50 mL) at 0 °C was treated with triphenylphosphine (2.95 g, 11.3 
mmol, 1.10 eq) followed by carbon tetrabromide (3.73 g, 11.3 mmol, 1.10 eq). The reaction was 
warmed to rt for 4 h. The solution was then concentrated, and the residue was purified by 
chromatography on SiO2 to afford tribromide 3-106 (2.62 g, 7.08 mmol, 69%) as a colorless oil. 
The material contained ~20% of allylic bromide (from unreacted cyclopropane in the previous 
step). After standing overnight, the material solidified. This solid was recrystallized from hexanes 
to afford 0.962 g (0.962 g, 25%) of material as a colorless solid: 1H NMR (400 MHz, CDCl3) δ 
7.44-7.31 (m, 5 H), 3.97, 3.84 (AB q, 2 H, JAB = 10.4 Hz), 2.25 (s, 1 H); 13C NMR (100 MHz, 
CDCl3) δ 138.2, 129.8, 128.4, 128.2, 42.5, 40.0, 34.7, 34.4 (1JCD = 25 Hz). 
 
 
N, 3-Diphenylbicyclo[1.1.0]butane-2-d-1-carboxamide (3-107). Prepared according to General 
Procedure G from tribromide 3-106 (0.898 g, 2.43 mmol, 2.00 eq), MeLi (1.5 mL, 2.4 mmol, 1.6 
M in Et2O), t-BuLi (1.4 mL, 2.4 mmol, 1.7 M in pentane), and phenyl isocyanate (0.13 mL, 1.2 
mmol) in Et2O (10 mL). Purification by chromatography on SiO2 (15-40% EtOAc/hexanes) 
afforded amide 3-107 (0.241 g, 0.963 mmol, 79%) as a colorless solid: 1H NMR (400 MHz, 
acetone-D6) δ 8.95 (br s, 1 H), 7.50 (d, 2 H, J = 7.6 Hz), 7.38 (d, 2 H, J = 7.2 Hz), 7.27 (t, 2 H, J 
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= 7.6 Hz), 7.18 (t, 3 H, J = 7.2 Hz), 6.94 (t, 1 H, J = 7.2 Hz), 3.06 (d, 2 H, J = 2.4 Hz), 1.53 (d, 1 
H, J = 1.2 Hz); 13C NMR (100 MHz, acetone-D6) δ 166.9, 140.3, 135.4, 129.3, 129.1, 127.3, 
126.9, 123.9, 120.4, 35.0, 34.7 (1JCD = 25 Hz), 31.3, 26.1. 
 
3-Fluoro-N,3-diphenylcyclobutane-2-d-1-carboxamide (3-108). Prepared according to General 
Procedure I from KHF2 (0.044 g, 0.57 mmol), diisopropylamine (0.32 mL, 2.3 mmol, 4.0 eq), 
pyridine • 9 HF (1.0 mL, 39 mmol HF, 68 eq HF) and amide 3-107 (0.142 g, 0.567 mmol) in 
CH2Cl2 (4 mL). Chromatography on SiO2 (25% EtOAc/hexanes) afforded less polar cis 3-108 (38 
mg, 0.14 mmol, 25%) as a colorless solid and the more polar trans 3-108 (28 mg, 0.15 mmol, 18%) 
as a colorless solid. cis 3-108: Mp 107–110 °C; 1H NMR (400 MHz, CDCl3) δ 7.53 (d, 2 H, J = 
7.6 Hz), 7.50 (d, 2 H, J = 8.0 Hz), 7.40 (t, 2 H, J = 7.6 Hz), 7.36-7.29 (m, 3 H), 7.24 (br s, 1 H), 
7.12 (t, 1 H, J = 7.6 Hz), 3.46 (ABX (app q), 1 H, J = 8.4 Hz), 3.12-2.93 (ABX (m), 2 H), 2.88-
2.75 (ABX (m), 1 H); 13C NMR (100 MHz, CDCl3) δ 172.1, 141.4 (2JCF = 23 Hz), 137.7, 129.1, 
128.4, 128.2, 124.64, 124.56, 124.51, 119.8, 97.4 (1JCF = 192 Hz), 38.7 (2JCF = 25 Hz), 34.2 (1JCD 
not resolved); 19F NMR (470 MHz, CDCl3) δ –146.3; trans 3-108: Mp 146–148 °C; 1H NMR (400 
MHz, CDCl3) δ 7.62 (br s, 1 H), 7.54 (d, 2 H, J = 7.6 Hz), 7.49 (d, 2 H, J = 7.6 Hz), 7.45-7.34 (m, 
3 H), 7.31 (t, 2 H, J = 7.6 Hz), 7.11 (t, 1 H, J = 7.6 Hz), 3.12-2.93 (m, 2 H), 2.88-2.72 (m, 2 H); 
13C NMR (100 MHz, CDCl3) δ 171.6, 140.8 (2JCF = 22 Hz), 137.8, 129.1, 128.7, 128.5, 124.9 (3JCF 
= 6 Hz), 124.5, 120.0, 91.3 (1JCF = 211 Hz), 38.7 (1JCD = 21 Hz, 2JCF = 25 Hz), 30.9 (3JCF = 13 Hz); 
19F NMR (470 MHz, CDCl3) δ –119.2; MS (ESI+) m/z 251 (100), 158 (5), 130 (5); HRMS (ESI+) 
m/z calcd for C17H15NOD [M+H–HF] 251.1295, found 251.1285. 
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5.5 CHAPTER 4 EXPERIMENTAL PART 
F
Br
4-5
1-(3-Bromoprop-1-en-2-yl)-4-fluorobenzene (4-5).171 A solution of methylstyrene 4-4 (4.78 g, 
35.1 mmol) in CHCl3 (7 mL) was treated with NBS (8.50 g, 47.7 mmol, 1.36 eq). The reaction 
was heated to reflux (~90 °C) for 6 h then it was cooled and filtered through Celite. The filter cake 
was washed with hexane (50 mL) and the eluent was concentrated. The residue was purified by 
chromatography on SiO2 (hexane) to afford bromide 4-5 (3.38 g, 15.7 mmol, 45%) as a colorless 
oil: 1H NMR (400 MHz, CDCl3) δ 7.48-7.43 (m, 2 H), 7.13-7.01 (m, 2 H), 5.50 (s, 1 H), 5.48 (s, 
1 H), 4.36 (s, 2 H); 19F NMR (376 MHz, CDCl3) δ –113.7. 
1-(2,2-Dibromo-1-(bromomethyl)cyclopropyl)-4-fluorobenzene (4-6). A solution of allylic 
bromide 4-5 (3.17 g, 14.7 mmol) and cetyltrimethyl ammonium bromide (0.054 g, 0.15 mmol, 1 
mol %) in CH2Cl2 (4 mL) was charged to a 100 mL 3-neck flask affixed with an N2 inlet, 
mechanical stirrer, and septum. Bromoform (3.9 mL, 44 mmol, 3.0 eq) was added by syringe, and 
the solution was cooled to 0 °C. Sodium hydroxide (7.07 g, 0.177 mol) was added as a solution in 
water (15 mL, ~50 g/100 mL) via syringe over 5 min. The ice bath was removed and the flask 
stirred for 26 h at 300 rpm (color changed from clear to a dark, opaque brown). The reaction 
mixture was then partitioned between water (50 mL) and CH2Cl2 (50 mL). The layers were 
separated, and the aqueous phase was extracted with CH2Cl2 (50 mL). The combined extracts were 
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washed with water (25 mL), 1:1 water/brine (25 mL), then were dried (Na2SO4) and concentrated. 
The residue was purified by column chromatography on SiO2 (10% EtOAc in hexane).  Upon 
concentration of the product-containing fractions, a solid mass formed. This material was then 
recrystallized from ~1:1 EtOAc/hexanes (~15 mL), and the crystals were washed with cold 
hexanes (30 mL). After drying under vacuum, tribromide 4-6 (1.68 g, 4.35 mmol, 30%) was 
obtained as a colorless crystalline solid: Mp 101–103 °C; 1H NMR (400 MHz, CDCl3) δ 7.38-7.30 
(m, 2 H), 7.08 (app t, 2 H, J = 8.8 Hz), 3.91 (dd, 2 H, J = 10.8 Hz, 1.6 Hz), 3.82 (d, 1 H, J = 10.4 
Hz), 2.21 (dd, 1 H, J = 8.0 Hz, 1.2 Hz), 2.01 (d, 1 H, J = 8.4 Hz); 19F NMR (376 MHz, CDCl3) δ –
113.2. 
F3C
OH
4-8
2-(4-(Trifluoromethyl)phenyl)prop-2-en-1-ol (4-8).181 Magnesium turnings (2.71 g, 0.111 mol) 
were charged to a 500 mL 3-neck round bottomed flask fitted with a reflux condenser, septum, 
and internal thermometer. After flushing with N2, the turnings were suspended in ether (120 mL). 
Neat aryl bromide 4-7 (15.8 mL, 0.111 mol) was added by syringe in ~1 mL portions over ~15 
min, which caused the formation of a dark brown Grignard solution and spontaneous heating of 
the reaction to reflux. After ~1 h, the reaction has cooled from reflux to rt. To the freshly prepared 
Grignard reagent was added CuI (1.27 g, 6.67 mmol) and the black suspension was stirred for 15 
min. A solution of propargyl alcohol (2.60 mL, 44.6 mmol) in ether (50 mL) was added via cannula 
over 1.75 h, causing an exotherm to 29 °C. The reaction was stirred at rt for 18 h, at which point a 
quenched aliquot showed consumption of propargyl alcohol by 1H NMR. The reaction was then 
cooled to 0 °C and quenched with sat aq NH4Cl (100 mL). The layers were separated and the 
aqueous layer was extracted with ether (2 x 100 mL). The organic extracts were washed with water 
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(100 mL) and brine (100 mL), then they were dried (MgSO4), filtered, and concentrated. The crude 
product was purified by chromatography on SiO2 (25% EtOAc/hexanes) to afford alcohol 4-8 
(4.86 g, 24.0 mmol, 54%) as a red-tinted oil: 1H NMR (300 MHz, CDCl3) δ 7.58 (AB q, 4 H, J = 
8.4 Hz, ∂AB = 0.05 ppm), 5.55 (s, 1 H), 5.46 (s, 1 H), 4.56 (s, 2 H), 1.62 (s, 1 H). 
F3C
OH
Br
Br
4-9
(2,2-Dibromo-1-(4-(trifluoromethyl)phenyl)cyclopropyl)methanol (4-9). A solution of alcohol 
4-8 (4.86 g, 24.0 mmol) in CH2Cl2 (40 mL) was treated with 3,4-dihydro-2H-pyran (3.1 mL, 34
mmol, 1.4 eq) followed by PPTS (0.604 g, 2.40 mmol, 0.10 eq). The resulting solution was stirred 
at rt for 2.5 h. The reaction mixture was then concentrated on the rotovap. The residue was 
partitioned between ether and water (75 mL each). The layers were separated, and the organic 
layer was washed with sat aq NaHCO3 (75 mL). The organic layer was then dried (Na2SO4) and 
concentrated to afford the protected alcohol (7.11 g) as a red-tinted oil. The material contained 
residual solvents and was carried on without further purification. 
A solution of protected alcohol (7.11 g, 24.8 mmol) and cetyltrimethyl ammonium bromide 
(0.091 g, 0.25 mmol, 1 mol %) in CH2Cl2 (12 mL) in a 250 mL 3-neck flask was affixed with an 
N2 inlet, mechanical stirrer, and septum. Bromoform (6.5 mL, 75 mmol, 3.0 eq) was added, and 
the solution was cooled to 0 °C. Sodium hydroxide (11.9 g, 298 mmol, 12.0 eq) was added as a 
solution in water (24 mL, ~50 g/100 mL) via syringe over 10 min. The ice bath was removed and 
the flask stirred for 24 h at 300 rpm. 1H NMR of an aliquot showed consumption of the alkene. 
The reaction mixture was partitioned between water (50 mL) and CH2Cl2 (50 mL), the layers were 
separated, and the aqueous phase was extracted with CH2Cl2 (50 mL). The combined extracts were 
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washed with water (25 mL), 1:1 water/brine (25 mL), then were dried (Na2SO4) and concentrated. 
This crude dark red oil was dissolved in MeOH (25 mL) and treated with p-toluenesulfonic 
acid monohydrate (0.472 g, 2.48 mmol, 10 mol %). After stirring at rt for 3 h, the reaction mixture 
was concentrated. The residue was partitioned between water and ether (75 mL each). The layers 
were separated and the organic layer was washed with water (75 mL), sat aq NaHCO3 (75 mL), 
and brine (75 mL). The organic layer was then dried (Na2SO4) and concentrated. Purification by 
chromatography on SiO2 afforded 4-9 (4.45 g, 11.9 mmol, 48% over 3 steps) as a colorless oil: 1H 
NMR (400 MHz, CDCl3) δ 7.65 (app d, 2 H, J = 8.4 Hz), 7.52 (app d, 2 H, J = 8.0 Hz), 4.01 (AB 
q, J = 12.0 Hz, ∂AB = 0.04 ppm), 2.11 (AB q, 4 H, J = 7.6 Hz, ∂AB = 0.03 ppm); 13C NMR (100 
MHz, CDCl3) δ 142.4, 130.2, 125.4 (q, 3JCF = 4 Hz), 70.1, 40.7, 31.9, 31.3, 21.1; 19F NMR (376 
MHz, CDCl3) δ –62.6. 
Br
Br
Br
F3C 4-10
1-(2,2-Dibromo-1-(bromomethyl)cyclopropyl)-4-(trifluoromethyl)benzene (4-10). A solution of 
alcohol 4-9 (4.45 g, 11.9 mmol) in CH2Cl2 (35 mL) was cooled to 0 °C under N2. PPh3 (3.75 g, 
13.1 mmol, 1.20 eq) was then charged, followed by CBr4 (4.34 g, 13.1 mmol, 1.10 eq). The 
reaction was warmed to rt and stirred for 20 h, then it was concentrated. Purification by 
chromatography on SiO2 (0-15% EtOAc in hexanes) afforded bromide 4-10 (4.31 g, 9.85 mmol, 
83%) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.66 (d, 2 H, J = 8.0 Hz), 7.49 (d, 2 H, J = 
8.0 Hz), 3.93 (dd, 1 H, J = 10.8 Hz, 1.2 Hz), 3.83 (d, 1 H, J = 10.8 Hz), 2.27 (dd, 1 H, J = 8.0 Hz, 
1.2 Hz), 2.06 (d, 1 H, J = 8.0 Hz); 13C NMR (100 MHz, CDCl3) δ 142.0, 130.6, 130.3, 125.4 (q, 
3JCF = 4 Hz), 41.7, 39.8, 34.8, 34.7, 33.4, 31.6, 14.1; 19F NMR (376 MHz, CDCl3) δ –62.6. 
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General Procedure J (Bicyclo[1.1.0]butyl carboxylic acid synthesis): 3-(4-
Fluorophenyl)bicyclo[1.1.0]butane-1-carboxylic acid (4-11). A solution of 
dibromocyclopropane 4-8 (0.880 g, 2.57 mmol) in Et2O (7 mL) and THF (3 mL) in a 50 mL round 
bottom flask was placed under N2 and cooled to –78 °C. MeLi (1.6 mL, 2.6 mmol, 1.0 eq) was 
added via syringe over 10 min. After 1.75 h at –78 °C, t-BuLi (1.5 mL, 2.6 mmol, 1.0 eq) was 
added via syringe over 10 min. After an additional 1 h at –78 °C, a balloon of dry CO2 was bubbled 
through the solution via a needle for 10 min (an external bubbler was used, providing a continuous 
stream of CO2 through the flask). The cooling bath was then removed, and the opaque grey reaction 
mixture was warmed to 0 °C over 20 min. The reaction mixture was then quenched with 1 M 
NaOH (10 mL), then it was partitioned between ether and 1 M NaOH (50 mL each). The light 
brown aqueous layer was acidified to litmus with conc HCl, which caused formation of a light 
brown precipitate. This suspension was then extracted with ether (40 mL). The organic layer was 
dried (Na2SO4) and concentrated to afford acid 4-11 (0.228 g, 1.19 mmol, 57%) as a buff solid: 
Mp 158–160 °C; IR (ATR) 1646, 1527, 1226, 841 cm-1; 1H NMR (300 MHz, CD3OD) δ 7.41-7.32 
(m, 2 H), 7.05 (app t, 2 H, J = 9.0 Hz), 2.88 (t, 2 H, J = 1.2 Hz), 1.60 (s, 2 H); 13C NMR (100 MHz, 
CD3OD) (1JCF not resolved) δ 172.2, 127.5 (d, 3JCF = 8 Hz), 114.9 (d, 2JCF = 21 Hz), 34.9, 31.8, 
22.4; 19F NMR (376 MHz, CD3OD) δ –117.7; HRMS m/z calcd for C11H10FO2 [M+H] 193.0665, 
found 193.0660.  
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3-(4-(Trifluoromethyl)phenyl)bicyclo[1.1.0]butane-1-carboxylic acid (4-12). Prepared 
according to General Procedure J from tribromocyclopropane 4-12 (1.50 g, 3.43 mmol), MeLi (2.1 
mL, 3.4 mmol, 1.6 M in Et2O), and t-BuLi (2.0 mL, 3.4 mmol, 1.7 M in pentane, 1.0 eq)  to afford 
acid 4-12 (0.416 g, 1.72 mmol, 50%) as a colorless solid: Mp 146–148 °C; IR (ATR) 2980, 1648, 
1616, 1463, 1318, 1167, 1116, 1061, 907, 842, 689 cm-1; 1H NMR (400 MHz, CD3OD) δ 7.61 (d, 
2 H, J = 8.4 Hz), 7.52 (d, 2 H, J = 8.4 Hz), 4.88 (s, 1 H), 2.99 (t, 2 H, J = 1.2 Hz), 1.68 (s, 2 H); 
13C NMR (100 MHz, CD3OD) δ 171.5, 140.0, 128.4 (q, 2JCF = 32 Hz), 126.2, 124.9 (q, 3JCF = 4 
Hz), 124.4 (q, 1JCF = 269 Hz), 35.0, 31.0, 24.2; 19F NMR (376 MHz, CDCl3) δ –64.0; MS (ESI)+ 
m/z 243 (80), 233 (50), 231 (50), 197 (60), 177 (40), 155 (100); HRMS (ESI)+ m/z calcd for 
C12H10F3O2 [M+H] 243.0633, found 243.0626. 
 
(4-(5-chloro-2-(trifluoromethyl)phenyl)piperazin-1-yl)(3-(4-fluorophenyl)bicyclo[1.1.0] 
butan-1-yl)methanone (4-13). A solution of bicyclobutane acid 4-11 (0.018 g, 0.096 mmol, 1.1 
eq) and piperazine free base (0.023 g, 0.087 mmol) in CH2Cl2 (1 mL) was cooled to 0°C and treated 
with Et3N (0.02 mL, 0.2 mmol, 2 eq). The transparent beige solution was then treated with T3P 
(50% solution in EtOAc) (0.09 mL, 0.13 mmol, 1.5 eq) dropwise via syringe over ~1 min. The 
reaction was stirred at 0°C for 30 min, then the ice bath was removed and the reaction was warmed 
to rt for 19.5 h. The reaction mixture was then directly purified by chromatography on SiO2 (15-
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25% EtOAc/hexanes) without workup to afford amide 4-13 (0.015 g, 0.038 mmol, 39%) as a 
colorless oil: IR (ATR) 2923, 1620, 1596, 1434, 1307, 1221, 1120, 1027, 906, 933, 725 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.56 (d, 1 H, J = 8.4 Hz), 7.34-7.27 (m, 2 H), 7.25-7.19 (m, 2 H), 7.01 
(app t, 2 H, J = 8.8 Hz), 4.1-3.5 (br m, 4 H), 2.9-2.7 (br m, 4 H), 2.75 (s, 2 H), 1.63 (s, 2 H); 13C 
NMR (100 MHz, CDCl3) (piperazine carbons broadened and are not clearly visible)  δ 167.7, 161.9 
(d, 1JCF = 243 Hz), 152.9, 138.8, 135.1, 129.7 (d, 4JCF = 3 Hz), 128.6 (q, 3JCF = 5 Hz), 128.0 (d, 
3JCF = 8 Hz), 126.3 (q, 1JCF = 272 Hz), 125.4 (q, 2JCF = 30 Hz), 115.4 (d, 2JCF = 21 Hz), 36.9, 30.6, 
30.0; 19F NMR (376 MHz, CDCl3) δ –60.3, –115.9; MS (ESI)+ m/z 439 (100), 265 (3), 175 (5), 
147 (45); HRMS (ESI)+ m/z calcd for C22H20ClF4N2O [M+H] 439.1195, found 439.1193. 
.  
(4-(5-Chloro-2-(trifluoromethyl)phenyl)piperazin-1-yl)(3-(4(trifluoromethyl)phenyl)bicyclo 
[1.1.0]butan-1-yl)methanone (4-14). A solution of bicyclobutane acid 4-12 (0.046 g, 0.19 mmol, 
1.0 eq) and piperazine HCl (0.057 g, 0.19 mmol) in CH2Cl2 (4 mL) cooled to 0 °C was treated 
Et3N (0.08 mL, 0.6 mmol, 3 eq). The transparent beige solution was then treated with T3P (50% 
solution in EtOAc) (0.2 mL, 0.28 mmol, 1.5 eq) dropwise via syringe over ~1 min. The reaction 
was stirred at 0 °C for 30 min, then the ice bath was removed and the reaction was warmed to rt 
for 22 h. The reaction mixture was then partitioned between water and CH2Cl2 (30 mL each). The 
layers were separated, and the aqueous layer was extracted with additional CH2Cl2 (30 mL). The 
combined extracts were washed with water (30 mL) and sat aq NaHCO3 (30 mL), then were dried 
(Na2SO4) and concentrated. Purification by chromatography on SiO2 (15-25% EtOAc/hexanes) 
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afforded amide 4-14 (0.051 g, 0.10 mmol, 55%) as a colorless solid: Mp 137–139 °C; IR (ATR) 
2902, 1604, 1466, 1438, 1312, 1100, 1027, 924, 838, 825 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.56 
(app d, 3 H, J = 8.4 Hz), 7.43 (app d, 2 H, J = 8.4 Hz), 7.23 (app q, 2 H, J = 8.4 Hz), 4.1-3.5 (br, 
4 H), 3.0-2.7 (br, 4 H), 2.83 (s, 2 H), 1.69 (s, 2 H); 13C NMR (100 MHz, CDCl3) (piperazine 
carbons broadened and are not clearly visible)  δ 167.1, 152.8, 138.8, 138.6, 128.5 (q, 2JCF = 32 
Hz), 128.5 (q, 3JCF = 4 Hz), 126.6, 125.7 (q, 2JCF = 29 Hz), 125.5, 125.3 (q, 3JCF = 3 Hz), 124.6, 
124.3 (q, 1JCF = 270 Hz), 123.6 (q, 1JCF = 272 Hz), 37.0, 30.0, 29.7, 22.7; 19F NMR (376 MHz, 
CDCl3) δ –60.3, –62.4; MS (ESI)+ m/z 489, 256 (5); HRMS (ESI)+ m/z calcd for C23H20F6ClN2O 
[M+H] 489.1168, found 489.1158. 
 
(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)(3-(4-(trifluoromethyl)phenyl) 
bicyclo[1.1.0]butan-1-yl)methanone (4-15). A solution of bicyclobutane acid 4-12 (0.052 g, 0.21 
mmol) and piperazine free base (1.1 eq, HCl salt washed with NaOH, dried and concentrated 
before use) in CH2Cl2 (2 mL) cooled to 0 °C and treated with Et3N (0.06 mL, 0.43 mmol, 2.0 eq). 
The transparent beige solution was treated with T3P (0.23 mL, 0.32 mmol, 1.5 eq, 50% solution 
in EtOAc) dropwise via syringe. The reaction was stirred at 0 °C for 30 min, then the ice bath was 
removed and the reaction was warmed to rt for 17 h. The reaction mixture was partitioned between 
water and CH2Cl2 (50 mL each). The layers were separated, and the aqueous layer was extracted 
with additional CH2Cl2 (30 mL). The combined extracts were washed with water (50 mL) and sat 
aq NaHCO3 (40 mL), then were dried (Na2SO4) and concentrated. Purification by chromatography 
on SiO2 (15-25% EtOAc/hexanes) afforded amide 4-15 (0.072 g, 0.154 mmol, 72%) as a colorless 
 184 
oil: IR (ATR) 2821, 1618, 1435, 1418, 1323, 1162, 1114, 1030, 840, 732 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.56 (d, 2 H, J = 8.0 Hz), 7.43 (d, 2 H, J = 8.4 Hz), 7.28 (app q, 2 H, J = 8.0 Hz), 
7.18 (s, 1 H), 4.1-3.5 (br, 4 H), 3.0-2.7 (br, 4 H), 2.84 (s, 2 H), 2.36 (s, 3 H), 1.70 (s, 2 H); 13C 
NMR (100 MHz, CDCl3) (piperazine carbons broadened and are not clearly visible) δ 167.1, 
151.2, 138.6, 136.8, 131.6, 129.1 (q, 2JCF = 32 Hz), 128.5 (q, 2JCF = 32 Hz), 126.6, 125.3 (q, 3JCF = 
4 Hz), 124.3 (q, 1JCF = 270 Hz), 124.2 (q, 1JCF = 271 Hz), 120.4 (q, 3JCF = 3 Hz), 116.0 (q, 3JCF = 4 
Hz), 37.0, 30.0, 22.8, 18.0; 19F NMR (376 MHz, CDCl3) δ –62.2, –62.4; MS (ESI)+ m/z 469 (100), 
197 (5); HRMS (ESI)+ m/z calcd for C24H23F6N2O [M+H] 469.1709, found 469.1705. 
 
General Procedure K (Rearrangement of Bicyclo[1.1.0[butyl amides): ((E)-(4-(2-methyl-5-
(trifluoromethyl)phenyl)piperazin-1-yl)(2-(4-(trifluoromethyl) benzylidene) 
cyclopropyl)methanone (4-16). A solution of amide 4-13 (0.680 g, 1.45 mmol) in CH2Cl2 (8 mL) 
was treated with camphorsulfonic acid (0.050 g, 0.22 mmol, 15 mol %). The vial was sealed and 
heated at 50 °C for 18 h. After cooling, the solution was partitioned between CH2Cl2 at sat aq 
NaHCO3 (20 mL each). The organic layer was dried (Na2SO4) and concentrated. Purification by 
chromatography on SiO2 afforded methylenecyclopropane 4-16 (0.484 g, 1.03 mmol, 71%) as an 
off-white foam: IR (ATR) 2921, 1638, 1417, 1324, 1116, 1069, 825, 729 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.58 (d, 2 H, J = 8.0 Hz), 7.46 (d, 2 H, J = 8.4 Hz), 7.33-7.27 (m, 2 H), 7.21 (s, 1 
H), 6.53 (d, 1 H, J = 0.8 Hz), 3.87 (app s, 1 H), 3.80 (q, 2 H, J = 5.2 Hz), 3.69 (t, 2 H, J = 4.8 Hz), 
3.17-3.07 (m, 2 H), 2.99 (t, 2 H, J = 4.8 Hz), 2.91 (t, 2 H, J = 4.4 Hz), 2.39 (s, 3 H); 13C NMR (100 
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MHz, CDCl3) δ 170.7, 151.2, 145.7, 136.94, 136.88, 131.6, 129.9 (q, 2JCF = 33 Hz), 129.1 (q, 2JCF 
= 32 Hz), 128.1, 126.6, 126.4, 125.4 (q, 3JCF = 4 Hz), 124.9, 124.2 (q, 1JCF = 271 Hz), 124.1 (q, 
1JCF = 271 Hz), 120.4 (q, 3JCF = 4 Hz), 116.0 (q, 3JCF = 4 Hz), 51.9, 51.7, 45.6, 42.1, 40.8, 32.7, 
29.7, 21.0, 18.0; 19F NMR (376 MHz, CDCl3) δ –62.2, –62.5; MS (ESI)+ m/z 469 (100), 371 (1), 
225 (2); HRMS (ESI)+ m/z calcd for C24H23F6N2O [M+H] 469.1709, found 469.1715. 
 
(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)(3-(4-(trifluoromethyl)phenyl) 
cyclobutyl)methanone (4-17). A solution of amide 4-13 (0.072 g, 0.153 mmol) in MeOH (3 mL) 
was placed under N2 and treated with Pd/C (3 mg, ~20 mol %). A hydrogen atmosphere of 6.43 
bar was then established on the Parr hydrogenator. The reaction was stirred at rt for 18 h, at which 
point the hydrogen was vented and the solution was purified by chromatography on SiO2 (25-40% 
EtOAc/hexanes) afforded cyclobutane 4-17 (0.037 g, 0.079 mmol, 51%) as a colorless oil. 
Alternatively, 4-17 was prepared by dissolving a solution of amide 4-16 (0.031 g, 0.080 
mmol, 1.0 eq) in MeOH (2 mL) and treating with Pd/C (2 mg, 20 mol%). A hydrogen atmosphere 
was then established with a balloon. After stirring at rt for 2 h, the reaction mixture was filtered 
through Celite and concentrated to afford cyclobutane 4-17 (0.015 g, 0.039 mmol, 48%) as a 
colorless oil: IR (ATR) 2939, 1641, 1618, 1417, 1324, 1308, 1161, 1112, 1067, 834, 732 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.55 (d, 2 H, J = 8.4 Hz), 7.36 (d, 2 H, J = 8.4 Hz), 7.32-7.24 (m, 2 H, 
J = 8.0 Hz), 7.19 (s, 1 H), 3.79 (t, 2 H, J = 4.8 Hz), 3.60 (t, 2 H, J = 5.2 Hz), 3.57-3.48 (m, 1 H), 
3.37-3.26 (m, 1 H), 2.95-2.86 (m, 4 H), 2.68-2.59 (m, 2 H), 2.53 (ddd, 2 H, J = 19.2 Hz, 9.6 Hz, 
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2.4 Hz), 2.37 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 172.4, 151.2, 148.7, 136.8, 131.6, 129.1 (q, 
2JCF = 32 Hz), 128.5 (q, 2JCF = 32 Hz), 126.9, 125.3 (q, 3JCF = 4 Hz), 124.3 (q, 1JCF = 270 Hz), 124.2 
(q, 1JCF = 270 Hz), 120.4 (q, 3JCF = 4 Hz), 116.0 (q, 3JCF = 5 Hz), 51.9, 51.7, 45.5, 42.2, 35.5, 33.1, 
32.6, 18.0; 19F NMR (376 MHz, CDCl3) δ –62.3; MS (ESI)+ m/z 471 (100), 355 (1), 246 (3), 179 
(3); HRMS (ESI)+ m/z calcd for C24H25F6N2O [M+H] 471.1871, found 471.1865. 
 
(E)-2-Benzylidene-N-phenylcyclopropane-1-carboxamide (4-18). Prepared according to 
General Procedure K from amide 3-96 (0.041 g, 0.16 mmol) and camphorsulfonic acid (6 mg, 
0.025 mmol, 15 mol %) in CH2Cl2 (1 mL). Purified by chromatography on SiO2 to afford amide 
4-18 (0.027 g, 0.011 mmol, 66%) as a colorless solid: Mp 149–152 °C; 1H NMR (400 MHz, 
CDCl3) δ 7.53 (d, 2 H, J = 8.0 Hz), 7.46-7.28 (m, 8 H), 7.10 (t, 1 H, J = 7.2 Hz), 6.41 (s, 1 H), 3.71 
(d, 1 H, J = 4.8 Hz), 3.24 (dd, 1 H, J = 13.6 Hz, 4.8 Hz), 3.00 (dd, 1 H, J = 13.6 Hz, 1.2 Hz); 13C 
NMR (100 MHz, CDCl3) δ 171.5, 150.9, 137.8, 133.4, 129.0, 128.9, 128.5, 124.9, 124.3, 123.8, 
119.8, 44.5, 34.1; MS (ESI+) m/z 250 (100), 185 (20), 129 (5); HRMS (ESI+) m/z calcd for 
C17H16NO [M+H] 250.1226, found 250.1224. 
 
(E)-2-(4-Chlorobenzylidene)-N-phenylcyclopropane-1-carboxamide (4-19). Prepared 
according to General Procedure K from the corresponding bicyclobutane (0.043 g, 0.15 mmol, 
crystallized material) and camphorsulfonic acid (5 mg, 0.023 mmol, 15 mol %) in CH2Cl2 (1 mL). 
Purification by chromatography on SiO2 afforded amide 4-19 (0.036 g, 0.13 mmol, 84%) as a 
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colorless semi-solid: 1H NMR (400 MHz, CDCl3) δ 7.45 (d, 2 H, J = 8.0 Hz), 7.33-7.15 (m, 7 H), 
7.02 (t, 1 H, J = 7.2 Hz), 6.32 (s, 1 H), 3.61 (d, 1 H, J = 3.6 Hz), 3.12 (dd, 1 H, J = 12.8 Hz, 4.8 
Hz), 2.91 (d, 1 H, J = 13.6 Hz); 13C NMR (100 MHz, CDCl3) δ 171.1, 149.5, 137.7, 129.1, 128.8, 
126.2, 124.6, 124.4, 119.8, 44.4, 33.9; MS (ESI+) m/z 284 (100), 195 (10); HRMS (ESI+) m/z calcd 
for C17H15ClNO [M+H] 284.0842, found 284.0836. 
 
(E)-(2-Benzylidenecyclopropyl)(4-phenylpiperazin-1-yl)methanone (4-20). Prepared 
according to General Procedure K from the corresponding bicyclobutane (0.057 g, 0.18 mmol) 
and camphorsulfonic acid (0.006 g, 0.03 mmol, 15 mol%) in CH2Cl2 (2 mL). Purification by 
chromatography on SiO2 (25-60% EtOAc/hexanes) afforded 4-20 (0.043 g, 0.14 mmol, 75%) as a 
colorless solid: Mp 138–142 °C; 1H NMR (400 MHz, CDCl3) δ 7.43-7.26 (m, 7 H), 7.10-6.92 (m, 
3 H), 6.42 (d, 1 H, J = 1.2 Hz), 3.88-3.77 (m, 3 H), 3.71 (dd, 2 H, J = 4.8 Hz, 4.8 Hz), 3.28-3.17 
(m, 4 H), 3.14-3.11 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 171.0, 151.0, 147.1, 133.8, 129.3, 
128.4, 128.2, 125.0, 124.7, 120.6, 116.8, 50.0, 49.5, 45.1, 41.6, 40.7, 32.6; MS (ESI+) m/z 319 
(100), 157 (10); HRMS (ESI+) m/z calcd for C21H23N2O [M+H] 319.1805, found 319.1802. 
 
(E)-(4-Phenylpiperazin-1-yl)(2-(4-(trifluoromethyl)benzylidene)cyclopropyl)methanone (4-
21). Prepared according to General Procedure K from the corresponding amide (0.067 g, 0.17 
mmol) and camphorsulfonic acid (0.006 g, 0.03 mmol, 15 mol%) in CH2Cl2 (2 mL). Purification 
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by chromatography on SiO2 afforded 4-21 (0.051 g, 0.013 mmol, 76%) as a colorless solid: Mp 
152–155 °C; 1H NMR (400 MHz, CDCl3) δ 7.58, 7.45 (ABq, 4 H, JAB = 8.0 Hz), 7.30 (app t, 2 H, 
J = 8.0 Hz), 6.99-6.89 (m, 3 H), 6.53 (s, 1 H), 3.90-3.86 (m, 1 H), 3.80 (dd, 2 H, J = 9.6 Hz, 4.0 
Hz), 3.72-3.65 (m, 2 H), 3.27-3.15 (m, 4 H), 3.12 (d, 2 H, J = 3.6 Hz); 13C NMR (100 MHz, CDCl3) 
δ 170.5, 151.0, 145.8, 136.9, 129.9 (2JCF  = 32 Hz), 129.3, 125.4 (3JCF  = 4 Hz), 124.9, 124.1 (1JCF  
= 271 Hz), 120.7, 116.8, 50.0, 49.5, 45.1, 41.7, 40.8, 32.6; MS (ESI+) m/z 387 (100), 225 (5); 
HRMS (ESI+) m/z calcd for C22H22N2OF3 [M+H] 387.1684, found 387.1674. 
 
(E)-Phenyl(2-(4-(trifluoromethyl)benzylidene)cyclopropyl)methanone (4-22). Prepared 
according to General Procedure K from the corresponding amide (0.027 g, 0.089 mmol) and 
camphorsulfonic acid (3 mg, 0.013 mmol ~15 mol%) in CH2Cl2 (1.5 mL). Purification by 
chromatography on SiO2 (30% EtOAc/hexanes) afforded amide 4-22 (0.008 g, 0.026 mol, 30%) 
as a colorless semi-solid:1H NMR (300 MHz, CDCl3) δ 8.01 (d, 2 H, J = 7.2 Hz), 7.65-7.56 (m, 3 
H), 7.56-7.41 (m, 4 H), 6.62 (s, 1 H), 4.53 (app s, 1 H), 3.28-3.13 (m, 2 H); 13C NMR (100 MHz, 
CDCl3) (1JCF not resolved) δ 198.7, 146.3, 136.9, 135.9, 133.3, 130.0 (2JCF  = 32 Hz), 128.8, 128.2, 
125.4 (3JCF  = 4 Hz), 124.9, 46.0, 32.6; MS (ESI+) m/z 303 (100), 225 (10), 167 (30); HRMS (ESI+) 
m/z calcd for C18H14OF3 [M+H] 303.0997, found 303.0989. 
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4-23
3-Methylene-N-phenylcyclobutane-1-carboxamide (4-23). A solution of amide 3-92 (0.042 g, 
0.22 mmol) in CH2Cl2 (1 mL) was treated with camphorsulfonic acid (0.008 g, 0.034 mmol, 15 
mol %). The reaction was stirred at rt for 3 h, then at 60 °C for 14 h, and then 120 °C for 6 h. The 
reaction mixture was directly purified by chromatography on SiO2 to afford methylenecyclobutane 
4-23 (7 mg, 0.04 mmol, 17%) as a colorless semi-solid: 1H NMR (300 MHz, CDCl3) δ 7.53 (d, 2 
H, J = 8.1 Hz), 7.32 (app t, 2 H, J = 7.8 Hz), 7.21-7.04 (m, 2 H), 4.84 (s, 2 H), 3.22-3.04 (m, 3 H), 
3.02-2.84 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 172.6 (s), 143.9 (s), 137.9 (s), 129.0 (d), 124.3 
(d), 119.7 (d), 106.8 (t), 35.9 (d), 35.6 (t). 
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APPENDIX A 
1H, 13C, 19F, AND 31P NMR SPECTRA FOR NEW COMPOUNDS 
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APPENDIX B 
ATOMIC COORDINATES, BOND LENGTHS, AND BOND ANGLES FOR X-RAY 
CRYSTAL STRCUCTURES 
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The coordinates for 1-36 were deposited in the CCDC (#997593) 
Sample and crystal data for 1-36: 
Identification code milligan21314 
Chemical formula C25H49B2F4N2P 
Formula weight 506.25 
Temperature 180(2) K 
Wavelength 1.54178 Å 
Crystal size 0.120 x 0.150 x 0.190 mm 
Crystal habit translucent colorless chunk 
Crystal system monoclinic 
Space group P 1 21/n 1 
Unit cell dimensions a = 12.0541(3) α = 90° 
b = 16.1202(4) β = 92.0953(12)° 
c = 15.0576(3) γ = 90° 
Volume 2923.95(12)  
Z 4 
Density (calculated) 1.150 g/cm3 
Absorption coefficient 1.174 mm-1 
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Data collection and structure refinement for 1-36: 
Diffractometer Bruker Apex II CCD 
Radiation source IMuS micro-focus source, Cu 
Theta range for data 
collection     4.02 to 68.42° 
Reflections collected 9574 
Independent reflections 9574 [R(int) = 0.0531] 
Coverage of independent 
reflections 
99.9% 
Absorption correction multi-scan 
Max. and min. transmission 0.8720 and 0.8080 
Structure solution technique direct methods 
Structure solution program SHELXS-97 (Sheldrick, 2008) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2013 (Sheldrick, 2013) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 9574 / 0 / 328 
Goodness-of-fit on F2 1.381 
Δ/σmax 0.001 
Final R indices 
8008 data; 
I>2σ(I)
R1 = 0.0468, wR2 
= 0.1300 
all data 
R1 = 0.0601, wR2 
= 0.1374 
Weighting scheme 
w=1/[σ2(Fo2)+(0.0680P)2] 
where P=(Fo
2+2Fc
2)/3 
Largest diff. peak and hole 0.414 and -0.281 eÅ-3 
R.M.S. deviation from mean 0.044 eÅ-3 
Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for 1-
36: 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
x/a y/b z/c U(eq) 
P1 0.73288(4) 0.20888(3) 0.53514(3) 0.02680(15) 
N1 0.75376(14) 0.37049(11) 0.60853(10) 0.0330(4) 
C1 0.96303(17) 0.22337(14) 0.55496(18) 0.0452(6) 
F1 0.76990(15) 0.13600(10) 0.78558(10) 0.0766(5) 
B1 0.7782(3) 0.09909(17) 0.86832(18) 0.0542(8) 
N2 0.72945(14) 0.35777(10) 0.45672(11) 0.0325(4) 
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x/a y/b z/c U(eq) 
C2 0.07055(19) 0.19561(16) 0.6021(2) 0.0595(7) 
F2 0.69015(14) 0.04416(9) 0.87708(11) 0.0687(4) 
C3 0.08718(18) 0.10302(15) 0.59521(17) 0.0458(6) 
F3 0.77869(16) 0.15727(9) 0.93442(11) 0.0794(5) 
C4 0.98875(18) 0.05588(16) 0.62831(19) 0.0506(6) 
F4 0.87055(18) 0.04995(13) 0.87643(16) 0.1005(7) 
C5 0.88235(17) 0.08340(13) 0.57994(19) 0.0459(6) 
C6 0.86364(15) 0.17631(12) 0.59062(13) 0.0293(4) 
C7 0.5883(2) 0.09087(15) 0.6026(2) 0.0587(8) 
C8 0.4942(2) 0.07218(18) 0.6640(2) 0.0656(9) 
C9 0.39146(19) 0.12236(18) 0.63972(19) 0.0563(7) 
C10 0.41609(19) 0.21424(17) 0.6345(2) 0.0552(7) 
C11 0.51084(16) 0.23259(14) 0.57355(16) 0.0397(5) 
C12 0.61460(16) 0.18340(12) 0.60323(13) 0.0309(4) 
C13 0.73887(15) 0.32474(11) 0.53658(12) 0.0279(4) 
C14 0.6671(2) 0.46339(14) 0.34972(16) 0.0455(6) 
C15 0.6780(2) 0.55434(15) 0.32248(18) 0.0589(7) 
C16 0.7974(2) 0.57870(16) 0.31101(16) 0.0569(7) 
C17 0.8682(2) 0.56057(15) 0.39427(17) 0.0526(6) 
C18 0.85816(19) 0.46994(14) 0.42199(16) 0.0438(5) 
C19 0.73767(17) 0.44611(11) 0.43351(13) 0.0326(4) 
C20 0.65632(18) 0.37163(14) 0.74970(14) 0.0389(5) 
C21 0.66051(19) 0.33682(15) 0.84361(14) 0.0440(5) 
C22 0.7661(2) 0.36165(14) 0.89481(14) 0.0461(6) 
C23 0.86914(19) 0.34039(15) 0.84469(15) 0.0445(6) 
C24 0.86404(18) 0.37282(14) 0.74934(14) 0.0399(5) 
C25 0.75805(16) 0.34242(11) 0.70144(12) 0.0305(4) 
B2 0.7180(2) 0.17385(16) 0.41319(17) 0.0408(6) 
Bond lengths (Å) for 1-36: 
P1-C12 1.8330(19) P1-C6 1.833(2) 
P1-C13 1.8691(19) P1-B2 1.923(2) 
N1-C13 1.318(2) N1-C25 1.469(2) 
N1-H1N 0.80(3) C1-C2 1.522(4) 
C1-C6 1.532(3) C1-H1A 0.99 
C1-H1B 0.99 F1-B1 1.381(3) 
B1-F3 1.367(3) B1-F4 1.369(4) 
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B1-F2 1.392(3) N2-C13 1.316(2) 
N2-C19 1.471(2) N2-H2N 0.85(3) 
C2-C3 1.510(3) C2-H2A 0.99 
C2-H2B 0.99 C3-C4 1.509(3) 
C3-H3A 0.99 C3-H3B 0.99 
C4-C5 1.518(3) C4-H4A 0.99 
C4-H4B 0.99 C5-C6 1.524(3) 
C5-H5A 0.99 C5-H5B 0.99 
C6-H6A 1.0 C7-C8 1.519(3) 
C7-C12 1.525(3) C7-H7A 0.99 
C7-H7B 0.99 C8-C9 1.512(3) 
C8-H8A 0.99 C8-H8B 0.99 
C9-C10 1.513(4) C9-H9A 0.99 
C9-H9B 0.99 C10-C11 1.520(3) 
C10-H10A 0.99 C10-H10B 0.99 
C11-C12 1.534(3) C11-H11A 0.99 
C11-H11B 0.99 C12-H12A 1.0 
C14-C19 1.521(3) C14-C15 1.529(3) 
C14-H14A 0.99 C14-H14B 0.99 
C15-C16 1.508(4) C15-H15A 0.99 
C15-H15B 0.99 C16-C17 1.519(4) 
C16-H16A 0.99 C16-H16B 0.99 
C17-C18 1.525(3) C17-H17A 0.99 
C17-H17B 0.99 C18-C19 1.518(3) 
C18-H18A 0.99 C18-H18B 0.99 
C19-H19A 1.0 C20-C25 1.523(3) 
C20-C21 1.520(3) C20-H20A 0.99 
C20-H20B 0.99 C21-C22 1.517(3) 
C21-H21A 0.99 C21-H21B 0.99 
C22-C23 1.516(3) C22-H22A 0.99 
C22-H22B 0.99 C23-C24 1.527(3) 
C23-H23A 0.99 C23-H23B 0.99 
C24-C25 1.525(3) C24-H24A 0.99 
C24-H24B 0.99 C25-H25A 1.0 
B2-H26A 1.06(3) B2-H26B 1.07(2) 
B2-H26C 1.09(3) 
Bond angles (°) for 1-36: 
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C12-P1-C6 110.75(9) C12-P1-C13 104.36(9) 
C6-P1-C13 104.40(9) C12-P1-B2 114.88(11) 
C6-P1-B2 113.56(11) C13-P1-B2 107.86(10) 
C13-N1-C25 127.55(16) C13-N1-H1N 116.3(18) 
C25-N1-H1N 116.1(18) C2-C1-C6 110.8(2) 
C2-C1-H1A 109.5 C6-C1-H1A 109.5 
C2-C1-H1B 109.5 C6-C1-H1B 109.5 
H1A-C1-H1B 108.1 F3-B1-F4 110.5(3) 
F3-B1-F1 111.1(2) F4-B1-F1 111.2(2) 
F3-B1-F2 110.5(2) F4-B1-F2 104.1(2) 
F1-B1-F2 109.2(2) C13-N2-C19 127.20(17) 
C13-N2-H2N 114.6(16) C19-N2-H2N 117.8(16) 
C3-C2-C1 111.81(19) C3-C2-H2A 109.3 
C1-C2-H2A 109.3 C3-C2-H2B 109.3 
C1-C2-H2B 109.3 H2A-C2-H2B 107.9 
C2-C3-C4 111.54(19) C2-C3-H3A 109.3 
C4-C3-H3A 109.3 C2-C3-H3B 109.3 
C4-C3-H3B 109.3 H3A-C3-H3B 108.0 
C3-C4-C5 110.8(2) C3-C4-H4A 109.5 
C5-C4-H4A 109.5 C3-C4-H4B 109.5 
C5-C4-H4B 109.5 H4A-C4-H4B 108.1 
C4-C5-C6 111.24(19) C4-C5-H5A 109.4 
C6-C5-H5A 109.4 C4-C5-H5B 109.4 
C6-C5-H5B 109.4 H5A-C5-H5B 108.0 
C5-C6-C1 109.21(16) C5-C6-P1 111.19(14) 
C1-C6-P1 111.65(16) C5-C6-H6A 108.2 
C1-C6-H6A 108.2 P1-C6-H6A 108.2 
C8-C7-C12 110.5(2) C8-C7-H7A 109.6 
C12-C7-H7A 109.6 C8-C7-H7B 109.6 
C12-C7-H7B 109.6 H7A-C7-H7B 108.1 
C9-C8-C7 111.7(2) C9-C8-H8A 109.3 
C7-C8-H8A 109.3 C9-C8-H8B 109.3 
C7-C8-H8B 109.3 H8A-C8-H8B 107.9 
C8-C9-C10 112.1(2) C8-C9-H9A 109.2 
C10-C9-H9A 109.2 C8-C9-H9B 109.2 
C10-C9-H9B 109.2 H9A-C9-H9B 107.9 
C9-C10-C11 112.0(2) C9-C10-H10A 109.2 
C11-C10-H10A 109.2 C9-C10-H10B 109.2 
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C11-C10-H10B 109.2 H10A-C10-H10B 107.9 
C10-C11-C12 110.3(2) C10-C11-H11A 109.6 
C12-C11-H11A 109.6 C10-C11-H11B 109.6 
C12-C11-H11B 109.6 H11A-C11-H11B 108.1 
C7-C12-C11 109.67(17) C7-C12-P1 112.44(15) 
C11-C12-P1 111.34(15) C7-C12-H12A 107.7 
C11-C12-H12A 107.7 P1-C12-H12A 107.7 
N1-C13-N2 121.96(17) N1-C13-P1 124.96(14) 
N2-C13-P1 113.05(13) C19-C14-C15 110.30(19) 
C19-C14-H14A 109.6 C15-C14-H14A 109.6 
C19-C14-H14B 109.6 C15-C14-H14B 109.6 
H14A-C14-H14B 108.1 C16-C15-C14 111.9(2) 
C16-C15-H15A 109.2 C14-C15-H15A 109.2 
C16-C15-H15B 109.2 C14-C15-H15B 109.2 
H15A-C15-H15B 107.9 C15-C16-C17 111.4(2) 
C15-C16-H16A 109.3 C17-C16-H16A 109.3 
C15-C16-H16B 109.3 C17-C16-H16B 109.3 
H16A-C16-H16B 108.0 C16-C17-C18 111.2(2) 
C16-C17-H17A 109.4 C18-C17-H17A 109.4 
C16-C17-H17B 109.4 C18-C17-H17B 109.4 
H17A-C17-H17B 108.0 C19-C18-C17 111.07(19) 
C19-C18-H18A 109.4 C17-C18-H18A 109.4 
C19-C18-H18B 109.4 C17-C18-H18B 109.4 
H18A-C18-H18B 108.0 N2-C19-C18 110.20(16) 
N2-C19-C14 109.51(17) C18-C19-C14 111.53(17) 
N2-C19-H19A 108.5 C18-C19-H19A 108.5 
C14-C19-H19A 108.5 C25-C20-C21 109.25(17) 
C25-C20-H20A 109.8 C21-C20-H20A 109.8 
C25-C20-H20B 109.8 C21-C20-H20B 109.8 
H20A-C20-H20B 108.3 C22-C21-C20 111.96(19) 
C22-C21-H21A 109.2 C20-C21-H21A 109.2 
C22-C21-H21B 109.2 C20-C21-H21B 109.2 
H21A-C21-H21B 107.9 C21-C22-C23 112.01(19) 
C21-C22-H22A 109.2 C23-C22-H22A 109.2 
C21-C22-H22B 109.2 C23-C22-H22B 109.2 
H22A-C22-H22B 107.9 C22-C23-C24 112.64(18) 
C22-C23-H23A 109.1 C24-C23-H23A 109.1 
C22-C23-H23B 109.1 C24-C23-H23B 109.1 
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H23A-C23-H23B 107.8 C25-C24-C23 109.81(17) 
C25-C24-H24A 109.7 C23-C24-H24A 109.7 
C25-C24-H24B 109.7 C23-C24-H24B 109.7 
H24A-C24-H24B 108.2 N1-C25-C20 110.99(16) 
N1-C25-C24 110.55(16) C20-C25-C24 110.50(17) 
N1-C25-H25A 108.2 C20-C25-H25A 108.2 
C24-C25-H25A 108.2 P1-B2-H26A 105.2(15) 
P1-B2-H26B 107.4(14) H26A-B2-H26B 114.(2) 
P1-B2-H26C 103.1(14) H26A-B2-H26C 110.5(19) 
H26B-B2-H26C 115.4(19) 
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The X-ray coordinates for 1-42 have been deposited in the CCDC (#1008171) 
Sample and crystal data for 1-42 
Identification code Milligan57743 
Chemical formula C23H34BN2P 
Formula weight 380.30 
Temperature 220(2) K 
Wavelength 1.54178 Å 
Crystal size 0.040 x 0.120 x 0.210 mm 
Crystal habit clear colourless shard 
Crystal system triclinic 
Space group P -1 
Unit cell dimensions a = 11.3394(5) Å α = 93.950(3)° 
b = 13.9575(7) Å β = 90.335(2)° 
c = 14.6789(8) Å γ = 104.560(2)° 
Volume 2242.63(19) Å3 
Z 4 
Density (calculated) 1.126 g/cm3 
Absorption 
coefficient 
1.134 mm-1 
F(000) 824 
Data collection and structure refinement for 1-42: 
HN N
P
t-Bu
t-Bu
1-42
H3B
381 
Diffractometer Bruker Apex II CCD 
Radiation source IMuS micro-focus, Cu 
Theta range for data 
collection 
3.02 to 68.37° 
Index ranges 
-13<=h<=12, -16<=k<=16, -
16<=l<=15 
Reflections collected 30798 
Independent 
reflections 
7969 [R(int) = 0.0330] 
Coverage of 
independent 
reflections 
96.6% 
Absorption 
correction 
multi-scan 
Max. and min. 
transmission 
0.9560 and 0.7970 
Structure solution 
technique 
direct methods 
Structure solution 
program 
direct methods 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2013 (Sheldrick, 2013) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / 
parameters 
7969 / 0 / 519 
Goodness-of-fit on F2 1.904 
Δ/σmax 0.012 
Final R indices 
6625 data; 
I>2σ(I)
R1 = 0.0628, 
wR2 = 0.1796 
all data 
R1 = 0.0743, 
wR2 = 0.1853 
Weighting scheme 
w=1/[σ2(Fo2)+(0.0680P)2] 
where P=(Fo
2+2Fc
2)/3 
Largest diff. peak 
and hole 
1.684 and -0.696 eÅ-3 
R.M.S. deviation 
from mean
0.050 eÅ-3 
Atomic coordinates and equivalent isotropic atomic displacement 
parameters (Å2) for 1-42: 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
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x/a y/b z/c U(eq) 
P1 0.04228(5) 0.27378(5) 0.19476(4) 0.03658(19) 
B1 0.0807(3) 0.2623(4) 0.3220(2) 0.0622(10) 
N1 0.84027(17) 0.28302(15) 0.10241(13) 0.0379(5) 
C1 0.7229(2) 0.29548(19) 0.08021(15) 0.0368(5) 
P2 0.30261(6) 0.24570(6) 0.68762(5) 0.0467(2) 
B2 0.2561(3) 0.2196(4) 0.8149(2) 0.0649(11) 
N2 0.8137(2) 0.2451(2) 0.25756(16) 0.0504(6) 
C2 0.7094(3) 0.3913(2) 0.07953(18) 0.0500(7) 
N3 0.51351(18) 0.27361(16) 0.59653(14) 0.0393(5) 
C3 0.6027(3) 0.4095(3) 0.0480(2) 0.0659(9) 
N4 0.5185(2) 0.22477(18) 0.74848(16) 0.0458(5) 
C4 0.5082(3) 0.3309(3) 0.0165(2) 0.0707(10) 
C5 0.5204(3) 0.2360(3) 0.01772(19) 0.0612(9) 
C6 0.6271(2) 0.2154(2) 0.04900(17) 0.0461(6) 
C7 0.6374(3) 0.1114(2) 0.0540(2) 0.0676(9) 
C8 0.6444(3) 0.0812(2) 0.1510(3) 0.0739(10) 
C9 0.6032(3) 0.1471(2) 0.2224(2) 0.0530(7) 
C10 0.4806(3) 0.1347(3) 0.2402(3) 0.0711(11) 
C11 0.4418(3) 0.1955(4) 0.3033(3) 0.0874(14) 
C12 0.5221(3) 0.2709(4) 0.3504(2) 0.0801(12) 
C13 0.6448(3) 0.2877(3) 0.33317(19) 0.0595(8) 
C14 0.6851(2) 0.2275(2) 0.26948(18) 0.0458(6) 
C15 0.8769(2) 0.26534(16) 0.18019(15) 0.0331(5) 
C16 0.0720(2) 0.1689(2) 0.12064(18) 0.0463(6) 
C17 0.0172(3) 0.1576(3) 0.0236(2) 0.0687(9) 
C18 0.0142(4) 0.0749(3) 0.1682(3) 0.0854(12) 
C19 0.2089(3) 0.1806(3) 0.1142(3) 0.0829(12) 
C20 0.1182(3) 0.3997(2) 0.1590(2) 0.0573(8) 
C21 0.0544(3) 0.4723(2) 0.2083(3) 0.0756(10) 
C22 0.1134(3) 0.4100(3) 0.0568(3) 0.0818(12) 
C23 0.2534(3) 0.4264(3) 0.1934(3) 0.0835(11) 
C24 0.6402(2) 0.29546(17) 0.57736(15) 0.0343(5) 
C25 0.7057(3) 0.3939(2) 0.58237(18) 0.0485(6) 
C26 0.8255(3) 0.4202(2) 0.5566(2) 0.0609(8) 
C27 0.8826(3) 0.3477(2) 0.52397(19) 0.0558(8) 
C28 0.8167(2) 0.2501(2) 0.51772(16) 0.0439(6) 
C29 0.6956(2) 0.22242(18) 0.54304(15) 0.0350(5) 
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x/a y/b z/c U(eq) 
C30 0.6267(2) 0.11453(19) 0.53692(17) 0.0453(6) 
C31 0.5911(2) 0.07151(19) 0.62884(19) 0.0466(6) 
C32 0.6682(2) 0.12844(17) 0.70757(16) 0.0366(5) 
C33 0.7793(2) 0.1097(2) 0.72948(18) 0.0443(6) 
C34 0.8534(2) 0.1631(2) 0.80008(19) 0.0524(7) 
C35 0.8195(3) 0.2372(2) 0.84994(19) 0.0529(7) 
C36 0.7109(2) 0.2588(2) 0.83046(17) 0.0463(6) 
C37 0.6347(2) 0.20477(19) 0.76007(17) 0.0389(6) 
C38 0.4661(2) 0.24739(17) 0.67143(16) 0.0349(5) 
C39 0.2962(3) 0.3734(3) 0.6635(2) 0.0671(9) 
C40 0.4026(4) 0.4444(3) 0.7203(3) 0.0889(13) 
C41 0.3069(4) 0.3917(3) 0.5619(3) 0.0809(11) 
C42 0.1752(4) 0.3913(3) 0.7022(3) 0.1004(15) 
C43 0.2135(2) 0.1441(2) 0.60545(18) 0.0438(6) 
C44 0.2623(3) 0.1411(2) 0.50951(19) 0.0572(7) 
C45 0.0815(3) 0.1530(3) 0.6005(2) 0.0788(11) 
C46 0.2177(3) 0.0470(2) 0.6468(2) 0.0691(9) 
Bond lengths (Å) for 1-42: 
P1-C15 1.860(2) P1-C16 1.864(3) 
P1-C20 1.865(3) P1-B1 1.942(3) 
B1-H3B 1.11(4) B1-H1B 1.12(3) 
B1-H1B 1.14(4) N1-C15 1.273(3) 
N1-C1 1.423(3) C1-C2 1.385(4) 
C1-C6 1.397(3) P2-C39 1.861(3) 
P2-C38 1.865(2) P2-C43 1.875(3) 
P2-B2 1.978(4) B2-H2B 1.07(4) 
B2-H2C 1.15(4) B2-H2D 1.04(5) 
N2-C15 1.355(3) N2-C14 1.430(3) 
N2-H2N 0.79(4) C2-C3 1.380(4) 
C2-H2A 0.94 N3-C38 1.263(3) 
N3-C24 1.425(3) C3-C4 1.377(5) 
C3-H3A 0.94 N4-C38 1.367(3) 
N4-C37 1.425(3) N4-H4N 0.87(4) 
C4-C5 1.368(5) C4-H4A 0.94 
C5-C6 1.394(4) C5-H5A 0.94 
C6-C7 1.493(5) C7-C8 1.520(5) 
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C7-H7A 0.98 C7-H7B 0.98 
C8-C9 1.502(5) C8-H8A 0.98 
C8-H8B 0.98 C9-C10 1.386(4) 
C9-C14 1.400(4) C10-C11 1.362(6) 
C10-H10A 0.94 C11-C12 1.352(6) 
C11-H11A 0.94 C12-C13 1.379(5) 
C12-H12A 0.94 C13-C14 1.371(4) 
C13-H13A 0.94 C16-C18 1.529(5) 
C16-C19 1.524(4) C16-C17 1.533(4) 
C17-H17A 0.97 C17-H17B 0.97 
C17-H17C 0.97 C18-H18A 0.97 
C18-H18B 0.97 C18-H18C 0.97 
C19-H19A 0.97 C19-H19B 0.97 
C19-H19C 0.97 C20-C22 1.519(5) 
C20-C21 1.532(5) C20-C23 1.557(4) 
C21-H21A 0.97 C21-H21B 0.97 
C21-H21C 0.97 C22-H22A 0.97 
C22-H22B 0.97 C22-H22C 0.97 
C23-H23A 0.97 C23-H23B 0.97 
C23-H23C 0.97 C24-C25 1.385(4) 
C24-C29 1.394(3) C25-C26 1.378(4) 
C25-H25A 0.94 C26-C27 1.392(5) 
C26-H26A 0.94 C27-C28 1.376(4) 
C27-H27A 0.94 C28-C29 1.390(3) 
C28-H28A 0.94 C29-C30 1.508(4) 
C30-C31 1.530(4) C30-H30A 0.98 
C30-H30B 0.98 C31-C32 1.498(3) 
C31-H31A 0.98 C31-H31B 0.98 
C32-C33 1.390(3) C32-C37 1.403(4) 
C33-C34 1.380(4) C33-H33A 0.94 
C34-C35 1.361(4) C34-H34A 0.94 
C35-C36 1.373(4) C35-H35A 0.94 
C36-C37 1.392(4) C36-H36A 0.94 
C39-C41 1.531(5) C39-C40 1.552(5) 
C39-C42 1.559(5) C40-H40A 0.97 
C40-H40B 0.97 C40-H40C 0.97 
C41-H41A 0.97 C41-H41B 0.97 
C41-H41C 0.97 C42-H42A 0.97 
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C42-H42B 0.97 C42-H42C 0.97 
C43-C44 1.518(4) C43-C46 1.535(4) 
C43-C45 1.535(4) C44-H44A 0.97 
C44-H44B 0.97 C44-H44C 0.97 
C45-H45A 0.97 C45-H45B 0.97 
C45-H45C 0.97 C46-H46A 0.97 
C46-H46B 0.97 C46-H46C 0.97 
Bond angles (°) for 1-42: 
C15-P1-C16 105.90(11) C15-P1-C20 103.98(12) 
C16-P1-C20 114.82(14) C15-P1-B1 109.86(14) 
C16-P1-B1 111.07(16) C20-P1-B1 110.78(18) 
P1-B1-H3B 104.(2) P1-B1-H1B 103.2(16) 
H3B-B1-H1B 118.(3) P1-B1-H1B 107.1(18) 
H3B-B1-H1B 115.(3) H1B-B1-H1B 108.(3) 
C15-N1-C1 126.5(2) C2-C1-C6 119.7(2) 
C2-C1-N1 118.0(2) C6-C1-N1 121.9(2) 
C39-P2-C38 103.44(14) C39-P2-C43 115.25(14) 
C38-P2-C43 105.99(11) C39-P2-B2 110.39(19) 
C38-P2-B2 110.43(13) C43-P2-B2 110.94(17) 
P2-B2-H2B 103.(2) P2-B2-H2C 110.(2) 
H2B-B2-H2C 112.(3) P2-B2-H2D 105.(2) 
H2B-B2-H2D 115.(3) H2C-B2-H2D 112.(3) 
C15-N2-C14 128.2(2) C15-N2-H2N 113.(3) 
C14-N2-H2N 119.(3) C3-C2-C1 121.2(3) 
C3-C2-H2A 119.4 C1-C2-H2A 119.4 
C38-N3-C24 126.07(19) C4-C3-C2 119.4(3) 
C4-C3-H3A 120.3 C2-C3-H3A 120.3 
C38-N4-C37 129.0(2) C38-N4-H4N 117.(2) 
C37-N4-H4N 113.(2) C5-C4-C3 119.9(3) 
C5-C4-H4A 120.1 C3-C4-H4A 120.1 
C4-C5-C6 121.9(3) C4-C5-H5A 119.0 
C6-C5-H5A 119.0 C5-C6-C1 117.9(3) 
C5-C6-C7 121.5(3) C1-C6-C7 120.5(2) 
C6-C7-C8 113.7(3) C6-C7-H7A 108.8 
C8-C7-H7A 108.8 C6-C7-H7B 108.8 
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C8-C7-H7B 108.8 H7A-C7-H7B 107.7 
C9-C8-C7 114.4(3) C9-C8-H8A 108.7 
C7-C8-H8A 108.7 C9-C8-H8B 108.7 
C7-C8-H8B 108.7 H8A-C8-H8B 107.6 
C10-C9-C14 117.0(3) C10-C9-C8 120.9(3) 
C14-C9-C8 121.9(3) C11-C10-C9 121.5(3) 
C11-C10-H10A 119.2 C9-C10-H10A 119.2 
C12-C11-C10 120.8(3) C12-C11-H11A 119.6 
C10-C11-H11A 119.6 C11-C12-C13 119.6(4) 
C11-C12-H12A 120.2 C13-C12-H12A 120.2 
C14-C13-C12 120.2(3) C14-C13-H13A 119.9 
C12-C13-H13A 119.9 C13-C14-C9 120.8(3) 
C13-C14-N2 117.9(3) C9-C14-N2 121.2(3) 
N1-C15-N2 129.5(2) N1-C15-P1 117.10(18) 
N2-C15-P1 113.31(16) C18-C16-C19 109.6(3) 
C18-C16-C17 108.3(3) C19-C16-C17 108.5(3) 
C18-C16-P1 105.8(2) C19-C16-P1 109.7(2) 
C17-C16-P1 114.80(19) C16-C17-H17A 109.5 
C16-C17-H17B 109.5 H17A-C17-H17B 109.5 
C16-C17-H17C 109.5 H17A-C17-H17C 109.5 
H17B-C17-H17C 109.5 C16-C18-H18A 109.5 
C16-C18-H18B 109.5 H18A-C18-H18B 109.5 
C16-C18-H18C 109.5 H18A-C18-H18C 109.5 
H18B-C18-H18C 109.5 C16-C19-H19A 109.5 
C16-C19-H19B 109.5 H19A-C19-H19B 109.5 
C16-C19-H19C 109.5 H19A-C19-H19C 109.5 
H19B-C19-H19C 109.5 C22-C20-C21 109.4(3) 
C22-C20-C23 109.5(3) C21-C20-C23 108.3(3) 
C22-C20-P1 114.6(2) C21-C20-P1 106.7(2) 
C23-C20-P1 108.2(2) C20-C21-H21A 109.5 
C20-C21-H21B 109.5 H21A-C21-H21B 109.5 
C20-C21-H21C 109.5 H21A-C21-H21C 109.5 
H21B-C21-H21C 109.5 C20-C22-H22A 109.5 
C20-C22-H22B 109.5 H22A-C22-H22B 109.5 
C20-C22-H22C 109.5 H22A-C22-H22C 109.5 
H22B-C22-H22C 109.5 C20-C23-H23A 109.5 
C20-C23-H23B 109.5 H23A-C23-H23B 109.5 
C20-C23-H23C 109.5 H23A-C23-H23C 109.5 
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H23B-C23-H23C 109.5 C25-C24-C29 119.2(2) 
C25-C24-N3 118.4(2) C29-C24-N3 121.9(2) 
C26-C25-C24 121.0(3) C26-C25-H25A 119.5 
C24-C25-H25A 119.5 C25-C26-C27 120.2(3) 
C25-C26-H26A 119.9 C27-C26-H26A 119.9 
C28-C27-C26 118.6(3) C28-C27-H27A 120.7 
C26-C27-H27A 120.7 C27-C28-C29 121.8(3) 
C27-C28-H28A 119.1 C29-C28-H28A 119.1 
C28-C29-C24 119.0(2) C28-C29-C30 120.5(2) 
C24-C29-C30 120.5(2) C29-C30-C31 114.9(2) 
C29-C30-H30A 108.6 C31-C30-H30A 108.6 
C29-C30-H30B 108.6 C31-C30-H30B 108.6 
H30A-C30-H30B 107.5 C32-C31-C30 113.4(2) 
C32-C31-H31A 108.9 C30-C31-H31A 108.9 
C32-C31-H31B 108.9 C30-C31-H31B 108.9 
H31A-C31-H31B 107.7 C33-C32-C37 117.1(2) 
C33-C32-C31 120.8(2) C37-C32-C31 122.1(2) 
C34-C33-C32 121.8(2) C34-C33-H33A 119.1 
C32-C33-H33A 119.1 C35-C34-C33 120.3(2) 
C35-C34-H34A 119.9 C33-C34-H34A 119.9 
C34-C35-C36 120.1(3) C34-C35-H35A 120.0 
C36-C35-H35A 120.0 C35-C36-C37 120.2(3) 
C35-C36-H36A 119.9 C37-C36-H36A 119.9 
C36-C37-C32 120.6(2) C36-C37-N4 117.5(2) 
C32-C37-N4 121.7(2) N3-C38-N4 129.8(2) 
N3-C38-P2 118.19(17) N4-C38-P2 111.91(18) 
C41-C39-C40 111.1(3) C41-C39-C42 111.3(3) 
C40-C39-C42 107.3(3) C41-C39-P2 113.0(2) 
C40-C39-P2 105.8(2) C42-C39-P2 108.0(3) 
C39-C40-H40A 109.5 C39-C40-H40B 109.5 
H40A-C40-H40B 109.5 C39-C40-H40C 109.5 
H40A-C40-H40C 109.5 H40B-C40-H40C 109.5 
C39-C41-H41A 109.5 C39-C41-H41B 109.5 
H41A-C41-H41B 109.5 C39-C41-H41C 109.5 
H41A-C41-H41C 109.5 H41B-C41-H41C 109.5 
C39-C42-H42A 109.5 C39-C42-H42B 109.5 
H42A-C42-H42B 109.5 C39-C42-H42C 109.5 
H42A-C42-H42C 109.5 H42B-C42-H42C 109.5 
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C44-C43-C46 107.8(3) C44-C43-C45 109.2(2) 
C46-C43-C45 109.9(3) C44-C43-P2 115.82(19) 
C46-C43-P2 105.41(19) C45-C43-P2 108.5(2) 
C43-C44-H44A 109.5 C43-C44-H44B 109.5 
H44A-C44-H44B 109.5 C43-C44-H44C 109.5 
H44A-C44-H44C 109.5 H44B-C44-H44C 109.5 
C43-C45-H45A 109.5 C43-C45-H45B 109.5 
H45A-C45-H45B 109.5 C43-C45-H45C 109.5 
H45A-C45-H45C 109.5 H45B-C45-H45C 109.5 
C43-C46-H46A 109.5 C43-C46-H46B 109.5 
H46A-C46-H46B 109.5 C43-C46-H46C 109.5 
H46A-C46-H46C 109.5 H46B-C46-H46C 109.5 
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Sample and crystal data for 1-44: 
Identification code milligan62414 
Chemical formula C29H30BN2P 
Formula weight 448.33 
Temperature 230(2) K 
Wavelength 1.54178 Å 
Crystal size 0.080 x 0.120 x 0.210 mm 
Crystal system monoclinic 
Space group P 1 21/c 1 
Unit cell dimensions a = 9.9801(4) Å α = 90° 
b = 10.0187(4) β = 96.4999(14)° 
c = 26.0554(9) γ = 90° 
Volume 2588.47(17) Å 
Z 4 
Density (calculated) 1.150 g/cm3 
Absorption 
coefficient 
1.065 mm-1 
F(000) 952 
Data collection and structure refinement for 1-44: 
1-44
HN N
PH3B
CH3
CH3
390 
Diffractometer Bruker Apex II CCD 
Radiation source IMuS micro-focus, Cu 
Theta range for 
data collection 
3.41 to 68.18° 
Index ranges -11<=h<=11, -12<=k<=11, -30<=l<=31
Reflections 
collected 
27146 
Independent 
reflections 
4683 [R(int) = 0.0273] 
Max. and min. 
transmission 
0.9200 and 0.8070 
Refinement 
method 
Full-matrix least-squares on F2 
Refinement 
program 
SHELXL-2013 (Sheldrick, 2013) 
Function 
minimized 
Σ w(Fo2 - Fc2)2 
Data / restraints / 
parameters 
4683 / 0 / 396 
Goodness-of-fit on 
F2 
1.551 
Δ/σmax 0.006 
Final R indices 4271 data; I>2σ(I) 
R1 = 0.0449, 
wR2 = 0.1435 
all data 
R1 = 0.0481, 
wR2 = 0.1467 
Weighting scheme 
w=1/[σ2(Fo2)+(0.0814P)2] 
where P=(Fo
2+2Fc
2)/3 
Largest diff. peak 
and hole 
0.416 and -0.225 eÅ-3 
R.M.S. deviation 
from mean
0.047 eÅ-3 
Table 3. Atomic coordinates and equivalent isotropic atomic displacement 
parameters (Å2) for 1-44: 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
x/a y/b z/c U(eq) 
P1 0.78683(3) 0.88794(4) 0.82935(2) 0.04084(16) 
N1 0.00867(11) 0.99504(12) 0.87989(4) 0.0412(3) 
B1 0.67095(18) 0.7413(2) 0.84310(8) 0.0527(4) 
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x/a y/b z/c U(eq) 
C1 0.94348(13) 0.88605(13) 0.87524(5) 0.0393(3) 
N2 0.96856(13) 0.76400(13) 0.89692(5) 0.0469(3) 
C2 0.12591(13) 0.01970(13) 0.91463(5) 0.0390(3) 
C3 0.10990(15) 0.08574(15) 0.96042(6) 0.0448(3) 
C4 0.22152(19) 0.12870(18) 0.99293(7) 0.0588(4) 
C5 0.3487(2) 0.1050(2) 0.97951(9) 0.0713(5) 
C6 0.36415(16) 0.0386(2) 0.93429(8) 0.0660(5) 
C7 0.25498(14) 0.99586(16) 0.90045(6) 0.0483(3) 
C8 0.2753(2) 0.9232(2) 0.85134(8) 0.0638(5) 
C9 0.2194(2) 0.77962(19) 0.84799(7) 0.0621(4) 
C10 0.21122(16) 0.71648(15) 0.89977(6) 0.0513(4) 
C11 0.3253(2) 0.6611(2) 0.92751(9) 0.0683(5) 
C12 0.3200(2) 0.6024(2) 0.97514(9) 0.0791(6) 
C13 0.2007(2) 0.59757(19) 0.99694(8) 0.0647(5) 
C14 0.08701(17) 0.65459(16) 0.97111(6) 0.0506(4) 
C15 0.09211(14) 0.71410(13) 0.92325(6) 0.0440(3) 
C16 0.84946(14) 0.88640(14) 0.76717(5) 0.0433(3) 
C17 0.93975(19) 0.98334(19) 0.75453(6) 0.0595(4) 
C18 0.9923(2) 0.97799(18) 0.70766(6) 0.0617(4) 
C19 0.95656(18) 0.87769(15) 0.67220(6) 0.0521(4) 
C20 0.86331(19) 0.78416(17) 0.68476(7) 0.0585(4) 
C21 0.81089(16) 0.78692(16) 0.73163(6) 0.0512(4) 
C22 0.0168(3) 0.8711(2) 0.62182(8) 0.0728(5) 
C23 0.71245(13) 0.04943(15) 0.83737(5) 0.0442(3) 
C24 0.6542(2) 0.1214(2) 0.79536(8) 0.0725(6) 
C25 0.5862(3) 0.2392(2) 0.80269(9) 0.0836(7) 
C26 0.57316(17) 0.28717(17) 0.85121(8) 0.0634(5) 
C27 0.63216(17) 0.21436(19) 0.89292(7) 0.0601(4) 
C28 0.70087(16) 0.09696(17) 0.88646(6) 0.0521(4) 
C29 0.4965(3) 0.4136(2) 0.85927(12) 0.0932(8) 
Bond lengths (Å) for 1-44: 
P1-C16 1.8013(15) P1-C23 1.8021(15) 
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P1-C1 1.8578(14) P1-B1 1.9279(19) 
N1-C1 1.2699(18) N1-C2 1.4176(17) 
B1-H1BC 1.12(2) B1-H1BB 1.11(2) 
B1-H1BA 0.99(2) C1-N2 1.3582(18) 
N2-C15 1.4315(19) N2-H2N 0.88(2) 
C2-C3 1.389(2) C2-C7 1.400(2) 
C3-C4 1.389(2) C3-H3 0.98(2) 
C4-C5 1.375(3) C4-H4 0.98(2) 
C5-C6 1.377(3) C5-H5 0.97(3) 
C6-C7 1.389(2) C6-H6 0.95(3) 
C7-C8 1.506(2) C8-C9 1.542(3) 
C8-H8 1.03(2) C8-H8B 1.03(3) 
C9-C10 1.501(3) C9-H9B 0.96(2) 
C9-H9 1.07(2) C10-C11 1.393(3) 
C10-C15 1.397(2) C11-C12 1.380(3) 
C11-H11 0.94(3) C12-C13 1.376(3) 
C12-H12 0.98(3) C13-C14 1.376(2) 
C13-H13 0.98(2) C14-C15 1.388(2) 
C14-H14 0.98(2) C16-C21 1.385(2) 
C16-C17 1.390(2) C17-C18 1.384(2) 
C17-H17 0.92(2) C18-C19 1.384(2) 
C18-H18 0.98(3) C19-C20 1.386(3) 
C19-C22 1.506(2) C20-C21 1.382(2) 
C20-H20 0.95(2) C21-H21 0.94(2) 
C22-H22A 0.97 C22-H22B 0.97 
C22-H22C 0.97 C23-C28 1.382(2) 
C23-C24 1.383(2) C24-C25 1.386(3) 
C24-H24 1.02(2) C25-C26 1.372(3) 
C25-H25 0.98(3) C26-C27 1.384(3) 
C26-C29 1.507(3) C27-C28 1.381(2) 
C27-H27 1.01(2) C28-H28 0.94(2) 
C29-H29A 0.97 C29-H29B 0.97 
C29-H29C 0.97 
Bond angles (°) for 1-44: 
C16-P1-C23 107.54(7) C16-P1-C1 103.09(6) 
C23-P1-C1 105.20(6) C16-P1-B1 115.92(8) 
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C23-P1-B1 113.50(8) C1-P1-B1 110.57(7) 
C1-N1-C2 125.99(12) P1-B1-H1BC 105.5(12) 
P1-B1-H1BB 108.6(11) H1BC-B1-H1BB 111.0(16) 
P1-B1-H1BA 109.1(13) H1BC-B1-H1BA 110.7(17) 
H1BB-B1-H1BA 111.6(16) N1-C1-N2 131.77(12) 
N1-C1-P1 115.93(10) N2-C1-P1 112.27(10) 
C1-N2-C15 128.45(12) C1-N2-H2N 115.2(12) 
C15-N2-H2N 116.3(12) C3-C2-C7 120.44(13) 
C3-C2-N1 117.68(12) C7-C2-N1 121.28(13) 
C4-C3-C2 120.59(15) C4-C3-H3 120.5(11) 
C2-C3-H3 118.8(11) C5-C4-C3 119.42(18) 
C5-C4-H4 120.2(13) C3-C4-H4 120.2(13) 
C4-C5-C6 119.81(16) C4-C5-H5 119.3(15) 
C6-C5-H5 120.9(15) C5-C6-C7 122.42(16) 
C5-C6-H6 121.9(15) C7-C6-H6 115.6(15) 
C6-C7-C2 117.31(15) C6-C7-C8 121.10(16) 
C2-C7-C8 121.56(14) C7-C8-C9 114.60(14) 
C7-C8-H8 108.0(12) C9-C8-H8 108.6(12) 
C7-C8-H8B 103.1(13) C9-C8-H8B 112.0(14) 
H8-C8-H8B 110.4(18) C10-C9-C8 113.49(15) 
C10-C9-H9B 108.3(13) C8-C9-H9B 109.1(13) 
C10-C9-H9 109.6(11) C8-C9-H9 109.2(11) 
H9B-C9-H9 107.0(16) C11-C10-C15 116.88(16) 
C11-C10-C9 120.66(16) C15-C10-C9 122.42(14) 
C12-C11-C10 121.58(18) C12-C11-H11 119.5(15) 
C10-C11-H11 118.8(16) C13-C12-C11 120.64(18) 
C13-C12-H12 120.8(17) C11-C12-H12 118.6(17) 
C12-C13-C14 119.16(19) C12-C13-H13 123.0(13) 
C14-C13-H13 117.9(13) C13-C14-C15 120.35(16) 
C13-C14-H14 120.6(13) C15-C14-H14 119.0(13) 
C14-C15-C10 121.33(14) C14-C15-N2 117.59(13) 
C10-C15-N2 120.91(13) C21-C16-C17 118.88(14) 
C21-C16-P1 120.60(12) C17-C16-P1 120.51(11) 
C18-C17-C16 120.21(15) C18-C17-H17 121.0(14) 
C16-C17-H17 118.7(14) C17-C18-C19 121.47(16) 
C17-C18-H18 120.2(14) C19-C18-H18 118.2(14) 
C18-C19-C20 117.55(15) C18-C19-C22 121.04(16) 
C20-C19-C22 121.41(15) C21-C20-C19 121.78(15) 
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C21-C20-H20 117.6(14) C19-C20-H20 120.7(13) 
C20-C21-C16 120.05(16) C20-C21-H21 119.7(12) 
C16-C21-H21 120.3(12) C19-C22-H22A 109.5 
C19-C22-H22B 109.5 H22A-C22-H22B 109.5 
C19-C22-H22C 109.5 H22A-C22-H22C 109.5 
H22B-C22-H22C 109.5 C28-C23-C24 118.78(15) 
C28-C23-P1 119.70(12) C24-C23-P1 121.20(12) 
C23-C24-C25 120.24(18) C23-C24-H24 117.8(13) 
C25-C24-H24 121.8(13) C26-C25-C24 121.62(19) 
C26-C25-H25 123.0(19) C24-C25-H25 115.4(19) 
C25-C26-C27 117.56(16) C25-C26-C29 121.7(2) 
C27-C26-C29 120.74(19) C28-C27-C26 121.73(17) 
C28-C27-H27 117.8(12) C26-C27-H27 120.4(12) 
C23-C28-C27 120.06(16) C23-C28-H28 119.4(12) 
C27-C28-H28 120.4(12) C26-C29-H29A 109.5 
C26-C29-H29B 109.5 H29A-C29-H29B 109.5 
C26-C29-H29C 109.5 H29A-C29-H29C 109.5 
H29B-C29-H29C 109.5 
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Sample and crystal data for 1-62: 
Identification code JM1r 
Chemical formula C63H60Cl4N4P2Pt 
Formula weight 1271.98 g/mol 
Temperature 240(2) K 
Wavelength 1.54178 Å 
Crystal size 0.040 x 0.080 x 0.080 mm 
Crystal system monoclinic 
Space group P 1 21 1 
Unit cell dimensions a = 11.2580(16) Å α = 90° 
b = 12.9240(19) Å β = 98.888(7)° 
c = 19.447(3) Å γ = 90° 
Volume 2795.5(7) Å3 
Z 2 
Density (calculated) 1.511 g/cm3 
Absorption coefficient 7.334 mm-1 
F(000) 1284 
Data collection and structure refinement for 1-62: 
Diffractometer Bruker Apex II CCD 
Radiation source IMuS micro-focus source, Cu 
396
Theta range for data 
collection 
2.30 to 70.25° 
Index ranges -13<=h<=13, -15<=k<=15, -23<=l<=23
Reflections collected 35162 
Independent reflections 10415 [R(int) = 0.0263] 
Absorption correction multi-scan 
Max. and min. 
transmission 
0.7580 and 0.5910 
Structure solution 
technique 
direct methods 
Structure solution 
program 
SHELXS-97 (Sheldrick, 2008) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-97 (Sheldrick, 2008) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / 
parameters 
10415 / 1 / 675 
Goodness-of-fit on F2 1.003 
Δ/σmax 0.002 
Weighting scheme w=1/[σ2(Fo2)+(0.0226P)2] 
Absolute structure 
parameter 
-0.0(0)
Largest diff. peak and 
hole 
0.668 and -0.651 eÅ-3 
R.M.S. deviation from 
mean
0.058 eÅ-3 
Table 3. Atomic coordinates and equivalent isotropic atomic displacement 
parameters (Å2) for 1-62: 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
x/a y/b z/c U(eq) 
P1 0.82425(9) 0.03999(8) 0.81485(5) 0.0319(2) 
Pt1 0.84217(2) 0.21192(2) 0.78668(2) 0.03098(5) 
Cl1 0.01676(10) 0.22898(11) 0.86398(6) 0.0489(3) 
N1 0.6436(4) 0.9058(3) 0.8170(2) 0.0417(8) 
C1 0.9224(4) 0.9794(4) 0.8906(3) 0.0435(10) 
P2 0.85031(9) 0.38228(8) 0.75273(5) 0.0320(2) 
Cl2 0.66348(9) 0.1981(2) 0.71102(6) 0.0476(5) 
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x/a y/b z/c U(eq) 
N2 0.6107(3) 0.0774(3) 0.8558(2) 0.0386(8) 
C2 0.9448(6) 0.8703(4) 0.8639(3) 0.0607(14) 
C3 0.9672(7) 0.8830(5) 0.7900(4) 0.0651(18) 
N3 0.7671(4) 0.4938(3) 0.6397(2) 0.0430(8) 
C4 0.8647(5) 0.9484(4) 0.7487(3) 0.0455(11) 
N4 0.8472(4) 0.3273(3) 0.6195(2) 0.0424(8) 
C5 0.8780(5) 0.0845(5) 0.9919(3) 0.0550(12) 
C6 0.8330(6) 0.0943(6) 0.0540(3) 0.0652(15) 
C7 0.7902(5) 0.0119(6) 0.0851(3) 0.0625(16) 
C8 0.7870(5) 0.9167(5) 0.0529(3) 0.0621(15) 
C9 0.8290(5) 0.9050(4) 0.9900(3) 0.0536(12) 
C10 0.8754(4) 0.9888(4) 0.9586(3) 0.0441(10) 
C11 0.0015(7) 0.0451(5) 0.6796(4) 0.0672(16) 
C12 0.0262(9) 0.0886(6) 0.6194(5) 0.089(3) 
C13 0.9405(11) 0.0892(5) 0.5604(5) 0.091(3) 
C14 0.8322(10) 0.0473(7) 0.5636(4) 0.087(3) 
C15 0.8074(7) 0.0022(6) 0.6248(4) 0.0687(18) 
C16 0.8922(6) 0.9991(4) 0.6837(3) 0.0507(12) 
C17 0.6699(5) 0.0000(4) 0.8294(3) 0.0356(11) 
C18 0.5285(4) 0.8626(4) 0.8195(2) 0.0417(9) 
C19 0.5224(5) 0.7769(4) 0.8615(3) 0.0535(12) 
C20 0.4148(5) 0.7234(7) 0.8609(3) 0.0709(17) 
C21 0.3138(6) 0.7557(6) 0.8168(4) 0.0710(18) 
C22 0.3196(5) 0.8412(5) 0.7751(3) 0.0579(14) 
C23 0.4257(5) 0.8958(4) 0.7751(2) 0.0451(10) 
C24 0.4259(5) 0.9916(4) 0.7307(3) 0.0504(11) 
C25 0.3806(5) 0.0897(4) 0.7653(3) 0.0520(12) 
C26 0.3909(4) 0.0836(4) 0.8427(3) 0.0454(10) 
C27 0.2900(5) 0.0860(5) 0.8754(3) 0.0594(14) 
C28 0.2972(5) 0.0766(5) 0.9461(3) 0.0636(15) 
C29 0.4070(5) 0.0601(5) 0.9873(3) 0.0563(13) 
C30 0.5099(4) 0.0575(4) 0.9566(3) 0.0456(10) 
C31 0.5027(5) 0.0699(4) 0.8853(3) 0.0371(11) 
C32 0.7516(5) 0.4704(4) 0.7940(2) 0.0429(10) 
C33 0.8381(6) 0.5545(4) 0.8293(3) 0.0577(13) 
C34 0.9399(6) 0.5700(4) 0.7865(3) 0.0503(14) 
C35 0.9892(4) 0.4614(4) 0.7758(2) 0.0419(10) 
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x/a y/b z/c U(eq) 
C36 0.5516(6) 0.4101(5) 0.8193(4) 0.0636(15) 
C37 0.4769(9) 0.3630(7) 0.8608(5) 0.076(2) 
C38 0.5261(8) 0.3201(6) 0.9216(5) 0.080(2) 
C39 0.6489(8) 0.3231(5) 0.9437(4) 0.079(2) 
C40 0.7242(7) 0.3714(5) 0.9026(3) 0.0653(16) 
C41 0.6764(7) 0.4167(5) 0.8397(3) 0.0481(14) 
C42 0.1016(5) 0.5297(4) 0.6820(3) 0.0575(13) 
C43 0.1887(6) 0.5196(5) 0.6393(4) 0.0701(17) 
C44 0.2568(6) 0.4329(6) 0.6417(4) 0.0695(16) 
C45 0.2373(6) 0.3537(6) 0.6860(4) 0.0715(17) 
C46 0.1496(6) 0.3633(5) 0.7286(3) 0.0610(14) 
C47 0.0811(4) 0.4517(4) 0.7271(3) 0.0429(10) 
C48 0.8118(4) 0.4056(3) 0.6575(2) 0.0347(9) 
C49 0.8527(5) 0.3284(4) 0.5464(2) 0.0389(10) 
C50 0.9633(5) 0.3450(4) 0.5254(3) 0.0460(10) 
C51 0.9739(5) 0.3361(4) 0.4553(3) 0.0548(13) 
C52 0.8740(6) 0.3116(4) 0.4075(3) 0.0575(13) 
C53 0.7653(5) 0.2968(4) 0.4283(3) 0.0539(12) 
C54 0.7506(5) 0.3031(4) 0.4981(3) 0.0445(10) 
C55 0.6303(5) 0.2859(5) 0.5209(3) 0.0571(13) 
C56 0.5735(5) 0.3840(5) 0.5488(3) 0.0553(13) 
C57 0.6277(4) 0.4841(4) 0.5291(3) 0.0462(11) 
C58 0.5818(5) 0.5347(5) 0.4668(3) 0.0582(14) 
C59 0.6322(6) 0.6239(5) 0.4460(3) 0.0638(15) 
C60 0.7317(6) 0.6665(5) 0.4871(3) 0.0631(15) 
C61 0.7772(5) 0.6194(4) 0.5491(3) 0.0524(12) 
C62 0.7265(4) 0.5292(4) 0.5712(2) 0.0412(9) 
C63 0.6119(8) 0.6943(6) 0.6913(4) 0.086(2) 
Cl3 0.4819(2) 0.6166(2) 0.6754(2) 0.1278(10) 
Cl4 0.5954(3) 0.80182(18) 0.63711(14) 0.1063(7) 
Table 4. Bond lengths (Å) for 1-62. 
P1-C4 1.857(5) P1-C1 1.871(5) 
P1-C17 1.875(6) P1-Pt1 2.3048(11) 
Pt1-Cl1 2.2932(11) Pt1-P2 2.3045(11) 
Pt1-Cl2 2.3085(10) N1-C17 1.267(7) 
N1-C18 1.418(6) C1-C10 1.504(7) 
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C1-C2 1.538(7) C1-H1A 0.99 
P2-C32 1.858(5) P2-C48 1.861(5) 
P2-C35 1.864(5) N2-C17 1.347(7) 
N2-C31 1.426(7) N2-H2N 0.83(6) 
C2-C3 1.504(9) C2-H2A 0.98 
C2-H2B 0.98 C3-C4 1.551(9) 
C3-H3A 0.98 C3-H3B 0.98 
N3-C48 1.272(6) N3-C62 1.415(6) 
C4-C16 1.497(7) C4-H4A 0.99 
N4-C48 1.349(6) N4-C49 1.433(6) 
N4-H4N 0.92(7) C5-C6 1.385(8) 
C5-C10 1.394(8) C5-H5A 0.94 
C6-C7 1.350(10) C6-H6A 0.94 
C7-C8 1.378(10) C7-H7A 0.94 
C8-C9 1.387(8) C8-H8A 0.94 
C9-C10 1.383(8) C9-H9A 0.94 
C11-C12 1.366(10) C11-C16 1.380(9) 
C11-H11A 0.94 C12-C13 1.380(15) 
C12-H12A 0.94 C13-C14 1.345(14) 
C13-H13A 0.94 C14-C15 1.393(11) 
C14-H14A 0.94 C15-C16 1.374(10) 
C15-H15A 0.94 C18-C19 1.384(7) 
C18-C23 1.400(7) C19-C20 1.393(8) 
C19-H19A 0.94 C20-C21 1.379(9) 
C20-H20A 0.94 C21-C22 1.378(9) 
C21-H21A 0.94 C22-C23 1.387(7) 
C22-H22A 0.94 C23-C24 1.510(7) 
C24-C25 1.558(8) C24-H24A 0.98 
C24-H24B 0.98 C25-C26 1.494(8) 
C25-H25A 0.98 C25-H25B 0.98 
C26-C27 1.386(7) C26-C31 1.407(7) 
C27-C28 1.371(9) C27-H27A 0.94 
C28-C29 1.382(9) C28-H28A 0.94 
C29-C30 1.383(7) C29-H29A 0.94 
C30-C31 1.386(8) C30-H30A 0.94 
C32-C41 1.490(8) C32-C33 1.547(7) 
C32-H32A 0.99 C33-C34 1.530(9) 
C33-H33A 0.98 C33-H33B 0.98 
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C34-C35 1.535(7) C34-H34A 0.98 
C34-H34B 0.98 C35-C47 1.512(7) 
C35-H35A 0.99 C36-C37 1.392(10) 
C36-C41 1.402(10) C36-H36A 0.94 
C37-C38 1.345(13) C37-H37A 0.94 
C38-C39 1.382(13) C38-H38A 0.94 
C39-C40 1.400(10) C39-H39A 0.94 
C40-C41 1.388(9) C40-H40A 0.94 
C42-C47 1.379(7) C42-C43 1.387(9) 
C42-H42A 0.94 C43-C44 1.354(10) 
C43-H43A 0.94 C44-C45 1.377(10) 
C44-H44A 0.94 C45-C46 1.390(9) 
C45-H45A 0.94 C46-C47 1.376(8) 
C46-H46A 0.94 C49-C50 1.386(7) 
C49-C54 1.405(7) C50-C51 1.391(8) 
C50-H50A 0.94 C51-C52 1.381(9) 
C51-H51A 0.94 C52-C53 1.361(9) 
C52-H52A 0.94 C53-C54 1.395(7) 
C53-H53A 0.94 C54-C55 1.506(7) 
C55-C56 1.555(8) C55-H55A 0.98 
C55-H55B 0.98 C56-C57 1.505(8) 
C56-H56A 0.98 C56-H56B 0.98 
C57-C58 1.403(7) C57-C62 1.403(7) 
C58-C59 1.373(10) C58-H58A 0.94 
C59-C60 1.385(10) C59-H59A 0.94 
C60-C61 1.377(8) C60-H60A 0.94 
C61-C62 1.395(7) C61-H61A 0.94 
C63-Cl4 1.737(9) C63-Cl3 1.763(9) 
C63-H63A 0.98 C63-H63B 0.98 
Table 5. Bond angles (°) for 1-62: 
C4-P1-C1 95.8(2) C4-P1-C17 105.1(2) 
C1-P1-C17 102.4(2) C4-P1-Pt1 114.21(16) 
C1-P1-Pt1 121.85(17) C17-P1-Pt1 114.76(17) 
Cl1-Pt1-P2 91.60(4) Cl1-Pt1-P1 91.98(4) 
P2-Pt1-P1 176.37(4) Cl1-Pt1-Cl2 178.22(7) 
P2-Pt1-Cl2 87.75(7) P1-Pt1-Cl2 88.69(7) 
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C17-N1-C18 124.0(4) C10-C1-C2 118.0(4) 
C10-C1-P1 114.4(3) C2-C1-P1 103.0(4) 
C10-C1-H1A 106.9 C2-C1-H1A 106.9 
P1-C1-H1A 106.9 C32-P2-C48 105.5(2) 
C32-P2-C35 95.5(2) C48-P2-C35 102.0(2) 
C32-P2-Pt1 114.14(16) C48-P2-Pt1 115.26(14) 
C35-P2-Pt1 121.61(15) C17-N2-C31 127.4(4) 
C17-N2-H2N 112.(4) C31-N2-H2N 120.(4) 
C3-C2-C1 106.4(5) C3-C2-H2A 110.4 
C1-C2-H2A 110.4 C3-C2-H2B 110.4 
C1-C2-H2B 110.4 H2A-C2-H2B 108.6 
C2-C3-C4 109.5(5) C2-C3-H3A 109.8 
C4-C3-H3A 109.8 C2-C3-H3B 109.8 
C4-C3-H3B 109.8 H3A-C3-H3B 108.2 
C48-N3-C62 127.0(4) C16-C4-C3 116.2(5) 
C16-C4-P1 114.2(3) C3-C4-P1 103.3(4) 
C16-C4-H4A 107.5 C3-C4-H4A 107.5 
P1-C4-H4A 107.5 C48-N4-C49 126.7(4) 
C48-N4-H4N 114.(4) C49-N4-H4N 119.(4) 
C6-C5-C10 120.1(6) C6-C5-H5A 119.9 
C10-C5-H5A 119.9 C7-C6-C5 121.5(6) 
C7-C6-H6A 119.3 C5-C6-H6A 119.3 
C6-C7-C8 119.1(6) C6-C7-H7A 120.4 
C8-C7-H7A 120.4 C7-C8-C9 120.6(6) 
C7-C8-H8A 119.7 C9-C8-H8A 119.7 
C10-C9-C8 120.4(6) C10-C9-H9A 119.8 
C8-C9-H9A 119.8 C9-C10-C5 118.2(5) 
C9-C10-C1 122.2(5) C5-C10-C1 119.6(5) 
C12-C11-C16 121.9(8) C12-C11-H11A 119.0 
C16-C11-H11A 119.0 C11-C12-C13 120.4(8) 
C11-C12-H12A 119.8 C13-C12-H12A 119.8 
C14-C13-C12 118.9(7) C14-C13-H13A 120.6 
C12-C13-H13A 120.6 C13-C14-C15 120.7(9) 
C13-C14-H14A 119.7 C15-C14-H14A 119.7 
C16-C15-C14 121.3(8) C16-C15-H15A 119.3 
C14-C15-H15A 119.3 C15-C16-C11 116.8(6) 
C15-C16-C4 120.5(6) C11-C16-C4 122.7(6) 
N1-C17-N2 132.1(5) N1-C17-P1 115.5(4) 
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N2-C17-P1 112.2(4) C19-C18-C23 119.8(5) 
C19-C18-N1 117.7(5) C23-C18-N1 122.0(4) 
C18-C19-C20 120.9(6) C18-C19-H19A 119.5 
C20-C19-H19A 119.5 C21-C20-C19 119.2(6) 
C21-C20-H20A 120.4 C19-C20-H20A 120.4 
C22-C21-C20 119.9(5) C22-C21-H21A 120.0 
C20-C21-H21A 120.0 C21-C22-C23 121.8(5) 
C21-C22-H22A 119.1 C23-C22-H22A 119.1 
C22-C23-C18 118.3(5) C22-C23-C24 119.6(5) 
C18-C23-C24 122.0(4) C23-C24-C25 113.0(4) 
C23-C24-H24A 109.0 C25-C24-H24A 109.0 
C23-C24-H24B 109.0 C25-C24-H24B 109.0 
H24A-C24-H24B 107.8 C26-C25-C24 114.3(4) 
C26-C25-H25A 108.7 C24-C25-H25A 108.7 
C26-C25-H25B 108.7 C24-C25-H25B 108.7 
H25A-C25-H25B 107.6 C27-C26-C31 117.0(5) 
C27-C26-C25 121.3(5) C31-C26-C25 121.6(5) 
C28-C27-C26 122.2(5) C28-C27-H27A 118.9 
C26-C27-H27A 118.9 C27-C28-C29 120.3(5) 
C27-C28-H28A 119.8 C29-C28-H28A 119.8 
C28-C29-C30 119.1(5) C28-C29-H29A 120.4 
C30-C29-H29A 120.4 C29-C30-C31 120.4(5) 
C29-C30-H30A 119.8 C31-C30-H30A 119.8 
C30-C31-C26 120.9(5) C30-C31-N2 119.3(5) 
C26-C31-N2 119.7(5) C41-C32-C33 116.0(5) 
C41-C32-P2 113.9(4) C33-C32-P2 104.2(4) 
C41-C32-H32A 107.4 C33-C32-H32A 107.4 
P2-C32-H32A 107.4 C34-C33-C32 108.9(4) 
C34-C33-H33A 109.9 C32-C33-H33A 109.9 
C34-C33-H33B 109.9 C32-C33-H33B 109.9 
H33A-C33-H33B 108.3 C33-C34-C35 105.7(4) 
C33-C34-H34A 110.6 C35-C34-H34A 110.6 
C33-C34-H34B 110.6 C35-C34-H34B 110.6 
H34A-C34-H34B 108.7 C47-C35-C34 117.2(4) 
C47-C35-P2 115.7(3) C34-C35-P2 103.1(3) 
C47-C35-H35A 106.7 C34-C35-H35A 106.7 
P2-C35-H35A 106.7 C37-C36-C41 122.1(8) 
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C37-C36-H36A 118.9 C41-C36-H36A 118.9 
C38-C37-C36 119.1(9) C38-C37-H37A 120.5 
C36-C37-H37A 120.5 C37-C38-C39 121.2(7) 
C37-C38-H38A 119.4 C39-C38-H38A 119.4 
C38-C39-C40 120.0(7) C38-C39-H39A 120.0 
C40-C39-H39A 120.0 C41-C40-C39 120.3(7) 
C41-C40-H40A 119.8 C39-C40-H40A 119.8 
C40-C41-C36 117.3(6) C40-C41-C32 122.9(7) 
C36-C41-C32 119.8(6) C47-C42-C43 121.1(6) 
C47-C42-H42A 119.4 C43-C42-H42A 119.4 
C44-C43-C42 120.3(6) C44-C43-H43A 119.8 
C42-C43-H43A 119.8 C43-C44-C45 119.5(6) 
C43-C44-H44A 120.2 C45-C44-H44A 120.2 
C44-C45-C46 120.2(6) C44-C45-H45A 119.9 
C46-C45-H45A 119.9 C47-C46-C45 120.6(6) 
C47-C46-H46A 119.7 C45-C46-H46A 119.7 
C46-C47-C42 118.2(5) C46-C47-C35 119.4(5) 
C42-C47-C35 122.4(5) N3-C48-N4 131.4(5) 
N3-C48-P2 116.0(4) N4-C48-P2 112.4(3) 
C50-C49-C54 121.2(5) C50-C49-N4 118.2(5) 
C54-C49-N4 120.3(5) C49-C50-C51 119.5(5) 
C49-C50-H50A 120.2 C51-C50-H50A 120.2 
C52-C51-C50 119.6(5) C52-C51-H51A 120.2 
C50-C51-H51A 120.2 C53-C52-C51 120.5(5) 
C53-C52-H52A 119.7 C51-C52-H52A 119.7 
C52-C53-C54 121.9(5) C52-C53-H53A 119.1 
C54-C53-H53A 119.1 C53-C54-C49 117.1(5) 
C53-C54-C55 121.6(5) C49-C54-C55 121.2(5) 
C54-C55-C56 114.8(4) C54-C55-H55A 108.6 
C56-C55-H55A 108.6 C54-C55-H55B 108.6 
C56-C55-H55B 108.6 H55A-C55-H55B 107.6 
C57-C56-C55 114.0(4) C57-C56-H56A 108.7 
C55-C56-H56A 108.7 C57-C56-H56B 108.7 
C55-C56-H56B 108.7 H56A-C56-H56B 107.6 
C58-C57-C62 117.6(5) C58-C57-C56 120.8(5) 
C62-C57-C56 121.6(5) C59-C58-C57 122.1(6) 
C59-C58-H58A 118.9 C57-C58-H58A 118.9 
C58-C59-C60 119.8(5) C58-C59-H59A 120.1 
404 
C60-C59-H59A 120.1 C61-C60-C59 119.2(6) 
C61-C60-H60A 120.4 C59-C60-H60A 120.4 
C60-C61-C62 121.6(6) C60-C61-H61A 119.2 
C62-C61-H61A 119.2 C61-C62-C57 119.5(5) 
C61-C62-N3 118.2(4) C57-C62-N3 121.8(4) 
Cl4-C63-Cl3 110.0(4) Cl4-C63-H63A 109.7 
Cl3-C63-H63A 109.7 Cl4-C63-H63B 109.7 
Cl3-C63-H63B 109.7 H63A-C63-H63B 108.2 
405 
Sample and crystal data for 2-66: 
Identification code milligan5 
Chemical formula C38H52B2P2 
Formula weight 592.35 g/mol 
Temperature 230(2) K 
Wavelength 1.54178 Å 
Crystal size 0.100 x 0.140 x 0.190 mm 
Crystal system triclinic 
Space group P -1 
Unit cell dimensions
a = 
10.7360(2) 
α = 
109.8510(10)° 
b = 
12.9572(3) 
β = 
93.0060(10)° 
c = 
13.9710(3) 
γ = 
94.6320(10)° 
Volume 1815.41(7) Å 
Z 2 
Density (calculated) 1.084 g/cm3 
Absorption coefficient 1.244 mm-1 
F(000) 640 
Data collection and structure refinement for 2-66: 
Diffractometer Bruker Apex II CCD 
Radiation source IMuS micro-focus source, Cu 
Theta range for data 
collection 
3.38 to 68.26° 
P
BH3
P
BH3
2-66
406 
Index ranges -12<=h<=12, -15<=k<=15, -16<=l<=16
Reflections collected 30565 
Independent 
reflections 
6499 [R(int) = 0.0247] 
Absorption 
correction 
multi-scan 
Max. and min. 
transmission 
0.8860 and 0.7980 
Structure solution 
technique 
direct methods 
Structure solution 
program 
SHELXS-97 (Sheldrick, 2008) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-97 (Sheldrick, 2008) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / 
parameters 
6499 / 0 / 412 
Goodness-of-fit on F2 1.601 
Δ/σmax 0.683 
Largest diff. peak 
and hole 
0.459 and -0.316 eÅ-3 
R.M.S. deviation 
from mean
0.042 eÅ-3 
Atomic coordinates and equivalent isotropic atomic displacement 
parameters (Å2) for 2-66: 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
x/a y/b z/c U(eq) 
P1 0.19966(3) 0.52444(3) 0.82114(3) 
0.03355(13
) 
P2 0.32664(3) 0.23653(3) 0.38012(2) 
0.02806(12
) 
B1 0.0721(2) 0.40690(18) 0.80845(17) 0.0507(5) 
B2 0.4100(2) 0.28633(19) 0.28232(15) 0.0471(5) 
C1 0.30086(14) 0.48894(13) 0.71670(11) 0.0369(3) 
C2 0.23159(14) 0.45774(12) 0.61122(11) 0.0359(3) 
C3 0.17927(14) 0.33626(12) 0.55564(11) 0.0361(3) 
C4 0.23208(14) 0.34194(12) 0.45546(11) 0.0326(3) 
407 
C5 0.31503(16) 0.44912(12) 0.52218(11) 0.0371(3) 
C6 0.13207(18) 0.36468(15) 0.38489(13) 0.0489(4) 
C7 0.26700(15) 0.53205(13) 0.01746(12) 0.0392(3) 
C8 0.34174(16) 0.56628(14) 0.10964(13) 0.0426(4) 
C9 0.45289(16) 0.63279(14) 0.11847(13) 0.0453(4) 
C10 0.49153(15) 0.66547(14) 0.03932(13) 0.0426(4) 
C11 0.41629(15) 0.63046(13) 0.94792(12) 0.0396(3) 
C12 0.30398(14) 0.56373(12) 0.93672(11) 0.0344(3) 
C13 0.3023(2) 0.5309(2) 0.19656(15) 0.0641(5) 
C14 0.61199(19) 0.7382(2) 0.05089(17) 0.0645(6) 
C15 0.03494(14) 0.68418(14) 0.87547(12) 0.0407(4) 
C16 0.99422(16) 0.78788(16) 0.89116(13) 0.0474(4) 
C17 0.06097(19) 0.85856(15) 0.85328(14) 0.0522(4) 
C18 0.1683(2) 0.83074(16) 0.80348(15) 0.0539(5) 
C19 0.20836(17) 0.72818(14) 0.79004(13) 0.0444(4) 
C20 0.14216(14) 0.65440(13) 0.82583(11) 0.0351(3) 
C21 0.8820(2) 0.8215(2) 0.94971(19) 0.0711(6) 
C22 0.2421(3) 0.9116(2) 0.7666(2) 0.0907(9) 
C23 0.56510(14) 0.24970(13) 0.47283(12) 0.0377(3) 
C24 0.65519(15) 0.22992(14) 0.53742(14) 0.0453(4) 
C25 0.61727(16) 0.17137(15) 0.59964(13) 0.0473(4) 
C26 0.49283(16) 0.13203(13) 0.59825(12) 0.0400(4) 
C27 0.40416(14) 0.15100(12) 0.53136(11) 0.0341(3) 
C28 0.43931(13) 0.21081(11) 0.46885(10) 0.0311(3) 
C29 0.79204(17) 0.2697(2) 0.53894(19) 0.0678(6) 
C30 0.4531(2) 0.06822(16) 0.66562(14) 0.0526(4) 
C31 0.26691(15) 0.03334(13) 0.23348(12) 0.0399(4) 
C32 0.20427(18) 0.92824(14) 0.18698(13) 0.0486(4) 
C33 0.10107(19) 0.89866(14) 0.23020(15) 0.0533(5) 
C34 0.05788(17) 0.97066(15) 0.31808(14) 0.0488(4) 
C35 0.12303(15) 0.07547(13) 0.36388(12) 0.0399(3) 
C36 0.22863(14) 0.10699(12) 0.32230(11) 0.0324(3) 
C37 0.2503(3) 0.84995(19) 0.09215(17) 0.0764(7) 
C38 0.9448(2) 0.9343(2) 0.3628(2) 0.0734(7) 
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Bond lengths (Å) for 2-66: 
P1-C12 1.8113(15) P1-C1 1.8200(15) 
P1-C20 1.8216(16) P1-B1 1.9184(19) 
P2-C36 1.8116(14) P2-C28 1.8164(14) 
P2-C4 1.8340(15) P2-B2 1.9285(17) 
B1-H1B1 1.12(3) B1-H1B2 1.07(2) 
B1-H1B3 1.12(2) B2-H2B1 1.13(2) 
B2-H2B2 1.10(2) B2-H2B3 1.19(2) 
C1-C2 1.523(2) C1-H1A 0.98 
C1-H1B 0.98 C2-C3 1.542(2) 
C2-C5 1.550(2) C2-H2A 0.99 
C3-C4 1.5595(19) C3-H3A 0.98 
C3-H3B 0.98 C4-C6 1.533(2) 
C4-C5 1.557(2) C5-H5A 0.98 
C5-H5B 0.98 C6-H6A 0.97 
C6-H6B 0.97 C6-H6C 0.97 
C7-C12 1.391(2) C7-C8 1.395(2) 
C7-H7A 0.94 C8-C9 1.389(3) 
C8-C13 1.505(2) C9-C10 1.383(2) 
C9-H9A 0.94 C10-C11 1.389(2) 
C10-C14 1.505(2) C11-C12 1.395(2) 
C11-H11A 0.94 C13-H13A 0.97 
C13-H13B 0.97 C13-H13C 0.97 
C14-H14A 0.97 C14-H14B 0.97 
C14-H14C 0.97 C15-C20 1.389(2) 
C15-C16 1.396(3) C15-H15A 0.94 
C16-C17 1.377(3) C16-C21 1.502(3) 
C17-C18 1.387(3) C17-H17A 0.94 
C18-C19 1.385(3) C18-C22 1.506(3) 
C19-C20 1.386(2) C19-H19A 0.94 
C21-H21A 0.97 C21-H21B 0.97 
C21-H21C 0.97 C22-H22A 0.97 
C22-H22B 0.97 C22-H22C 0.97 
C23-C24 1.386(2) C23-C28 1.394(2) 
C23-H23A 0.94 C24-C25 1.390(3) 
C24-C29 1.514(2) C25-C26 1.388(3) 
C25-H25A 0.94 C26-C27 1.393(2) 
C26-C30 1.505(2) C27-C28 1.397(2) 
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C27-H27A 0.94 C29-H29A 0.97 
C29-H29B 0.97 C29-H29C 0.97 
C30-H30A 0.97 C30-H30B 0.97 
C30-H30C 0.97 C31-C32 1.391(2) 
C31-C36 1.390(2) C31-H31A 0.94 
C32-C33 1.378(3) C32-C37 1.505(3) 
C33-C34 1.394(3) C33-H33A 0.94 
C34-C35 1.397(2) C34-C38 1.507(3) 
C35-C36 1.395(2) C35-H35A 0.94 
C37-H37A 0.97 C37-H37B 0.97 
C37-H37C 0.97 C38-H38A 0.97 
C38-H38B 0.97 C38-H38C 0.97 
Bond angles (°) for 2-66: 
C12-P1-C1 105.45(7) C12-P1-C20 102.99(7) 
C1-P1-C20 106.08(7) C12-P1-B1 113.92(9) 
C1-P1-B1 112.26(9) C20-P1-B1 115.18(9) 
C36-P2-C28 104.87(6) C36-P2-C4 109.45(7) 
C28-P2-C4 107.39(7) C36-P2-B2 113.35(8) 
C28-P2-B2 111.13(8) C4-P2-B2 110.37(8) 
P1-B1-H1B1 102.4(13) P1-B1-H1B2 104.9(13) 
H1B1-B1-H1B2 114.2(18) P1-B1-H1B3 109.5(12) 
H1B1-B1-H1B3 111.8(17) H1B2-B1-H1B3 113.1(17) 
P2-B2-H2B1 104.2(11) P2-B2-H2B2 102.3(10) 
H2B1-B2-H2B2 111.1(16) P2-B2-H2B3 106.6(10) 
H2B1-B2-H2B3 115.3(15) H2B2-B2-H2B3 115.7(15) 
C2-C1-P1 114.11(10) C2-C1-H1A 108.7 
P1-C1-H1A 108.7 C2-C1-H1B 108.7 
P1-C1-H1B 108.7 H1A-C1-H1B 107.6 
C1-C2-C3 118.42(13) C1-C2-C5 115.84(13) 
C3-C2-C5 88.73(11) C1-C2-H2A 110.7 
C3-C2-H2A 110.7 C5-C2-H2A 110.7 
C2-C3-C4 89.55(11) C2-C3-H3A 113.7 
C4-C3-H3A 113.7 C2-C3-H3B 113.7 
C4-C3-H3B 113.7 H3A-C3-H3B 111.0 
C6-C4-C3 112.14(13) C6-C4-C5 112.06(13) 
C3-C4-C5 87.83(10) C6-C4-P2 109.88(11) 
C3-C4-P2 121.35(10) C5-C4-P2 111.82(10) 
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C2-C5-C4 89.36(11) C2-C5-H5A 113.8 
C4-C5-H5A 113.8 C2-C5-H5B 113.8 
C4-C5-H5B 113.8 H5A-C5-H5B 111.0 
C4-C6-H6A 109.5 C4-C6-H6B 109.5 
H6A-C6-H6B 109.5 C4-C6-H6C 109.5 
H6A-C6-H6C 109.5 H6B-C6-H6C 109.5 
C12-C7-C8 120.42(15) C12-C7-H7A 119.8 
C8-C7-H7A 119.8 C7-C8-C9 118.32(15) 
C7-C8-C13 120.36(17) C9-C8-C13 121.32(17) 
C10-C9-C8 122.31(15) C10-C9-H9A 118.8 
C8-C9-H9A 118.8 C9-C10-C11 118.69(15) 
C9-C10-C14 121.36(16) C11-C10-C14 119.94(16) 
C10-C11-C12 120.37(15) C10-C11-H11A 119.8 
C12-C11-H11A 119.8 C7-C12-C11 119.89(14) 
C7-C12-P1 118.94(12) C11-C12-P1 121.05(12) 
C8-C13-H13A 109.5 C8-C13-H13B 109.5 
H13A-C13-H13B 109.5 C8-C13-H13C 109.5 
H13A-C13-H13C 109.5 H13B-C13-H13C 109.5 
C10-C14-H14A 109.5 C10-C14-H14B 109.5 
H14A-C14-H14B 109.5 C10-C14-H14C 109.5 
H14A-C14-H14C 109.5 H14B-C14-H14C 109.5 
C20-C15-C16 120.91(16) C20-C15-H15A 119.5 
C16-C15-H15A 119.5 C17-C16-C15 118.22(16) 
C17-C16-C21 121.28(19) C15-C16-C21 120.49(18) 
C16-C17-C18 121.91(17) C16-C17-H17A 119.0 
C18-C17-H17A 119.0 C17-C18-C19 119.03(17) 
C17-C18-C22 120.64(19) C19-C18-C22 120.32(19) 
C20-C19-C18 120.50(17) C20-C19-H19A 119.7 
C18-C19-H19A 119.8 C19-C20-C15 119.40(16) 
C19-C20-P1 121.93(12) C15-C20-P1 118.39(12) 
C16-C21-H21A 109.5 C16-C21-H21B 109.5 
H21A-C21-H21B 109.5 C16-C21-H21C 109.5 
H21A-C21-H21C 109.5 H21B-C21-H21C 109.5 
C18-C22-H22A 109.5 C18-C22-H22B 109.5 
H22A-C22-H22B 109.5 C18-C22-H22C 109.5 
H22A-C22-H22C 109.5 H22B-C22-H22C 109.5 
C24-C23-C28 121.15(14) C24-C23-H23A 119.4 
C28-C23-H23A 119.4 C23-C24-C25 118.50(15) 
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C23-C24-C29 120.72(17) C25-C24-C29 120.77(17) 
C26-C25-C24 121.96(15) C26-C25-H25A 119.0 
C24-C25-H25A 119.0 C25-C26-C27 118.61(15) 
C25-C26-C30 121.43(16) C27-C26-C30 119.96(16) 
C26-C27-C28 120.68(14) C26-C27-H27A 119.7 
C28-C27-H27A 119.7 C23-C28-C27 119.09(14) 
C23-C28-P2 118.92(11) C27-C28-P2 121.98(11) 
C24-C29-H29A 109.5 C24-C29-H29B 109.5 
H29A-C29-H29B 109.5 C24-C29-H29C 109.5 
H29A-C29-H29C 109.5 H29B-C29-H29C 109.5 
C26-C30-H30A 109.5 C26-C30-H30B 109.5 
H30A-C30-H30B 109.5 C26-C30-H30C 109.5 
H30A-C30-H30C 109.5 H30B-C30-H30C 109.5 
C32-C31-C36 121.45(16) C32-C31-H31A 119.3 
C36-C31-H31A 119.3 C33-C32-C31 118.37(16) 
C33-C32-C37 121.76(18) C31-C32-C37 119.9(2) 
C32-C33-C34 122.11(16) C32-C33-H33A 118.9 
C34-C33-H33A 118.9 C33-C34-C35 118.45(17) 
C33-C34-C38 120.15(18) C35-C34-C38 121.39(19) 
C36-C35-C34 120.56(16) C36-C35-H35A 119.7 
C34-C35-H35A 119.7 C35-C36-C31 119.04(14) 
C35-C36-P2 124.30(12) C31-C36-P2 116.57(12) 
C32-C37-H37A 109.5 C32-C37-H37B 109.5 
H37A-C37-H37B 109.5 C32-C37-H37C 109.5 
H37A-C37-H37C 109.5 H37B-C37-H37C 109.5 
C34-C38-H38A 109.5 C34-C38-H38B 109.5 
H38A-C38-H38B 109.5 C34-C38-H38C 109.5 
H38A-C38-H38C 109.5 H38B-C38-H38C 109.5 
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Sample and crystal data for 3-98: 
Identification code jam81878 
Chemical formula C13H16FNO2 
Formula weight 237.27 g/mol 
Temperature 230(2) K 
Wavelength 1.54178 Å 
Crystal size 0.008 x 0.030 x 0.160 mm 
Crystal system orthorhombic 
Space group P b c a 
Unit cell dimensions a = 8.9568(11) Å α = 90° 
b = 11.5358(14) Å β = 90° 
c = 24.472(3) Å γ = 90° 
Volume 2528.5(6) Å3 
Z 8 
Density (calculated) 1.247 g/cm3 
Absorption coefficient 0.778 mm-1 
F(000) 1008 
Data collection and structure refinement for 3-98: 
Theta range for 
data collection 
3.61 to 68.24° 
Index ranges -10<=h<=10, -13<=k<=13, -29<=l<=24
Reflections 
collected 
19125 
Independent 
reflections 
2309 [R(int) = 0.1553] 
Max. and min. 
transmission 
0.7500 and 0.3400 
Structure solution
technique 
direct methods 
413 
Structure solution
program 
SHELXT 2014/4 (Sheldrick, 2014) 
Refinement method Full-matrix least-squares on F2 
Refinement 
program 
SHELXL-2016/6 (Sheldrick, 2016) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / 
parameters 
2309 / 0 / 160 
Goodness-of-fit on 2 1.000 
Final R indices 1047 data; I>2σ(I) 
R1 = 
0.0587, wR2 = 
0.1453 
all data 
R1 = 
0.1376, wR2 = 
0.1924 
Weighting scheme
w=1/[σ2(Fo2)+(0.0866P)2] 
where P=(Fo
2+2Fc
2)/3 
Largest diff. peak
and hole 
0.190 and -0.163 eÅ-3 
R.M.S. deviation
from mean
0.036 eÅ-3 
Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for 3-98:
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
x/a y/b z/c U(eq) 
O1 0.1658(2) 0.2099(2) 0.20833(11) 0.0881(9) 
N1 0.3726(3) 0.2658(3) 0.25405(13) 0.0743(9) 
F1 0.4198(3) 0.1106(3) 0.04365(11) 0.1451(12) 
C1 0.2177(5) 0.2229(6) 0.0737(2) 0.145(2) 
C2 0.3527(4) 0.1543(4) 0.09125(18) 0.0969(13) 
O2 0.1180(3) 0.5585(2) 0.40871(14) 0.1059(10) 
C3 0.4619(5) 0.2137(4) 0.12880(19) 0.1062(15) 
C4 0.4023(4) 0.1408(3) 0.17685(16) 0.0810(11) 
C5 0.3238(4) 0.0642(3) 0.13499(19) 0.0930(13) 
C6 0.3011(3) 0.2069(3) 0.21450(16) 0.0729(10) 
C7 0.3060(3) 0.3389(3) 0.29391(16) 0.0668(9) 
C8 0.3536(4) 0.3338(3) 0.34713(17) 0.0789(11) 
C9 0.2972(4) 0.4060(3) 0.38702(17) 0.0819(11) 
C10 0.1850(4) 0.4842(3) 0.37262(18) 0.0797(11) 
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x/a y/b z/c U(eq) 
C11 0.1361(4) 0.4887(3) 0.31983(19) 0.0824(11) 
C12 0.1951(4) 0.4179(3) 0.28017(16) 0.0745(10) 
C13 0.1727(5) 0.5652(5) 0.4624(2) 0.1249(18) 
Bond lengths (Å) for 3-98: 
O1-C6 1.221(3) N1-C6 1.345(4) 
N1-C7 1.421(4) N1-H1N 0.89(3) 
F1-C2 1.405(4) C1-C2 1.507(6) 
C1-H1A 0.97 C1-H1B 0.97 
C1-H1C 0.97 C2-C3 1.507(6) 
C2-C5 1.515(6) O2-C10 1.369(4) 
O2-C13 1.404(5) C3-C4 1.540(5) 
C3-H3A 0.98 C3-H3B 0.98 
C4-C6 1.501(5) C4-C5 1.525(5) 
C4-H4A 0.99 C5-H5A 0.98 
C5-H5B 0.98 C7-C8 1.372(5) 
C7-C12 1.390(4) C8-C9 1.379(5) 
C8-H8A 0.94 C9-C10 1.396(5) 
C9-H9A 0.94 C10-C11 1.365(5) 
C11-C12 1.373(5) C11-H11A 0.94 
C12-H12A 0.94 C13-H13A 0.97 
C13-H13B 0.97 C13-H13C 0.97 
Bond angles (°) for 3-98: 
C6-N1-C7 126.4(3) C6-N1-H1N 119.(2) 
C7-N1-H1N 115.(2) C2-C1-H1A 109.5 
C2-C1-H1B 109.5 H1A-C1-H1B 109.5 
C2-C1-H1C 109.5 H1A-C1-H1C 109.5 
H1B-C1-H1C 109.5 F1-C2-C1 107.2(4) 
F1-C2-C3 113.0(3) C1-C2-C3 117.1(4) 
F1-C2-C5 114.4(4) C1-C2-C5 115.1(4) 
C3-C2-C5 89.5(3) C10-O2-C13 119.0(4) 
C2-C3-C4 89.6(3) C2-C3-H3A 113.7 
C4-C3-H3A 113.7 C2-C3-H3B 113.7 
C4-C3-H3B 113.7 H3A-C3-H3B 111.0 
415 
C6-C4-C5 115.3(3) C6-C4-C3 113.6(3) 
C5-C4-C3 87.9(3) C6-C4-H4A 112.6 
C5-C4-H4A 112.6 C3-C4-H4A 112.6 
C2-C5-C4 89.9(3) C2-C5-H5A 113.7 
C4-C5-H5A 113.7 C2-C5-H5B 113.7 
C4-C5-H5B 113.7 H5A-C5-H5B 110.9 
O1-C6-N1 123.2(3) O1-C6-C4 122.5(3) 
N1-C6-C4 114.2(3) C8-C7-C12 118.7(3) 
C8-C7-N1 119.8(3) C12-C7-N1 121.6(3) 
C7-C8-C9 122.2(4) C7-C8-H8A 118.9 
C9-C8-H8A 118.9 C8-C9-C10 118.4(4) 
C8-C9-H9A 120.8 C10-C9-H9A 120.8 
C11-C10-O2 116.5(4) C11-C10-C9 119.6(4) 
O2-C10-C9 123.9(4) C10-C11-C12 121.5(4) 
C10-C11-H11A 119.2 C12-C11-H11A 119.2 
C11-C12-C7 119.6(4) C11-C12-H12A 120.2 
C7-C12-H12A 120.2 O2-C13-H13A 109.5 
O2-C13-H13B 109.5 H13A-C13-H13B 109.5 
O2-C13-H13C 109.5 H13A-C13-H13C 109.5 
H13B-C13-H13C 109.5 
416 
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